Secondary use of electronic medical records for early identification of raised condition likelihoods in individuals: a machine learning approach by Turner, Jonathan
              
City, University of London Institutional Repository
Citation: Turner, Jonathan (2019). Secondary use of electronic medical records for early 
identification of raised condition likelihoods in individuals: a machine learning approach. 
(Unpublished Doctoral thesis, City, University of London) 
This is the accepted version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  http://openaccess.city.ac.uk/id/eprint/22626/
Link to published version: 
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
1 
 
Secondary use of electronic medical 
records for early identification of raised 
condition likelihoods in individuals:         
a machine learning approach 
 
 
 
Jonathan Eric Turner 
Centre for Health Informatics 
School of Mathematics, Computer Science & Engineering 
City, University of London 
 
This dissertation is submitted for the degree of Doctor of Philosophy 
June 2019 
  
2 
 
  
3 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is more important to know what person the disease has than what disease 
the person has. 
Hippocrates of Cos 
 
 
 
 
When you have exhausted all the possibilities, remember this: You haven't. 
Thomas Edison 
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ABSTRACT 
With many symptoms being common to multiple diseases, there is a challenge in 
producing an initial diagnosis or recommendation for diagnostic tests from a set of 
symptoms that could have been produced by a number of diseases. Often the initial 
choice of diagnosis or testing is based on a clinician’s impression of the likelihood of 
that condition in a general population; however the opportunity may exist for 
modification of these likelihoods based on individuals’ recorded medical histories. This 
data-driven approach utilises existing data and is thus cheap and non-invasive. A 
method is proposed by which an individual’s likelihoods of having specified medical 
conditions are modified by the similarity of that individual’s medical history to the 
medical histories of other individuals, comparing the prevalence of conditions in those 
other individuals’ records who are similar to the individual of interest versus the 
prevalence of the conditions in those individuals who are dissimilar.  
In order to maximise the number of records available for analysis, a process was 
developed for the merging of data from disparate sources that used different clinical 
coding systems, including extensive development of a technique for semi-automatically 
mapping clinical events coded in ICD9-CM to Clinical Terms Version 3 (CTV3), for 
which no existing mapping table was found. Semantically similar fields in the source 
code sets were identified and retained in the combined data set. ‘Codelists’ comprising 
multiple CTV3 codes for a variety of conditions were built that defined the presence of 
those conditions within individual records. The hierarchical structure of the CTV3 code 
table was utilised as a method of identifying codes that differed in structure but had 
clinically similar or related meaning. The optimum degree of granularity of the coded 
data to use in identifying similar records was investigated and used in subsequent 
analysis.  
Two methods were used for discovering groups of similar and dissimilar individuals: 
the ‘nearest neighbours’ method and the grouping of records using a clustering process. 
Altered likelihoods for a range of conditions were investigated and results for the 
nearest-neighbours approach compared to the clustering approach.  Results for adjusted 
condition likelihoods for 18 conditions are reported, together with a discussion of 
possible reasons for a change, or otherwise, in the condition likelihood, and a discussion 
of the clinical significance and potential use of information about such a change. logistic 
regressions performed on a selection of conditions  KNN performed better than logistic 
regression when judged by F-score (or sensitivity and specificity separately), however 
situation more nuanced when looking at likelihood ratios: Logistic regression produced 
higher (better) positive likelihood ratios, but KNN produced lower (better) negative 
likelihood ratios. Logistic regression produced higher odds ratios. 
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1 INTRODUCTION 
1.1 Motivation 
There is a growing understanding that there may be useful information stored in the 
large amount of clinical records data that are now being created and stored 
electronically: if these records can be accessed and their data released for research then 
perhaps we can gather useful information on diseases, their prevalence and prevention 
for the purposes of general medical research and for enhancing the care of an individual. 
However there is also a growing understanding of the challenges involved in accessing 
and processing these data.  
Medical diagnosis is an inexact science, with many signs & symptoms, or combinations 
thereof, being explicable by more than one condition. Indeed the number of conditions 
far outweighs the number of symptoms. Given a set of symptoms that could be caused 
by more than one different condition, it is natural for a clinician first to consider the 
most common conditions as being the prime candidates as the cause of the conditions. 
However, it is possible that a patient exists in a population sub-group in which the 
likelihood of different conditions varies from that of the general population. A 
technique is proposed which utilises information from an individual’s record and from 
others to modify the likelihood of various conditions. 
1.2 Aims and objectives 
The objectives for this research were: 
(i) A review of the literature relating to secondary use of clinical records, including 
an overview of relevant legislation and guidance. A review of the literature 
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relating to secondary use of clinical records is presented in the second chapter of 
this thesis. 
(ii) To investigate potential sources for data to use in the work described in this 
thesis. A survey of data sources is given in chapter three. 
(iii) Develop techniques for aggregating data from different sources and which use 
different coding systems, in order to maximise the potential number of data 
sources. The techniques developed are described in the fourth chapter of this 
thesis; the fifth chapter shows the validation of a composite data set from three 
data sources. 
(iv) To build ‘codelists’ – lists of clinical event codes that each indicate the 
diagnosed presence of particular conditions. 
(v) Determination of the optimum granularity of clinical event data and the 
development of a technique of matching records in order to produce modified 
condition likelihoods for individuals and for groups. In the sixth chapter, the 
various factors required to prepare the data set for analysis and testing are 
described and derived. Results from the techniques developed are given in the 
seventh chapter of this thesis. 
(vi) To discusses the results of this work and its clinical significance, including brief 
discussions for each condition evaluated concerning the benefits of earlier 
discovery of those conditions in individuals. 
1.3 Contributions 
Several contributions were made during the course of this work: 
1.3.1 Code mapping 
No existing mapping of ICD-9-CM codes to CTV3 codes was found. A semi-automatic 
technique for indirect mapping of these codes via SNOMED CT was developed and a 
mapping table for 4342 ICD-9-CM codes to equivalent CTV3 codes was generated and 
verified by a domain expert. The technique developed is generalizable. A paper based 
on this work is under review at the Health Informatics Journal. 
1.3.2 Codelists 
In order to determine whether a particular record is ‘positive’ or ‘negative’ for a 
particular condition it was necessary to generate sets of codes, or ‘codelists’, that each 
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indicated the presence of that condition. The codelists generated for use in this project 
are presented in the Appendix 2. 
1.3.3 Methods for patient matching by event history 
Methods were developed for preparing data from clinical event histories to make the 
histories suitable for processing. These methods included mapping event codes to a 
specified granularity, classification of event codes as administration, symptom or 
diagnosis codes, and the development of techniques to identify individual records with 
raised condition likelihood for a particular condition, based on other events in those 
records. 
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2 LITERATURE REVIEW 
2.1 Introduction 
Although the general use of electronic records systems in healthcare has become 
increasingly common over the last 30 years [1], the use of electronic computers to 
benefit medical care was proposed longer ago. Lipkin and Hardy [2, 3] described the 
use of a mechanical punched card system as an aid to the differential diagnosis of 26 
haematological diseases, with the system recommending further tests if it had 
insufficient information to recommend a diagnosis. By 1960 their punched-card 
mechanical system had been implemented on an electronic computer [4]; one year later, 
Warner et al [5] wrote of a computerized mathematical system to aid with the diagnosis 
of congenital heart disease. Also around this time, Ledley and Lusted [6]  wrote of the 
potential for the use of electronic computers as an aid to clinical decision making, 
investigating the theoretical foundation for such assistance and concluding that “The 
great significance and importance of such a health computer network cannot be 
overestimated as an aid to increasing individual good health” but were forced to 
conclude that 'no such project is under investigation at present. This is surprising since 
the advantages of such a system are well recognized and present technological 
capabilities are more than adequate.' 
By 1965, Spencer and Vallbonna [7] were able to write of several applications of 
computers in clinical practice and included a list of problems in the use of computers as 
a clinical aid – including 'lack of clinical relevance of the data provided as computer 
input', 'the paucity of proper statistical and mathematical techniques for analysing the 
data collected', 'insufficiency of data reduction techniques', 'the difficulty in establishing 
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adequate usage of the computer by the physician' and 'equipment failures' – at least 
some of which challenges may still apply today.  
These examples of the early use of computers in medical care are notable in that they 
are all examples of the secondary use of electronic medical records data - use that goes 
beyond the original, primary, purpose for which the data were recorded. Indeed, the first 
published article discussing electronic medical records appears to be Larry Weed's 1964 
paper 'Medical Records, Patient Care and Medical Education' [8], with his PROMIS 
system in operation by the early 1970s [9]. 
For the purposes of this thesis, the definition of secondary use of clinical data proposed 
by the American Medical Informatics Association in 2007 is used: "non-direct care use 
of personal health information (PHI) including but not limited to analysis, research, 
quality/safety measurement, public health, payment, provider certification or 
accreditation, and marketing and other business including strictly commercial activities" 
[10]. 
Aickin [11] has written that challenges still remain in the re-use of existing clinical 
records as a basis for drawing research conclusions. He wrote that there is a 'paradox 
that the most prevalent conditions are also the research orphans', since it is 'difficult to 
do randomized controlled trials for these conditions' and there is a 'lack of 
generalizability of such trials to clinical populations.' Prokosch and Ganslandt [12] 
wrote of the challenges inherent in reusing medical records data, noting that 
'[c]onsideration of regulatory requirements, data privacy issues, data standards as well 
as people/organizational issues are prerequisites in order to vanquish existing obstacles'. 
D'Avolio et al [13] further discussed some of these challenges, crucially noting that 
most EMRs were designed to support clinician-patient interaction and not 'analysis of 
aggregated data as required by many secondary uses.' One effect of this is a problem 
discussed by D'Avolio et al, namely, that much potentially useful information is stored 
in medical records as free text, requiring the development of processing techniques to 
retrieve information. Kukafka et al [14] support the view that the design of electronic 
health records systems does not support the aggregated reuse of the data held in them, 
arguing the case for redesigning Electronic Health Records systems to support a 'focus 
on preventive health and socio-behavioural factors'.  Judd and Kim [15] discuss the 
feasibility of having one system that can function both as an Electronic Medical 
Records system supporting patient care and as a medical research database, concluding 
that it was possible to design a system that allowed two views into the data held within 
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– one view giving a clinician all the required information about an individual, another 
giving researchers access to the data in the system but only after the system had stripped 
out information that could be used to identify individuals. Kim et al [16], in a paper 
specifically looking at the benefits of clinical data re-use for the pharmaceutical 
industry, wrote that 'as the [USA] continues towards increasing utilization of electronic 
health records, the potential value of ancillary activities such as monitoring quality, 
assessing population health, and clinical research, is becoming possible'. 
The American Medical Informatics Association published a white paper in 2007 [10], 
which suggests that re-use of clinical data had an important role, but '[l]ack of coherent 
policies and standard "good practices" for secondary use of health data impedes efforts 
to strengthen the U.S. health care system. The nation requires a framework for the 
secondary use of health data with a robust infrastructure' [17]. A further AMIA white 
paper [18] built on the 2007 paper, suggesting possible items for inclusion in a national 
framework for reuse of clinical data. 
The UK Department of Health published a 'Summary of Responses to the Consultation 
on the Additional Uses of Patient Data' in 2008 [19], covering several topics, including 
the use of anonymised data, pseudonymised data and identifiable data.  
Examples of re-use of clinical data by computerised analysis dating back at least to the 
1950s can be found in the literature – the work of Lipkin and Hardy , Ledley and 
Lusted, and Warner have been discussed earlier in this report. More recent work on the 
reuse of clinical records stored in electronic information systems is discussed here and 
is divided into particular areas of research. 
2.2 Advantages of secondary use of clinical records data 
Aickin [11] wrote that it was worth pursuing the potential of using information held in 
clinical records since formal clinical trials were expensive and that it was 'not obvious 
that a therapy administered in the setting of a trial is the same as would be administered 
in usual care.' Others too have written of the potential for reusing existing health data 
for research: Dean et al [20] described 'the Electronic Medical Records' flexibility to 
examine large cohorts as well as identify patients with rare diseases''; Pearson et al [21] 
felt that there was potential to combine data from health records with real-time 
information from online social networking sites and mobile technologies, which would 
'undoubtedly play a role in future research efforts by making available a veritable flood 
of information, such as real-time exercise monitoring, to health researchers'. Walton et 
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al [22] noted that reuse of clinical record data 'can provide information that is 
inaccessible to randomised, controlled clinical trials, which require ethical approval and 
informed patient consent because they are prospective and experimental. These 
requirements greatly reduce the inclusion of young children, pregnant women, very old 
and very sick people, and those unable to give informed consent. However, medical 
practice includes a high proportion of such patients who are underrepresented or 
excluded from clinical trials. Furthermore, considerations of feasibility and cost often 
limit the numbers of patients exposed to a drug to a maximum of a few thousand for 
comparatively short times. Computerised databases in primary care can extend times to 
many years of continuous care and the numbers of patients to millions; this would be 
impossible to do in any other way'. 
In a large review of 136 published clinical studies, Grove et al [23] showed that "in 
general, mechanical prediction matched or out-performed expert prediction" both in 
terms of accuracy of prediction and in cost-effectiveness, though it was noted that this 
was not the case in all studies included in the review. 
 
2.3 Challenges in re-using clinical data 
 
It is not a simple matter to obtain a set of clinical data and analyse it. There are several 
areas of difficulty in doing this, in particular the identification of sources of suitable 
data, ensuring appropriate privacy and data security protection for patients who are the 
source of the data used, quality and content of the data set(s) used and homogeneity of 
coding. Elkin et al [24] has a list of some of the barriers to secondary use of clinical 
data, including issues with data interoperability (including having a common coding 
system), data being stored as free text rather than coded, errors in data entry. Other 
challenges include coding accuracy, equality of meaning, completeness and precision. 
2.3.1 Identifying and obtaining data 
One of the challenges involved in re-using clinical data for research occurs at the outset: 
identifying sources of data and gaining access to the data.  
Publications concerning research based on existing clinical records are naturally 
focussed on the outcomes of analysis of their data sets and are often written by authors 
who deal with the source clinical data as part of their normal daily responsibilities and it 
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is understandable that they do not address the challenge of obtaining a set of data to 
work with. No papers were found that specifically addressed the issue of identifying 
clinical data sets suitable for research and obtaining access to these data.  
Gaining access to identified sources of clinical data requires ethical approval to use the 
data (or an exemption from ethical approval) and the agreement of the organisation 
holding the data – which may entail some cost. 
A further potential source of data is the Personal Health Record (PHR). The PHR has 
been defined by the Medical Library Association/National Library of Medicine as "a 
private, secure application through which an individual may access, manage, and share 
his or her health information. The PHR can include information that is entered by the 
consumer and/or data from other sources such as pharmacies, labs, and health care 
providers. The PHR may or may not include information from the electronic health 
record (EHR) that is maintained by the health care provider and is not synonymous with 
the EHR. PHR sponsors include vendors who may or may not charge a fee, health care 
organizations such as hospitals, health insurance companies, or employers" [25].  
In 2008 it was been estimated that around 70 million US citizens have access to a PHR, 
through their employer, healthcare provider or health insurer 'though most patients 
would not be aware of it' [26]. However, the number of patients actively using a PHR is 
less than this figure suggests: a survey for the California Healthcare Foundation in 2010 
[27] suggested that only 7% of the US population (about 22 million people) used a 
PHR; a similar survey in early 2011 [28] found that about 10 % of the US population 
(about 31 million people) reported using a PHR. Aside from the low take-up rate, 
Zulman et al [29] in a survey of active users of PHRs  found that users of PHRs were 
not representative of general population (90% were aged over 50, 92% were male, 39% 
reported 'poor' or 'fair' health).  
No studies on the accuracy of the information entered into PHRs by patients or other 
non-professional sources were found, whether compared to information held within 
EHRs or independently Pre-dating the onset of PHRs, Harlow and Linet [30] evaluated, 
by review of the available literature, the accuracy of patients' recall of their medical 
histories (when compared to their medical records) and found that there were some 
significant differences: some conditions were more likely to be recalled by patients than 
to appear in their records (e.g. hay fever), others were less likely to be recalled (e.g. 
thyroid conditions) while other, perhaps more serious conditions were as likely to be 
recalled as to appear in their records (e.g. heart disease, diabetes).  Van Deursen et al 
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[31] propose a method of ranking reliability of data according to its source by means of 
a reputation engine, but do not assess any actual data themselves. 
 
2.3.2 Privacy of individuals and the security of their data 
When reusing clinical records data it is essential to be mindful of the privacy of the 
individuals whose data form those records, from both a legal and ethical aspect. A 
review of the literature and legislation pertaining to patient privacy and data security is 
included in section 2.6 of this literature review.  
It is important to limit access to identifiable clinical records only to those who have a 
need to see the records at any particular moment. Boxwala et al [32] investigated 
accesses to clinical records in one institution, taking a set of manually-categorized (as 
'suspicious' or 'appropriate') accesses as a gold standard for machine learning models. 
The authors note that their methods ''may not generalize because of interinstitutional 
differences', reflecting the challenges involved in re-using clinical data from different 
sources discussed in the introduction to this section. 
 
2.3.3 Data quality, coding and text-mining 
Effective re-use of clinical records data depends on that data being semantically 
consistent, accurate and complete enough for the purpose of the re-use. Ignoring image 
data, data items within records are either single values for a defined field (i.e. coded 
fields) or free text.  
Stein et al  [33] queried a clinical data set of around 5,000 discharge summaries that 
contained both coded fields and free text fields, to see whether the two types of fields 
contained information that was conflicting, confirming or complementary. Both the 
coded fields and the free text fields were searched for answers to particular clinical 
questions and the degree of concordance between the free and coded fields was 
calculated. The researchers concluded that there could be significantly disparate results 
between coded and free text fields, and that to obtain the best information it was 
necessary to search both types of field (turning to human assessment for the most 
accurate information).  A similar study by Turchin et al [34] looked at 18,000 medical 
records which contained both structured data and free text fields. They found that 
around one third of the records had events recorded in both structured and free text 
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fields, suggesting that, with two-thirds of the events recorded in only one of the 
structured and free-text fields, both types of field should be considered to obtain the 
most complete set of information. It is possible automatically to map text from clinical 
documents to codes: Friedman et al [35] describe a system that performs such work to a 
level of performance claimed to be comparable to human experts, while Turchin [36] 
utilised regular expressions to achieve a similar level of performance, reporting that 
""By some estimates free text physician notes contain over 50% of the data in the 
patient's medical record." 
Following on from a review of studies of EHR quality in primary care by Thiru [37] et 
al in 2003, Chan et al [38] published a review of the literature concerning data quality in 
electronic health records, reviewing 25 studies, each of which investigated some or all 
of data accuracy, data completeness or data comparability. They concluded that 'Issues 
related to data accuracy, completeness, and comparability must be addressed before 
routine EHR-based quality of care measurement can be done with confidence'. 
A similar review by Liaw et al [39] suggested evaluating data quality using four 
dimensions, of 'completeness, consistency, correctness and timeliness', drawing similar 
conclusions to the Chan et al study as to the need to improve data quality to allow for 
improved reuse of clinical data. 
 
2.4 Examples of clinical data re-use 
Examples of re-use of clinical data by computerised analysis dating back at least to the 
1950s can be found in the literature – the work of Lipkin and Hardy [2,3], Ledley and 
Lusted [6], and Warner [5] have been discussed earlier in this report. More recent work 
on the reuse of clinical records stored in electronic information systems is discussed 
here and is divided into particular areas of research. 
2.4.1 Syndromic surveillance 
Detection of outbreaks of diseases in populations have relied on clinicians informing 
public health bodies of patients in their care who have a notifiable condition – typically 
infectious diseases that can pose a serious health threat to an individual. Examples of 
such notifiable diseases in the UK include Legionnaires' disease, rabies and cholera 
[40]. Early identification of such outbreaks is vital for the control of the spread of these 
diseases, but delays in notification can hinder the detection of outbreaks [41]. Systems 
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based on automatic interrogation of clinical records, with the intention of improving 
both speed and accuracy of notification, have been described by several authors.  
Gesteland et al [41] report on an 'Automated Syndromic Surveillance' system installed 
for the 2002 Winter Olympics in Utah. This system took information on patient 
encounters from 28 clinics, taking free text information on the reason for patient 
presentation and coding this for analysis. Two warnings were flagged during the period 
of the Winter Olympics but these proved to be false alarms, and fortunately there were 
no genuine disease outbreaks during this period.  
Klompas et al [42] at Harvard University discuss their system for interrogating existing 
EMR data and automatically messaging information about any new cases of notifiable 
disease to the appropriate authority. This system was further developed for the 
particular case of Hepatitis B, scanning electronic medical records data for laboratory 
test results that would indicate the presence of hepatitis B [43]. Also from Harvard, 
Calderwood et al [44] discuss the algorithm they used to predict the presence of TB in 
patients, based on coded data in the records, determining that 'Live, prospective 
[tuberculosis] surveillance using EHR data is feasible and promising'. 
Hripcsak et al [45] compared the use of structured data with free text information for 
syndromic surveillance, concluding that structured data performed best but required 
knowledge of the structure of the health records system, whereas the free text 
information performed less well but had applicability to a broader range of systems. 
Buckeridge et al [46] developed a model that they suggest can be used as the basis for 
comparing different detection algorithms for their performance.  Dailey et al[47] 
compared sources of data that are used to detect influenza outbreaks, including sources 
outside hospital records, including over-the-counter pharmaceutical sales and work 
absenteeism. 
 
2.4.2 Performance and care quality measurement 
Records have long been used in hospitals to keep a record of the number of patients 
examined or treated, to measure the quantity of work performed for the purposes of 
reimbursement. Korner Units were commonly used in the UK National Health Service, 
which quantified the workload of each treatment episode [48]. 
Several researchers have investigated the potential to analyse the information held 
within clinical records for the purposes of performance measurement and measurement 
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of the quality of care received by patients. Owen et al [49] performed a feasibility study 
to see if the data held in an Electronic Medical Record system could be used to measure 
the quality of treatment of schizophrenia patients, deciding that it was possible to 
perform such measurements but that "electronic recording of depot prescriptions was 
possible but usually incomplete ... providers and facilities should improve recording so 
that automated data could be used to more accurately monitor and improve ... 
medication management for schizophrenia." Voorham and Denig  [50] performed a 
study evaluating the feasibility of using free text data to extract the information required 
to assess the quality of care of diabetes patients, concluding that this was a practical 
technique. Also in the area of diabetes care quality measurement by use of free text data 
was studied by Pakhomov et al [51], who looked at findings from foot examinations 
(which are part of the programme of diabetes care), and again concluding that such 
automated analysis was practical. 
Another study that relied on the processing of free text to assess quality of care was that 
of Chiang et al [52] who took quality control measures from electronic discharge notes 
in order to estimate the standard of care, claiming "reasonable agreement with medical 
experts." Chan et al [53] developed a process to assess the quality of co-ordination 
during the patient's transition from primary care to specialist care, although their method 
required recording of data additional to that recorded as standard in the records systems. 
The problems of using information sourced from several records systems were 
addressed by Lee et al [54], who described a "virtual medical record", a single 
repository for key data extracted from different systems, from which quality indicators 
were calculated.  
2.4.3 Outcomes research 
Dean et al [20] published a literature review of research covering the use of electronic 
medical records for outcomes research, for papers published between 2000 and 2006, 
finding 126 studies. It was noted that the number of studies published increased with 
each year, reflecting perhaps the increased uptake of EMR systems over this time period 
and the increased interest in using EMR systems as a source of data for research. The 
authors concluded with a comment that reflects others' concerns: “It is essential that 
standardized terms and codes be incorporated into EMR data for EMR-based research to 
be translated into clinical best practices.” 
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2.4.4 Specific outcomes predictions for individual patients 
Prediction of patient outcomes following admission or treatment has been studied by 
several researchers. Himes et al [55] used a Bayesian network model to identify the 
clinical factors which could be used to predict asthma patients' progression to chronic 
obstructive pulmonary disease, taking data from the clinical records of one organisation. 
Testing on a set of nearly 10,000 patients achieved an accuracy of 83%. 
A tool to predict an individual's chance of developing type II diabetes within the next 10 
years was developed by Hippisley-Cox et al [56], who used a Cox proportional hazards 
model to estimate the effects of various risk factors.  
Sebastiani et al [57], having selected a cohort of patients which covered all common 
phenotypes of sickle cell disease, used Bayesian network modelling to estimate the risk 
of death within the next 5 years, taking this as a measure of sickle cell disease severity. 
Their technique identified new markers, in addition to previously known risk factors, 
that contributed to the calculation of the risk score. 
 
2.4.5 Decision support 
A clinical decision-support system (CDSS) is, in its broadest definition, "any computer 
program designed to help health professionals make clinical decisions" [58]. Output 
from these programs can be derived from existing knowledge, from individual cases 
using artificial intelligence (AI) methods or from a combination of both; a variety of AI 
methods can be used, including rule-based reasoning, Bayesian inference, artificial 
neural networks and case-based reasoning. 
Case-based reasoning (CBR) aims to solve new problems by "finding, adapting and 
reusing solutions to previously encountered problems" [59]. Useful introductions to this 
technique are given in Kolodner [60], Schmidt et al [61] and Yusof and Buckingham 
[62]. Recent developments are described by Bichindaritz and Marling [63] and 
Bichindaritz and Montani [64], who describe the CBR process from a physician's 
viewpoint. They list key application areas for CBR as being diagnosis, treatment 
planning, image analysis, long-term follow-up, quality control, tutoring and research 
assistance. A useful introduction to the usefulness of CBR is given by Ting et al [65], 
although they do note that "Despite numerous researches showing CBR is effective in 
problem-solving in the medical domain, several researchers argued that the chance of 
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reusing a case from CBR is not high in some areas, such as ... multiple medical disorder 
cases". 
Applications in the medical literature have generally utilised this technique to assist 
clinicians by employing information on similar previous cases to those under current 
consideration. For example, Kahn and Anderson [66] used CBR in a system that 
suggested the most appropriate diagnostic imaging procedure (within the ultrasound and 
computed tomography domains only), based on text information within case histories to 
choose the imaging procedure. Their study used 200 cases as the training set. Marling 
and Whitehouse [67] developed a system to aid in the care of Alzheimer's Disease, 
using CBR to determine whether a patient would benefit from administration of 
neuroleptic drugs, but using a rule-based procedure to choose precisely which of the 
available drugs should be prescribed. This study used 28 cases in its training set. In a 
study utilising 166 patients in their training set, Chuang et al [68] investigated using 
CBR with several other classification methods to support liver disease diagnosis, 
concluding that a hybrid model of CBR with back-propagation neural network gave the 
most accurate diagnosis results. 
These studies take data, including outcomes data, from similar prior cases in order to 
help with decisions on care for newly-presenting cases. A key component of a CBR 
system is the task of finding similar matching cases has been addressed by researchers 
including. O'Sullivan et al [69] and van den Branden et al [70]. 
2.4.6 Drug actions and reactions 
An active area of research is the study of identifying adverse drug reactions from 
medical records. Honigman et al  [71], performing a retrospective analysis of data from 
an electronic medical record system, were successful in identifying adverse drug 
reactions, finding that "free-text searches were especially useful." Working exclusively 
with free text, Wang et al [72] processed discharge summaries to identify medications 
and adverse reactions, relying on natural language processing to do this. 
Nadkarni [73] describes the problems in detecting adverse drug reactions using existing 
medical records data and in particular identifying problems with using ICD-9 and 
SNOMED CT, suggesting that free text fields can help with better detection of adverse 
events. Savova et al [74] looked at drug treatment patterns, rather than adverse events, 
combining drug treatment events from free text fields in clinical records with data from 
a prescribing system.    
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2.4.7 Identifying patients suitable for trials or other analysis 
Wilke et al [75] describe a system for identifying patients with diabetes from electronic 
medical records. When searching using solely diabetes diagnosis codes they found false 
positive rates of up to 44 %; much reduced after implementing an algorithm that also 
included laboratory data and medical history. Kho et al (2012) also searched electronic 
medical records for diabetes patients, developing an algorithm that used a combination 
of diagnoses, medications and laboratory results. Subjects were identified across 
different records systems, with "the use of standard terminologies to define data 
elements ... across five different institutions"" noted as being key to the success of the 
work,  
Clark et al [76] looked at free text in clinical reports to determine whether patients were 
smokers or non-smokers (or "unknown" if no references to smoking were found), 
reporting an accuracy of above 90 % in their data sets. 
Attempting a more general approach to identifying patients for research purposes, 
Yamamoto et al [77] developed a system to identify patients from a single hospital 
medical records system based on appropriate clinical research criteria. They noted that 
"Enabling medical records retrieval system use in and across multiple institutions is an 
important future task." 
 
2.4.8 General health outcomes events prediction 
For more general health event predictions (i.e. predictions of likely future conditions, 
based on records of previous health events), fewer publications were found. McCormick 
et al [78] give a primarily theoretical description of a Bayesian hierarchical model for 
the selection of association rules, testing their method on a sample of patients from a 
clinical trial, predicting future medical conditions on the basis of common clinical 
histories. 
2.5 Methods of analysis 
Aickin [11] compared the maturity of analysis techniques used in clinical trials data 
with those techniques employed on data acquired during clinical practice, stating that 
'Methods of analysis that deal with the biases caused by lack of a research intervention 
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have not been developed to the same degree as methods for intervention trials.' This is 
not to say, however, that work has not been done on clinical practice data.  
Doddi et al [79] studied medical insurance claims records, which included information 
on medical procedures and diagnosis, to see if there was an association between 
procedures and diagnoses, looking for association rules using similar techniques to 
market basket analysis (a technique used in retail business management to identify 
which products are most often bought together, in order to make predictions or 
recommendations of other products that the customer may purchase –– see, for example, 
Tan et al [80] for a description of this technique).  Tsui et al [81] used Bayesian text 
classifiers to analyse messages from health systems in real time, for subsequent 
statistical analysis in order to detect disease outbreaks. Investigating models for disease 
outbreak detection more deeply, Jiang and Cooper [82] took retrospective data from one 
US hospital's emergency department for one year, injecting synthetic data to simulate 
disease outbreaks. They used a Bayesian network framework to identify the disease 
outbreaks by time and geographic location. Also working in the area of disease outbreak 
detection, Que and Tsui [83] introduced a 'rank-based spatial clustering algorithm' as an 
alternative method for identifying disease outbreaks, claiming improved computational 
efficiency over previous methods. 
Creighton and Hanash [84] developed an algorithm for mining association rules from 
genome data, although they did not suggest that this technique could be applied to 
clinical events.  
A primarily theoretical paper on prognostic Bayesian networks was published by 
Verduijn et al [85], describing the potential for using this technique to clinical data. This 
paper was accompanied by a second paper [86] describing an application of this 
technique for predicting mortality following cardiac surgery. Also in the same year, 
Reynolds et al [87] described the use of Bayesian belief networks with test results from 
a variety of sources, giving an example of the use of this method for classifying 
tumours. Other examples of the use of Bayesian networks for clinical prediction have 
been given in the work of van Gerven et al [88] and Sakai et al [89]. 
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2.6 Data privacy and security 
2.6.1 Introduction 
A key consideration in the re-use of data obtained from real patients is the 
confidentiality of the patients who are the source of the data. This section of the report 
describes the current thinking around confidentiality issues - thinking that is both 
influenced and captured by legislation, codes of practice and recommendations from 
professional bodies concerned with patient care.  Confidentiality of medical records that 
are made available to researchers not directly involved in a patient's care is primarily 
achieved by anonymising or pseudo-anonymising the medical records. 
 
2.6.2 Review of the legal issues 
A literature review was performed with the aim of achieving an understanding of the 
issues relating to confidentiality, in particular anonymisation and pseudo-anonymisation 
(hereafter referred to as 'pseudonymisation', as is common in the healthcare literature), 
including definitions of terminology; the need for anonymisation and/or 
pseudonymisation; legal requirements, including relevant permissions required; 
techniques for anonymisation and pseudonymisation; risks of re-identifying patients 
from anonymised or pseudonymised data; and any other issues with use of patient-
derived health records. 
The NHS Confidentiality Code of Practice defines the terms 'anonymised' and 
'pseudonymised'' and their definitions and spellings are those adopted within this report, 
unless an original publication is being quoted. Their definitions are given here: 
“This is information which does not identify an individual directly, and which cannot 
reasonably be used to determine identity. Anonymisation requires the removal of name, 
address, full post code and any other detail or combination of details that might support 
identification.” 
“Pseudonymised Information: This is like anonymised information in that in the 
possession of the holder it cannot reasonably be used by the holder to identify an 
individual. However it differs in that the original provider of the information may retain 
a means of identifying individuals. This will often be achieved by attaching codes or 
other unique references to information so that the data will only be identifiable to those 
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who have access to the key or index. Pseudonymisation allows information about the 
same individual to be linked in a way that true anonymisation does not.” 
2.6.3 Legal requirements and professional guidance 
The Hippocratic Oath, dating from the 5
th
 Century BC, includes the words 'Whatever I 
see or hear in the lives of my patients, whether in connection with my professional 
practice or not, which ought not to be spoken of outside, I will keep secret, as 
considering all such things to be private' [90] and this requirement to keep information 
about a patient private remains. The General Medical Council writes that [the] “duty of 
confidentiality continues after a patient has died.”  [91] 
Kalra et al, quoting the European Parliament, noted that  “data protection, and therefore 
the need for consent, does not apply if the data have been anonymised and the 
individual cannot be identified through linking the information to other publicly 
available data” [92, 93]. This requirement was enacted in UK law in the Data Protection 
Act of 1998 [94] and subsequently in the Data Protection Act 2018 [95]. A decision by 
the English Court of Appeal in 1999 ruled that use of anonymised patient data for 
research did not breach confidentiality [96]. 
Bourke and Wessely [97], writing from the UK, in a review of confidentiality issues in 
various areas of medical practice and research state that "data may be fully anonymised 
so that individual patients cannot be identified, in which case the Data Protection Act 
does not apply." Legislation and other literature relevant to issues of patient 
confidentiality are listed at the end of this section. 
In the UK, the Department of Health's 1997 'Report on the Review of Patient-
Identifiable Information' [98], known colloquially as ''The Caldicott Report', reviewed 
the use and transfer of patient-identifiable information from between NHS organisations 
and from NHS to non-NHS organisations, making recommendations that should be 
implemented to safeguard patient privacy. A second report by the Caldicott Committee, 
(''Caldicott 2') was published in early 2013 [99]. 
 
2.6.4 The General Data Protection Regulation (GDPR) 
 
Data protection regulations in the UK are now led by the General Data Protection 
Regulation (GDPR) of the EU (Regulation (EU) 2016/679) of 27th April 2016 [100],  
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enacted into UK law on 23rd May 2018 by the Data Protection Act 2018 [95], although 
since it was enacted as a Regulation rather than a Directive the GDPR did not require 
UK legislation to become legally enforceable in the UK. Cornock [101] notes that the 
changes over the last two decades in the amount of information available on individuals, 
how that data is collected and the uses to which it can be put mean that the original 
1995 directive is ' no longer fit for purpose’. Article 5 of the GDPR contains the seven 
principles of the Regulation, these being noted by Chico [102]: 
[The GDPR requires] “that personal data is processed:   
(a) lawfully, fairly and in a transparent manner;  
(b) collected for specified, explicit and legitimate purposes and not further processed in 
a manner; that is incompatible with those purposes (purpose limitation);  
(c) adequate, relevant and limited to what is necessary; in relation to the purposes for 
which they are processed (data minimization);  
(d) accurate and, where necessary, kept up to date (accuracy);  
(e) kept in a form which permits identification of data subjects for no longer than is 
necessary (storage limitation);  
(f) in a manner that ensures appropriate security (integrity and confidentiality);  
(g) in a way which demonstrates compliance (accountability).” 
Chico goes on to state that Article 5.1(b) of the GDPR says that ‘There is an exception 
to the ‘purpose limitation’ principle for scientific research (see principle (b) above) 
which states: further processing for archiving purposes in the public interest, scientific 
or historical research purposes or statistical purposes shall, in accordance with Article 
89(1), ‘not be considered to be incompatible’ with the initial purposes’ (Article 5 1. (b)’ 
and is thus ‘a significant relaxation of the restrictions on repurposing personal data for 
scientific research purposes’. 
 
The GDPR also includes some definitions of terms, which it is useful to note here: 
“Pseudonymisation” means the processing of personal data in such a manner that the 
personal data can no longer be attributed to a specific data subject without the use of 
additional information, provided that such additional information is kept separately and 
is subject to technical and organizational measures to ensure that the personal data are 
not attributed to an identified or identifiable natural person (Article 4, Recital 30(5).  
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“Anonymous information” is defined as information which does not relate to an 
identified or identifiable natural person or to personal data rendered anonymous in such 
a manner that the data subject is not or no longer identifiable (Article 4, Recital 26) 
“Identifiers” are pieces of information which are closely connected with a particular 
individual which could be used to single him out (Recital 159). 
“Personal data” means any information relating to an identified or identifiable natural 
person ('data subject'); an identifiable natural person is one who can be identified, 
directly or indirectly, in particular by reference to an identifier such as a name, an 
identification number, location data, an online identifier or to one or more factors 
specific to the physical, physiological, genetic, mental, economic, cultural or social 
identity of that natural person (Article 4:1). 
 
Mourby et al [103] quote advice from the UK Information Commissioner’s Office that 
‘pseudonymised data may be personal data or may be considered to be anonymised, 
depending on how easy it is to obtain the pseudonym keys’. Olimid et al [104] state that 
the GDPR does not apply to anonymous data, according to Recital 26 of the GDPR; the 
GDPR ‘recognizes the difference between two main categories of data: personal data 
and anonymous data’. Furthermore, quoting Schaar [105]“complete anonymisation of 
data is no longer explicitly required” . 
 
The current GDPR legislation in Article 22:1 includes a ‘right to explanation’ of 
individuals regarding how decisions about them have been made. The individual ‘shall 
have the right not to be the subject to a decision based solely on automated processing, 
including profiling, which produces legal effects concerning him or her or similarly 
significantly affects him or her.’ Further, the GDPR in Article 22 Paragraph 4 states that 
decisions “which produces legal effects concerning him or her” or are of similar 
importance shall not be based on the following categories of personal data specified in 
Article 9 Paragraph 1: 
    …personal data revealing racial or ethnic origin, political opinions, religious or 
philosophical beliefs, or trade union membership, and the processing of genetic data, 
biometric data for the purpose of uniquely identifying a natural person, data concerning 
health or data concerning a natural person’s sex life or sexual orientation. 
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There is currently some debate on how this right is to be interpreted and implemented in 
practice. Wachter et al [106] in a paper entitled ‘Why a Right to Explanation of 
Automated Decision-Making Does Not Exist in the General Data Protection 
Regulation’, take the position that it is sufficient to inform individuals that their data has 
been used by an algorithm(s) to make decisions about them, giving them the basic 
design of the algorithm, but would not require giving details of any algorithms used. 
Wachter et al note that GDPR Article 22 Paragraph 3 states that a data controller “shall 
implement suitable measures to safeguard…at least the right to obtain human 
intervention on the part of the controller, to express his or her point of view and to 
contest the decision”, otherwise a person has “the right not to be subject to a decision 
based solely on automated processing”; they go on to say that this does not appear to be 
a legally-binding ‘right to explanation’. 
However, Goodman and Flaxman [107] quote Articles 13 to 15 of the GDPR as giving 
persons the right to be told the purpose of collecting data about them and the right to 
access that data, including the right to receive “meaningful information about the logic 
(algorithm) and possible impact.”  
Selbst and Powles [108] discuss both the Goodman and Flaxman [107] and the Wachter 
et al [106] interpretations of the Regulation, concluding that there is a right to 
explanation but that this right should be interpreted ‘functionally [and] flexibly”. 
In summary, it appears that the GDPR allows for research use of data for purposes 
beyond which those data were originally collected, provided that the data is protected by 
anonymization or, provided that the keys are strongly protected, pseudonymisation. 
Legislation, guidance and codes of practice. This suggests that the work described in 
this report remains compliant with UK and EU law, as it did at the commencement of 
the work.It is unclear as yet as to how strictly the ‘right to explanation’ will be 
interpreted, however the algorithms explored are explainable. 
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2.6.5 Legislation and other literature relevant to issues of patient 
confidentiality 
There is a substantial body of legislation, guidance, codes of practice and 
recommendations relevant to the storage, use, transmission, protection and 
anonymisation of health records in the UK. The key documents are listed here: 
 UK legislation 
o Data Protection Act 1998 [94] 
o Human Rights Act 1998 [109] 
o Access to Health Records Act, 1990 [110] 
o Computer Misuse Act, 1990 [111] 
o Freedom of Information Act, 2000 [112] 
o Regulation of Investigatory Powers Act, 2000 [113] 
o Common Law 
o Copyright, Designs & Patents Act, 1988 [114] 
o Data Protection Act 2018  [95] 
  European Union legislation 
o Data Protection Directive, 1995 [93] (note: now repealed and 
superseded by the GDPR of 2016) 
o General Data Protection Regulation (GDPR), 2016 [100]  
  Guidance papers, codes of practice 
o Caldicott report [98] 
o NHS Care Records Guarantee 2011 [115]  
o NHS Confidentiality Code of Practice [116]  
o CfH Pseudonymisation Implementation Project [117] 
o Data Protection & Medical Research [118]  
o Anonymisation: managing data protection risk code of practice [119] 
o Guidance Regarding Methods for De-identification of Protected Health 
Information in Accordance with the Health Insurance Portability and 
Accountability Act (HIPAA) Privacy Rule Recommendations [120] 
o Confidentiality as part of a bigger picture--a discussion paper from the 
BMA [121] 
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2.6.6 Why anonymise or pseudonymise the patient data? 
The right to use data derived from patients' records must be considered. A statement 
from the British Medical Association that 'Legally and ethically health professionals are 
responsible to patients for the confidentiality of the health information they hold.... there 
should be no use or disclosure of any confidential patient identifiable information 
gained in the course of professional work for any purpose other than the clinical care of 
the patient to whom it relates' [121] which reflects existing UK and European legislation 
governing the use of personal information, and implies that disclosure of clinical data 
obtained from patients to individuals other than those responsible for their care requires 
the removal of patient identifiable information. The implications for secondary use of 
clinical data are that the anonymisation or pseudonymisation process must be robust and 
non-reversible (except for cases where pseudonymised data should be traced back to the 
original patient, requiring relevant permissions so to do). The process should be 
reversible only when there is a potential benefit to the patient in doing so and when 
permission has been agreed by the patient's carer(s) that this re-identification can be 
done. 
2.6.7 Techniques for anonymisation and/or pseudonymisation 
The basic technique for achieving patient privacy when their records have a secondary 
use (e.g. in health research) is to remove those parts of the record that can be used to 
identify the patient. Some identifiers are obvious – the patient's name, for example – but 
others are not so immediately obvious – for example, should the patient live in a small 
community and within that community be the only sufferer from a particular disease.  
Also, simply removing identifying information and leaving the field blank or entering 
randomised information may not be in the patient's best interest; Pommerening [122] 
notes that "it could be important for the patient ... to learn about the results of a research 
project, for example, a genetic disposition." 
The Health Insurance Portability and Accountability Act (HIPAA) of 1996 [123] lists 
18 identifiers that need to be removed from patient information for it to be considered 
anonymous. Although HIPAA is American legislation having no jurisdiction in the UK, 
these identifiers provide a useful checklist when deciding whether patient data has been 
appropriately anonymised. A summary of the 18 items in the list is given in Table 2.1. 
As an alternative to removing the 18 identifiers, HIPAA also allows for 'professional 
statistical analysis and opinion regarding de-identification', deeming information to be 
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de-identified for HIPAA purposes if a person “with appropriate knowledge and 
experience” deems that the risk of re-identification of an individual or individuals is 
'very small'' (all quotes from US Department of Health and Human Services guidance 
[120]). 
 
Item number Item 
1 Names 
2 Geographical subdivisions smaller than a State, including street address, 
city, county, precinct, zip code, and their equivalent geocodes 
3 All elements of dates (except year) for dates directly related to an 
individual, including birth date, admission date, discharge date, date of 
death 
4 Telephone numbers 
5 Fax numbers 
6 Electronic mail addresses 
7 Social Security number 
8 Medical record numbers 
9 Health plan beneficiary numbers 
10 Account numbers 
11 Certificate/license numbers 
12 Vehicle identifiers and serial numbers, including license plate numbers 
13 Device identifiers and serial numbers 
14 Web Universal Resource Locators (URLs) 
15 Internet Protocol (IP) address numbers 
16 Biometric identifiers, including finger and voice prints 
17 Full face photographic images and any comparable images; 
18 Any other unique identifying number, characteristic, or code (note this 
does not mean the unique code assigned by the investigator to code the 
data) 
Table 2.1 HIPAA patient identifiers [123] 
In the UK, the Information Commissioner's Office has produced guidance on 
anonymisation [119], though not specific to health records. The guidance states that 
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"The current Data Protection Directive, dating from 1995, says that the principles of 
data protection shall not apply to data rendered anonymous in such a way that the data 
subject is no longer identifiable. It also says that a code of practice can provide guidance 
as to the ways in which data may be rendered anonymous and retained in a form in 
which identification of the data subject is no longer possible", adding that "The DPA 
does not require anonymisation to be completely risk free – you must be able to mitigate 
the risk of identification until it is remote." The guidance also draws a distinction 
between a general release of data and a more limited release, to known individuals or 
organisations, to which conditions can be attached. 
2.6.8 Re-identification risk for individuals 
There are many papers in the literature discussing work carried out on the risks of re-
identifying patients from their medical records, even after key identifiers have been 
removed. Several researchers have identified free-text fields that may appear in medical 
records as an area of potential weakness. For fields that contain well-defined data items 
that can be used to identify patients (e.g. name, date of birth), it is clear that the original 
data in these fields must be removed or disguised. Free text fields, however, present a 
greater challenge – they contain clinically important information but may also contain 
information that can identify the patient. Dorr et al [124] describe the difficulties in 
ensuring all such identifiers are removed from medical records prior to making them 
available to researchers, concluding that a significant time input is needed to manually 
remove identifiers, and that automated removal is difficult. Beckwith et al [125], 
however, describe an open source software tool that attempts to find identifiers in 
pathology reports and they claim a high degree of success in doing this. Neamatullah et 
al [126] also describe a software tool that attempts to de-identify free text in medical 
records to HIPAA requirements, again claiming a high degree of success.  
2.6.9 Patient attitudes towards secondary use of de-identified clinical data 
A survey for the NHS Information Authority in 2002 [127] found that "people felt that 
any information released outside of the NHS, or used inside the NHS for purposes other 
than treatment, should be anonymised - or patient permission sought to use identifiable 
data. Once information was anonymised, a majority ... were happy not to be asked for 
consent to share it."  
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In a survey from Ireland, Buckley found that "89.5 % [of survey respondents] said they 
would agree to ... allowing the sharing by GPs of anonymous personal health 
information with researchers without the need for consent" [128]. 
In New Zealand, Whiddett et al [129] surveyed 200 patients, finding that although they 
were generally unwilling to have their information shared with "other [non-health 
professional] stakeholders such as ... researchers", "they were more prepared to share 
anonymous information." Again in New Zealand, Parkin et al [130] report the results 
from a "citizen's jury" who unanimously concluded, after discussion, that "researchers 
contracted by a public body should be permitted to use medical information about 
identifiable people, without their consent" provided that "existing ethical guidelines and 
relevant laws" were followed. 
Page and Mitchell in Canada [131] found that, of the 278 patients they surveyed, "the 
majority of subjects wanted to be asked for their consent unless anonymity was 
assured." 
2.7 Predictive Analytics 
 
Predictive analytics has been defined by Kelleher et al [132] as ‘the art of building and 
using models that make predictions based on patterns extracted from historical data’. 
Cousins et al [133]have written “Predictive modeling tools incorporate mathematical 
formulas that allow users to interpret historical data and make predictions about the 
future. More specifically, these tools are used to create a predictive model by mapping 
associations and their statistical relationships among data elements to a specific target. 
The empirically derived model is then used to forecast future events based upon the 
identified relationships.” Steyerberg [134] notes that ‘prediction is primarily an 
estimation problem’ and introduces specific areas in healthcare where such estimation 
can be of benefit to individuals: Screening, diagnosis, therapy impact. There are a 
variety of techniques available to build these predictive models and these will be 
discussed in this section. Particular reference will be made to work that has repurposed 
data from electronic health records. Goldstein et al write that “there are multiple 
advantages to EHR-based risk prediction ...  allows one to observe more metrics, on 
more individuals, at more time points, and at a fraction of the cost of prospective cohort 
studies. One can use the same set of data to predict a wide range of clinical outcomes – 
something not possible in most cohort studies. As data are sometimes observed with 
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greater frequency … it is also easier to predict near-term risk of events. Furthermore, 
patient populations derived from the EHR may be more reflective of the real-world than 
cohort studies that rely on volunteer participation.” However, Rose notes that “it is 
critical to remember that these data are not collected to answer specific research 
questions, which is a central difficulty in relying on them for these purposes.” 
It has been a long established ambition to be able to prediction future health states and 
events from previous knowledge. Rahe et al in 1970 [135], for example, aimed to 
predict near-future health events in sailors based on information about their recent-years 
life events gathered by questionnaire. They concluded that there was a positive 
correlation in the rank-order of recent life events and illnesses experienced by the 
sailors during the 8 months of the study.  
A number of techniques have been described in the literature. Steyerberg [134]writes 
that “Statistical models for medicine can be discerned in main classes: regression, 
classification, and neural networks”. Islam et al [136] identify several main areas of data 
mining techniques:  
• Regression - Relationship estimation between variables 
• Association - Finding relation between variables 
• Classification - Mapping to predefined class based on shared characteristics 
• Clustering - Identification of groups and categories in data 
• Anomaly - detection Detection of out-of-pattern events or incidents 
• Sequential pattern mining - Identification of statistically significant patterns in a 
sequence of data 
 
Common techniques found in the literature are briefly introduced, together with 
examples from the literature of work done using these techniques. 
2.7.1 Linear regression  
Regression analyses aim to describe the relationship between dependent variable(s) and 
independent variables. Linear regression particularly analyses the linear relationship 
between a dependent variable, which must be continuous, and one or more independent 
variables, which may be continuous, binary or categorical. An introduction to linear 
regression is given by Schneider et al[137].   
Work done using linear regression models includes that of Flemons et al [138], who 
used this method to predict the likelihood of sleep apnoea in 200 patients, of whom 82 
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were diagnosed with sleep apnoea, finding that their model was ‘superior to physician 
impression’. More recently, in 2018, another clinical prediction rule using linear 
regression was developed by Sanchez-Santos et al [139], whose model predicted the 
likelihood of patient-reported pain after total knee replacement. Combes et al [140]used 
linear regression techniques to predict hospital length of stay following admission to an 
emergency department, concluding that although there were limitations to their model, 
perhaps because of non-linearity in the data, the simplicity of their model meant that the 
medical staff using it could understand it. 
 
2.7.2 Logistic regression 
 
Logistic regression analyses the relationship between a binary dependent variable and a 
set of independent variables. Unlike linear regression, which aims to predict the value of 
a dependent variable from the set of independent variables, logistic regression aims to 
predict the category of the dependent variable from the set of independent variables, for 
example presence or absence of a disease. 
This was a very common method found for creating predictive models in healthcare. 
Recent work employing logistic regression models includes that of Devin et al [141] 
who developed a model to predict the likelihood of return to work 3 months after 
cervical spine surgery; - A predictive model and nomogram for predicting return to 
work at 3 months after cervical spine surgery; Park et al [142], who used information 
held within Electronic Health Records to predict future incidence of Alzheimer’s 
Disease; and Kim et al [143], who used linear regression to predict osteonecrosis of the 
jaw following dental extraction. Kim et al compared their logistic regression model to 
other methods, concluding that it worked better than decision tree model but not as well 
as random forest, neural network or support vector machine, although their logistic 
regression model had the advantage of explainability. Other work using logistic 
regression includes D’Agostino’s work [144] on cardiovascular risk profiles for 
calculating patient risk of heart disease as part of the Framingham Heart Study; 
Chhatwal et al [145]who used logistic regression methods to aid breast cancer 
diagnosis; Singal et al [146], who used the technique to identify cirrhosis patients who 
were at raised risk of re-admission to hospital; and Jacobs et al [147] who used the 
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method to combine three diagnostic methods in order to predict the risk of individual 
women having ovarian cancer. 
In a recent systematic review, Christodoulou et al [148]have shown that they found no 
performance benefit of machine learning over logistic regression for clinical prediction 
models, although there was some suggestion that other techniques could perform better 
on data with a large (>100) number of variables.  
 
2.7.3 K Nearest Neighbours 
 
Another long-established technique is k nearest neighbours. “K-nearest neighbor 
classification involves retrieving the nearest neighboring entities to a new entity and 
assigning a category, or set of categories, to this new entity based on those already 
assigned to other entities in the space.” [149] Another conceptually simple technique, it 
has long-standing popularity. Many researcher have used the method to leverage 
similarity in patient records or other patient-related data, for example in 2017 Tayeb et 
al [150] used the method to predict medical conditions in individuals by inspecting 
conditions in similar patients; similarly, Zhu et al [151]matched new patients to existing 
patients in a community care database in rural Canada to the predict rehabilitation 
potential of the new patient, concluding that the method was an improvement over the 
existing clinical assessment protocol. 
A common application of the k nearest neighbours method is in predicting or detecting 
heart disease: Polat et al [152] used the technique for this purpose in 2007, as did 
Shouman et al [153] in 2012 and Enriko in 2016 [154], all claiming success for the 
technique. 
 
2.7.4 Neural Networks 
 
A Neural network is "a computer program that operates in a manner inspired by the 
natural neural network in the brain. The objective of such artificial neural networks is to 
perform such cognitive functions as problem solving and machine learning. The 
primary appeal of neural networks is their ability to emulate the brain’s pattern-
recognition skills" [155] Neural networks are another technique that is frequently 
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applied to making predictions from medical records. Rajkomar et al [156] have applied 
the technique to “predicting multiplemedical events from multiple centers”, achieving 
high accuracy for in-hospital mortality, 30-day unplanned readmission, prolonged 
length of stay and final discharge diagnoses and concluding that the technique 
“outperformed traditional, clinically-used predictive models in all cases.” Pham et al 
used a similar approach to predict future health events from medical records, as did 
Chen et al [157]. Ma et al combined neural networks with medical knowledge for their 
risk prediction method, stating that their method “outperformed existing risk prediction 
models.” 
 
2.7.5 Naïve Bayes 
 
“The Naïve Bayes classifier is a family of simple probabilistic classifiers based on a 
common assumption that all features are independent of each other, given the category 
variable” [158. Much work has been done using this method for the prediction and 
identification of heart disease and breast cancer. Hollon et al {Hollon, 2018 #259]used 
this method to predict early outcomes after pituitary adenoma. 
 
2.7.6 Decision trees 
 
“Decision trees are sequential models, which logically combine a sequence of simple 
tests; each test compares a numeric attribute against a threshold value or a nominal 
attribute against a set of possible values. Such symbolic classifiers have an advantage 
over “black-box” models, such as neural nets, in terms of comprehensibility. The logical 
rules followed by a decision tree are much easier to interpret than the numeric weights 
of the connections between the nodes in a neural network” [159] 
Decision trees have been successfully used in many predicitive and prognostic models, 
incuding in work by Lynch et al [160], who used the method to predict lung cancer 
patient survival; and Scheer [161], who developed a preoperative predictive model for 
pseudoarthritis. 
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2.7.7 Clustering 
 
The clustering method involves grouping objects or records together in some way such 
that those objects in a cluster are more ‘similar’ to each other than to objects in other 
clusters. Hivert et al [162]used this method to identify primary care patients who were 
at risk of future diabetes or cardiovascular disease, based on information in their and 
others’ medical records. 
2.7.8 Collaborative filtering 
 
Collaborative filtering is a method used primarily in recommender systems, where 
information on an individual’s past behaviour, for example purchasing history, can be 
used to predict future behaviour by comparing them to others with similar histories. It 
“analyzes relationships between users and interdependencies among products, in order 
to identify new user-item associations. For example, some CF systems identify pairs of 
items that tend to be rated similarly or like-minded users with similar history of rating 
or purchasing to deduce unknown relationships between users and items. The only 
required information is the past behavior of users, which might be their previous 
transactions or the way they rate products.” This method can be extended into 
healthcare, substituting medical event history for purchasing history, and patients for 
users.  
Less work utilising the collaborative filtering method was found in the healthcare 
domain, however one paper, by Davis et al [163], used the method. In their work, Davis 
et al used collaborative filtering techniques on a large (13,039,018) database of 
Medicare records of elderly people in the USA to predict their future health risks. They 
utilised the structure of ICD-9-CM in order to collapse disparate 5-digit codes to 
aggregate 4- or 3-digit codes, although they noted that this code collapse did not always 
improve their results. They conclude that their system performed “well” at capturing 
future disease risks. 
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2.8 Code mapping 
Medical records since their inception have contained free text, with medical conditions 
and symptoms described by natural language terms that may be imprecise or 
ambiguous. Recent decades have seen a steady increase in the uptake of electronic 
health records (EMR) systems [164, 165]. There are now a large number and variety of 
terminologies used to code events recorded in these EMR systems, with it being 
estimated that there are over 100 terminologies currently in use [166]. For aggregation 
of data or analysis over time, a controlled, pre-defined vocabulary is required, with 
codes representing concepts that allow for descriptive synonyms [167]. A number of 
coding systems have been created over recent decades, including the International 
Classification of Diseases [168]; the Read Codes [169], the most common system in UK 
primary care, which in its latest iteration is Clinical Terms Version 3 (CTV3) but is 
most commonly used in version 2; and SNOMED CT [170], the largest coding system 
in terms of number of concepts. Modern electronic health records systems may use any 
of these existing systems, with different countries or regions favouring one system over 
another: in 2001, de Lusignan et al [171], in a survey of systems in use in Europe, found 
that the Read Codes were the most common system in use in primary care in the UK, 
ICD-10 the most common in primary care in Austria and Germany, and ICPC in a 
further 10 European countries. ICD-9, until its recent supersession by ICD-10, has been 
the dominant system in primary care in the USA.  
There are several reasons why it may be necessary to move from one coding system to 
another: government mandate; the desire to use an up-to-date coding system; 
compatibility with other data repositories, e.g. in a newly-shared EHR system; 
combining data sets from disparate sources for research or audit purposes. Code 
mapping is an approach to enable codes from one system to be translated to their 
semantically equivalent codes in another system, a process that has been defined as “the 
process of associating concepts or terms from one coding system to concepts or terms in 
another coding system and defining their equivalence in accordance with a documented 
rationale and a given purpose” [172][9]. In order to combine data from diverse datasets 
coded using different coding systems it is necessary to converge the data sets onto a 
common coding system. At a minimum, translation of data items recorded in the coding 
system used in one of the source data sets to another coding system is required. 
However, the opportunity exists for all event codes from multiple sources to be mapped 
to a third coding system if that system has advantages over either of the coding systems 
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in use in the existing data sets. When combining or comparing data sets from different 
sources using different coding systems, it is necessary to map clinical event codes to a 
single common coding system, which may be a system used by one or more of the 
source datasets or may be a new coding system. Bonney et al [173][10] write: “Mapping 
data elements in EHRs to a reference classification and/or terminology system not only 
facilitate reuse of primary care data for multiple purposes, but they also support data 
analysis, health information exchange and interoperability, and data comparison across 
the continuum of different healthcare providers [and] improves the quality of the 
research output derived from EHRs.” 
An issue which can occur when combining datasets is that of semantic interoperability, 
in particular equivalence in the coding of clinical concepts. It is relatively 
straightforward to combine demographic information between systems since, for 
example, “there is general agreement as to what ‘age’ means in relation to a patient” 
[174][11] and there is similar agreement for names of individuals and dates, but it is less 
straightforward to map clinical concepts or their coded representation between different 
terminologies. One long-standing method is to match the text description of concepts 
(e.g. [175-179][12] [13] [14]; [15] [16]). The majority of work in automatic mapping 
has focused on the lexical approach, using techniques similar to those used for 
automatic mapping from free text clinical notes to concept codes (for example [180] 
[17] and [181][18]).  However, Fung et al [182][19] found that ‘Semantic mapping 
performed better than lexical mapping’. Cimino and Barnett [183][20] proposed a 
method of semantic mapping by which each concept in a terminology was characterised 
by a set of properties, with concepts being mapped across terminologies according to 
the closest similarity in properties. This method requires each concept to be 
characterised manually in a process described as ‘tedious [but] not complicated’. A 
similar approach was proposed by Rocha et al [184]. 
Mappings exist between some of the major coding systems in current use, particularly 
between older and newer versions of coding systems, e.g. ICD-9-CM and ICD-10-CM; 
Read Codes Version 2 and CTV3, provided by several organisations and individuals, 
often those responsible for the maintenance of the coding systems. In the UK, the 
Department of Health Technology Reference-data Update Distribution service (TRUD) 
[185] provides mappings between a number of coding systems, in particular those 
systems in common use in the UK: SNOMED CT, Read 2, CTV3. In the US, mappings 
are provided between systems more common in that country by the Centers for 
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Medicare and Medicaid Services (CMS), International Health Terminology Standards 
Development Organisation (IHTSDO), Unified Medical Language System (UMLS), 
National Library of Medicine (NLM). Brouch [186] gives an introduction to the 
mapping process and contains a glossary of relevant terms. Nandigam and Topaz [187], 
describing their work in mapping SNOMED CT to ICD10-CM, note that the SNOMED 
CT to ICD10-CM mappings from NLM “may need to be modified on the basis of the 
clinical specialty and patient population and further validated.” Previous work on 
creating mapping tables between coding systems has been primarily by human experts 
comparing text descriptions of codes in different coding systems, e.g. [188]; with the 
assistance of a text search tool, e.g. [189], [183]; or by automated text matching [184]. 
One problem described by Nadkarni & Darer [189] was that of missing mappings: in 
their work in investigating the completeness of mapping a data set from ICD-9-CM to 
SNOMED CT they found that 784 (of 2199; 35.8%) ICD-9-CM codes in their data set 
had no map to an equivalent SNOMED CT code in the UMLS ICD-9-CM to SNOMED 
CT cross-map, requiring them to create these mappings by hand.  
2.9 Potential sources of data 
A number of sources of data were identified for possible use in this project. They are 
listed here in Table 2.2. All are from clinical records or other professional records. It is 
not intended to use data from personal health records for the reasons of relatively low 
take-up and population bias noted in 2.3.1, although there may be scope for future use 
should analysis based on clinical data only prove promising. Note that the Harlow and 
Linet review [30] suggests that individuals may recall more conditions than they take 
time to report to clinicians and so using data volunteered by individual patients may 
help to increase the richness of the data set. However there are caveats to this approach: 
conditions may be inaccurately described or may be imaginery; dates may be 
misleading; bias can be introduced  by those with better memory (hyperthymesia) 
recalling more conditions or conversely age-related memory impairment may lead to 
fewer conditions being recalled or being recalled inaccurately; older (or more recent) 
conditions may be preferentially recalled [190]; self-medication may lead to 
inappropriate treatment; ;  
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Data source Country Notes 
Helseundersøkelsene i 
Nord-Trøndelag 
(HUNT) 
Norway Information on around 20,000 individuals 
from a geographically small region of mid-
Norway. An application submitted to 
relevant Norwegian Regional Ethics 
Committee for use of the data, however 
following negotiations regarding fields to 
be supplied and the cost of doing so it was 
decided not to use data from this source 
EPI-CT Norway The Norwegian part of this project aimed 
to acquire data on around 30,000 
patients, all of whom had had CT scans. 
Clinical history for each individual was 
limited to information relevant to their CT 
scans and potentially to later-life cancers. 
Data coding was project-specific. 
Clinical Practice 
Research Datalink 
(CPRD) 
UK Data from UK general practice patients, 
coded in Read Codes version 2, containing 
longitudinal medical event histories 
The Health 
Improvement Network 
(THIN) 
UK Data from UK general practice patients, 
coded in Read Codes version 2, containing 
longitudinal medical event histories 
Nottingham University 
Hospitals NHS Trust 
UK Data from patients attending specific 
clinics at a Nottingham hospital, access to 
the data to be arranged via the original 
PhD supervisor to this project, following 
on from previous work. Data was uncoded 
but some had been coded into SNOMED 
CT as part of the earlier work. Access to 
data later proved not possible due to 
supervisor absence 
Practice Fusion USA Data from US general practice patients, 
coded in ICD-9-CM, containing 
longitudinal medical event histories 
Informatics for 
Integrating Biology and 
The Bedside (i2b2) 
USA Contains uncoded discharge summaries 
for around 1500 patients 
Mexican Health and 
Aging Study 
Mexico Data on medical and lifestyle histories of 
individuals acquired by interview of 
subjects and relatives, not captured 
contemporaneously. 11,000 households 
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invited to participate. Responses are 
uncoded 
Boston Medical Centre 
Clinical Data 
Warehouse 
USA Contains data from various information 
systems within the Boston Medical 
Center. Data is coded in ICD-9-CM and 
CPT.  
Danish National 
Database of 
Reimbursed 
Prescriptions 
Denmark Contains prescriptions records only, not 
diagnoses or other event history and so 
not useful for this project. 
 
Health Informatics 
Centre, Dundee 
UK Contains hospital laboratory data, 
prescriptions data, but no primary care 
records. Do data processing on-site and 
return aggregated results only. Unlikely to 
be useful for this project. 
 
QResearch UK  
The Hampshire 
Healthcare Record 
UK  
PHARMO The 
Netherlands 
Based in The Netherlands; have general 
practice and other data. PHARMO do 
research in-house but may be able to 
make raw data available. 
German Statutory 
Health Insurance 
Claims 
Germany  
Veterans 
Administration 
Encounter Data 
USA  
US Hospitals 
Databases: Premier, 
Cerner Health Facts 
USA  
GE Healthcare EMR USA  
Hospital Episode 
Statistics 
USA  
Mediplus   
Disease Analyzer 
project 
  
Oncology Analyzer 
project 
  
Healthcare Cost and 
Utilization Project 
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(HCUP) 
Centers for Disease 
Control and Prevention 
National Health and 
Nutrition Examination 
Survey (NHANES) 
USA  
The Trauma Audit and 
Research Network 
TARN  
Table 2.2 Potential data sources 
2.10 Conclusions 
There were a number of trends evident from the review of the literature. There was clear 
evidence of successful secondary use of clinical record data in many areas. Data from 
electronic medical records systems has been utilised both in near-real-time (e.g. for 
detection of disease outbreaks) and retrospectively (e.g. for selection of patients suitable 
for clinical trials). Successful secondary use of clinical records data used well-coded 
data or utilised natural language processing of free text fields; it is a challenge to use 
coded data from a typical electronic medical record system and a greater challenge to 
combine data from several systems. 
Little work has been done on the detection of patients with similar clinical histories to 
that of a sample patient, although some work has been done for detecting patients with 
similar genomes. Likewise, little work seems to have been done on general predictions 
of future health events based on lifetime clinical histories, although there has been some 
work in specific areas. This gives rise to the key research area for this thesis: is it 
possible to modify individuals’ likelihoods of future health events simply by matching 
them with others who have experienced similar medical events to the individual of 
interest? 
 67 
 
3 RESEARCH OBJECTIVES 
3.1 Background 
The research area identified in the literature review as being an opportunity for further 
research will be explored here. "Strong patterns, if found, will likely generalize to make 
accurate predictions on future data" [191]. However, "Mathematics works in Physics 
because purely physical processes can be idealized, and therefore simplified, to an 
extent that permits their handling by mathematical formulas. When it comes to 
biological phenomena, one finds that they are too complex to be represented by ideal 
cases without destroying their true nature, If, however, their complexity is kept intact, 
sufficiently powerful mathematical techniques will be lacking for their satisfactory 
handling" [192] quoting [193]. This is not the only challenge when re-using clinical 
data, and one relevant to the challenge of making risk predictions from medical records 
event histories. Drake and McHugo [194] note that data may well exist within electronic 
medical records, but since it was not collected for the purposes of research it may not be 
of a quality sufficient for it to be suitable for research use.  
3.2 Research question 
 
Clinical trials have brought much benefit and key knowledge.  However there are areas 
where clinical trials are inappropriate. They may be ethically impermissible – 
encouraging a group to smoke; giving a 'placebo' CT scan; trialling a drug on pregnant 
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women; or there may be insurmountable practical challenges. We therefore need to look 
at other ways to draw conclusions about health outcomes for patients. 
In a related area, that of genome research, work has been done in associating genetic 
variants with phenotypes and further into associating genetic variants with the risk of 
individuals with particular variants being affected by a disease, their prognosis if they 
have a disease and their likely response to a particular treatment. For example, Kruppa 
et al [195] investigate a machine-learning approach to genome association for 
rheumatoid arthritis. However, it appears that little work has been done on performing 
similar analyses based on previous diagnoses and clinical events rather than the 
presence of particular genetic variants. 
This leads to the key research question for the work presented here: 
Is there potential to re-use data from multiple data sets, acquired for the primary 
purpose of the care of individuals, to enhance our knowledge of health events of 
populations, and to improve the future health of individuals based on this knowledge? 
 
3.3 Practical uses 
There are some practical applications for which this knowledge can be beneficial: 
3.3.1 Screening: Pre-emptive care 
Should it become apparent that an individual's clinical history suggests a probable 
future health path, then some appropriate pre-emptive care may be available. For 
example, should an individual demonstrate a raised risk of atherosclerosis, appropriate 
interventions can be put in place, such as encouraging increased exercise in the 
individual at risk [196] 
3.3.2 Screening: Lifestyle adjustments 
Future health states may be improved more by some lifestyle changes than others. It 
may be possible to establish this from analysis of individuals with similar clinical 
histories who have subsequently made different lifestyle choices – for example with 
diet, exercise or tobacco use changes. 
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3.3.3 Treatment options decisions 
Some types of patient may respond better to one type of treatment; another type may 
respond better to another treatment; some patients may respond best with no treatment 
3.3.4 Healthcare enterprise resource management 
If a healthcare enterprise is better able to predict the likely care needs of its patients it 
may better be able to allocate resources 
3.3.5 Other potential benefits 
Decision support: An individual’s raised likelihood of a condition compared to prior 
assumptions of that likelihood can be presented to a clinician as an additional source of 
information to aid diagnosis. 
3.4 Contributions 
It is anticipated that new contributions to knowledge may be possible as a result of this 
work. In particular: 
3.4.1 Combining datasets 
Many of the examples found in the literature of re-use of clinical data have relied on 
data from a single data set or have reported challenges when using multiple data sets. 
This suggests that improving the ease with which data sets can be combined would be a 
useful area of work.  
3.4.2 Selection of patients with similar clinical histories 
Part of the core work for this project will be to attempt to predict the likelihood of future 
clinical outcomes or health states by comparing a single patient with others who have 
similar longitudinal clinical histories. The important elements of those clinical histories 
need to be established. 
3.5 Testing predictions  
Predictions made following analysis of the data sets must be tested. It is planned to 
retain a subset of the obtained data to be used as a test set against the techniques 
developed using the rest of the data. 
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3.6 Project outline and methods overview 
3.6.1 Summary 
It is intended to acquire clinical event history data from existing clinical records 
repositories and to combine these data sets into a single repository of longitudinal 
records data. From this data set, methods will be developed to group individual records 
by the similarity of their contained events. Using the grouped data set, predictions will 
be made regarding the likelihood of a record containing a condition off interest.  A 
summary of the process is described in this chapter. 
 
3.6.2 Data acquisition and consolidation 
Acquire data from existing repositories of longitudinal records and combine into a 
single composite repository, as shown schematically in Figure 3.1. A similar system 
was suggested by Celi et al [197]. 
 
Figure 3.1 Schematic of data acquisition 
Repositories A, B, C, …  hold details of clinical events for individuals. These data may 
be held in different ways, with different fields and utilising different coding systems. 
Data from A, B, C ... are extracted and merged into a single repository D. 
 
One issue that can arise with acquiring data from multiple sources is that of data 
consistency. In the traditional definition of data consistency, data across all systems 
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reflect the same information and are synchronised with each other [198]. However, with 
the system proposed here, there may be subtleties with the consistency of the data 
caused by use of data from multiple clinical systems. It is possible that an individual 
patient is present in multiple systems but in the work here an assumption has been made 
that there is only a realistic possibility of that happening in the two UK-sourced data 
sets; it has been assumed that the chance of an individual having a primary care record 
in both the UK and the US is small. The two UK-sourced data sets have data sourced 
primarily from different system providers and so the chances are small (but still finite) 
that the same practices are used so only patients who move practice may be in multiple 
practices, but their records should move with them rather than be copied. Section 6.2.f 
tried to find duplicate records. No adult exact duplicates were found.  
 
If an individual’s records are split across multiple data sets (or , indeed, split across 
separate records within the same source data set) then they will not be recombined since 
all data used for this project were de-identified at source, and so they will be treated as 
separate records. The assumption is that for UK-sourced records the established system 
of maintaining the integrity of patient records works well. However, should an 
individual’s records be split over multiple ‘patient’ records then this is likely to reduce 
the ability to make accurate predictions for that individual. However, since all records 
used in this work were sourced from primary care via reputable data aggregators an 
assumption was made that records were likely to be consistent, 
 
Within single records there is a possibility that record events are internally inconsistent, 
with a later event occurring after an earlier event would have made the later event 
impossible, for example arthritis recorded in a foot that had previously been amputated. 
These events have not been tested for. Although it would be possible to do so, this 
would rely in many cases on specialist medical knowledge that was beyond the 
resources available for this work. It should also be noted that (i) should any ‘impossible’ 
event combination be detected, it would not necessarily be simple to determine whether 
the earlier or later event was incorrect, and (ii) any event determined to be incorrect 
should still remain in the medical record as part of the medical history, although 
labelled as incorrect. In this work it was accepted that there would be some 
inconsistency in the real-world data used. 
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3.6.3 Content of composite data repository 
The repository will contain, for each record, a set of event codes. Codes that are 
significant for this work will be identified and retained. Figure 1.2 shows an illustrative 
timeline of events contained in one record. 
 
Figure 3.2 Illustrative timeline of events for one record 
3.7 Considerations for data content 
3.7.1 Level of detail 
Consideration will be given to how detailed each data item should be.  Recorded events 
may have a very fine level of detail, which may cause challenges in finding matches in 
other records, or may have a coarser level of detail, which may reduce the potential for 
differentiating between events and thus differentiating between records. 
For example, a bone fracture can have information on the fracture site, in ascending 
order of granularity: 
(a) Bone fracture (no site information) 
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(b) Fracture of the foot 
(c) Fracture of a toe 
(d) Fracture of the third toe on the left foot 
A disease type ‘diabetes’ could be: 
(a) Diabetes (with no particular information about the type of diabetes) 
(b) Type 1 diabetes 
(c) Type 2 diabetes 
(d) Gestational diabetes 
(e) One of several other less common forms 
 
3.7.2 Finding matches and making predictions 
It is intended to make predictions about future medical events (what, when, how bad) 
for newly-presenting individuals based on life histories of 'similar' individual(s) already 
in the composite repository.  This breaks down in to two basic tasks: 
(a) Finding matches 
(b) Making predictions based on matches 
As a simple example, if the patient illustrated in Figure 3.2 was in our database, and a 
new patient presented with a similar history but with one or more events not in the first 
patient’s history, we may be able to make a prediction of likely future health events 
(provided, of course, that there was not a greater weight of counter-predicting 
individuals also in our database). In practice it is expected that a number of matching 
individuals will be used to make predictions.   
 
Possible differences in the ‘type’ of event have not been taken advantage of, although 
this remains possible for future work. A “likely externally induced fracture” could have 
had its likelihood increased by previous conditions or not (was it because the individual 
was a young person playing football? Or an elderly person with osteoporosis?); the 
fracture itself could make other conditions more likely, perhaps by reducing an 
individual’s exercise in both the short term and the long term. “Internal” conditions may 
have an internal cause (genetic) or an external cause (lung cancer, some diabetes). It is 
also difficult to say whether a particular event has a long “incubation” period (e.g. poor 
diet/poor exercise -> diabetes; smoking -> lung cancer) or a short one (food poisoning, 
for example). Without any a priori evidence for hard divisions between conditions it 
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was felt inappropriate to make judgements about what conditions to include and 
exclude. Similarly, no different weighting was given to diagnoses over symptoms. This 
work focused on events in the record and made no medical judgement on the possibility 
of some conditions having a greater effect on other future conditions than others. 
 
 
Figure 3.3 Timeline of lifetime events from a record existing in our database 
compared with timeline of newly-presenting record. 
 
Thus, given a close match of the newly-presenting record to a record (or set of records) 
in our database, it would be possible to make a prediction of future events. In the 
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example shown in Figure 3.3, there is a close match for most of the life history and so 
we could predict that future life events are likely to include fracture and glaucoma. 
3.8 Finding matches 
3.8.1 Choices for matching set 
Several options exist for finding matches and acting on information gleaned from those 
matches to make predictions for the record of interest. These include: 
(a) Find the single closest match and only use the information in that single match. 
See Kantardzic [199] for a discussion of the issues with this technique. 
(b) Find a group of close matches, with the size of that group to be imposed in 
advance or determined from the characteristics of the data set under 
investigation, and use the information from that matching group. See, for 
example, Kelleher et al [[132] 
(c) Find all the individuals that match to a defined degree (e.g. ’70 % or more of 
events in a record must match the target record to qualify as a match’). See Wu 
et al [200] for a discussion of this method. 
(d) Where more than one record is included in the matching group, there may be 
potential to weight members of the matching set according to their individual 
degree of match to the target record. Dudani [201] has a description of this 
method. 
3.8.2 Challenges 
(a) 'Missing' events. Did a condition or event never happen for an individual? Or 
was the event just not recorded, or not reported by the individual?  
(b) Incomplete longitudinal records. Is the complete set of events for an individual 
available, or are some records left-censored, right-censored or have gaps?  
(c) Is it enough to look only at recorded conditions, or should such factors as age, 
tobacco use history, alcohol consumption history be used? 
(d) Should different conditions be weighted relative to each other as well as with 
their own intra-condition severity? E.g. heavy cold vs mild pneumonia – which 
is more important? 
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3.9 Methods 
This work falls into three main parts:  
(i) Data aggregation;  
(ii) Validation of the aggregated data set;  
(iii) Calculation of modulated condition risks for a defined set of conditions.  
Methods expected to be employed are briefly outlined here but will be described in 
more detail in the relevant sections of this report. 
 
3.9.1 Data aggregation 
Primary care records data will be taken from several sources. It is expected that the 
records will have some common fields (e.g. patient gender, age) but may have greater or 
lesser information on other demographic information, such as marital status or 
prescriptions. Events recorded in the records may be in different coding terminologies 
and so records from some sources may need to be mapped to a single coding 
terminology. It is expected that existing code mappings (e.g. from the UK NHS TRUD 
or NIH UMLS) will be sufficient for such code translations. 
 
3.9.2 Validation of aggregated data set 
Once the aggregated data set has been built, it will be examined to ensure it is 
representative of the general population. It is anticipated that this will be done by (i) 
analysing the data set for general demographic information and comparing this to 
demographic information available from population census information or similar and 
(ii) checking that prevalence of particular conditions in the data set are not significantly 
different from the prevalence of the same conditions found in the literature. 
3.9.3 Calculation of modulated condition risks 
Having prepared and validated the data set, its use in a system to use clinical records 
data to screen individuals for increased risk of particular conditions is investigated. 
Methods of calculating an individual’s risk modulated by that individual record’s 
similarity to other records will be developed and analysed. Any increase or decrease in 
risk will be presented in a clinically meaningful fashion, by likelihood ratio, prior and 
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posterior probabilities, and odds ratio as appropriate, together with appropriate 
measures of uncertainty, and by comparison of change in absolute risks. 
As a means of gaining familiarity with secondary use of data, a case study on the EPI-
CT project is discussed in Chapter 4. A second case study looking at the acquisition of 
health histories directly from individuals and the feasibility of its use as a data source in 
this work is also discussed in Chapter 4. 
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4 CASE STUDIES 
Two case studies are described: The EPI-CT project, which re-used clinical data as a 
key part of the project, and a project to obtain individuals’ recollections of their medical 
histories. The projects illustrate the potential for secondary use of historical record data 
for research and the need for appropriate data management. Good and bad points from 
each use case will be discussed and used to inform later work. 
4.1 Case Study: EPI-CT project 
A presentation based on work in the EPI-CT project, an international epidemiological 
study to quantify risks for paediatric computerized tomography and to optimize doses, 
was made to the ‘Data: storage, management, generation and legislation ‘ meeting in 
London in 2013: Turner J, Istad TS, Olerud HM, Flatabø S, Liland A, Ali W, Kjærheim 
K. "EPI-CT: International Epidemiological Paediatric CT Study. Data extraction and 
patient privacy protection: The approach in Norway." At IPEM Data: storage, 
management, generation and legislation, London, 16th April 2013. This case study 
report is based on that presentation. 
Note: I worked with the EPI-CT project in Norway for six months, installing data 
extraction software in several hospitals, checking that data extraction was running as 
intended and with minimal impact on clinicians, and checking that the data extraction 
was appropriate and secure. 
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4.1.1 Introduction 
A case study is described that illustrates some of the points discussed in Chapter 2 
regarding re-use of clinical data for research purposes. In particular, the project shows 
some of the advantages and disadvantages of re-use of clinical data versus prospective 
clinical trials and also shows how the necessary patient privacy considerations have 
been addressed. The project is intended to investigate the effect of only one clinical 
event (exposure to diagnostic ionising radiation, which may be repeated) on the risk of 
another clinical event (cancer, although of several different types) in later life. However, 
although limited in the breadth of input and output events under investigation, the 
project illustrates the feasibility of re-using clinical data for research. 
 
4.1.2 The EPI-CT project 
The "Epidemiological study to quantify risks for paediatric computerized tomography 
and to optimise doses" (EPI-CT) investigated the relationship between exposure to 
ionizing radiation from diagnostic x-ray examinations (in particular, CT scans in 
childhood, adolescence and young adulthood) and increased health risks (specifically 
cancers). Eighteen centres from Belgium, Denmark, Germany, Finland, France, 
Luxembourg, the Netherlands, Norway, Spain, Sweden and the United Kingdom 
cooperated in this project, which aimed to enrol approximately one million patients over 
the 5-year duration of the study. Work was funded under programme FP7-EURATOM-
FISSION, Grant agreement ID 269912. Table 4.1 gives information on each country’s 
contribution to the project, including projected cohort numbers [202]. 
The EPI-CT study was coordinated by the Section of Environment and Radiation at the 
International Agency for Research on Cancer (IARC). It received financial support from 
the Seventh Framework Program of the European Commission. The project completed 
in 2017, with results available on the CORDIS website [203] 
This case study focuses on the contribution from Norway to this study. The Norwegian 
team comprises of staff from two centres:  the Norwegian Radiation Protection Agency 
(NRPA) and Cancer Registry of Norway (CRN). Both centres are based in Oslo. Each 
centre had responsibility for different parts of the Norwegian contribution to the study. 
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 Cohort and exposure information  Outcomes  
Country Cohort 
Age 
range 
Start 
cohort 
accrual 
Source of cohort 
information 
Projected 
cohort size at 
outset 
Childhood 
cancer 
incidence 
Adult 
cancer 
incidence 
Belgium 0-15 2002  PACS 30000 Yes Yes 
Denmark 0-18 2000  PACS 30000  Yes  Yes  
France 0-5 2000 RIS/PACS 90000 Yes Possible 
Germany 0-15 1985 RIS/PACS 140000 Yes No 
Netherlands 0-18 1998 PACS 40000 Yes Yes 
Norway 0-20 2005 RIS/PACS 
20000  (now 
35 000+) 
Yes Yes 
Spain 0-20 2005 RIS/PACS/other 200000 Yes Since 2010 
Sweden 0-18  1984 RIS/PACS/other 95000 Yes Yes 
UK 0-21 1985 RIS/PACS/other 400000 Yes Yes 
Total 0-21 1984-
2002 
 1045000   
Table 4.1 Data Collection in Europe for the EPI-CT project  
 
4.1.3 Project Design 
At high levels of exposure, the effect of radiation on the human body is deterministic, 
i.e. above a particular threshold the severity of the effects of the radiation increases with 
increasing radiation dose (for example skin reddening, hair loss). Below the threshold 
effects are stochastic, i.e. effects are independent of the radiation dose, although their 
probability of occurring does depend on the radiation dose (for example cancer, genetic 
damage).  
Most of our understanding of the long-term effects of ionising radiation exposure on the 
human body is derived from studies of survivors of the atomic bombs dropped on 
Hiroshima and Nagasaki in 1945 [204]. Although it is possible to find individuals who 
are estimated to have been exposed to similar levels of ionising radiation as those 
produced during diagnostic x-ray examinations, other factors may not be comparable, 
for example the length of time over which the radiation exposure took place or other 
factors that may pose a risk to health. There is also little information on early childhood 
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cancers in Japan in the years immediately after 1945. However, studies on atomic bomb 
survivors and others have suggested that radiation at a level broadly similar to that used 
in diagnostic radiology can cause a small increase in the risk of induced cancer (Hall 
and Brenner, 2008). 
In order to establish the existence of risks associated with diagnostic ionising radiation 
it is necessary to gather information on individuals who have received such diagnostic 
examinations. Since the effect of such relatively low levels of radiation is expected to be 
small, a large study cohort was required to achieve sufficient precision and statistical 
power to draw meaningful conclusions. In particular, the following design decisions 
were made [205]: 
 To study only those individuals who have had one or more CT examinations 
when they were children, since CT examinations are responsible for 
approximately 80% of the population radiation dose due to medical examination 
and any effects of low-level radiation exposure are expected to take years, 
perhaps decades, to become apparent, so younger individuals would have more 
time for any ill effects to become apparent [206]. Prior to the relatively recent 
introduction of specific paediatric protocols, children were examined using the 
same protocols as were used for adults, thus causing them to receive higher 
effective radiation doses than adults during each CT examination [205]. For 
those individuals who had CT examinations as children, include also any CT 
examinations they may have had as adults 
 To allow each country to run its own data collection programme, according to a 
common protocol. Record-keeping practices and definitions of "child" vary 
among the countries participating in the study; the protocol must allow for this. 
 To incorporate existing studies underway in the United Kingdom, France and 
Germany. 
 Use information on each examination to estimate radiation dose, producing a 
lifetime cumulative radiation dose for each individual due to CT examinations 
 Follow patients over time to ascertain information regarding the incidence of 
leukaemia and other cancers. 
Data collection commenced at any particular hospital by extraction of a list of 
examinations of patients who underwent at least one CT scan in the hospital when they 
were a child. This was done by querying the hospitals Radiology Information System 
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(RIS) for a list of all accession numbers (essentially serial numbers of examination 
requests) that match the stated criteria. It should be noted that in Norway, patients who 
were aged 20 or less at the time of their first CT examination were included; other 
countries vary as to the age at which they consider a patient to be a child. 
Radiology Information Systems in Norwegian hospitals have been common since the 
early 1980s, approximately and fortuitously for this project coinciding with the 
widespread introduction of CT scanners in the country. Information held on the RIS 
included patient details (name, date of birth, ID number) and information on the 
examination (date of examination, body part scanned, scanner used, accession number). 
From the information on the body part scanned and the scanner used, a typical radiation 
dose for each type of CT scan (e.g. "head") was be assigned using the results of a CT 
radiation dose survey carried out in Norway in the early 1990s [207]. Other countries 
did not necessarily have such results of radiation dose surveys available and used other 
methods to estimate the radiation dose for each type of examination, typically specially 
developed questionnaires completed by staff working in the CT departments, results 
included in scientific publications or expert interviews with radiography staff still 
working in the relevant departments. 
Beginning around the year 2000, Picture Archiving and Communications Systems 
(PACS) were installed in Norway and these provided a much richer set of data for each 
examination. In addition to the data provided by the RIS, the PACS gave information on 
the exposure parameters used, sufficient to enable calculation of radiation dose for each 
individual examination.  
Data was extracted from PACS using PerMoS software [208]. This software ran on a 
PC attached to the PACS network and functioned like a normal PACS workstation. It 
used DICOM Query/Retrieve commands to retrieve individual CT examinations, based 
on the accession numbers obtained from the RIS. The metadata within each 
examination's data allows for calculation of exposure information. A feature developed 
during the course of the project was the use of the images within each examination's 
data to determine the physical start and end points of each scan on the patient's body. 
This was used to help determine more precise dose data for organs; for example, a 
"head" scan may or may not directly expose the thyroid, depending on where the start 
and end points of the scan were set, which will change the radiation dose received by 
the thyroid. This information will not be apparent from the metadata but can be 
determined from image data. 
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Installation of PerMoS was been technically straightforward but benefited from the 
cooperation of local staff; its use required some planning, since constant retrieval of CT 
examinations had the potential to overload some PACS networks. Image data for each 
CT examination can be large, in the order of tens or hundreds of megabytes. Continuous 
retrieval of CT examination data by PerMoS had the potential to slow down a hospital's 
PACS network and so PerMoS allowed for a configurable delay between each complete 
examination retrieval. Typically the setting was for a 10 minute delay between each 
retrieval but this was expected to reduce over time. PerMoS also allowed retrievals to 
run only at set times of the day, so that periods of high use of the network and PACS 
could be avoided. Retrieval times were set to avoid the busy morning reporting periods, 
the evening pre-fetch of examinations required for the next day’s clinics and times 
(generally in the middle of each night) when system backups were set to run. This 
retrieval strategy ran successfully in Norway during the data collection period of the 
project and has caused no problems to local PACS. 
The Norwegian cohort was originally projected to be around 20,000 patients but 
achieved more than 35,000 by project completion. 
4.1.4 Patient privacy protection in the EPI-CT project Norway. 
Following retrieval, each examination had its patient-identifying data removed and 
replaced with a pseudonym. Patient-identifying data and pseudonym only were sent to 
Cancer Registry of Norway for investigation of clinical histories; CT examination 
metadata with pseudonym were sent via the Norwegian Radiation Protection Authority 
to a central database for calculation of radiation doses. Calculated radiation doses were 
matched with clinical histories by their pseudonyms, then anonymised and made 
available for statistical analysis by the central EPI-CT study. 
4.1.5 Advantages and disadvantages of secondary use of data in EPI-CT 
The EPI-CT project illustrates some of the considerations and benefits when re-using 
clinical data for research purposes. These include: 
4.1.5.1 Patient privacy protection 
The minimum amount of patient-identifying information was acquired and was sent 
only to those groups needing it. In this case, the Cancer Registry of Norway required 
sufficient information to identify individuals' health records. Other organisations, those 
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involved in estimating individuals' radiation doses, did not require knowledge of the 
identity of individuals and so received only pseudonyms with the data they were sent.  
4.1.5.2 Economic access to large numbers of patients 
The EPI-CT project utilised data which already existed in clinical information systems. 
This avoided the time and expense necessary to recruit individuals into a study. The 
effect of the intervention (the CT scan) on individuals was expected to be small and so 
large numbers of patients were required to demonstrate a significant effect. The effect of 
the intervention was expected to take many years to become apparent and so access to 
historical data on interventions was an advantage. 
4.1.5.3 Ethical advantages 
Some interventions do not lend themselves to clinical trials simply because it would be 
unethical to give the intervention if it not clinically indicated and likewise it would be 
unethical to withhold the intervention if it would normally clinically be requested. By 
using existing clinical records, this ethical issue is avoided. 
4.1.5.4 Uncontrolled conditions 
Initial criteria for inclusion of patients into the study were solely those of patient history 
of CT examination at a young age. The aim of the project was to establish whether there 
was a link between history of CT examination and incidence of cancer in later life. 
However, some patients may have had particular medical conditions that may have 
increased the incidence of cancer – and these conditions may also increase their 
likelihood of having CT scans. It may not prove as easy to allow for these conditions as 
it would be in a controlled trial. 
Before data harvesting from PACS began, a RIS query is made for the patients to be 
included in the EPI-CT study, i.e. for the Norwegian cohort, all patients who have 
undergone a CT examination while being 0-20 years of age. From the RIS query a list 
of patient IDs was produced. These IDs were used to retrieve examinations from the 
PACS. 
1. PerMoS Data Collector acted as a DICOM node on the PACS network, 
harvesting data from the PACS using standard DICOM query-retrieve. PerMoS 
Data Collector used the patient ID list from the RIS query to identify the 
relevant CT examinations from the PACS. 
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2. PerMoS Data Collector removed all image data, separated all patient-
identifying information, generated pseudonyms and stored the harvested 
DICOM header data in local temporary files. 
3. PerMoS Data Collector built a local database to keep track of which 
patients and which examinations had been harvested from the PACS. The 
database also contained the link between the pseudonyms and the identifying 
information for each patient. 
4. The harvested DICOM header data was uploaded to the central PerMoS 
database. The data only contained CT scan parameters and pseudonyms, with no 
identifying information. This could be done either by automatic upload over 
secure Internet connection (HTTPS/SSL/TLS), or by manually moving the local 
temporary files on a hard disk (or other physical medium) from the hospital to 
the Norwegian Radiation Protection Authority for uploading from there. In both 
cases the hospital IT manager could inspect the files before uploading/copying. 
Figure 4.1 shows transfer of data out of the hospital using physical storage 
media. 
5. The Norwegian Radiation Protection Authority checked the collected 
DICOM header data from all the Norwegian hospitals and used the collected CT 
scan parameters to calculate the radiation dose for each CT scan.  
6. A linkage table consisting of pseudonyms + identifying info was 
transferred from the local PerMoS database at the hospital to the secure national 
database at the Cancer Registry of Norway. Only the database administrator and 
the personnel responsible for checking the harvested data at the Norwegian 
Cancer Registry had access to the identifying information.  
7. The Cancer Registry used identifying information to collect health status 
(e.g. cancer disease status) and confounders from other Norwegian health 
registries and Statistics Norway. 
8. Pseudonyms and calculated radiation doses were transferred from the 
central PerMoS database to the Cancer Registry. The pseudonyms were used for 
linking doses with patients in the national database at the Cancer Registry. 
9. Dose, health status and confounders for each patient were transferred to 
the central epidemiological database at IARC (International Agency for 
Research on Cancer/WHO) for analysis. At this stage data was anonymous only, 
with all identifying information (including pseudonyms) having been removed. 
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All the relevant Norwegian data for the EPI-CT study was thus collected in a national 
database located at the Cancer Registry of Norway. This database contained the data 
from the RIS harvesting, including patient-identifying information, selected DICOM 
header parameters from the PACS, calculated radiation doses, the patient's health status, 
and confounders. 
The database was secured according to the Cancer Registry's routines for handling 
personal information and according to the requirements of the Norwegian data 
protection act. Only anonymised data, which are impossible to link to individuals, were 
sent to the central EPI-CT research groups for analysis. 
The number of workers handling personal information was kept at an absolute 
minimum. All those who had access to personal information were employees at the 
Cancer Registry of Norway, who signed a confidentiality agreement, and who were 
either database administrators or responsible for data cleaning. 
The central PerMoS database in Luxembourg contained information on all the CT 
examinations included in the project, but no personal information. The purpose of this 
database was centralised, automated calculation of radiation doses from CT scan 
parameters. 
No personally-identifiable information left Norway at any point. 
In the central epidemiological database, the Norwegian anonymised data were 
combined with the data from the other European participant countries for 
epidemiological analysis. 
 
4.1.6 Key points 
 All data acquired for the project existed in various systems and databases, 
including hospital information and imaging systems and in cancer registries. No 
new data was required for the project. 
 Impact on clinicians during data capture was the minimum necessary. 
 Data acquired were kept secure, anonymised or pseudonymised as appropriate. 
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Figure 4.1 Data flow using PerMoS for the EPI-CT project in Norway.  
Diagram courtesy Norwegian Radiation Protection Authority 
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4.2 Case study 2: Self-reported medical histories 
4.2.1 Background 
This project was intended to collect anonymous information via the World Wide Web 
on individuals' recollections of their health events throughout their life, for the purpose 
of (i) comparing individuals’ aggregated recollections of events to those stored in 
average health records and (ii) to see whether such individual-recalled events can be 
used to modulate predictions of future health events. 
Note: I designed and implemented this project at City, University of London, Centre for 
Health Informatics, in order to investigate the challenges of acquired information from 
individuals about their medical histories, including quantity of responses, level of detail 
of individual events reported, and comparison with formal health records. 
4.2.2 Methods 
Survey respondents were invited to list, to the best of their recollection and without 
historical time limit, personal health events and ongoing conditions including, but not 
limited to, those events that were reported to or required the intervention of a general 
practitioner or other healthcare professional. Respondents were also invited to note their 
age group, weekly exercise habits, smoking status and alcohol consumption, and 
country of birth. In order to preserve anonymity, respondents were not asked for their 
name, exact age or current country of residence.  
Once data had been collected, it was intended to use the data to: 
i) To see how individuals’ recollections of medical conditions compare, on 
average, to the quantity and detail of events typically stored in general practice records; 
ii) As input to a health event prediction algorithm, in order to see whether patient-
recalled data is of adequate quality to have practical use in such an algorithm. 
 
It was expected that meaningful results would be obtained once 50 responses were 
received. This figure was calculated by use of the sample size calculator at 
http://www.raosoft.com/samplesize.html [209], using the default suggestions of 95% 
confidence and a 20,000 population size, but with a 10% margin of error rather than the 
suggested 5%, and a 10% response distribution (approximately the proportion of 
diabetes or hypertension in the general Western population) rather than the suggested 
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50%, which gave a sample size of 35, which was rounded up to 50 to allow for invalid 
or incomplete responses. 
In order to maximise the survey completion rate, questions were designed to be simple 
and as few in number as possible, with only age and gender being compulsory. An 
open-ended question asking respondents to recall and list all medical conditions 
experienced through their life was deliberately asked before a closed list asking whether 
or not the respondent had suffered from particular named conditions.  
The survey was implemented on a website using LimeSurvey survey software [210] 
installed on a server located in the UK using the URI 
http://www.predictivehealth.org.uk. The survey was advertised on 
www.callforparticipants.com, to the then current MSc Health Informatics students at 
City, University of London, and via Twitter. 
The questions used in the survey are shown in Figure 4.2, taken directly from the survey 
web pages. 
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What is your age group? 
Choose one of the following answers 
 Under 18  
 18-25  
 26-40  
 41-50  
 51-60  
 61-70  
 71-80  
 81 or older  
 What is your gender? 
Choose one of the following answers 
 Female  
 Male  
 Intersex  
 MtF Female  
 FtM Male  
 Other  
 
 
What is your country of birth? 
 
Answer  
What ethnicity listed most closely 
matches yours? 
Choose one of the following answers 
 Other  
 Black  
 Mixed/multiple  
 Asian  
 White  
 No answer  
What is your highest level of education 
attained? Please choose the closest 
match. 
Choose one of the following answers 
 Compulsory school 
education only  
 Optional school education  
 Trade/technical/vocational 
qualifications  
 Bachelor's degree  
 Master's degree  
 Doctorate  
 No answer  
About how many cigarettes do you 
smoke in a typical day? 
Choose one of the following answers 
 None - I have never smoked  
 None - I am an ex-smoker  
 Occasional (not a daily 
smoker)  
 1-4 a day  
 5-9 a day  
 10-19 a day  
 20-39 a day  
 40 or more a day  
 No answer  
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Do you regularly smoke a pipe and/or 
cigars? 
Choose one of the following answers 
 Yes  
 No - have never regularly 
smoked a pipe or cigars  
 No - but used to  
 No answer 
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Please enter all the conditions you can remember and please don't worry if you can only 
recall your approximate age at the time. We don't mind if you use the common name 
(e.g. "hay fever") or the formal medical term (e.g. "seasonal allergic rhinitis") 
We are primarily interested in those conditions for which you attended a hospital or 
clinic, or consulted a GP. However, any conditions which you feel worth noting can be 
recorded. 
Please enter each condition on a new line together with your age in years, as best you 
can recall, when the condition first occurred. The conditions do not need to be recorded 
in chronological order. 
For example: 
Field's disease - 24 
Progeria - 1 ongoing 
We appreciate that it can be difficult to remember all your medical conditions but please 
try to remember as many as you can. 
 
 94 
 
 Answer  
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Have you suffered or do you suffer from any of the following conditions? Please enter 
your age in years when the condition first occurred. 
  
 
Hypothyroidism 
(underactive thyroid)  
Age  
Anxiety disorders  Age  
Insomnia  Age  
Chronic Pain (including 
back pain)  
Age  
Depression  Age  
Diabetes (please note 
type)  
Age  
Chicken pox  Age  
Chronic Obstructive 
Pulmonary Disease 
(COPD)  
Age  
Hypertension (high blood 
pressure)  
Age  
Attention Deficit Disorder  Age  
A "rare disease" (please 
describe)  
Age  
Tooth decay / gum 
disease  
Age  
Neuropathic pain  Age  
Gastrointestinal disorders  Age  
Bipolar Disorder  Age  
Crohn's Disease  Age  
Otitis (ear infection)  Age  
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Asthma  Age  
Allergies  Age  
Sinusitis (sinus infection)  Age  
Deep Vein Thrombosis 
(DVT)  
Age  
Chronic Dry Eye  Age  
Arthritis/Osteoarthritis  Age  
Rheumatoid Arthritis  Age  
Anaemia  Age  
Upper respiratory tract 
infection (coughs, 
colds, "flu")  
Age  
I have suffered 
from none of the 
above (write 
'none' in the 
box)  
 
 
Do you have any allergies? Please list them here if you do, together with the age at 
which the allergy was first noticed (if you can recall this). 
Answer  
Please note any medications that you are currently taking. 
These can be prescription medications or over-the-counter treatments. 
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Answer  
If you have any comments or wish to give further information about any of your 
answers, please do so here. 
Answer  
Figure 4.2 Self-reported health histories web questionnaire. 
4.2.3 Results 
Unfortunately only a small number of responses were received: there were 17 responses 
of which 14 were completed and one partially complete. Of the completed or partially-
completed responses, the gender of respondents was 10 female, 5 male; the country of 
birth of the respondents was UK 8 respondents, USA 2 respondents, with 1 respondent 
each from Canada, Australia and Poland. Two respondents declined to give their 
country of birth, although the rest of their survey responses were fully completed. 13 
respondents described their ethnicity as ‘white’, with one describing their ethnicity as 
‘Asian’. One respondent declined to give their ethnicity. 
Further results are summarised in Table 4.2, Table 4.3 and Table 4.4. 
 
Age range of 
respondent (years) 
Number of respondents 
Not given 1 (abandoned the survey at this point) 
<18 
1 (respondent not allowed to complete due to age 
restriction) 
18-25  2 
26-40 5 
41-50 6 
51-60 2 
> 60 0 
Table 4.2 Age of respondents to self-reported health histories study 
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Event category Mean number of 
events in survey 
Median number of 
events in survey 
Unprompted recollection 7.3 8 
Prompted recollection 4.9 6 
In both categories 1.4 2 
Total recalled conditions 9.2 10 
Events recorded in formal records 25.8 11 
Table 4.3 Number of recalled events entered to self-reported health histories study 
 
The prevalence of common conditions from the 15 valid responses are shown in Table 
4.4. 
 
Condition Number of 
respondents 
recalling condition 
Prevalence in 
respondents 
Prevalence in 
general 
records 
Autism 1 7 % 0.2 % 
Depression 6 43 % - 
Chicken pox 8 57 % - 
Asthma 2 14 % 12 % 
Eczema 1 7 % 5 % 
Hay fever/allergic 
rhinitis 
6 43 % 20 % 
Sinusitis 6 43 % 15 % 
Anxiety 2 14 % - 
Bone fracture 3 21 % - 
Hypertension 2 14 % - 
Bronchitis 1 7 % 16 % 
Table 4.4 Prevalence of common conditions entered to self-reported health 
histories study 
 
Due to the low number of responses to the survey, no statistical comparison of the 
number of recalled events versus number of events recorded in formal records was 
attempted, although it can be seen that the median number of recalled events is close to 
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the median from formal records. The rate of occurrence of conditions in the survey 
responses compared to the conditions prevalence is shown in Table 4.4, however the 
numbers for any one condition in the response set is small. Figures for formal records 
have been taken from the composite data set described in Chapter 6, with prevalences 
for some conditions calculated using the codelists described in Chapter 7. 
 
4.2.4 Conclusions 
The response rate to the survey was low and so no detailed analysis of the responses 
was attempted. It was clear that the responses were insufficient for analysis of 
associations between conditions for the purpose of calculating risks of unreported 
conditions. For this work, it was necessary to use record sets derived from formal 
medical records. 
However, given the closeness of the median number of events reported by individuals 
when compared to the median number of events in formal records, it appeared that there 
would be potential for using information acquired in this way should it be possible to 
increase the response rate. It would also be possible for individual records to be 
compared to sets of formal medical records for the purpose of calculating condition risk, 
although this would require individuals’ responses to be coded into the same coding 
system as the formal records sets. 
4.3 Discussion 
Privacy and data security was important in both projects. The EPI-CT project allowed 
identifiable records to leave hospitals only under strict conditions, with use of 
pseudonyms (EPI-CT) elsewhere. The web survey of individuals’ recollections acquired 
data anonymously. The minimum useful data set was acquired in each project. The 
quantity of data acquired was important: EPI-CT was a very large project with good 
statistical power but required a large investment in time, money and staff. The web 
survey of individuals’ recollections project had a low response but gave some 
qualitative information and, once set up, was low maintenance, running unsupervised on 
a web server, and low cost. 
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5 CONSOLIDATION OF 
ELECTRONIC HEALTH 
RECORDS DATA FROM 
MULTIPLE SOURCES 
5.1 Introduction and background 
 
An Electronic Health Record (EHR) has been defined as ‘a system specifically designed 
to support users by providing accessibility to complete and accurate data …’ [211]. The 
ASTM E1384 Standard Guide on Content and Structure of Electronic Health Records 
[212] gives a comprehensive list of data items that an EHR system should be able to 
record. These data items include, but are not limited to, patient demographic or 
identifying items as date of birth, gender, occupation and address; clinically relevant 
information such as blood pressure, weight, height and allergy alerts; and outcomes of 
consultations and investigations such as diagnoses, prescriptions and referrals.  
Three data sets of de-identified primary care records were obtained from three 
independent sources. The work required to combine them into a single data set is 
described, including translation of coded clinical events from the three source data sets 
to a common coding system, selection of fields common across the source data sets and 
the mapping of individual data items from the source data sets into a single composite 
data set.  
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The source data sets included data from both UK and US systems. The advantage of this 
was that this increased the quantity of data available. Possible disadvantages were that 
the two countries may have different definitions for some conditions and different 
population profiles. The potential problem of differing condition definitions was 
addressed to some extent by mapping codes to a single coding system and then using 
less granular codes to group together closely-related conditions. 
 
 
5.2 The source data sets 
5.2.1 THIN 
As noted in section 2.9, THIN holds data from UK general practice patients, coded in 
Read Codes version 2, containing longitudinal medical event histories and sourced 
primarily from practices using Epic/Cegedim systems. Following discussion, THIN 
were able to supply a set of data that they had divided into ‘train’ and ‘test’ sets. The 
data were supplied in standard system agnostic .csv files. 
 Each set contained seven tables of patient, event and related data, plus 11 lookup tables 
which give the meanings behind the codes used to store information in the data tables. 
Figure 5.1 shows the THIN data table schema. All files are supplied as simple text files 
fields determined by their position within the text files. Five data tables from the sets 
supplied by THIN were used:[213] 
 
 Two patient data tables, each of which includes patient pseudo-ID, date of birth, 
date of death (note that dates are displaced from the conventional calendar and 
need to be adjusted), gender, marital status, family number as well as a number 
of other items that are not used. 
 Two clinical event tables, each of which includes patient pseudo-ID (allowing 
linkage to the patient data table), event pseudo-ID, event date, date of event data 
entry, ‘medcode’ (local THIN code for the recorded event), as well as a number 
of other items that are not used. 
 THIN stores codes for medical events as 7-byte Read Codes version 2, where 
the last two bytes allow for synonyms but only the first 5 bytes of the code are 
clinically significant. 
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 A look-up table which converts a code for marital status to an English-language 
description of the status as a character string 
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5.2.2 CPRD 
CPRD holds data from UK general practice patients, coded in Read Codes version 2, 
containing longitudinal medical event histories and sourced primarily from practices 
using EMIS systems. The data were supplied in standard system agnostic .csv files. The 
CPRD data structure is similar to that of the THIN data. Figure 5.2 shows the CPRD 
data table schema. CPRD supply nine tables of patient, event and related data, plus 99 
lookup tables which give the meanings behind the codes used to store information in the 
data tables. All files are supplied as simple text files with tab-separated variables. Five 
data tables from the set supplied by CPRD are used: 
 The patient data table, which includes patient pseudo-ID, date of birth, date of 
death (note that dates are displaced from the conventional calendar and need to 
be adjusted), gender, marital status, family number as well as a number of other 
items that are not used. 
 The clinical event table, which includes patient pseudo-ID (allowing linkage to 
the patient data table), event pseudo-ID, event date, date of event data entry, 
‘medcode’ (local CPRD code for the recorded event), as well as a number of 
other items that are not used. 
 The immunisations table, which records immunisations for each patient and 
includes patient pseudo-ID, date of immunisation, date of immunisation data 
entry, ‘medcode’ as well as a number of other items that are not used. 
 A look-up table which maps CPRD medcodes to their equivalent Read Code 
(Read version 2). The mapping is 1:1. The Read Codes mapped to are 7-byte 
codes, where the last two bytes allow for synonyms but only the first 5 bytes are 
clinically significant. 
 A look-up table which converts a code for marital status to an English-language 
description of the status as a character string 
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5.2.3 Practice Fusion 
 
Practice Fusion holds data from US general practice patients, coded using ICD-9-CM, 
containing longitudinal medical event histories and sourced exclusively from practices 
using Practice Fusion’s systems. The data were supplied in standard system agnostic 
.csv files.The most complex of the three source data sets is that from Practice Fusion. 
The data set schema is shown in Figure 4.3. Practice Fusion supplied two sets of data, 
each containing 17 tables of patient data, event data and related data. Each table was 
stored as a text file with comma-separated variables. Five of these tables were used 
from each data set. Additionally, a bespoke lookup table was used to map clinical event 
codes recorded in the Practice Fusion data from ICD-9-CM to Clinical Terms version 3. 
The process of building this mapping table is described later in this chapter. A second 
lookup table was created to map information on patient smoking to CTV3 codes. 
The ‘Transcript’ table records information pertaining to a clinic visit – date of visit, and 
any measurements made on the patient (e.g. weight, height, blood pressure). Also at 
these visits information about diagnoses will be recorded, in a separate ‘Diagnosis’ 
table. Linking these two tables is a third table, ‘TranscriptDiagnosis’. In the Diagnosis 
table, conditions have a start date and end date recorded.  Where diagnosis start date 
(i.e. the year in which the event was first recorded) is missing, the Transcript date is 
used. 
The Practice Fusion data set was supplied as a set of 17 tables, shown in Figure 4.3. 
These tables are: 
 Patient: Contains the basic demographic information for each patient: Gender, 
Year of Birth, State, Patient’s practice identifier, and a unique identifier for each 
patient. 
 Diagnoses: Contains patient identifiers, the ICD9-CM code for each diagnosis 
together with the description associated with the ICD-9CM code, the start year 
and end year for the diagnosis, whether the condition is acute or chronic, and an 
identidier for the provider who recorded the diagnosis. 
 Condition: A table which contains valid patient conditions, as codes and 
descriptions 
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 Transcript: Records details of patient visits to providers. Contains patient ID, 
year of the visit, records of patient vital signs and indicators – height, weight, 
BMI, blood pressure, respiratory rate, heart rate and temperature. 
 Transcript Diagnosis: an associative table that lists the diagnoses per transcript. 
 Smoking Status: lists the valid values for smoking status together with the 
description of the status. 
 PatientSmokingStatus: Lists smoking statuses for each patient together with the 
year of the recorded status. 
 Allergy: The list of allergies recorded for each patient. 
 TranscriptAllergy: an associative table recording the list of allergies recorded 
per transcript. 
 Immunization 
 LabResult: Contains patient lab test results. Lists the patient ID and the provider 
ID, the transcript ID for the visit that ordered the lab test; the identifiers for the 
patient’s medical practice and for the lab test facility and the year of the test. 
 LabPanel: Contains the lab test panels reported in the lab test result. An 
associative table linking LabResults with LabObservations. 
 LabObservation: Contains laboratory test results: the HL7 code for the lab test 
observation and its name; the coding system used by the laboratory; the value of 
the observation, its units and its reference range; a flag indicating whether the 
result is abnormal; the status of the test; the year of the test. 
 Medication: the list of medications (including NDC code, name, strength and 
schedule) for each patient and ID of the diagnosis linked to the medication. 
 TranscriptMedication: an associative table linking medications and transcripts. 
 Prescription: The prescription records for each patient, including year of 
prescription, quantity, number of repeats and whether the patient can order a 
repeat prescription. 
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5.3 Merging of source data sets 
 
The process for of combining data from the source data sets into the composite data set 
has several stages, illustrated in Figure 5.4. Part 1 of Figure 5.4 illustrates the process of 
creating an aggregated dataset whereas part 2 shows how aggregated data may be 
analysed.  Each stage is of the aggregation process described in detail later in this 
chapter.  
Additionally, for subsequent analysis it was advantageous to flag each code in the 
composite data set as being an ‘administrative’, ‘symptom or treatment’, or ‘diagnosis’ 
code. The methodology for automating the process of assigning such flags to CTV3 
codes is described. 
Once the composite data set has been produced, it must be validated (described in 
Chapter 6) and is then available for analysis (described in Chapter 7). 
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Figure 5.4 Workflow for creation and analysis of composite data set 
 
Data fields to be included in the composite data set are limited to those fields that are 
present in each of the three data sets to be merged or can be deduced from those or other 
fields. Inspection of the three source data sets reveals a number of fields that are 
common to all three data sets, and a number that are present in only one or two of the 
source data sets.  
The set of common fields was inspected to ensure that each group of common fields 
were semantically interoperable. It was necessary to ensure data items in each field were 
converted to lowest common denominator. This was done by manual inspection of each 
field to determine which level of detail would ensure that data was captured at the 
broadest level of granularity across the source data sets. For example age and event 
dates in the composite data set were captured in years only: years for event occurrences 
(e.g. dates of birth) are available across all three data sets but in finer detail (for dates of 
birth, years and months) in only some of the data sets. The set of fields to be included in 
the composite data set is the intersection of the list of fields across all three data sets. 
Table 5.1 shows which fields are present in each data set, with a list of descriptions for 
each field that falls under that topic for each source data set.  
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Composite Data 
Set Field Name 
Practice Fusion 
Field Name CPRD Field Name THIN Field Name 
Patient ID Pseudo-ID Pseudo-ID Pseudo-ID 
Gender M or F Integer integer 
Date of birth Year of birth month and year of 
birth 
year of birth (and 
month for children) 
Date of death  date of death date of death 
Cause of death   cause of death 
Address State GP practice region urban or rural; 
ethnicity of ward; 
pollution in ward; 
whether a residential 
institute 
marital status  current marital status marital status 
Family 
information 
 Family ID number Family ID number 
child health 
surveillance 
 whether registered 
with CHS, date of 
registration 
 
prescribing 
exemption 
 type of exemption prescription 
exemption code 
capitation 
supplement 
 type of supplement  
socio-economic 
status 
 [Included in CPRD 
data dictionary but not 
populated] 
 
First 
Registration 
with practice 
 date first registered 
with practice 
registration date with 
practice 
Current 
registration with 
practice 
 date current period of 
registration began 
 
registration 
status 
 registration status registration status; 
whether they are a 
dispensing patient 
registration gaps  count of days missing 
in registration status 
 
internal transfer 
outs 
 number of internal 
transfer out periods 
 
date transferred 
out 
 date the patient 
transferred out of the 
practice 
date the patient 
transferred out of the 
practice 
reason 
transferred out 
 reason patient 
transferred out of the 
practice 
 
 114 
 
other 
registration 
information, 
registration 
acceptance type 
  extended registration 
info 
Practice ID Practice 
identifier 
encrypted identifier  
last collection 
date 
 date of last collection 
for the practice 
 
practice data 
quality 
 date at which the 
practice data is of 
research quality 
 
Diagnosis ICD9 code  GPRD code Read code 
Diagnosis description   
Diagnosis start year   
Diagnosis stop year   
Diagnosis acute or chronic   
Diagnosis provider 
recording info 
  
Diagnosis  Date of diagnosis 
event 
Date of diagnosis 
event 
Diagnosis  diagnosis type, e.g. 
diagnosis or symptom 
 
Diagnosis  ID of staff member 
entering info 
ID of staff member 
entering info; source 
of record 
Diagnosis  episode type  
Diagnosis   event end date 
Allergy type   
Allergy start year   
Allergy allergic reaction 
name 
  
Allergy Severity   
Allergy NDC code of 
medication 
taken for the 
allergy 
  
Allergy name of 
medication 
taken for the 
allergy 
  
Allergy provider 
recording info 
  
Conditions Condition code   
Conditions Condition name   
Conditions Year   
Smoking status status 
description 
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Smoking status NIST code   
Smoking status  year   
Immunizations vaccine name   
Immunizations year of 
administration 
date of administration  
Immunizations CVX code compound 
administered 
 
Immunizations  individual 
components of 
compound 
administered 
 
Immunizations immunization 
provider 
staff ID, location of 
administration 
 
Immunizations  immunization type  
Immunizations  GPRD medcode  
Immunizations  stage of the 
immunization given 
 
Immunizations  immunisation status  
Immunizations  immunisation reason  
Immunizations  immunisation route  
Transcript year   
Transcript height   
Transcript weight   
Transcript BMI   
Transcript blood pressure   
Transcript respiratory rate   
Transcript heart rate   
Transcript temperature   
Transcript physician 
specialty 
  
Transcript Transcript 
provider 
  
Transcript Diagnosis   
Consultation  Consultation date  
Consultation  type of consultation  
Consultation  consultation ID  
Consultation  Staff ID  
Consultation  Consultation duration  
Additional 
clinical details 
 dependent on entity 
type 
 
Referral  referral date  
Referral  referral category  
Referral  GPRD med code  
Referral  staff ID entering data event recorded in 
practice; private or 
NHS 
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Referral  source of referral  
Referral  NHS classification of 
referral specialty 
 
Referral  FHSA classification 
of referral specialty 
 
Referral  Referral type episode type 
Referral  Attendance type  
Referral  Referral urgency  
Referral   Referral location 
Referral   Cat of medical entry 
Test  Test date  
Test  consultation type  
Test  GPRD medcode  
Test  staff ID  
Test  qualifier  
Test  normal range from, to, 
basis 
 
Test  various fields 
depending on test type 
 
Therapy year of 
prescription 
date of event prescription date 
Therapy NDC code and 
medication 
name 
GPRD product code drug code 
Therapy User ID Staff ID staff ID 
Therapy strength daily dose dosage; calculated 
daily dosage 
Therapy  BNF code BNF chapter 
Therapy quantity quantity, number of 
packs, pack size or 
type 
quantity prescribed or 
number of packs; pack 
size 
Therapy start year, stop 
year, schedule 
treatment days duration 
Therapy number of 
refills 
available for repeat 
prescription 
acute or repeat 
prescription; sequence 
number for repeat 
prescriptions; max 
number of repeat 
issues 
Therapy   private or NHS 
prescription 
Therapy   source of drug 
Therapy   event recorded in 
practice Y/N 
Hospital event   Clinical specialty - 
code & description 
Hospital event   Clinical sub-specialty 
- description 
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Table 5.1 Description of fields present in each data set 
 
Table 5.2 shows, for each of the candidate fields for the composite data set whether that 
field is present in each of the source data sets or can be derived from other fields in the 
source data sets. 
The fields for each source data set have been colour coded in Table 5.2 as follows: 
  Fields that match at a higher level of granularity  
  Fields that match at a lower level of granularity 
  Fields with no data in that particular source data set 
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Field 
number 
Topic Practice  
Fusion 
example CPRD example THIN example 
 
  
 
 
 
 
 
1 Patient ID BC78C551   
2 Gender  F     
3 Date of birth  1981     
4 Date of death 
 
NULL     
5 Cause of death 
 
     
6 Address 
 
NY 
 
 
 
 
7 marital status 
 
   
8 family relationships 
 
     
9 child health 
surveillance 
 
 
 
 
 
 
10 prescribing exemption 
 
     
11 capitation supplement 
 
     
12 socio-economic status 
 
     
13 First Registration with 
practice 
 
  
 
 
14 Current registration 
with practice 
 
 
 
 
 
 
15 registration status 
 
     
16 registration gaps 
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17 internal transfer outs 
 
     
18 date transferred out 
 
     
19 reason transferred out 
 
     
20 other registration 
information 
 
 
 
 
  
 
21 Practice ID 3E08ED81    
22 last collection date       
23 practice data quality       
24 Clinical event code       
25 Clinical event 
description  
 
 
 
 
 
26 Clinical event start 
date  
2011 
 
 
 
 
27 Clinical event end 
date  
NULL 
 
 
 
 
28 Acute or chronic  Acute     
29 Diagnoser provider 
information  
 
 
 
 
 
31 Diagnosis  272.2; 402.1; 715.16     
32 Diagnosis episode 
type  
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33 Allergy type  Medication     
34 Allergy start date  2011     
35 Allergy name  Tongue swelling     
36 Allergy severity  Severe     
37 Allergy medication 
code  
247224300 
 
 
 
 
38 
Allergy medication 
name   
Trilipix (fenofibric 
acid) oral delayed 
release capsule 
 
 
 
 
39 Allergy diagnoses 
provider info  
F7998EB6 
 
 
 
 
40 Smoking status 
description 
 
0 cigarettes per day 
(non-smoker or less 
than 100 in lifetime)  
 
 
 
41 Smoking status code  5ABBAB35   
 
 
42 Smoking status  date  2010   
 
 
43 Immunization name      
44 
Immunization date  
2008 (Hepatitis B 
vaccine, adolescent 
(2 dose schedule), 
for intramuscular  
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use) 
45 Immunization code  43     
46 Immunization 
components  
 
 
 
 
 
47 Immunization 
provider  
 
 
 
 
 
48 Immunization type       
49 Immunization stage       
50 Immunization status       
51 Immunization reason       
52 Immunization route       
53 Physical 
characteristics date  
 
 
 
 
 
54 Physical 
characteristics height  
63 
 
 
 
 
55 Physical 
characteristics weight  
120 
 
 
 
 
56 Physical 
characteristics BMI  
21.255 
 
 
 
 
57 Physical 
characteristics blood  
120/80 
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pressure 
58 Physical 
characteristics 
respiratory rate  
18 
 
 
 
 
59 Physical 
characteristics heart 
rate  
NULL 
 
 
 
 
60 Physical 
characteristics 
temperature  
95.2 
 
 
 
 
61 Physical 
characteristics 
physician speciality  
Internal Medicine 
 
 
 
 
62 Physical 
characteristics 
provider  
 
 
 
 
 
63 Consultation date 
 
2011  
 
 
64 Consultation type 
 
   
 
 
65 Consultation - staff 
ID 
 
A75DB583 
 
 
 
 
66 Consultation duration 
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67 Referral date 
 
   
 
 
68 Referral category 
 
     
69 Referral code 
 
   
 
 
70 Referral - staff ID 
 
   
 
 
71 Referral source 
 
   
 
 
72 Referral - 
classification of 
referral specialty 
 
 
 
 
 
 
73 Referral type 
 
   
 
 
74 Referral attendance 
type 
 
 
 
 
 
 
75 Referral urgency 
 
   
 
 
76 Test date 
 
   
 
 
77 Test type 
 
   
 
 
78 Test code 
 
   
 
 
79 Test - staff ID 
 
   
 
 
80 Test qualifier     
81 Test - normal range       
82 Test other       
83 Therapy date  2011     
84 Therapy - drug or  378710177 -     
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other product code Fenofibrate oral 
tablet 
85 Therapy - staff ID  1E961D5D     
86 Therapy - dose  160 mg     
87 Therapy - BNF code       
88 Therapy quantity  14    
89 Therapy length  NULL     
90 Therapy repeat  0    
91 Therapy private or 
NHS prescription  
 
 
 
 
 
92 Therapy drug source       
93 Therapy event 
recorded in practice 
 
 
 
 
  
 
94 Hospital event - specialty code 
and description 
 
 
 
  
 
95 Hospital event - subspecialty 
description 
 
 
 
  
 
Table 5.2 Fields present in each of the source data sets
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Combining all three data sets into a single data set, the following common fields are 
retained from the source data sets: 
Patient ID [P] 
Gender [P] 
Year of birth [P] 
Year of death [P] 
Practice ID [P] 
Clinical event code [M] 
Clinical event start year [M] 
Acute or chronic [M] 
Allergy type [M] 
Allergy start year [M] 
Allergy name [M] 
Smoking status code [P] 
Smoking status date [P] 
Immunisation code [M] 
Immunisation date [M] 
Therapy date [M] 
Therapy code [M] 
Therapy dose [M] 
Therapy quantity [M] 
Therapy length [M] 
 
[P] patient-level fields – one per patient.  
[M] event-level fields – many per patient. 
5.4 Convergence of event codes onto a single coding system 
5.4.1 Coding system convergence 
There exist a number of different systems into which clinical events can be coded. for 
example the International Classification of Diseases (ICD) widely used in the US which 
in its latest mature iteration is version 10 but many healthcare enterprises are using 
earlier versions; SNOMED CT, the largest coding system in terms of number of 
concepts; Read Codes, the most common system in UK primary care, which in its latest 
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iteration is Clinical Terms Version 3 (CTV3) but is most commonly used in version 2. It 
should be noted that the UK Department of Health has mandated the use of SNOMED 
CT from April 2020. When combining or comparing data sets from different sources 
using different coding systems, it is necessary to map clinical event codes to a single 
common coding system, which may be a system used by one or more of the source 
datasets or may be a new coding system. Bonney et al [214] write: “Mapping data 
elements in EHRs to a reference classification and/or terminology system not only 
facilitate reuse of primary care data for multiple purposes, but they also support data 
analysis, health information exchange and interoperability, and data comparison across 
the continuum of different healthcare providers [and] improves the quality of the 
research output derived from EHRs.” 
In this section, it is demonstrated how events recorded in one clinical coding system 
may be mapped to codes in a different system where no direct mapping between the two 
systems exists but where mapping is possible via a third coding system. 
The work described in this section has been submitted as a paper to Methods of 
Information in Medicine and is under review at the time of writing. The paper can be 
found in Appendix 1. 
 
Medical records since their inception have contained free text, with medical conditions 
and symptoms described by natural language terms that may be imprecise or 
ambiguous. Recent decades have seen a steady increase in the uptake of electronic 
health records (EMR) systems [1] [2]. There are now a large number and variety of 
terminologies used to code events recorded in these EMR systems, with it being 
estimated that there are over 100 terminologies currently in use [3]. For aggregation of 
data or analysis over time, a controlled, pre-defined vocabulary is required, with codes 
representing concepts that allow for descriptive synonyms [4]. A number of coding 
systems have been created over recent decades, including the International 
Classification of Diseases [5]; the Read Codes [6], the most common system in UK 
primary care, which in its latest iteration is Clinical Terms Version 3 (CTV3) but is 
most commonly used in version 2; and SNOMED CT [7], the largest coding system in 
terms of number of concepts. Modern electronic health records systems may use any of 
these existing systems, with different countries or regions favouring one system over 
another: in 2001, de Lusignan et al [8], in a survey of systems in use in Europe, found 
that the Read Codes were the most common system in use in primary care in the UK, 
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ICD-10 the most common in primary care in Austria and Germany, and ICPC in a 
further 10 European countries. ICD-9, until its recent supersession by ICD-10, has been 
the dominant system in primary care in the USA.  
There are several reasons why it may be necessary to move from one coding system to 
another: government mandate; the desire to use an up-to-date coding system; 
compatibility with other data repositories, e.g. in a newly-shared EHR system; 
combining data sets from disparate sources for research or audit purposes. Code 
mapping is an approach to enable codes from one system to be translated to their 
semantically equivalent codes in another system, a process that has been defined as “the 
process of associating concepts or terms from one coding system to concepts or terms in 
another coding system and defining their equivalence in accordance with a documented 
rationale and a given purpose” [9]. In order to combine data from diverse datasets coded 
using different coding systems it is necessary to converge the data sets onto a common 
coding system. At a minimum, translation of data items recorded in the coding system 
used in one of the source data sets to another coding system is required. However, the 
opportunity exists for all event codes from multiple sources to be mapped to a third 
coding system if that system has advantages over either of the coding systems in use in 
the existing data sets. When combining or comparing data sets from different sources 
using different coding systems, it is necessary to map clinical event codes to a single 
common coding system, which may be a system used by one or more of the source 
datasets or may be a new coding system. Bonney et al [10] write: “Mapping data 
elements in EHRs to a reference classification and/or terminology system not only 
facilitate reuse of primary care data for multiple purposes, but they also support data 
analysis, health information exchange and interoperability, and data comparison across 
the continuum of different healthcare providers [and] improves the quality of the 
research output derived from EHRs.” 
An issue which can occur when combining datasets is that of semantic interoperability, 
in particular equivalence in the coding of clinical concepts. It is relatively 
straightforward to combine demographic information between systems since, for 
example, “there is general agreement as to what ‘age’ means in relation to a patient” 
[11] and there is similar agreement for names of individuals and dates, but it is less 
straightforward to map clinical concepts or their coded representation between different 
terminologies. One long-standing method is to match the text description of concepts 
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(e.g. [12] [13] [14]; [15] [16]). The majority of work in automatic mapping has focused 
on the lexical approach, using techniques similar to those used for automatic mapping 
from free text clinical notes to concept codes (for example [17] and [18]).  However, 
Fung et al [19] found that ‘Semantic mapping performed better than lexical mapping’. 
Cimino and Barnett [20] proposed a method of semantic mapping by which each 
concept in a terminology was characterised by a set of properties, with concepts being 
mapped across terminologies according to the closest similarity in properties. This 
method requires each concept to be characterised manually in a process described as 
‘tedious [but] not complicated’. A similar approach was proposed by Rocha et al [21]. 
Mappings exist between some of the major coding systems in current use, particularly 
between older and newer versions of coding systems, e.g. ICD-9-CM and ICD-10-CM; 
Read Codes Version 2 and CTV3, provided by several organisations and individuals, 
often those responsible for the maintenance of the coding systems. In the UK, the 
Department of Health Technology Reference-data Update Distribution service (TRUD) 
[22] provides mappings between a number of coding systems, in particular those 
systems in common use in the UK: SNOMED CT, Read 2, CTV3. In the US, mappings 
are provided between systems more common in that country by the Centers for 
Medicare and Medicaid Services (CMS), International Health Terminology Standards 
Development Organisation (IHTSDO), Unified Medical Language System (UMLS), 
National Library of Medicine (NLM). Brouch [23] gives an introduction to the mapping 
process and contains a glossary of relevant terms. Nandigam and Topaz [24], describing 
their work in mapping SNOMED CT to ICD10-CM, note that the SNOMED CT to 
ICD10-CM mappings from NLM “may need to be modified on the basis of the clinical 
specialty and patient population and further validated.” Previous work on creating 
mapping tables between coding systems has been primarily by human experts 
comparing text descriptions of codes in different coding systems, e.g. [25]; with the 
assistance of a text search tool, e.g. [26], [20]; or by automated text matching [21]. One 
problem described by Nadkarni & Darer [26] was that of missing mappings: in their 
work in investigating the completeness of mapping a data set from ICD-9-CM to 
SNOMED CT they found that 784 (of 2199; 35.8%) ICD-9-CM codes in their data set 
had no map to an equivalent SNOMED CT code in the UMLS ICD-9-CM to SNOMED 
CT cross-map, requiring them to create these mappings by hand. 
 129 
 
5.4.2 Choice of target coding system 
UK data consisted of with clinical events coded in Read Codes V2, and US data was 
composed of clinical events coded in ICD-9-CM. Several coding systems were 
considered as candidates for the target common coding system. These coding systems 
were: 
 
 Read Codes Version 2 (Read 2). The standard clinical terminology in use in UK 
general practice, introduced in 1990. The base Read Codes are 5 bytes, with an 
optional 2 byte extension to allow for synonyms. The UK dataset used in this 
work had clinical events coded using Read Codes version 2. 
 
 Read Clinical Terms Version 3 (CTV3). Introduced in the late 1990s, with an 
increased number of codes compared to Read v2 and improvements to the code 
ontology and terminology. However, the majority of UK general practices 
continue to use Read v2. 
 
 SNOMED CT. Created in 2001, a merger of CTV3 and SNOMED RT. Use of 
SNOMED CT rather than Read Codes (whether version 2 or 3) is mandated for 
UK General Practices by April 2018 and for UK NHS secondary care by April 
2020. 
 
 International Classification of Diseases 9th edition, Clinical Modification (ICD-
9-CM) or 10
th
 edition (ICD-10-CM). ICD codes are maintained by the World 
Health Organisation. Version 9 was introduced in 1978, with ICD-10 introduced 
from 1994 (ICD-9 is still maintained annually). The US dataset used in this 
work had clinical events coded using ICD-9-CM. 
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CTV3 was chosen as the target common coding system for the following reasons: 
(i) This is the most recent development of the Read Codes, which allows for 
parent-child hierarchies to be represented by a separate table rather than by 
the structure of the codes themselves; Read Codes are optimised for 
secondary use [215]; 
(ii) A simple, complete and clinically validated mapping exists from Read 2 to 
CTV3. The mapping is freely available under licence from NHS TRUD; 
(iii) No mappings exist from ICD-9-CM to either Read 2 or CTV3 and so there is 
no reduced effort required in mapping ICD-9-CM to Read 2 compared to 
CTV3; 
(iv) CTV3 is closely aligned to SNOMED CT which is mandated for use in UK 
NHS  primary care by April 2018 and in UK NHS secondary care by April 
2020; 
(v) CTV3 is a simpler coding system than SNOMED CT, with a single code per 
condition, which was an advantage for subsequent analysis of the merged 
data set; 
(vi) Both Read 2 and ICD-9-CM include clinically obsolete terms (e.g. ICD-9-CM 
318.0 ‘imbecile’) or relationships (e.g. Read Codes version 2 code E220. 
‘Homosexuality’ is categorised under code E22.. ‘Sexual deviations or 
disorders’ (whereas in CTV3 ‘Homosexuality’ is categorised under code 
X766p ‘Sexual orientation’), a situation which is addressed in CTV3; 
(vii) CTV3 is well structured, with an existing, clinically-validated, table of parent-
child relationships within the coding hierarchy; 
(viii) There exists a simple mapping available from TRUD for mapping from Read 2 
to CTV3 suitable for the UK data sets.  
(ix) Mappings exist between some of the major coding systems in current use, 
provided by several organisations and individuals. In the UK, the 
Department of Health Technology Reference-data Update Distribution 
service (TRUD) provides mappings between a number of coding systems, in 
particular those systems in common use in the UK: SNOMED CT, Read 2, 
CTV3. In the US, mappings are provided between systems more common in 
that country by the Centers for Medicare and Medicaid Services (CMS), 
International Health Terminology Standards Development Organisation 
(IHTSDO), Unified Medical Language System (UMLS), National Library of 
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Medicine (NLM). Additionally, some mappings were found for ICD-9-CM 
to SNOMED CT in the work of Nadkarni and Darer [189], who had created 
some mappings for ICD-9-CM codes present in their data but not mapped in 
the NLM table.  
(x) Existing mappings found are listed in Table 5.3. Note that mappings may not 
be bi-directional. 
 
 
Target 
coding     
Source 
coding 
ICD-9-CM ICD-10-CM SNOMED CT Read 2 CTV3 
ICD-9-CM - CMS NLM, ND   
ICD-10-CM CMS -    
SNOMED CT 
TRUD, 
IHTSDO 
UMLS - TRUD TRUD 
Read 2  TRUD TRUD - TRUD 
CTV3  TRUD TRUD TRUD - 
Table 5.3 Available inter-system code mappings and their sources 
Sources for the available code mappings: 
TRUD - Department of Health Technology Reference-data Update Distribution service 
 CMS - Centers for Medicare and Medicaid Services 
 IHTSDO - International Health Terminology Standards Development 
Organisation 
 UMLS - Unified Medical Language System 
 NLM – National Library of Medicine 
 ND – Nadkarni & Darer 
 
 
NLM provides mapping tables which map 6285 ICD-9-CM codes 1:1 to SNOMED CT 
codes and 3508 ICD-9-CM codes in 1:many maps to SNOMED CT codes, a total of 
9793 unique ICD-9-CM codes. The data set which is required to be mapped to CTV3 
contains 4342 unique ICD-9-CM codes, 44.3 % of the codes in the NLM mapping table.  
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NHS TRUD provides a SNOMED CT to CTV3 mapping table, which comprises of 
747,717 unique SNOMED CT codes. The 4342 ICD-9-CM codes in the data set map to 
2640 SNOMED CT codes, a mere 0.35 % of the codes in the NHS TRUD mapping 
table.  
 
Both the Read Codes version 2 to CTV3 and the ICD-9-CM to CTV3 mapping 
processes were implemented using the Konstanz Information Miner (KNIME) [216]. 
KNIME is an open source data analytics and exploration modular environment 
providing a number of data manipulation and analysis modules. KNIME has several 
advantages over traditional programming which suggested it as a suitable tool for this 
work. These advantages include: 
 
Rapid programming. Many of the required tasks, such as file reading and writing, SQL-
type joining of tables, selection by field content, are available in pre-defined nodes that 
are quick to set up; 
 Reduction in the programming required and thus reduction in the potential for 
programming error; 
 It is possible to inspect the data after each step, helping find where errors have 
been made in the programming; 
 Typographic errors are reduced by presenting a pull-down list of valid variables 
at each step; 
 The program is open-source and well supported by the development team and 
community of users; 
 Workflows created can be saved and are simple to share; 
 Workflows created are easy to display and are a useful tool for describing the 
manipulation performed on data sets. 
 
A simple KNIME workflow was written to enable the Read Codes version 2 mapping. 
This workflow is shown in Figure 1. Of the 14239 unique Read Codes Version 2 codes 
from the UK-sourced data, 100 % successfully mapped to a CTV3 code using tables 
from the UK Technology Reference Data Update Distribution (TRUD), mapping to 
13947 unique CTV3 codes.  
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Figure 5.5 Read Codes Version 2 to CTV3 mapping process using NHS TRUD 
mapping. 
This simple workflow has three steps: (i) the source data file containing Read Codes 
Version 2 codes is read; (ii) using a simple look-up table derived from NHS TRUD 
mappings, Read 2 codes are paired with their equivalent CTV3 codes; (iii) the mapped 
file is saved. 
 
No existing mapping was found from ICD-9-CM to CTV3 (see Table 5.3). However, 
mappings were available from ICD-9-CM to SNOMED CT from the US National 
Library of Medicine [217] (“NLM”) and from SNOMED CT to CTV3  from the NHS 
Digital Technology Reference data Update Distribution [218] (“TRUD”).  
For mapping the US data to CTV3, a two stage process was proposed: 
1. Map ICD-9-CM to SNOMED CT using NLM look up table; 
2. Map SNOMED CT to Read CTV3 using TRUD look up table. 
 
NLM supplies ICD-9-CM to SNOMED CT mapping tables in two tables: a 1:1 mapping 
table, where a single ICD-9-CM code maps to a single SNOMED CT code; and a 
1:many mapping table, where a single ICD-9-CM code maps to many SNOMED CT 
codes, reflecting the increased nuance of description allowed by the larger number of 
SNOMED CT codes when compared to the less expressive ICD-9-CM codes. For 
example, the single ICD9-CM code 578.1 ‘Blood in stool’ has 8 SNOMED CT codes: 
405729008 ‘Hematochezia (finding)’; 2901004 ‘Melena (disorder)’; 59614000 ‘Occult 
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blood in stools (finding)’; 300392005 ‘Stool flecked with blood (finding)’; 272045003 
‘Complaining of melena (finding)’; 269900004 ‘Feces: fresh blood present (finding)’; 
249624003 ‘Blood in feces symptom (finding)’; 275782008 ‘Melena on examination of 
feces (disorder)’. Some ICD-9-CM codes have a very large number of matching 
SNOMED CT codes: ICD-9-CM code 995.29 ‘Unspecified adverse effect of other drug, 
medicinal and biological substance’ maps to 1636 unique SNOMED CT codes, each 
specifying the particular adverse reaction, e.g. SNOMED CT code 293199005 
‘Glymidine adverse reaction (disorder)’. Given the potentially large number of possible 
matches in the 1:many table, a decision was made to map codes automatically using 
only the 1:1 mapping table, manually mapping any codes that were not mapped by the 
1:1 mapping table. 
 
Once the necessary mapping tables had been obtained from NLM and from TRUD, the 
ICD-9-CM codes present in the data set were mapped to SNOMED CT. These mapped 
codes were then further mapped from SNOMED CT to CTV3 and a single, direct ICD-
9-CM to CTV3 mapping table was generated. The mapping process was then checked 
for completeness and exactness. Codes that failed the mapping process or were judged 
to have been incorrectly mapped were mapped manually. Figure 5.6 illustrates the 
proposed mapping. Also included is a route for mapping directly from ICD-9-CM to 
CTV3 for codes which fail to map at either of the indirect mapping stages and which 
have to be mapped manually.  
 
 
Figure 5.6 ICD-9-CM to CTV3 mapping process via SNOMED CT 
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Figure 5.7 KNIME workflow implementing the ICD-9-CM to CTV3 mapping process
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A KNIME workflow was written which combined the existing ICD-9-CM to SNOMED 
CT and SNOMED CT to ICD-9-CM mappings to create a single ICD-9-CM to CTV3 
mapping table. Six steps are used within the KNIME workflow to produce the ICD-9-
CM to CTV3 mapping table. These steps are combined into the single KNIME 
workflow shown in Figure 5.7. 
. The workflow is broken down into six discrete sections: 
 
 
Figure 5.8 Import and prepare ICD-9-CM to SNOMED CT mapping files 
  
The two external ICD-9-CM to SNOMED CT mapping files, from NLM and from the 
work of Nadkarni and Darer, are imported and combined into a single mapping table. 
An entry is made against each ICD-9-CM code to note the source of its mapping to 
SNOMED CT. Figure 5.8 shows the subsection from the complete workflow that 
performs these tasks. 
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Figure 5.9 Import and preparation of the SNOMED CT to CTV3 mapping file 
and associated CTV3 codes descriptions file 
 
The SNOMED CT to CTV3 mapping file obtained from TRUD is imported. The table 
of CTV3 codes and corresponding descriptions, also from TRUD, is imported. Unused 
fields in the CTV3 descriptions table are removed and the remaining fields renamed to 
ensure consistency across the complete workflow. This section of the workflow is 
shown in Figure 5.9. 
 
 
Figure 5.10 Import of local ICD-9-CM to CTV3 mapping file 
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For those ICD-9-CM codes that failed to map to SNOMED CT codes, or for which 
improved mappings have been found, a manually created local mappings file is 
imported. A field noting the source of these mappings is added. This stage of the 
workflow is shown in Figure 5.10. 
 
 
Figure 5.11 Building the complete ICD-9-CM to CTV3 mapping table 
 
In this stage, the composite (NLM and Nadkarni-Darer) ICD-9-CM to SNOMED CT 
code mapping table and the SNOMED CT to CTV3 mapping table are joined by use of 
an inner join on SNOMED CT codes, i.e. all maps that have SNOMED CT values 
present in both the ICD-9-CM to SNOMED CT table and the SNOMED CT to CTV3 
table are selected to produce a table of ICD-9-CM to SNOMED CT to CTV3 mappings. 
Examples of the mappings produced are shown in Table 2. The intermediate SNOMED 
CT fields are now dropped from the table, and duplicate mappings are removed by 
forcing unique values for ICD-9-CM codes. This automatically generated ICD-9-CM to 
CTV3 mapping table is then augmented by combining it with the manually-created 
local table to give the fullest mapping table. Figure 5.11 shows the section of the 
workflow that builds the most complete ICD-9-CM to CTV3 mapping table. 
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ICD-9-CM 
code 
ICD-9-CM 
description 
SNOMED 
CT code 
SNOMED CT 
description 
CTV3 
code 
CTV3 
description 
427.31 Atrial 
fibrillation 
49436004 Atrial fibrillation 
(disorder) 
G5730 Atrial 
fibrillation 
599.0 Urinary tract 
infection, site 
not specified 
68566005 Urinary tract 
infectious 
disease 
(disorder) 
XE0e0 Urinary 
tract 
infection 
585.6 End stage 
renal disease 
46177005 End stage renal 
disease 
(disorder) 
X3030 End stage 
renal 
disease 
Table 5.4 Example automatic ICD-9-CM - SNOMED CT - CTV3 mappings 
 
 
 
Figure 5.12 Save ICD-9-CM to CTV3 mapping table and file of unmapped codes 
 
In this stage, shown in Figure 5.12, the data set coded in ICD-9-CM is imported. This is 
the data set containing codes that are required to be mapped to CTV3. To perform this 
mapping, each ICD-9-CM code in the data set is searched for in the ICD-9-CM to 
CTV3 mapping table and, should a mapping be found, the equivalent CTV3 code is 
added to the data set. If no mapping is found, the ICD-9-CM code is flagged as being an 
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unmapped code. Those ICD-9-CM codes that mapped to a CTV3 code had that CTV3 
code's description added. Items in the data set with ICD-9-CM codes that did not map to 
CTV3 codes were then split from the data set and passed to step 6; data set items which 
now had a CTV3 code were written to file for further analysis.  
 
 
 
Figure 5.13 Capture of ICD-9-CM codes that require to be manually mapped. 
 
Data set items where the ICD-9-CM code did not have an equivalent CTV3 code in the 
mapping table were then operated on in this section of the workflow, shown in Figure 
5.13. Firstly, unique values for the unmapped ICD-9-CM codes were extracted and the 
frequency of occurrence of each of these unmapped codes calculated. These unique 
codes and their frequencies were then placed in a table which was written to a file which 
was then available for manual inspection and mapping. Manually mapped codes in this 
stage were then appended to the existing local manual mapping table imported in stage 
3, or if the local manual mapping table did not yet exist, this table was saved and used 
as the first iteration of the manual mapping table. The KNIME workflow was run each 
time that the manual mapping table was updated. 
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Results 
 
Figure 5.14 Results of the complete mapping processes. 
When the complete workflow was run on the source dataset, it was observed that a 
significant number of codes did not map successfully, i.e. there was no ICD-9-CM to 
CTV3 mapping for these codes produced by the workflow, implying either that the 
ICD-9-CM to SNOMED CT mapping or the subsequent SNOMED CT to CTV3 
mapping was incomplete. Additional mappings generated by Nadkarni and Darer [189], 
who had previously found this problem of missing mappings in their own work 
mapping ICD-9-CM codes to SNOMED CT codes, were added to the ICD-9-CM to 
SNOMED CT mapping table. Nadkarni and Darer had mapped 784 codes from ICD-9-
CM to SNOMED CT, of which 399 were present in the data set used in this work (2 of 
which codes were also mapped in the NLM mapping table: ‘345.11 Generalized 
convulsive epilepsy, with intractable epilepsy’ and ‘V10.82 Personal history of 
malignant melanoma of skin’). This left a further 1562 codes in the data set that did not 
map from ICD-9-CM codes to SNOMED CT codes. For the subsequent SNOMED CT 
to CTV3 mapping, there were 6 SNOMED CT codes produced by the ICD-9-CM to 
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SNOMED CT mapping that failed the subsequent map to CTV3, giving a total of 1568 
ICD-9-CM codes that did not map automatically from ICD-9-CM codes to CTV3. 
Figure 5.14 shows the results for each stage of the mapping process, both automatic and 
manual. 
 
There were some areas of concern with the mappings. For the ICD-9-CM to SNOMED 
CT mapping, there were many one-to-one code mappings but there were also some one-
to-many code mappings (for example, ICD-9-CM code 722.52 ‘Degeneration of lumbar 
or lumbosacral intervertebral disc’ maps to SNOMED CT code 26538006 
‘Degeneration of lumbar intervertebral disc (disorder)’ or 60937000 ‘Degeneration of 
lumbosacral intervertebral disc (disorder)’ ) and it was not always possible to map to 
more a more granular SNOMED CT code that would be a single parent of the ‘many’ 
target codes (see US National Library of Medicine, 2016 for a discussion of this issue). 
For those ICD-9-CM codes for which many SNOMED CT codes were suggested, the 
first suggested code was taken as the mapped code and this code was then used as the 
basis for the subsequent mapping to CTV3.  
 
To further reduce the number of unmapped codes, a fourth mapping table was created, 
directly mapping ICD-9-CM to CTV3. This table was created by generating a list of 
unmapped codes, prioritised by the frequency with which these codes appeared in the 
source data set (in order to allow development work on analysis of this data set to 
proceed before this manual mapping table was complete by focussing mapping work on 
the most common unmapped codes) but also opportunistically mapping clinically 
related unmapped codes at the same time as mapping the unmapped more-frequent 
codes. Equivalent ICD-9-CM to CTV3 code mappings were deduced by inspection of 
code descriptions and by each code’s position in the CTV3 code hierarchy. Some codes 
in ICD-9-CM had very similar descriptions in CTV3, perhaps differing only in US vs 
UK spelling or in word ordering in the description and so the mapping was 
straightforward (e.g. ICD-9-CM code 782 “Disturbance of skin sensation” was mapped 
to CTV3 code XM07D “Skin sensation disturbance”), others had markedly different 
descriptions in the two coding systems and relied on an understanding of synonyms for 
the same conditions (e.g. ICD-9-CM code 734 “Flat foot” was mapped to CTV3 code 
N34.. “Pes planus”). 
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1944 ICD-9-CM to CTV3 manual mappings were created. There were 14 ICD-9-CM 
codes that were not mapped automatically and could not be mapped manually, since a 
search of ICD-9-CM and CTV3 concept descriptions (including synonyms) did not find 
a close match in the CTV3 descriptions to the ICD-9-CM concept description. It is 
believed that these ICD-9-CM codes remain unmapped because there is no equivalent 
CTV3 code to be found. These unmapped codes are listed in Table 4. 
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Examples of codes that required to be matched manually: 
(1) Simple match 
ICD-9-CM code 477 "Allergic rhinitis" mapped to CTV3 code XE0Y5 "Allergic 
rhinitis" 
Failed to map at the ICD-9-CM to SNOMED CT stage: code 477 not found in UMLS 
1:1 or 1:many mapping tables, nor in the Nadkarni-Darer mapping table.  
 
(2) Match with minor US vs UK spelling variation: 
ICD-9-CM code 599.7 "Hematuria" mapped to CTV3 code K197. "Haematuria" 
Failed to map at the ICD-9-CM to SNOMED CT stage: code 599.7 not found in UMLS 
1:1 or 1:many mapping tables, nor in the Nadkarni-Darer mapping table.  
 
(3) More complex match: different word: 
ICD-9-CM code 54.7 "Other Repair Of Abdominal Wall And Peritoneum" mapped to 
CTV3 code Xa9ZY "Repair of mesentery" 
Failed to map at the ICD-9-CM to SNOMED CT stage: code 54.7 not found in UMLS 
1:1 or 1:many mapping tables, nor in the Nadkarni-Darer mapping table. 
 
(4) More complex match: different order of words: 
ICD-9-CM code 715.04 ‘Osteoarthritis, generalized, involving hand’ mapped to CTV3 
code XE1DW ‘Generalised osteoarthritis of the hand’ 
Failed to map uniquely at the ICD-9-CM to SNOMED CT stage: code 54.7 not found in 
UMLS 1:1 table, 6 options found in the 1:many mapping tables; not in the Nadkarni-
Darer mapping table. 
 
Mapping accuracy and efficiency was improved by experience and knowledge of the 
terms in the mapping tables, in particular an understanding of the differences between 
US and UK spellings and of English terms versus Latin terms. Searching for equivalent 
terms could also be expedited by search for word stems rather than complete words, for 
example if searching for a CTV3 equivalent to the ICD-9-CM code 601 ‘Inflam 
diseases of prostate’, a search for the stem ‘prostat’ would find the CTV3 code XE0e7 
‘Prostatic inflammatory disease’, which would have been missed by a search for the 
whole word ‘prostate’. 
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The complete workflow built the latest version of the mapping table using input from 
the US National Library of Medicine mapping table for ICD-9-CM to SNOMED CT, 
the Nadkarni-Darer mapping table for ICD-9-CM to SNOMED CT, the NHS Digital 
Technology Reference data Update Distribution mapping table for SNOMED CT to 
CTV3, and the manual direct mapping table for ICD-9-CM to CTV3. This allowed the 
latest version of the manual mapping table to be used and further allowed the latest 
versions of the NLM, Nadkarni-Darer and TRUD tables to be used should they be 
updated during the development period of this work. 
 
Run time to build the complete mapping table and to remap the ICD-9-CM event codes 
in the source data set to CTV3 was primarily the time taken to read in the source data 
tables: the code mapping tables, the CTV3 code and description table, and the source 
data set. The complete workflow ran in approximately 45 seconds from a start position 
where no tables had been read (Asus, Windows 10 64-bit, intel Core i7-3610QM CPU 
@ 2.0 GHz, Nvidia GeForce GT 630M GPU, 8 GB RAM, 750GB hard, all inputs reset, 
all output tables re-written during the mapping table building process) to an end position 
where a mapped table of events coded in in ICD-9-CM and their code equivalents in 
CTV3 and a table of unmapped codes were both written.  
 
There were 4342 unique ICD-9-CM codes present in this data set. Of these, 2780 (64.0 
%) were mapped to SNOMED CT codes using mappings obtained from the NLM (2383 
codes, 54.9 %) or from the work of Nadkarni and Darer (397 codes, 9.1 %), for a 
combined total of 2780 codes (64.0 %). Note that 2 codes further codes were mapped in 
the Nadkarni-Darer tables that were already in the NLM tables; for these codes the 
NLM table was given precedence. This overlap was likely due to these ICD-9-CM code 
mappings not being present in the NLM tables at the time (2007) that Nadkarni and 
Darer did their work but were present in the later (December 2016) version of the NLM 
table used in this work. It is recommended to always use the latest available versions of 
the mapping tables. These SNOMED CT codes were then mapped to CTV3 using 
mapping tables from NHS TRUD: 2774 codes mapped successfully, 63.9 % of the 
complete set of unique ICD-9-CM codes, 99.8 % of those codes that had been mapped 
to SNOMED CT. 6 codes failed to map from SNOMED CT to CTV3 codes using the 
TRUD mapping. 
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This left 1568 unique codes in the data set that did not map to CTV3 (36.0 % of the data 
set), failing to map at either the ICD-9-CM to SNOMED CT stage (1562 codes) or at 
the SNOMED CT to CTV3 stage (6 codes). It should be noted that 942 codes of these 
codes (21.7 % of the data set) were found in the NLM ICD-9-CM to SNOMED CT 
1:many mapping table, however a decision had been made that it was not possible to 
select which of the “many” codes to select for the intermediate step towards CTV3 
codes and so these codes were left as unmapped codes. These 1568 codes were then 
mapped manually. 1554 codes were mapped successfully, leaving 14 codes (0.3 %) that 
could not be mapped from ICD-9-CM to CTV3 due to no equivalent code being found. 
This gave a combined total of 4328 codes (99.7 %) that were mapped from ICD-9-CM 
to CTV3 using either the automatic or the manual process. 
5.4.3 Summary of mapped codes. 
Of the 4342 unique ICD-9-CM codes in the US-sourced data set, 2774 codes (64.0 %) 
were successfully mapped to a CTV3 code using an automatic approach, 96.3 % of 
these being mapped exactly or approximately as judged a domain expert. Of the 1568 
remaining ICD-9-CM codes, 1554 were mapped manually, 95.6 % being mapped 
appropriately when judged by a domain expert. The success of the automatic mapping 
was compared to the success of the manual mapping, showing that automatic mapping 
was less successful than manual mapping in exact mapping (p < 0.01) but as successful 
when both exact and approximately successful mappings were compared (p = 0.29).  
 
Number of unique ICD-9-CM codes present in the US data set: 4342 
Number of unique ICD-9-CM codes that map to SNOMED CT using the NLM mapping 
table: 2383 
Number of unique ICD-9-CM codes that map to SNOMED CT using the extra 
mappings from Nadkarni and Darer: 397* 
Number of unique ICD-9-CM codes that map to SNOMED CT using NLM + Nadkarni 
& Darer: 2780 
Number of unique ICD-9-CM codes that have no map from ICD-9-CM to SNOMED 
CT: 1562 
* 2 further ICD-9-CM codes were mapped in the Nadkarni and Darer table that already 
had a map in the UMLS table. 
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Number of codes that map completely from ICD-9-CM to CTV3 (using the NLM and 
Nadkarni & Darer mappings to map from ICD-9-CM to SNOMED CT, and then the 
TRUD mapping to map from SNOMED CT to CTV3):  2774 
 
A sample of the manual mapping table is shown in Table 3.  
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Source codes Mapped codes  
ICD-9-
CM code 
ICD-9-CM code description CTV3 
code 
CTV3 code description Search method 
250 type II diabetes mellitus [non-insulin dependent type] 
[NIDDM type] [adult-onset type] or unspecified type, 
not stated as uncontrolled, without mention of 
complication 
X40J5 Type II diabetes mellitus Search string matching 
401 Essential hypertension                                                                                                                                                                                                                                          XE0Uc Essential hypertension Search string matching 
311 Depressive disorder, NOS E2B.. Depressive disorder NEC Search string matching 
305.1 Tobacco use disorder Eu170 [X]Mental & behav dis due to use 
tobacco: acute intoxication 
Key word matching 
V70.0 Routine general medical examination at a health care 
facility 
ZV700 [V]Routine health check-up Concept matching 
782 Disturbance of skin sensation XM07D Skin sensation disturbance Key word matching 
729.2 Neuralgia, neuritis, and radiculitis, unspecified XE1Fn Neuralgia, neuritis or radiculitis 
NOS 
Search string matching 
250.6 Diabetes with neurological manifestations XE10H Diabetes mellitus with neurological 
manifestation 
Key word matching 
54.7 Other Repair Of Abdominal Wall And Peritoneum Xa9ZY Repair of mesentery Concept matching 
519.11 Acute bronchospasm Xa0Ns Bronchospasm Key word matching 
250 type II diabetes mellitus [non-insulin dependent type] 
[NIDDM type] [adult-onset type] or unspecified type, 
not stated as uncontrolled, without mention of 
complication 
X40J5 Type II diabetes mellitus Search string matching 
704.8 Other specified diseases of hair and hair follicles M24.. Hair and hair follicle diseases Search string matching 
435.9 Unspecified transient cerebral ischemia G65z. Transient cerebral ischaemia NOS Search string matching 
333.1 Essential and other specified forms of tremor F131. Essential and other specified forms 
of tremor 
Search string matching 
272.4 Other and unspecified hyperlipidemia Cyu8D [X]Other hyperlipidaemia Key word matching, 
spelling difference 
Table 5.5 Example manual mappings from ICD-9-CM codes present in the US data set to CTV3 codes
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ICD-9-
CM 
code 
ICD-9-CM code description Frequency of 
code occurrence 
in data set 
V45.8 Other postsurgical status 1 
V45.86 Bariatric surgery status 6 
V45.89 Other postsurgical status 20 
V58.63 Encounter for long-term (current) use of 
antiplatelets/antithrombotics 
2 
V68.01 Disability examination 4 
V68.8 Other specified administrative purpose 2 
V68.89 Encounters for other specified administrative purpose 5 
V68.9 Encounters for unspecified administrative purpose 1 
V76.47 Screening for malignant neoplasms of the vagina 6 
V78.8 Screening for other disorders of blood and blood-forming 
organs 
6 
V85.51 Body Mass Index, pediatric, less than 5th percentile for 
age 
1 
V85.52 Body Mass Index, pediatric, 5th percentile to less than 
85th percentile for age 
2 
V85.53 Body Mass Index, pediatric, 85th percentile to less than 
95th percentile for age 
1 
V87.2 Contact with and (suspected) exposure to other potentially 
hazardous chemicals 
1 
 
Table 5.6 ICD-9-CM codes present in the US data set for which no conceptual match in the 
CTV3 codes set was found 
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ICD-9-CM codes that did not map automatically to a CTV3 code and for which no 
equivalent CTV3 code could be found manually are shown in Table 5.6. These failed 
mappings were checked by a domain expert, who could find no suitable code match. It 
can be seen that none of the unmatched codes are codes for symptoms or conditions; 
should the data be used for analysis of symptoms and conditions, as is the case here, it 
may not be worth expending too much effort into finding maps for codes that will have 
no further use in any analysis. 
5.4.4 Verification of the mapping process. 
 
ICD-9-CM codes were mapped to CTV3 codes either by an automatic process via 
SNOMED CT or, for those codes that failed the automatic mapping process, by a 
manual process. Either route required verification and an assessment of the exactness of 
the mapping pairs. 
Codes that failed to map automatically were mapped manually by the author of this 
report (JT), with these mappings verified by a domain expert (Dr Hugh O’Sullivan 
(HO’S), a general practice clinician based at Temple Street Children's University 
Hospital, Temple Street, Dublin 1, Ireland). To determine the degree of success of 
matching, code descriptions for ‘matched’ ICD-9-CM and CTV3 codes were inspected 
for equivalence and a judgement made using the success definitions defined by De 
[219]: exact matching: ‘both codes have the exact clinical meaning’; approximate 
matching: ‘the two codes have similar clinical meaning although the underlying clinical 
contexts are not the same’. When codes’ descriptive terms were identical or differed 
only in minor spelling variation the verification was simple. More complex differences 
required some knowledge of clinical terminology. Where matching was not exactly 
successful, consideration was given by HO’S to replacing the mapped code with a 
CTV3 code that achieved exact success status.  
Similarly, the automatic mappings were inspected for equivalence using the same 
criteria, but this time the inspection was performed by JT. With the high degree of 
successful matching by JT (95.7%, as judged by HO’s) in the manual mapping, there 
was confidence in the judging of the success of the automatic mapping. Again, mapping 
success was judged using the definitions of De and for inexact or incorrect mappings an 
improved mapping was suggested. 
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ICD-9-CM 
code 
ICD-9-CM description CTV3 
code 
CTV3 description Exact 
mapping 
Approx. 
mapping 
Improved 
code 
Improved code 
description 
493.21 Chronic obstructive 
asthma with status 
asthmaticus 
H3121 Emphysematous 
bronchitis 
 
N N   
EP186 STATIN INTOLERANCE Xa1pS Drug allergy N Y XaG2V Statins contraindicated 
385.24 Partial loss or necrosis 
of ear ossicles 
F5523 Partial 
loss/necrosis,ossicles 
Y (Y)   
680.6 Carbuncle and 
furuncle of leg, except 
foot 
M007. Carbuncle of foot N N M006. Carbuncle of leg (excl. 
foot) 
286.9 Other and unspecified 
coagulation defects 
D30.. Bleeding diathesis N Y XE14m Coagulation defects 
151.0 Malignant neoplasm 
of cardia 
B110. Malignant tumour of 
cardia 
Y (Y)   
Table 5.7 Examples of automatically-generated code mappings from ICD-9-CM to CTV3 with score of success of mapping and 
suggested improved mappings 
(Y) indicates an implicit successful approximate mapping due to a successful exact matching    
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In Table 5.7, mapping for ICD-9-CM code 680.6 to CTV3 code M007. is scored as 
neither an exact mapping nor an approximate mapping. This is due to the ICD-9-CM 
code explicitly excluding the foot as the site of the carbuncle or furuncle, but the 
automatic mapping returning a CTV3 that explicitly includes the foot as the site. 
 
Results from the verification of the success of the automatic code mappings are shown 
in Table 6. 
 
 
 All 
auto 
Nad NLM NAD 
% 
NLM 
% 
All % 
Exact mapping 2219 235 1984 59.2 83.3 79.8 
approximate, replacement code 
suggested 
273 54 219 13.6 9.2 9.8 
approximate, no replacement 
code suggested 
186 73 113 18.4 4.7 6.7 
incorrect, replacement code 
suggested 
84 26 58 6.5 2.4 3.0 
incorrect, no replacement code 
suggested 
18 9 9 2.3 0.4 0.6 
all correct (exact and 
approximate) 
2682 366 2316 91.2 97.2 96.3 
Total 2780 397 2383 100 100 100 
Table 5.8 Results of verification of automatic code mapping. 
 
79.8 % of the automatically-generated code mappings were judged to be exact 
mappings. A further 16.5 % of the automatically-generated code mappings were judged 
to be approximately successful code mappings, again using the success definitions of 
De [2012]. 3.6 % of the automatic code mappings were judged to have produced an 
incorrect mapping. 
 
1568 ICD-9-CM codes failed to map, in that the automatic mapping process failed to 
produce a CTV3 code as an output. For each of these ICD-9-CM codes, JT proposed a 
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best matching CTV3 code. All these manually mapped codes were scored for accuracy 
and exactness by a domain expert (HO’S). Results of this verification are shown in 
Table 7. 
 
 
Absolute % 
Exact mapping 1421 91.4 
approximate, replacement code suggested 13 0.8 
approximate, no replacement code suggested 53 3.4 
incorrect, replacement code suggested 13 0.8 
incorrect, no replacement code suggested 54 3.5 
all correct (exact and approximate) 1487 95.7 
Total 1554 100 
Table 5.9 Results of verification of manual code mapping 
 
Success of mapping Manual Automatic Chi-
square 
P 
Exact mapping 1421 2219 100.1 <0.01 
Approximate mapping 66 459   
Correct mapping (exact + approximate) 1487 2678 1.1 0.29 
Incorrect mapping 67 102 1.1 0.29 
Total codes 1554 2780   
Table 5.10 Number of codes mapped by automatic and manual processes and their 
success 
 
The relative success of the manual and automatic mapping processes was tested by 
comparison of the proportions of the codes that were successfully mapped by each 
method, using Pearson’s chi-squared test as the test for significant difference between 
the groups. Table 5.10 shows the results from these tests. 
 
Chi-square tests: manual vs automatic mapping. 
 
Exact mapping: 1421 of 1554 codes (91.4 %) for manual mapping, 2219 of 2780 codes 
(79.8 %) for automatic mapping. 
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Chi-square: 100.1; p < 0.01. Manual mapping was significantly more successful for 
exact mapping than automatic mapping. 
 
All ‘correct’ mapping (exact and approximate): 1487 of 1554 codes (95.7 %) for manual 
mapping, 2678 of 2780 codes (96.3 %) for automatic mapping. 
Chi-square: 1.1; p = 0.29. No significant difference in the rate of successful mapping. 
 
Incorrect mapping: 67 of 1554 codes (4.3 %) for manual mapping, 102 of 2780 (3.7 %) 
codes for automatic mapping. 
Chi-square: 1.1; p = 0.29. No significant difference in the rate of incorrect mapping. 
 
Automatic mapping performs as well as manual mapping when comparing the number 
of incorrect mappings or the number of successful (in the broadest definition, including 
both exactly successful and approximately successful) mappings. However manual 
mapping outperforms automatic mapping when the number of exactly successful 
mappings are considered. 
Where it was determined that a code mapping, whether automatic or manual, could be 
improved, these improved code mappings were added to the manual mapping table. The 
manual mapping table was prioritised over the automatic mapping table in the final 
mapping table generation and used in subsequent data set analysis. 
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5.5 Merging process 
 
Merging of the source data sets is performed as a four-stage process and illustrated in 
Figure 2. The stages in the process are: 
 
5.5.1 Across all data sources: 
Decide on a common set of fields and a common data standard for each field, for 
example ‘event date’ to be recorded as a year, since this is the coarsest granularity of 
date available across all source data sets. 
5.5.2 For each source data set independently:  
Merge the individual data set files supplied by each data source as appropriate: some 
sources supply data in more than one set; each set contains several tables. Source data 
sets may also be structured quite differently from each other, some as normalized tables, 
others as more flattened tables.  
5.5.3 For each source data set independently: 
Remove any fields that are not required in the final merged data set. Rename all fields 
to the common name set. The prepared data is then saved to disk, one file per source 
data set. 
5.5.4 For each source data set independently: 
Map the event codes from the coding systems used in the source to the target coding 
system (i.e. in our sets, from Read v2 to Clinical Terms Version 3 or from ICD-9-CM to 
Clinical Terms Version 3 as appropriate). This process is described separately later in 
this chapter in section 5.6. 
5.5.5 Combine the source data sets to form a single composite data set:  
This is a flattened data file with one line per patient, each line containing patient 
demographic information together with a complete set of event codes from the medical 
history.  
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5.5.6 Remove any events that are not required for the analysis, mostly 
administration-only events (e.g. "registered at practice"). 
 
These events are those that have no clinical significance, i.e. are neither a symptom, a 
treatment nor a diagnosis. 
 
Figure 5.15 illustrates the data set merging process described above. 
 
Figure 5.15 Workflow for creation of single composite data set from several 
clinical data sources
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Steps 1 to 3 in the merging process were run independently for each source data set 
using KNIME. One KNIME workflow was written for each source data set. These 
workflows vary slightly according to the demands of the structures of the source data 
sets and the format of the source data (e.g. date formats, some information in look-up 
tables, etc.). Each workflow is discussed in turn below. In step 4, event codes are 
mapped to a common coding system. For step 5, a further KNIME workflow is 
discussed. This workflow merges the separate data files and removes data items that are 
not required for future analysis. These are primarily records of administration events, 
which are not present in all data sources. 
Note that if data becomes available from other sources, this new data set will be 
required to go through steps 1 to 4 in the above process before running step 5 on all data 
sets - the previously-acquired data sets will not need to go through steps 1 to 3 again 
unless there is a change in the desired set of fields to be included in the merged data set. 
However if no new fields are to be included then field removal can be performed in the 
data set merging step. Note also that once the merged data set has been created, it is 
saved to disk, and is then read by the data analysis system; it is a simple matter to drop 
unrequired fields at the point of reading the merged data file. 
 
5.6 Preparation of the individual source files 
5.6.1 THIN data preparation using KNIME 
 
Figure 5.16 shows the KNIME workflow used to prepare the data supplied in the THIN 
data tables. The process implemented in the KNIME workflow is as follows: 
 
a. The ‘patient information’ section in the KNIME workflow prepares data from 
the patient information file: 
(i) The patient information files are read. They are plain text files - note 
that each row in the input file is a single text string, with no separator 
between fields – fields are split by position. For each source file, a field 
is added to the data table to note which file is the source of the data. 
The two tables are then concatenated to form a single data table.  
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(ii) The input character strings are now split into separate fields, according 
to the position in the file as described in the THIN data dictionary. 
(iii) Unknown dates are recorded in the THIN data as the string ‘00000000’. 
These unknown date strings are replaced with an empty character 
string. 
(iv) Years of birth and death are extracted from the date of birth and date of 
death fields, saved as new fields and converted to integers. 
(v) Fields unwanted for later processing are removed from the data table. 
 
 
b. The ‘Event information’ section in the KNIME workflow prepares data from 
the event information files. 
(i) The event information files are read. They are plain text files - note that 
each row in the input file is a single text string, with no separator 
between fields – fields are split by position. The two data tables are 
then concatenated to form a single data table. 
(ii) The input character strings are now split into separate fields, according 
to the position in the file as described in the THIN data dictionary. 
(iii) Unknown dates are recorded in the THIN data as the string ‘00000000’. 
These unknown date strings are replaced with an empty character 
string. 
(iv) Unknown event dates are replaced by the system dates, i.e. the date 
when the data item was entered into the GP system. 
(v) Events are sorted by date and an “order number” assigned to each event 
in order to preserve event ordering. 
(vi) The year of each event is extracted and placed in a new field in the data 
table. 
(vii) Unwanted columns are removed from the data table. 
(viii) The THIN table of Read Codes and descriptions is read into its own 
data table; like other THIN tables each row is a single character string. 
These strings are split by position into their constituent data items. 
(ix) Read Code descriptions are added to the event table by an inner join on 
‘medcode’ between the event table and the Read Code table. Note that 
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at this point, Read Codes are still 7-byte, i.e. they retain the final 2 
bytes that allow for synonyms. 
 
c. The ‘Event information’ section in the KNIME workflow prepares data from 
the event information files. Patient information table and event table are 
combined by an inner join on Patient ID. 
 
 
d. The combined patient and event information table is then tidied: 
(i) Numeric codes for marital status are converted to ‘M’ or ‘F’ 
(ii) Read Codes for events are trimmed from 7 bytes to the base 5 
bytes 
(iii) Patient age at each event was calculated and stored 
(iv) Numeric codes for marital status are converted to descriptive 
strings 
(v) Year of end of event is extracted (or missing value recorded if 
there is no end date) 
(vi) Patient age at date of data collection, or age at death if applicable, 
is calculated and saved. 
(vii) Unwanted fields are removed 
(viii) Data table columns are reordered. 
(ix) The data table is written to csv file. 
 
 
There were 732 events with an event start year of “2” after import into KNIME and 
conversion to year-only. The mode event year was 2009. The oldest event year was 
1911, excluding years recorded as “2”.  “2” in fact is an artefact of date conversion in 
KNIME, from a “missing” date, which is coded with a value of “00000000” and which 
gets converted to a year of 2 and month of November - but note that months get 
removed in this data tidying process. Investigating this problem highlighted another 
problem: dates that are stored in the THIN data set as a years-only string (e.g. 
“19270000”) are translated by KNIME to a date format which has the previous year – in 
this case 19270000 gets converted to 30-Nov-1926. The solution used in the data 
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tidying process was to replace the substring “0000” in the date field with “0702” (i.e. 
2nd July, the middle of the calendar year – note that we are not expecting to use months 
and days later in the analysis but this would allow for that). This was done AFTER 
converting “00000000” years to a missing value by searching for the complete strings 
“00000000” and replacing with “?”, the representation used for missing values in 
KNIME. Then strings “nnnn0000” were searched for with simple regex search for 
“0000$” and replaced with “nnnn0702”.  
For events without a date, the date that the event was recorded on the practice system 
was assigned to the event date. For those events where both the system date and the 
event date were earlier than the patient’s date of birth, the year of birth was taken as the 
event year. Following this process, no events were without an event year. 
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Figure 5.16 KNIME workflow for preparation of THIN data set
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5.6.2 CPRD data preparation using KNIME 
The KNIME workflow shown in Figure 5.17 illustrates the CPRD data preparation 
process. The process implemented in this KNIME workflow is as follows: 
a. The ‘patient information’ section prepares data from the patient 
information file.  
(i) The file is read 
(ii) Patient gender in the file is coded as ‘1’ or ‘2’. These are 
converted to ‘M’ or ‘F’ 
(iii) Marital status is converted from a code (1 to 6) to a English 
language character string (e.g. ‘divorced’, ‘engaged’) by means 
of a look-up table supplied as part of the CPRD data set. 
(iv) Year of birth is stored in the CPRD data set as (actual year of 
birth – 1800) and so 1800 has to be added back to the stored 
value to obtain the real year of birth. 
(v) Date of death is stored as a fully day-specific date. The year of 
death is extracted from this. 
(vi) Fields that will not be used are removed. 
b. The ‘Event information’ section prepares date from the clinical event 
information file and from the immunisations data file. 
(i) File ‘event information’ is read 
(ii) File ‘immunisation data’ is read 
(iii) The two tables are merged by simple concatenation – they have the 
same fields. 
(iv) Missing event dates are replaced by the system date, i.e. the date that 
the event was entered into the GP system. This give the latest date by 
which the event will have occurred, although it is possible that the 
event occurred earlier than the system date. 
(v) A column is added to the table containing the source of the event 
data, in all cases here this will be ‘C13’ for the CPRD 2013 data set. 
(vi) Event dates are extracted from the event date field. 
(vii) The event tables is sorted by event date 
(viii) An ‘order’ number is assigned to each event. 
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(ix) The CPRD lookup table to map the CPRD ‘medcode’ to Read 
Version 2 codes is read 
(x) The Read codes in the look-up table are shortened to retain only the 
first 5 bytes (bytes 6 and 7 are to allow for synonyms but have no 
additional clinical significance). 
(xi) An inner join is performed between the events table and the 
medcode-to-Read-code table so that the CPRD medcodes in the 
events table can be replaced by Read Codes (Read version 2). 
(xii) Fields not needed are now dropped. 
c. An inner join is now performed between the patient information table 
and the events table (modified to contain Read Codes rather than 
‘medcodes’). This produces a flattened table, each row containing 
information on one event together with the patient information for that 
event. 
d. The flattened patient-event table is now prepared for output: 
(i) Dates are converted from strings to integers 
(ii) Patient age at date of data set preparation is calculated (or date of 
death if the patient died before data set preparation) 
(iii) The patient’s age at the date of each event is calculated 
(iv) An ‘event end date’ field is added for compatibility with other 
data sets, although CPRD data does not contain this information. 
(v) Fields not needed are now dropped. 
(vi) Columns in the data table are sorted into the desired order, for 
compatibility with tables output from other data sets. 
(vii) The data table of data from the CPRD data set is saved. 
 
This data set has 14,323 unique codes represented. This is a much higher figure than the 
other two data sets. Inspection of the data set suggests that a large proportion of the 
codes are administration codes that have little or no use for this analysis (e.g. "patient 
attended clinic"). These administration codes are kept in the data set at this stage but 
will be removed, along with any administration codes present in data sourced from the 
other data sets, prior to final analysis performed on the composite data set. 
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December is a very much more frequent month of event than other months recorded in 
this data set. It is not known why this is the case but it is conjectured that when the 
month of event is unknown, December is used as a default value. 
One individual’s year of death was recorded as 1963. It is not clear why or how are they 
were in the data set. It is possible that 1963 was entered in error, or that they had a rare 
and/or hereditary condition and that their data was entered retrospectively for this 
reason. On inspection of this record, it was seen that the individual’s year of birth was 
also recorded as 1963. Looking further, this individual had tens of events recorded, the 
most recent being in 2005. There was no record of death in the patient's recorded events. 
It was therefore assumed that 1963 was entered erroneously.  It is possible to check all 
data for event dates for an individual that were recorded as taking place before their 
birth or after their death. 
Some further tidying of the data was also performed. For example, some event dates 
were recorded as occurring before the patient was born: these events were assigned a 
new date of the date on which the event was entered into the GP system (this date was 
available in the data set). Some other events were recorded as being the same year as the 
year of birth, which may thought to be unreasonable (for example, a patient recorded in 
2000 as having “notes summary on computer” in 1912, their year of birth) or reasonable 
(a patient recorded in 2001 as having “normal birth” in 1941, their year of birth). These 
event dates were left unchanged. 
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Figure 5.17 KNIME workflow for preparation of CPRD data set 
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5.6.3 Practice Fusion data preparation using KNIME 
Data tables containing the various data items in the Practice Fusion data set were read in 
to the KNIME workflow, for both the supplied “train” and “test” file sets. Data sets 
were merged and flattened.  Figure 5.18 shows the KNIME workflow for the 
preparation of this data set. 
a. The ‘patient and event information’ section prepares and combines data 
from the ‘Patient’, Transcript’, ‘TranscriptDiagnosis’ and ‘Diagnosis’ 
files and the local ICD9-CM to CTV3 event codes look-up table..  
(i) The ‘Transcript’ files are read and concatenated. 
(ii) The ‘TranscriptDiagnosis’ files are read and concatenated. 
(iii) The Transcript and TranscriptDiagnosis tables are joined  
(iv) This table is then joined with the complete Diagnosis records 
table 
(v) This joined table is then joined with the combined Patient 
information table 
(vi) ICD9-CM codes in the 
Patient/Transcript/TranscriptDiagnosis/Diagnosis table are 
replaced with CTV3 codes from the local look-up table 
b. The ‘Perform tidying of data and matching fields to other data sets’ 
section of the KNIME workflow calculates fields not natively in the 
Practice Fusion data set, remove fields not required in the final saved 
data set and renames fields for consistency with the final composite data 
set: 
(vii) The event date is checked for validity and corrected if necessary 
(viii) Events are sorted to be in chronological order and assigned a 
sequence number 
(ix) Fields no longer required are removed 
(x) Fields are renamed to conform to the fields required in the 
composite data set 
(xi) Missing value character for event year of ‘0’ replaced with ‘?’ for 
consistency with other fields and data sets 
(xii) Fields for family number and marital status added for consistency 
with other data sets, although information on these items not 
available in the Practice Fusion data sets 
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(xiii) Age in years at events calculated and stored 
(xiv) Columns in the data table sorted to match the composite data set 
order 
c. The ‘smoking information’ was read and prepared for joining to the 
patient event information table 
(xv) Smoking information files were read and concatenated 
(xvi) The ICD9-CM codes in the smoking information data were 
replaced with CTV3 codes from the local look-up table 
(xvii) Fields no longer required were removed 
d. The ‘Join smoking information to patient information’ section of the 
workflow adds tobacco use history to the patient information 
(xviii) Smoking information joined to the patient event table 
(xix) Fields are renamed to conform to the fields required in the 
composite data set 
(xx) Age in years at events calculated and stored 
e. The final section of the workflow, ‘Final internal data set merging’, 
combines the tobacco use information with the full table of patient 
information and event history and saves the prepared Practice Fusion 
data set in the composite data set format 
(xxi) The tobacco use history information is concatenated to the patient 
event history table 
(xxii) The patient age at date of data capture is calculated 
(xxiii) The file is saved for further analysis 
 
Events in the Practice Fusion data set were recorded in ICD9-CM and required 
translation to CTV3. This was done by use of a look-up table. No direct mapping of 
ICD9-CM codes to CTV3 (or ICD9-CM to Read v2) codes was found and so a mapping 
table required to be created. Creation of this look-up table is described in the paper 
included at the end of this chapter. 
 
This data set has 4246 unique event codes represented. This is a smaller number than 
for either the CPRD or THIN data sets, each of which have fewer individuals’ records 
than the Practice Fusion data set. This suggests that ICD9-CM codes are less granular 
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than Read Codes or that administration codes were not included in this data set.  These 
4246 ICD9 codes were mapped, in a process later described, to 3465 CTV3 codes. 
There was no explicit "date of death" for patients in the Practice Fusion data set.  
Individuals whose records were used in the Practice Fusion data set were aged 18 to 90 
years inclusive only. This was most likely due to restrictions in the HIPAA regulations 
[123] designed to prevent re-identification of individuals from their medical records. 
Events have an “event start” date.  For some patients this value was missing; in these 
cases the date of clinic visit was assigned to the “event start” date. Some transcripts did 
not have a recorded visit date. The final data set had 457,232 events with a recorded 
year and 240 events for which the year was unknown. 
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Figure 5.18 Workflow for preparation of Practice Fusion data set
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5.7 Merging of source data sets into single composite data set 
The source data sets having been prepared as described to consistent format, they can 
now be combined into a single composite data set. This process was carried out in a 
simple KNIME workflow and is shown in Figure 5.19. The single output data file is in 
comma-separated variable format and contains the fields chosen in the analysis of 
common fields described earlier in this chapter. 
 
 
Figure 5.19 Aggregation of source data sets into single composite data set 
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5.8 Assignation of CTV3 code significance values 
 
Clinical Terms Version 3 provides a coded thesaurus of clinical terms, structured in a 
hierarchical classification [220]. Classifications start from a single root node at the first 
level of the hierarchy, ‘…..’ ‘Read thesaurus’, which has 18 child nodes, each 
corresponding to a broad subject heading. Each of these nodes, in turn, has its own child 
nodes, with the detail of the concept captured by each node increasing as the tree depth 
increases. New nodes are added to the hierarchy at each new level until the finest 
concept detail is reached, at the 19
th
 level of the hierarchy. For convenience, the 
hierarchy levels will be referred to relative to their distance from the root node, i.e. the 
root node is ‘level 1’, all the child nodes of the root node is ‘level 2’, and so on. 
An example of how codes are placed in the hierarchy is shown in figure n. At the top of 
the hierarchy, at ‘level 1’, is a placeholder code, ‘…..’ Read thesaurus; all codes below 
this are members of the CTV3 hierarchy. ….. has 18 child codes, each at ‘level 2’. For 
clarity, only one code is shown: XaBVJ ‘Clinical findings’, still a very broad subject 
heading which has no useful clinical significance. XaBVJ in turn has 7 child nodes at 
level 3, one of which is shown: A…. ‘Infective disorder’. Again a broad subject heading 
but the granularity of the detail in this code is beginning to demonstrate some clinical 
significance. Below this code, at level 4, are 54 new, more granular, codes, one of 
which is shown: X70Gv ‘Bacterial disease’, which also has 54 child codes. Two of 
these child codes are shown. Following the tree down further, there are three terminal 
nodes: A3By1, X100G and H0608. Each of these is a precise concept describing a 
particular condition. None have child codes. A3By1 and H0608 are at ‘level 7’ of the 
hierarchy; X100G is at ‘level 6’. 
A history of the development of the Read Codes is given by Benson [220]. Robinson et 
al give detailed description of the structure of the various iterations of the Read Codes 
[221]. 
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CTV3 code granularity 
As noted in the section on assigning significance flags to individual CTV3 codes, the 
CTV3 codes are in a tree structure with 19 levels: level 1, the root node ‘…..’, is merely 
a place-holder code indicating that these codes are CTV3 codes. Below this root node, 
at level 2, are 17 high-level codes indicating the broad category of codes that their 
descendant codes fit into, e.g. ‘9….’ Administration, ‘0….’ Occupations or ‘XaBVJ’ 
Clinical findings. Each code can have 0, 1 or many child codes: 
 
CTV3 
Level 
Number of 
new codes 
introduced at 
this level 
Mean number 
of child codes 
for codes at 
this level 
Ratio of 
significant (flag 
value 1 or 2):not 
significant (flag 
value 0) codes 
1 1 17 0/1: 0 
2 17 25.4 0/17: 0 
3 432 7.1 15/417: 0.04 
4 3082 4.4 351/2731 : 0.13 
5 13468 3.7 3572/3041 : 1.2 
6 49825 1.1 10226/39599 : 0.3 
7 56788 0.8 19880/36908 : 0.5 
8 46332 0.7 21413/24919 : 0.9 
9 34340 0.6 15896/18444 : 0.9 
10 22092 0.7 10162/11930 : 0.9 
11 15632 0.6 5787/9845 : 0.6 
12 9165 0.6 2645/6520 : 0.4 
13 5686 0.3 854/4832 : 0.2 
14 1580 0.2 246/1334 : 0.2 
15 345 0.2 70/275 : 0.3 
16 56 0.1 0/56 : 0 
17 7 0.4 0/7 : 0 
18 3 0.7 0/3 : 0 
19 2 0 0/2 : 0 
20 0 - - 
Table 5.11 Number of CTV3 new codes at each level of the CTV3 hierarchy. 
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It can be seen from Table 4.7 that level 15 of the CTV3 hierarchy is the deepest level at 
which new clinically-significant codes are introduced; below this level no new 
significant codes are added. Levels 8, 9 and 10 have the highest ratio of significant to 
non-significant codes. Level 8 has the highest absolute number of new significant 
codes. 
 
 
                                  
 
..... 
Read thesaurus 
(18 child codes) 
XaBVJ  
Clinical findings  
(7 child nodes) 
A....          
Infective disorder  
(54 child codes) 
X70Gv      
Bacterial disease 
(54 child nodes) 
A3By3  
Mycoplasma 
infection 
(5 child nodes) 
A3By4  
Mycoplasmal 
pneumonia 
(1 child node) 
A3By1               
Eaton's agent 
infection 
X100G   
Atypical pneumonia 
XSCDz 
Haemophilus 
infection 
(1 child node) 
A3B5.  
Haemophilus 
influenzae infection 
(5 child nodes) 
H0608               
Acute haemophilus 
influenzae bronchitis 
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Figure 5.20 An example of codes in the CTV3 hierarchy 
 
Figure 5.20 shows a small extract from the CTV3 hierarchy, illustrating the relationship 
between codes relating to bacterial chest infections. This Figure shows that Acute 
haemophilus influenza bronchitis is a Haemophilus influenzae infection; there are four 
other codes that are child codes of Haemophilus influenzae infection. Haemophilis 
influenzae infection itself is a Haemophilus infection, which in turn is a Bacterial 
disease. Bacterial disease is an Infective disorder, a child code of Clinical findings, a 
category coming under the root node of the CTV3 tree. 
 
The composite data set holds all events that have been recorded for individuals. Each of 
these codes has a defined meaning – its “concept” - and significance, but this 
significance may only be for the duration of a particular circumstance, for example 
recording an episode of illness, for recording symptoms or for recording administrative 
events. The work described in this report focusses on events of clinical significance, in 
particular symptoms and diagnoses of conditions that form part of an individual’s 
clinical history. Events that are of no significance for this work need to be flagged as 
such and perhaps removed from the data set prior to further analysis of the composite 
data set. 
 
Many codes have no or trivial clinical information, would add to processing time and/or 
memory requirements, would add noise to the information contained in clinically-
significant codes. Dividing the clinically significant codes into two groups gives the 
potential for future work in which ‘most likely next condition’ can be predicted, in 
which case need to know what are the codes that could be predicted. However, in this 
work, the two groups of significant codes are not distinguished between. 
Examples of codes that have little useful clinical information are code XaE42 ‘Medical 
records review’, or 932... ‘A4 records folder’. Other codes contain more obviously 
relevant information, such as A796. ‘Parvovirus infection’ or B2211 ‘Malignant 
neoplasm of hilus of lung’. 
 
Codes were initially to be divided into two groups, ‘significant’ and ‘not significant’, 
with those codes determined to contain no useful clinical information assigned to the 
‘not significant’ group. However, following early exploratory work on the data and 
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consideration for future work it was decided to categorise codes into one of three 
groups: ‘Administrative’, ‘Symptom’ or ‘Condition’. These were broad definitions with 
Administrative codes including such events as the performing of screening tests, which 
do not of themselves indicate the presence or absence of a condition, or information 
topic headings where the information was not available or otherwise recorded, e.g. 
XaKTj ‘Abstinence history’ or XaBVJ ‘Clinical findings’.  Codes were assigned a flag 
value according to the expected significance of the code: 0 for administration codes, 1 
for symptom codes, 2 for condition codes.  
 
Decision making process for assigning flags: 
Three categories: ‘administration’, ‘symptom’ and ‘condition’. More fully, 
‘administration and management’, ‘symptom, sign, complaint or procedure or physical 
attribute’ (i.e. the manifestation of an underlying condition) and ‘diagnosis, disorder or 
condition’ (i.e. the underlying cause of an illness or complaint). 
 
Some codes were easy to assign: 
A70z0 ‘Hepatitis C’ - an infectious disease caused by a viral infection, assigned a flag 
value of 2. 
N094P ‘Ankle joint pain’ could have a number of causes, assigned a flag value of 1. 
932.. ‘A4 record folder’ – a purely administrative piece of information containing no 
useful clinical information, assigned a flag value of 0. 
Other decisions were more difficult: 
X77BL ‘Tachycardia’ – can be caused by specific conditions (e.g. hyperthyroidism, 
anxiety) or be a condition of itself. A decision was made to assign a flag value of 2 but 
there are arguments that it should be assigned a value of 1. Note that for in this work it 
was ultimately decided to assign equal predictive weight to flag 1 codes and flag 2 
codes, so in this case choosing to assign the alternative flag value would have had no 
influence on the outcome of the prediction. 
Nodes that are indicative of the presence of a disorder but of themselves contain little 
further information, for example X0003 ‘Disorders’ – does suggest that a condition is 
present but that the code at this level is insufficiently granular to provide any 
meaningful information about the condition. For nodes with this minimum level of 
information, it was decided to assign a flag value of 0. 
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With 16,258 CTV3 codes in the composite data set (and 258,854 codes in the complete 
CTV3 code set) it was a large task to inspect each code and assign a significance flag 
value to each code. Advantage was therefore taken of the CTV3 table structure, with 
each code (bar the root node, ‘…..’) having a parent code and 0:many child nodes. As a 
starting point for significance code assignation, each code passed its significance value 
to its child nodes, starting at the root node at level 1 and propagating down through each 
level in turn.  
 
The highest level (level 1) of the CTV3 tree, the root node ‘…..’, was assigned level 0, 
since it was a code with no clinical significance. All codes with the root node as their 
parent were assigned the same significance as the root node. There were 17 codes with 
the root node as their parent, i.e. at ‘level 2’. Each of these codes was inspected to 
ensure that the significance level assigned was appropriate, with any changes being 
made manually as appropriate. With no specific clinical information being present in 
any of the 17 codes at this level, each code retained its significance value of 0. 
Codes at level 3 were assigned the significance level of their parent codes. There were 
432 codes introduced to the hierarchy at this level; all 432 codes were automatically 
assigned a significance value of 0, (inheriting the value of their parent code). On 
inspection of these codes, 15 codes were determined to have a clinical significance 
value of 1 and so had their significance flag value manually set to 1.  The remained 417 
level 3 codes retained their significance value of 0 inherited from their parent level 2 
codes. 
 
Similarly, level 4 codes inherited the significance values of their parent codes, 0 or 1 as 
appropriate. There were 3082 codes introduced at this level, 41 of which inherited a flag 
value of 1 from their parent codes, 3041 inheriting a value of 0. Again, each was 
inspected and the significance level adjusted as appropriate: there were now 65 codes 
assigned a significance of 2, 290 a level of 1 and 2727 a level of 0. 
At level 5, there were 13,468 CTV3 codes making their first appearance. This quantity 
of codes was of a similar order to the total number of unique codes in the merged data 
set (22,764 codes, including codes in the data set plus ancestor codes) and so at this 
point it was decided only to inspect those codes that were present in the merged data set. 
Prior to doing this, after manual inspection and correction of level 4 codes, the 
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automatic propagation was continued until all CTV3 codes had been assigned a flag 
value.  
Once all codes in the CTV3 tree had had significance codes assigned, all codes that 
were present in the composite data set were inspected and the significance assigned to 
each of those codes accepted or changed as appropriate. The inspection of the 
significance code level was expedited by this process: all codes from each significance 
level group (0, 1 or 2) could be inspected as a batch, with codes assigned an incorrect 
significance level being corrected. 
 
Flag values for codes that were present in the merged data set were then inspected and 
corrected as necessary. Note that the presence of the automatically-assigned flags 
increased the efficiency with which this could be done: codes with one flag value were 
grouped together and quickly inspected to find any codes that belonged to a different 
group. 
 
The corrected flag values for the codes in the composite data set were then fed back into 
the automatic flag value assignation program, allowing for improved automatic flag 
value assignation for codes that were not present in the merged data set. However these 
codes were superfluous to the analysis of the merged data set and so were not subject to 
further inspection and correction. 
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5.8.1 Results 
(1) Automatic flag assignation followed by manual correction for levels 2 to 4; 
levels 5 to 18 automatic flag assignation only. 
Code 
level 
Flag 0 
code 
count 
Flag 1 
code 
count 
Flag 2 
code 
count 
Total 
codes at 
this level 
Cumulative 
code count 
1 1 0 0 1 1 
2 17 0 0 17 18 
3 432 0 0 432 450 
4 3041 41 0 3082 3532 
5 9896 2121 1451 13468 17000 
6 39599 5045 5181 49825 66825 
7 36908 8572 11308 56788 123613 
8 24919 8456 12957 46332 169945 
9 18444 5739 10157 34340 204285 
10 11930 2664 7498 22092 226377 
11 9845 1104 4683 15632 242009 
12 6520 378 2267 9165 251174 
13 4832 104 750 5686 256860 
14 1334 62 184 1580 258440 
15 275 20 50 345 258785 
16 56 0 0 56 258841 
17 7 0 0 7 258848 
18 3 0 0 3 258851 
19 2 0 0 2 258853 
20 0 0 0 0 258853 
Table 5.12 Number of new codes introduced at each level of the CTV3 hierarchy 
 
After manually inspecting and correcting the flags assigned to the codes present in the 
merged data set, the automatic assignation program was run again, with the following 
results: 
 
Inspect discrepancies between in-program corrections and manual look-up table, 
removing codes changes from the program or making changes to the look-up table as 
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appropriate. Then need to re-run the program, again checking numbers before and after 
in-program correction 
Once these flag values had been assigned to the CTV3 codes (codes in the data set and 
their ancestor codes were verified by manual inspection and correction, CTV3 codes not 
in the composite data set had flag values automatically assigned but not verified they do 
not appear in our data set) the flag values assigned to CTV3 codes were frozen and 
available for later use. 
CTV3 codes not in our data set were also assigned significance flag values, but these 
were not manually verified. However, by automatically assigning these values it was 
possible to see how the code set divided up into administration, symptom and diagnosis 
codes.  
The R code used to automatically assign the significance flags is given in Appendix 4. 
The significance flags assigned for a sample of CTV3 code are shown in Appendix 5. 
 
5.9 Recommendations for good practice for merging data sets 
 
The work required to create a single composite data set from three source data sets, 
combining fields with common meanings across the data sets and syntactically and 
semantically consistent data within those fields, has been described. For efficient 
implementation of this process, some recommendations are given: 
1. Utilise existing mappings as much as possible – TRUD, NIH, independents 
2. Do not spend time trying to get the automatic mappings as complete as 
possible: missing mappings can be defined manually 
3. Be concerned only with codes that are present in the source data set and will be 
used in the final analysis 
4. Manual mappings: Most can be mapped by searching for key words in the 
descriptions. But be aware of minor differences in spellings (UK English vs US English, 
singular vs plural) and completely different words to describe the same conditions 
(Common English terminology vs Latin-based terminology; disease-centred vs body 
part-centred ;).  
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5. Take care not to introduce artefacts into the data (e.g. KNIME converts a string 
of “00000000” to a date with a year of “2” so convert source data codes for missing 
values to appropriate values in your system. 
6. Related coding systems may appear similar but have subtle differences and 
must be treated as separate systems. For example, Read Codes Version 2 is an ancestor 
system to Clinical Terms Version 3 and the two systems have many codes in common, 
but some codes are different and, unlike in Read Codes Version 2, it cannot be assumed 
that the first 4 characters of a CTV3 code is the parent code of the full five character 
code. 
7. Coding systems that allow for synonyms within single concepts may be 
amenable to simple editing of codes to revert all synonyms to the base concept. For 
example for CTV3, the first 5 characters only are significant. Characters 6 and 7, if 
present, allow for synonyms for the same concept. The base concept as defined by the 
first 5 bytes is not changed by any characters in characters 6 and 7 and so these least 
significant characters can be dropped from the mapping (however, the synonyms may 
assist in manual mapping if a match between the first table (e.g. ICD9-CM codes) and 
the CTV3 table base concept description cannot be found).  
8. Care should be taken with coding systems that use the complete ASCII 
character set and allow for character strings that comprise only numerals or numerals 
with a final decimal point. These strings may get converted automatically by some 
programs (e.g. Microsoft Excel) into numbers. For example, a trailing decimal point 
(e.g. E251.) can get dropped if the code is otherwise all-numeric (e.g. 1972. -> 1972) 
and the code is treated as a numeric value. It is therefore recommended to treat all codes 
as character strings at all times. 
 
5.10 Results from this chapter 
 
This chapter has described the process of creating a single composite data set from 
disparate source data sets, and the challenges involved in that process. Three data sets 
were merged and, where necessary, mapped from one coding terminology to the target 
terminology, to form a single aggregate data set.  In this process, the fields common to 
each of the source data sets were determined and used for the minimum aggregate data 
set. The fields common across all three data sources are: 
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Patient ID; Gender; Year of birth; Year of death; Clinical event code; Clinical event 
start year; Acute or chronic; Allergy type; Allergy start year; Allergy name; Smoking 
status code; Smoking status date; Immunisation code; Immunisation date; Therapy date; 
Therapy code; Therapy dose; Therapy quantity; Therapy length. 
Event codes were mapped to CTV3 from Read Codes Version 2 (for the UK sourced 
data) or from ICD9 (from the US sourced data). An existing mapping table obtained 
from NHS TRUD was used to map Read Codes Version 2 codes to CTV3 codes. This 
mapping was complete. For mapping event codes in the US data set, coded in ICD9, no 
existing mapping table was found and so a more complex process was required, a two-
stage mapping process via an intermediate coding system which mapped a high 
proportion of the codes required to be mapped, provided that the mapping tables 
required for each of the intermediate mapping steps (into and out from SNOMED CT) 
existed. The automatic mapping process produce a list of failed mappings and the 
frequency of occurrence in the source data set of each code that failed to map, which 
was used as the basis for manual completion of the local ICD-9-CM to CTV3 mapping 
table. 
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6 VALIDATION AND 
VERIFICATION OF DATA SET 
6.1 Introduction 
 
Chapter 4 outlined how the three source data sets were combined into a single 
composite data set, with semantically equivalent data fields, a common coding system, a 
simplified record of smoking and alcohol consumption, and a field indicating the source 
data set for each record. This chapter describes how data items in the composite data 
were cleaned and checked for validity. The information in the source data sets and in the 
composite data set were verified against each other and against information on the 
general population to determine whether the source data were representative of the 
general population or whether the data needed to be weighted to compensate for being 
unrepresentative. 
Areas for validation and verification in this chapter include: 
(i) Data cleaning and error checking;   
(ii) Demographic comparison of the source data sets by age and by gender; 
(iii) Comparison of condition prevalences in the composite data set versus condition 
prevalences in the literature; 
(iv) Calculation of risk factors from the composite data and comparison with known risk 
factors for particular conditions; 
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6.2 Data cleaning 
Maletic and Marcus [222] give a useful introduction to data cleansing principles, though 
they do not deal with problems with health data specifically. They give some techniques 
for data cleaning, and refer to studies by Orr [223] and Redman [224] who states that 
“error rates in the data acquisition phase are typically around 5% or more.” There is no 
reason to assume that the source data used in this work is ‘clean’: validity of data in 
records is not guaranteed to have been imposed at the time of data acquisition or entry, 
and so should be checked before use for implausible or outlying values. Further, Maletic 
and Marcus note that in any composite data set created from merging several sources 
the issue of duplicate records must be addressed and duplicates removed where 
possible. Data should be cleaned as early as possible and certainly before use. Note that 
some data cleansing had been performed as part of the data set merging described in 
Chapter 3, including removal of fields that were not common to all three source data 
sets and correction of obviously incorrect dates, such as date of death preceding other 
event dates. 
The basic checklist used for cleaning the data in the composite data set was: 
a. Data types should be valid for each field; 
b. Data values must be within an allowed or plausible range for numerical values 
(e.g. age to be between 0 and 130 years inclusive) or within a set of 
allowed values (e.g. male/female/unknown); 
c. Mandatory field values must be present; 
d. Cross-field validation to be performed (e.g. the date of birth in a record must be 
earlier than all other recorded events); 
e. Data must have consistent and appropriate units (e.g. all weights to be in kg) 
where units are recorded with data values; 
f. Duplicate records to be identified and removed. 
 
a. Data types should be valid for each field 
Data type consistency was checked. All fields were either numeric or text fields as 
appropriate. Data type consistency had been enforced by default by the KNIME 
workflow for the data set merging stage in Chapter 4. 
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b. Data values to be within an allowed or plausible range. 
Values for age were checked and all found to be in the range 0 to 130 years. All records 
had a gender of either male or female. 
 
c. Mandatory field values must be present; 
(i) Demographic information. Each record was checked for presence of year 
of birth and gender information. All records were found to be complete 
for gender and year of birth information. No other identifying 
information, such as name, address, telephone number, zip or postal code 
was included in any of the source data sets, apart from the inclusion of 
home state information in the US-sourced data. 
(ii) Clinical events information. Each record contained a wide range of 
number of events, from 1 event to 1481 events. Irrespective of the 
number of events in each record, there is no guarantee that all events for 
any individual are recorded, either because a clinician neglected to 
record the condition or felt it was not worthy of recording, or the 
individual did not feel that the severity of the condition warranted a 
consultation, or for reasons of data loss or non-entry. Given the difficulty 
in deciding between an event that never happened versus an event that 
happened but was not recorded, it was decided to use the events records 
as they were with no attempt made to impute any ‘missing’ events 
records, which would be theoretically possible from a history of 
prescriptions or other treatments that may be condition-specific, though 
still likely to be incomplete. 
 
d. Cross-field validation 
Records were checked to ensure that event dates were the same year or later than the 
year of birth. 
 
e. Data must have consistent and appropriate units 
Unit checking and conversion had been carried out in the data set merging stage 
described in Chapter 4. All dates had been converted to the lowest common unit, years. 
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Event codes had all been mapped to a single common coding system, Clinical Terms 
Version 3. 
 
f. Duplicate records to be identified and removed 
It is possible that multiple records derived from the same individual are present in the 
data. As many duplicate records as possible should be removed in order to avoid giving 
undue weight to those duplicate records in later analysis. Given the limited demographic 
information available for each individual, identifying the duplicate records is no simple 
task. A simple set of rules was established in order to identify potential duplicates. 
These rules were: 
(i) records should be from the same country source (i.e. it is possible for a 
record(s) derived from the same individual to be present in each of the UK data sources 
but not in both a UK source and the US source; 
(ii) year of birth and gender in each record must match; 
(iii) the first twenty events in the records must match. 
 
Testing for duplicates was carried out after data set merging to allow for cross-source 
duplicate testing. 
 
Analysis of the records using the above criteria showed that there were no duplicates 
within the US data set, no duplicates within the UK THIN data set, no duplicates across 
the UK THIN and CPRD data sets but six potential duplicates within the UK CPRD 
data set, in two sets of three records. These were all for minors – three aged five years at 
the time of data capture (three males), and three aged six years at the time of data 
capture (two females, one male). The duplicate records with the fewer number of events 
were removed, on the assumption that the records with more recorded events presented 
a more recent and fuller list of the events for the individual.  
 
Following inspection of the data it was concluded that after the removal of potential 
duplicate records, the composite data set was clean and suitable for verification of its 
contents against known attributes of the general population. 
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6.3 Demographic comparison 
 
There were two obvious pieces of demographic information on which to compare the 
source data sets: age and gender. The two UK source data sets were compared to each 
other and the combined UK data compared to the US data set.  
6.3.1 Age 
Age is recorded in all source data sets in years. The distribution of age in each of the 
source data sets is shown in Figure 5.1. As can be seen from the histograms, the US data 
set was both left-censored and right-censored for age. This finding had not been 
revealed by the earlier simple testing for presence of age (or, equivalently, date of birth) 
information in the data sets. This censoring is understood to be due to the HIPAA 
regulations [123] governing the release of data derived from individuals, even if the data 
are de-identified. The HIPAA regulations include a number of rules governing the 
release of data. Section 164.514(b) of the HIPAA regulations defines the ‘Safe Harbor’ 
method for de-identification by giving 18 rules for removal or de-granularisation of data 
items. Rule 3 states that ‘All elements of dates (except year) for dates that are directly 
related to an individual, including birth date, admission date, discharge date, death date, 
and all ages over 89 and all elements of dates (including year) indicative of such age, 
except that such ages and elements may be aggregated into a single category of age 90 
or older’. Practice Fusion also chose to exclude records derived from those under 18 
years of age. It can be seen from Rule 3 that HIPAA also recommend releasing only the 
year of birth, reflected in the detail of the data released by Practice Fusion It was 
necessary to filter the UK-sourced records to mimic the distribution of the US-sourced 
data; this was done by removing records with an age of 18 years or less or greater than 
90 years. The number of records removed is shown in Table 6.1.   
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Figure 6.1 Age distribution from the three source data sets 
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Source data  
set 
Number of 
records in 
source data 
set 
Number of 
records after 
age filtering 
Number of  
records 
removed 
CPRD 4711 3908 803 
THIN 3674 3070 604 
All UK 8385 6978 1407 
Practice 
Fusion 
14740 14740 0 
All UK + US 23125 21718 1407 
Table 6.1 Number of records in the source data sets, before and after filtering by 
age 
The filtered data set, with all records from individuals aged 17 years or younger or 90 
years or older removed, was used for all subsequent analysis 
6.3.2 Age distribution comparison 
The age distributions in the age-filtered data sets were compared using a two-sample 
Kolgomorov-Smirnov test (see e.g. [225]), producing the Kolgomorov-Smirnov ‘D’ 
statistic,  where  
 
The ‘ks.test’ function from the R ‘stats’ package [226] is used to compare cumulative 
age frequencies in the CPRD data to cumulative age frequencies in the THIN data.  
D = 0.429, p = 0.5752 
Conclusion: the two UK data sets do not have significantly different age distributions (p 
> 0.05) and so can be merged. 
Comparing the merged UK data set to the Practice Fusion data set: 
D = 0.71429, p-value = 0.05303 
Conclusion: the UK data set and the US data set do not have significantly different age 
distributions (p > 0.05) and so were merged without weighting. 
6.3.3 Gender distribution 
The gender balance between data sets was compared, using Pearson’s chi-squared test 
(Pearson, 1900) 
For CPRD vs THIN: 
CPRD: 1980 Male, 1928 Female 
Error! No text of specified style in document. 
190 
THIN 1501 male, 1569 female 
The chi-squared test was performed using the ‘chisq.test’ function from the base R 
‘stats’ package [226]: 
chisq.test (as.table(rbind(c(1980, 1928), c(1501,1569)))) 
 Pearson's Chi-squared test with Yates' continuity correction 
data:  as.table(rbind(c(1980, 1928), c(1501, 1569))) 
X-squared = 2.0911, df = 1, p-value = 0.1482 
Conclusion: the two UK data sets do not have significantly different gender distribution 
and so can be merged 
 
For combined UK vs US: 
UK: 3481 male, 3497 female 
US: 7225 male, 7505 female 
chisq.test (as.table (rbind(c(3481, 3497), c(7225,7505)))) 
 Pearson's Chi-squared test with Yates' continuity correction 
data:  as.table(rbind(c(3481, 3497), c(7225, 7505))) 
X-squared = 1.2901, df = 1, p-value = 0.256 
 
Conclusion: the UK data set and the US data set do not have significantly different 
gender distribution and so can be merged. 
 
Overall conclusion: there is no significant difference between the source data sets that 
would preclude the merging of the source data sets into a single composite data set for 
further analysis. 
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6.4 Condition prevalences: composite data set vs population 
 
In order to validate the combined data set as a source of data for further work, the 
combined data set was assessed to check that (1) that the most common conditions in 
the data set matched the most common conditions in the general population; (2) various 
conditions present in patients in the data set had similar prevalence to the same 
conditions present in the general population, as found in published studies; (3) that risk 
factors associated with particular conditions could be established and compared with 
risk factors published in the literature. 
6.5 Most frequent conditions. 
The first exercise was to discover the most frequent conditions in the composite data set 
and compare this list to an external study listing the most prevalent conditions in the 
general population.  
A Practice Fusion study on most prevalent conditions in 2016 was used as the basis for 
this exercise (https://www.practicefusion.com/blog/25-most-common-diagnoses/) 
Note that this is prevalence of condition – no account is taken of relative burden of each 
condition, or contribution to mortality. It is merely prevalence of condition as recorded 
in their patient records system. Note also that this data is derived from patients in the 
USA only. 
 
The top 10 most frequent conditions in 2016 listed in the study were: 
1. Hypertension 
2. Hyperlipidaemia 
3. Diabetes 
4. Back pain 
5. Anxiety 
6. Obesity 
7. Allergic rhinitis 
8. Reflux esophagitis 
9. Respiratory problems 
10. Hypothyroidism 
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6.6 Semantic mapping. 
The composite data set with events coded in a single coding system and data cleaned, 
with clear duplicates removed, was now ready for validation and analysis. However, 
from inspection of the event codes, it was clear that a single medical condition could be 
indicated by multiple codes. For example, the presence of type 2 Diabetes could be 
indicated by X40J5 ‘Type II diabetes mellitus’, XaIfI ‘Type II diabetes on diet only’, 
XaIfG ‘Type II diabetes on insulin’, Xa2hA ‘Dietary advice for type II diabetes’, and/or 
C1011 ‘Type 2 diabetes mellitus with ketoacidosis’ and a number of other codes. Other 
sets of codes, or ‘codelists’, exist for other conditions.  
At the time of commencement of this work no standard sets of codelists were found to 
be available. It was therefore necessary to generate lists of CTV3 codes for each 
condition of interest, each list containing the set of codes that indicated the presence of 
the condition. Some recent work has been published that indicates the desirability of 
standardising such codelists in publically available repositories and a project is 
underway at the University of Manchester Institute of Population Health to acquire and 
disseminate such codelists (see codelists.org) and to which repository the codelists used 
in this work will be offered. 
However, this project has yet to reach the point where they are able to make codelists 
publically available [227]. Other recent work on codelists has been described by Watson 
et al [228], who although working towards automated codelist generation, still rely in 
large part on manual processes. 
Codelists for use in this project were created by a manual process of searching code 
descriptions and making a judgment as to whether the description of the code was 
indicative of the presence of the condition of interest.  Skills acquired in the manual 
mapping of ICD9-CM codes to CTV3 codes were beneficial, in particular knowledge of 
synonyms for particular conditions and knowledge of the CTV3 hierarchy which 
enabled rapid searching for related codes. 
In the list of example given above for Type 2 Diabetes, code Xa2hA ‘Dietary advice for 
type II diabetes’ was considered to be a strong enough indicator of the presence of the 
condition for it to be included in the code list, although it was not a formal record of a 
diagnosis of the condition. It should be noted that CTV3 codes exist in a hierarchy and 
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so any ambiguity in a code description could be resolved by inspection of the code’s 
parent code or child code(s). 
With the unknown number of event codes that could indicate the presence of a 
condition, the variability in event code descriptions, the possibility that event codes 
could appear in disparate regions of the CTV3 hierarchy, and the large number of 
unique codes in the CTV3 hierarchy, it was challenging to produce codelists that were 
complete. A technique was developed to check that no significant event codes had been 
omitted from the codelist in which they should be present. 
To check that no significant codes had been omitted from codelists, an R program was 
developed that implemented a decision tree algorithm on the composite set of records, 
following the process shown in 
 
Error! No text of specified style in document. 
194 
Figure 6.2.  
 
 
Figure 6.2 Process for discovering candidate codes for addition to codelists 
 
 
For each condition, codes in the draft codelist were removed from the set of records, 
with those records having a ‘condition’ code present, i.e. a code that was in the codelist 
being flagged as a ‘condition positive’ record. The decision tree algorithm was then 
trained to use the remaining codes in all records to predict the ‘condition positive’ 
records. Codes that were strong predictors for condition positive records were inspected 
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and those codes that themselves recorded the presence of the condition were added to 
the relevant codelist.  
As an example, the codelist for type 2 diabetes is used. All codelists can be found in 
Appendix 2. This codelist has 32 event codes, each of which, if found in a record, is 
taken to be indicative of the presence of the condition ‘type 2 diabetes’. Removing two 
codes from the codelist and running the decision tree program on the composite data set 
produced the following results: 
Codes temporarily removed from the data set: 
XaOPu ‘Latent autoimmune diabetes mellitus in adult’, X40J5 ‘Type II diabetes 
mellitus’ and C1092 ‘Type II diabetes mellitus with neurological complications’ 
Running the partition tree algorithm produces a set of codes as being used to split the 
tree and should be inspected to see if they should be included in the codelist set for the 
condition under consideration. These codes produced in the example for type 2 diabetes 
with some event codes omitted are shown in Table 5.2.  
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CTV3 code CTV3 code description 
14L.. H/O: drug allergy 
29H1. O/E - vibration sense normal 
66AE. Feet examination (& diabetic) 
X40J5 Type II diabetes mellitus 
C100. Diabetes mellitus with no mention of complication 
XE10G Diabetes mellitus with renal manifestation 
Cyu8D [X]Other hyperlipidaemia 
XE2QC Impacted wax 
G2101 Malignant hypertensive heart disease with CCF 
1361. Teetotaller 
Ub1na Ex-smoker 
XE15k Diabetic polyneuropathy 
Xa8Hh Thrombocytopenic disorder 
XE10G Diabetes mellitus with renal manifestation 
C1082 Type I diabetes mellitus with neurological 
complications 
XE11U Mixed hyperlipidaemia 
66AP. Diabetes: practice programme 
XM06e Dizziness and giddiness 
G200. Malignant essential hypertension 
XE1EZ Shoulder joint pain 
24E1. O/E -R.-leg pulses all present 
24F1. O/E - L.leg pulses all present 
XaJvF O/E - Right dorsalis pedis normal 
XaJvH O/E - left dorsalis pedis normal 
22K4. Body mass index index 25-29 - overweight 
XE1hO O/E - peripheral pulses R.-leg 
XE1hP O/E - peripheral pulses L.leg 
ZV700 [V]Routine health check-up 
Table 6.2 Codes suggested as being missing from a codelist 
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Note that not all the ‘missing’ codes were discovered, This is because the codelists were 
built on the complete CTV3 code set, whereas the partition algorithm is run only on the 
composite code set which contains only a subset of the complete CTV3 code set. Since 
later analysis could only be performed on the existing composite data set, it was 
important only to have codelists that were complete for event codes within the 
composite data set and not also those in the complete CTV3 code set. 
Alternatively, the tree can be plotted, as shown in Figure 6.3. 
 
Figure 6.3 Plot of decision tree used to discover candidate codes for addition to 
codelists 
Codelists were built for each of the 'top 10' conditions, with some conditions requiring a 
large number of codes to identify all occurrences of the condition. For example, the 
most common condition, hypertension, required 134 codes in its codelist. As a shorter 
example, codes making up the codelist for hyperlipidaemia are shown in Figure 6.3. 
Codelists for all the most frequent conditions can be found in Appendix 2. 
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CTV3 
code 
CTV3 code description 
U60C6 [X]Antihyperlipidaem/antiarterioscl drg caus adv ef ther use 
XaJYh Hyperlipidaemia clinical management plan 
Xa2hC Dietary advice for hyperlipidaemia 
Cyu8D [X]Other hyperlipidaemia 
XE13A Disord lipid metab (& [Fredrick types] or [hyperlipidaemia]) 
X40Wy Hyperlipidaemia 
X40Vm Familial combined hyperlipidaemia 
XE11U Mixed hyperlipidaemia 
C324. Hyperlipidaemia NOS 
X40XI Primary combined hyperlipidaemia 
X40XO Secondary combined hyperlipidaemia 
C3202 Hyperlipidaemia, group A 
C322. (Mix hyperlipid) or (Fredr lip: [IIb][III]) or (xanthom tub) 
Table 6.3 Codes in the codelist for hyperlipidaemia 
 
Once codelists had been created and tested, the full record set could be validated for 
condition prevalences against condition prevalences in the literature. 
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Table 5.4 shows these top 10 conditions, their 'top 10' rank and their frequency rank in 
the composite data set following discovery using the codes in the codelists. Note that 
the composite data set prevalences shown in this table are raw prevalences, unadjusted 
for age. 
 
Practice 
Fusion 
Prevalence 
Rank 
Condition Composite 
data set 
prevalence 
(per 
100,000) 
Composite 
Table 
rank 
No. of 
 CTV3 codes 
1 Hypertension 30169 1 134 
2 Hyperlipidaemia 21342 2 13 
3 Diabetes 11749 6 73 
4 Back pain 16552 3 41 
5 Anxiety 11663 7 38 
6 Obesity 13310 5 77 
7 Allergic rhinitis 14754 4 18 
8 Reflux 
oesophagitis 
8832 8 14 
9 Respiratory 
problems 
3333 10 329 
10 Hypothyroidism 7412 9 56 
Table 6.4 Prevalence of the ‘Top 10’ most common conditions in the population in 
the composite data set, their rank order of prevalence in the general US population 
and in the composite data set, and the number of CTV3 codes in the codelists that 
indicate the presence of the condition 
 
The degree of association between the two ranked lists was tested using Kendall’s tau 
coefficient [229]. Calculation were performed using the on-line Kendall’s tau rank 
correlation calculator at wessa.net [230] 
 
This calculator produced a value for tau of 0.689, with a 2-sided p-value of 0.007. 
Given this result, the null hypothesis of independence between the two rank orders is 
rejected. 
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Investigation is now made of each of these conditions to compare the prevalence found 
in the composite data set to the prevalence in the general Western population as found 
in the literature. This serves both to validate the prevalence of the conditions in the 
composite data set and to give confidence in the codelists that have been built. A 
summary of the results is shown in Table 6.5. Each condition is then briefly discussed. 
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 Composite data set prevalence Literature prevalence Literature source 
Condition Unadjusted 
Prevalence 
US Age 
adjusted 
prevalence 
UK Age 
adjusted 
prevalence 
Unadjusted 
Prevalence 
Age adjusted 
prevalence (if 
given) 
  
Hypertension 29467 16786 20431 28000-44000 36000 (Europe), 
31000 (“high 
income” countries) 
Wolf-Maier et al [231], Mills 
[232] 
 
Hyperlipidaemia 22542 13224 15914 39000  WHO [233] 
Type 2 diabetes 8614 4748 5933  8700 Centers for Disease 
Control and Prevention [234] 
 
All diabetes 10733 6201 7552 6000  Diabetes.co.uk [235] 
Back pain 16433 12098 12992 12000 - 
20000 
 Meucci et al [236] 
Anxiety disorder 13118 11859 12064 2000-13000  Martin [237] 
Obesity 7623 5663 6071 23000 (UK), 
33800 (USA) 
 OECD [238] 
Allergic rhinitis 15423 13417 13748 ~23000  Bauchau and Durham [239]  
Gastro-
oesaphageal 
reflux disease 
9369 6566 7309 6600-28000  Dent et al [240] 
Respiratory 
problems 
3333 2644 2351 4100  Eurostat [241]  
Hypothyroidism 7753 5570 4815 600 - 12000  Vanderpump [242] 
Table 6.5 Table of crude and age-adjusted prevalence (per 100,000) in composite data set   
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6.7 Condition prevalences in the data set versus in the literature 
Age-adjusted prevalences were calculated for the US and UK derived records in the 
expectation that some of the data sources in the literature would report age-adjusted 
prevalence. Age-adjusted prevalence is useful when comparing populations that may 
have different age distributions. See Naing [243] for an introduction to age adjustment. 
The method used here is taken from the NIH National Cancer Institute [244] 
implemented locally in an R program. 
Condition prevalences in the literature 
This is a more challenging area for validation for several reasons:  
a. Getting condition prevalence for general populations from the literature is not 
straightforward; definition of what is the condition is may not be well-
established; the presence of a condition in a record can be indicated by multiple 
different CTV3 codes. It is therefore necessary, for each condition, to build lists 
of CTV3 codes that indicate the presence of each condition of interest, as has 
been previously described. 
b. Condition prevalences in the literature are sometime vague, giving a wide range 
for prevalence value. Prevalences are often for a particular sub-population rather 
than for a general population. 
c. Condition prevalences can be reported as an unadjusted prevalence or as an age-
adjusted prevalence (prevalence may be different in different age groups; 
contribution of different age groups in the overall result is different – e.g. age 
31to 40 years has more people than age 91-100 years). In the composite data set, 
both unadjusted and age-adjusted prevalence is calculated and the appropriate 
prevalence is compared to the prevalence noted in the literature. However it is 
not always clear which prevalence is being presented in published work. 
d. Condition prevalences may be calculated following testing of a sample group, 
which may give a different (higher) prevalence than calculating prevalence in a 
set of records – undiagnosed conditions will not be recorded, diagnosed 
conditions may be mis-recorded or recorded elsewhere than the primary care 
record. 
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Each of the top 10 conditions is now briefly discussed, focussing on the condition 
prevalence discovered in the composite data set, using the generated codelists, and 
condition prevalences found in the literature. 
 
6.7.1 Hypertension 
 
The most common condition in the composite data set and in the figures found for the 
general population, hypertension is estimated to cause around 13 % of deaths globally.  
Information on the prevalence of hypertension was taken from the work of Wolf-Maier 
et al (2003) and a meta-analysis by Mills et al (2016). 
Figures taken for comparison: 
Wolf-Maier et al: USA: 28 % prevalence rate; Europe: 42 % prevalence rate.  
Mills et al: globally 31 % prevalence rate; Europe 36 % prevalence rate; ‘high income 
economies’ 31 % prevalence rate.  
Prevalence rates quoted in both studies were age-adjusted. 
The unadjusted prevalence of 29.5 % found in the composite data set is similar to the 
prevalence rates presented by Wolf-Maier and by Mills. However, the age-adjusted 
prevalence rates in the composite data set of 16.8 % (USA) and 20.4 % (UK) are lower 
than the age-adjusted figures of Wolf-Maier and of Mills. 
These lower figures may be due to under-reporting of hypertension in clinical records, 
with many cases not being reported to clinicians, or may be due to the codelist for 
hypertension being incomplete. However, given the composite data set figures are of 
similar magnitude to the estimates of the general population and they were not the 
subject of further investigation. 
 
6.7.2 Hyperlipidaemia 
Hyperlipidaemia, or raised cholesterol levels, is the leading risk factor in death from 
cardiovascular disease, the leading cause of death in the United States. Estimates vary 
as to the prevalence of hyperlipidaemia but reported prevalences are generally higher 
than that found in the composite data set (22.5 %). The Centers for Disease Control and 
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Prevention reported (2011) that an estimated 33.5 % of US adults had hyperlipidaemia, 
a figure not indicated as being age-adjusted.  
Given the composite data set figures are of similar magnitude to the estimates of the 
general population, they were not the subject of further investigation 
 
6.7.3 Type 2 diabetes 
There are two main types of diabetes – type 1 and type 2. In the UK, around 90 % of 
individuals with diabetes have type 2. It is not always clear from the event codes in the 
records in the composite data set which type of diabetes is being recorded. The 
prevalence of specifically type 2 diabetes of 8.6 % in the composite data set is close to 
that described in CDC 2017; the prevalence of both types of diabetes is close to that 
shown on diabetes.co.uk. It may be that the prevalence discovered from the composite 
data set is closer to that in the literature because diabetes is less likely to remain 
unrecorded than some other conditions, or it may be that the event code that indicate 
diabetes are clearer and so the diabetes codelists are more complete. 
Holman et al in 2014 [245] reported a recorded prevalence for type 2 diabetes of 5.7 % 
for adults in the UK, with an estimated actual prevalence (diagnosed and undiagnosed) 
of 8.9 %. The figures for prevalence given by Holman et al were not indicated in their 
paper to be age-adjusted (see Naing [243] for more information on age-adjusted 
prevalences and their calculation) and so the assumption was made that they were not 
age-adjusted.  
 
6.7.4 Back pain 
Back pain is a condition where it is challenging to find a definitive estimate of 
population prevalence, perhaps because it is a condition that an individual may not feel 
worthy of investigation or it may be recorded clinically under another name. The 
prevalence in the composite data set of 16.4 % is no different to the estimates found in 
the literature. Meucci et al, in a review of studies into back pain prevalence [236], find 
that prevalence rates in these studies varied from 4.2 % to 25.4 % depending on the 
population studied.  
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6.7.5 Anxiety 
Anxiety was a condition with a wide range of estimates for its prevalence, perhaps 
reflecting a difficulty in precisely defining clinical anxiety. The prevalence in the 
composite data set of 13.1 % is no different to the estimates found in the literature. A 
review by Martin [237] quotes a prevalence of 2 % to 30 % over a lifetime, with a one-
month prevalence of 7.3 %. 
 
6.7.6 Obesity 
A condition that appears to be under-recorded in the composite data set, with a 
prevalence of 7.6 %. This could be due to under-presenting or under-recording of 
individuals with the condition or the condition being recorded as other conditions. It 
should be noted that event codes indicating high BMI have been included in the obesity 
prevalence calculation 
The US NHANES survey of 2013-2014 suggests an (age-adjusted) obesity prevalence 
of 70.2 % for US adults [246], while a UN Food and Agriculture report of 2013 [247] 
quotes an obesity prevalence in the UK of 26.9 %. 
 
6.7.7 Allergic rhinitis 
Allergic rhinitis, or hay fever, has a higher prevalence recorded in the literature than it 
does in the composite data set, which records a prevalence of 15.4 %. This may be 
because the condition has a range of severity, from mild to severe, and individuals with 
mild allergic rhinitis may not present themselves for medical care, preferring to self-
medicate with over the counter medication. Bauchau and Durham [239] quote a 
prevalence of allergic rhinitis Italy of 17 % and in Belgium of 29 %; the World Allergy 
Organisation [248] quote a global prevalence of between 10 % - 30 %. 
 
6.7.8 Reflux oesophagitis 
Reflux oesophagitis, or simply “reflux disease”, has a wide range of prevalence in the 
literature. The prevalence recorded in the composite data set of 9.4 % is within the 
range of prevalence in Dent et al [240] of 6.6 % to 28 %. 
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6.7.9 Respiratory problems 
“Respiratory problems” covers a number of complaints, including COPD, asthma, 
bronchitis, lung cancer, pneumonia. The prevalence found in the composite data set 
excludes bronchitis and asthma as these conditions are subject to their own codelists and 
are recorded separately in the table of most common conditions (at positions 20 and 21 
respectively). 
The prevalence of respiratory problems found in the composite data set of 3.3 % is 
broadly in line with that reported in the literature. Eurostat reported that in 2014, 4.1 % 
of the population of the EU self-reported a non-asthma respiratory problem [241]. 
 
6.7.10 Hypothyroidism 
Estimates for the prevalence of hypothyroidism vary widely (see Vanderpump [242] for 
an analysis of work in this area, reporting estimates of prevalence ranging from 0.6 % to 
12 %). The prevalence of 7.7 % calculated from the composite data set is roughly in the 
middle of the range of estimates in the literature. 
 
6.8 Validation of risk factors 
We know from previous work that some conditions have known risk factors, for 
example the risk of an individual suffering from type II diabetes is increased if they are 
overweight or have high blood pressure, among other risk factors. 
It is possible to investigate whether the risk factors established in previous research can 
be detected for any particular condition in the composite data set. The top 10 conditions 
previously investigated were used to test for discovery of risk factors.  
For each condition, the top risk factors can be determined. This was done by, for each 
record, determining the presence or absence of the condition of interest, placing the 
record into the set of records with the condition or the set of records without the 
condition, and then comparing the positive and negative condition groups for 
prevalence of other conditions and symptoms, determining whether any increase in 
presence of a potential risk factor was significant or not. Note that additional codelists 
for potential symptoms were required to be generated. 
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A program was written in R to group records, for each condition under investigation, by 
“contains this condition” and “does not contain this condition”. For records which 
contain the condition, event codes that occurred prior to the diagnosis of the condition 
are checked for the presence of potential risk factors, i.e. they are checked against the 
risk factor codelists. For those records which did not contain the condition, all event 
codes were checked.  
The group of records with the condition under investigation was then split into two 
groups: those with the potential risk factor and those without. Similarly, the group of 
records without the condition was split into a ‘with risk factor’ and ‘without risk factor’ 
groups. The ratio of with-risk to without-risk for with-condition against without-
condition was then checked using a chi-squared test, using the chisq.test function from 
the base R stats package [226]. 
 
 
6.8.1 Bias between cases and controls 
 
Index dates are different for cases and controls: for cases, those records that contain the 
condition of interest, the index date is the date on which the presence of the condition of 
interest was first recorded, with subsequent events discarded from the analysis, whereas 
for the controls, those records that do not contain the condition of interest, the index 
date is the date of the most recent event. These different ways of selecting index date 
can cause bias. In order to mitigate the effect of this bias, each ‘case’ record should have 
been matched with a ‘control’ case where later events after the index date were also 
discarded. 
Grimes and Schulz [249] describe three main areas of bias: selection bias, information 
bias and confounding. The possibility of each of these areas of bias affecting the work 
described in this report is briefly described: 
Selection bias: the data set is comparable to the general population in terms of age 
distribution, gender balance, and prevalence of conditions (see section 6.3).  
Information bias: It cannot be guaranteed that information on each record has been 
gathered in the same way (for example, some patients may attend practices that record 
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information more assiduously, or code data more accurately, than others; the threshold 
for recording an event may differ between practices and between nations). However, the 
training set and the test set are randomly sampled from a single data set and so records 
with a greater degree of precision or accuracy than others are as likely to be in the 
training set as the test set; they are as likely to have the condition of interest as not. 
Confounding: Positive cases for each condition of interest are determined by identifying 
the presence of a condition code indicating that condition of interest in a record. Events 
occurring subsequent to the condition of interest are removed, since they cannot be used 
as predictors for the condition of interest for that record. However, negative cases - 
records that do not contain a code indicating the presence of the condition of interest - 
remain unchanged, and so the record is not curtailed. This could introduce bias by 
allowing for the negative cases to have records covering a longer time span and this 
potentially a greater number of events. The mean number of events for positive cases 
(up to the occurrence of the condition of interest) was compared to the mean number of 
events for negative cases; results of this are show in Table 6.6.  
Table 6.6 shows that in general, the positive records had a greater or equal number of 
events before the occurrence of the condition of interest, with two exceptions: 
thyrotoxicosis and colon cancer, each of which had fewer recorded events before the 
occurrence of the condition of interest. There is no obvious explanation for this 
difference. 
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acuteSinusitis 1325 7936 19.6 20.1 11 12 -0.70 1668.6 0.49 
Bronchitis 1439 7822 19.4 21.1 12 12 -2.61 1825.2 0.01 
colonCancer 34 9227 20.2 27.4 15.5 12 -1.68 33.18 0.10 
osteoarthritis 1031 8230 19.5 22.2 12 12 -3.26 1184.25 0.001 
allergicRhinitis 1619 7642 20.0 20.2 13 12 -0.24 2222.81 0.81 
anyCancer 410 8851 19.6 32.5 17 12 -7.72 422.93 8.74E-14 
Asthma 1100 8161 18.8 29.3 17 12 -11.18 1220.35 1.06E-27 
Autism 13 9248 20.2 30.7 28 12 -1.44 12.02 0.18 
breastCancer 105 9156 20.0 39.9 31 12 -5.89 104.87 4.73E-08 
Eczema 464 8797 19.1 40.5 35 12 -14.69 483.33 1.17E-40 
Gastroparesis 19 9242 20.3 16.2 16 12 1.93 18.40 0.07 
Obesity 1446 7815 17.7 33.1 20 11 -17.83 1600.9 4.89E-65 
praderWilli 2 9259 20.3 27.0 27 12 -0.37 1.00 0.77 
prostateCancer 96 9165 20.2 23.3 9.5 12 -0.92 95.84 0.36 
refluxDisease 987 8274 19.9 22.2 13 12 -2.54 1118.95 0.01 
Stress 255 9006 19.7 40.0 28 12 -8.77 258.36 2.51E-16 
T2Diabetes 907 8354 20.2 19.8 11 12 0.44 1027.84 0.66 
thyrotoxicosis 39 9222 20.3 12.9 11 12 6.89 41.51 2.18E-08 
Table 6.6 Comparison of number of events for positive cases vs number of events for negative cases
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Conditions that show a significant difference in mean no of events for patients with 
condition vs patients without condition are highlighted in bold. Generally, those 
individuals with the conditions have a higher number of reported events than those 
without, excepting for thyrotoxicosis. Also note that the data set has a representative 
sample of codes at all levels (see section 7.3.1) 
A table of conditions vs risk factors is shown in Table 6.7. Risk factors that are found to 
be strongly associated with conditions (p < 0.01) are marked          in the table. Each 
condition and their associated ‘risk factors’ is then briefly discussed.
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Hypertension -          
Hyperlipidaemia  -         
Type 2 diabetes   -        
Back pain    -       
Stress     -      
Obesity      -     
Allergic rhinitis       -    
Reflux disease        -   
Resp.  problems         -  
Hypothyroidism          - 
Age > 45           
History of heart attack           
Tobacco use           
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Alcohol use           
Passive smoking           
Low vitamin D in diet           
Sleep apnoea           
Illegal drug use           
Eczema           
Hiatus hernia           
Gastroparesis           
Physical inactivity           
Table 6.7 ‘Risk factors’ associated with conditions found in the composite data set 
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The analysis of risk factors for particular conditions shown in Table 6.7 shows 
associations between conditions but cannot establish causality. However it was 
considered a useful exercise to check whether known risk factors for conditions are 
discovered to have associations with those conditions. 
 
6.8.2 Hyperlipidaemia 
The Centers for Disease Control and Prevention (CDC) list a number of factors that 
increase the risk of hyperlipidaemia: having type 2 diabetes, eating a diet high in 
saturated fats, being physically inactive, being obese, and being older [250]. The 
composite data set picks out type 2 diabetes, hypertension, tobacco consumption, poor 
diet (‘low vitamin D in diet’ is taken as a marker for poor diet in general for this 
condition and for other conditions examined) and illegal drug use and age as risk factors 
for hyperlipidaemia. 
 
6.8.3 Hypertension 
The CDC [251] lists type 2 diabetes, an unhealthy diet, physical inactivity, obesity, high 
alcohol consumption and tobacco use and being older as risk factors for hypertension. 
The composite data set picks out type 2 diabetes and being older as having a significant 
association with hypertension. 
 
6.8.4 Type 2 diabetes 
The CDC lists being overweight, being older, being physically inactive as risk factors 
for developing type 2 diabetes, as well as other factors not tested such as having 
prediabetes, having a close relative with type 2 diabetes or being from certain ethnic 
groups. The composite data set picks out age > 45, tobacco use and poor diet as having 
a significant association with hypertension. 
 
6.8.5 Anxiety and stress disorders 
The Mayo Clinic [252] notes that there are a number of possible causes for anxiety 
disorders or stress, including medical problems such as heart disease, diabetes, thyroid 
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problems, respiratory disorders, drug use, withdrawal from alcohol or some 
medications, chronic pain or irritable bowel syndrome, some rare cancers, some 
medications. Risk factors include trauma, stress due to illness, build-up of stress from 
multiple causes, some personality types, other mental health disorders, having close 
relatives with an anxiety disorder or drug or alcohol use or withdrawal.  
 
6.8.6 Back pain 
The Mayo Clinic [253] give being older, being inactive, obesity, having arthritis or 
some cancers, being depressed, tobacco use and improper lifting as risk factors for back 
pain.  
 
6.8.7 Obesity 
The Mayo Clinic [254] give genetics, lifestyle, physical inactivity, poor diet, certain 
medical conditions and medications, social and economic issues, being older, 
pregnancy, stopping smoking, and poor sleep patterns as risk factors for obesity. The 
composite data set picks out age > 45, tobacco use and poor diet as having a significant 
association with hypertension. 
 
6.8.8 Allergic rhinitis 
The Mayo Clinic [255] give eczema, having a close relative with allergies or asthma, 
having other allergies or asthma, being constantly exposed to allergens or having a 
mother who smoked while you were an infant as risk factors for allergic rhinitis. The 
composite data set picks out eczema, tobacco use, obesity and poor diet as having a 
significant association with allergic rhinitis. 
 
6.8.9 Gastro-oesophageal reflux disease 
The NHS Choices website [256] gives consuming certain foods, obesity, tobacco use, 
pregnancy, stress and anxiety, some medications and hiatus hernia as risk factors for 
gastro-oesophageal reflux disease (‘acid reflux’).   
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6.8.10 Respiratory problems 
The NHS Choices website [257] lists tobacco use, regularly breathing in fumes or dust, 
air pollution and genetic factors as risk factors for respiratory problems. Hypertension, 
hyperlipidaemia, type 2 diabetes, back pain, stress, obesity, age over 45 years, tobacco 
use, poor diet, eczema and physical inactivity are associated with respiratory problems 
in the composite data set. 
 
6.8.11 Hypothyroidism 
The NHS Choices website [258] gives immune system problems and previous thyroid 
treatment as the main causes of underactive thyroid, with less common risk factors 
being type 1 diabetes, iodine deficiency or congenital factors. Hypertension, 
hyperlipidaemia, type 2 diabetes, back pain, stress, obesity, respiratory problems, being 
older, tobacco use, poor diet, eczema and physical inactivity are associated with 
hypothyroidism in the composite data set. 
 
6.9 Summary 
 
The composite data set has been verified for completeness and for plausible data values. 
Records that strongly appear to be duplicates have been removed. The source data sets 
have been validated against each other to ensure that there are no significant differences 
in age distribution or gender distribution. 
Condition prevalences in the composite data set have been validated against condition 
prevalences described in the literature for the 10 most common conditions in the USA. 
The ordering of the most common conditions in the composite data set had some 
differences to the top 10 conditions in the US study, but this difference in ordering was 
not found to be significant. The prevalence of each these 10 most common conditions 
were calculated for the composite data set and compared to the prevalence reported in 
the literature. Some differences were found although all prevalences were within the 
same order of magnitude. 
Risk factors for the most common conditions were investigated, comparing significant 
associations of risk factors to conditions in the composite data set against accepted risk 
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factors for these conditions. In general, the accepted risk factors were identified in the 
analysis of the composite data set. 
 
Contribution: In order to identify conditions and risk factors from the composite data 
set, it was necessary to build codelists comprising all the CTV3 codes that indicated the 
presence of a particular condition or risk factor. These codelists are detailed in 
Appendix 2. On completion of this work the codelists will be uploaded to the University 
of Manchester Institute of Population Health codelist repository. 
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7 ESTIMATION OF CONDITION 
RISK: METHODS 
7.1 Introduction 
At the population level, identification of groups of individuals at risk of particular 
conditions can help with health care resource planning, particularly for conditions that 
have a high individual cost of treatment and/or affect a high proportion of the 
population, and promotion of lifestyle choices that will reduce the numbers of 
individuals developing such conditions.  
It is therefore proposed that identification of individuals at raised risk of particular 
conditions and an indication of the degree to which that risk is raised will have value to 
their healthcare. In order to estimate the raised risk for those individuals at increased 
risk of particular conditions, a system has been developed to interrogate clinical 
histories for previous diagnoses and symptoms and using these data estimate the 
changed risk. Opportunities for use of this information are two-fold: as a pre-screening 
tool to identify groups of individuals at raised risk of particular conditions, and as an 
opportunistic calculation of modified risk for an individual when attending a clinical 
practice, for presentation of modified risk to a clinician. 
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7.1.1 Background 
One of the challenges of healthcare is to achieve timely diagnoses for conditions, i.e. a 
diagnosis that is early enough to improve outcomes for individuals with those 
conditions, whether that improved outcome is an improved chance of a cure, no cure but 
alleviation of ill-effects, or a combination of the two. Early diagnosis can be 
problematic since symptoms that are indicative of a particular condition may not be 
fully present, or symptoms may be present that could be indicative of a number of 
different condition. A measure of the challenge of diagnosis can be seen from the 
estimate of the number of diseases of more than 10,000 [259] versus the number of 
symptoms of less than 400 [158], and so it is clear that any one symptom could have 
many different underlying causes. When making a diagnosis it is natural to base that 
diagnosis on the symptoms, combinations of symptoms, history of the symptoms and of 
previously diagnosed conditions, and on the prevalence of candidate. 
There are around 7,000 diseases considered to be rare diseases (diseases that affect less 
than 5 persons in 10,000 according to the EU definition [260]). Unless there are clear 
symptoms indicating that one of these conditions is present, it is natural to consider 
more common conditions as an explanation for symptoms presented. For conditions that 
are not rare but less prevalent than others, this preferential diagnosis may also be the 
case. For example, thyrotoxicosis (prevalence = 0.06 % in the composite data set) 
shares many symptoms with diabetes (prevalence = 6.0 %), depression (3.3 %) [261] 
and viral infection (varies by infection type) and is formally diagnosed by blood test, 
which has a financial cost. 
A simple method of identifying individuals who are at increased risk of particular 
conditions can be the first step towards an earlier diagnosis than may otherwise be 
achieved. Should an early diagnosis be obtained, this can lead to earlier treatment with 
the possibility of improved outcome, although this may not be true for all conditions, 
particularly those that are not treatable or are slow-developing conditions identified in 
later life. Individuals who are identified as being in an ‘at-risk’ group for a particular 
condition but who have yet to develop the condition can have the opportunity to modify 
their behaviour to reduce the risk of developing that condition, for example improving 
diet to reduce the risk of developing type 2 diabetes or hyperlipidaemia. The NHS 
Health Check for over-40-year-olds in the UK aims to identify patients at-risk of several 
conditions, including diabetes and heart disease, diagnosing those who have developed 
conditions undiagnosed prior to their health check and offering lifestyle advice to those 
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at risk of some conditions. However this health check is offered only to a sub-group of 
the population (those aged over 40), relies on individuals actively responding to the 
offer of a health check, and costs money to UK health providers and has some level of 
inconvenience, invasiveness and possibly cost to the individuals who are checked. 
It is proposed that knowledge of the likelihood of a condition is useful information to a 
clinician when making a diagnosis. For example, around 10 % of the population has 
diagnosed diabetes, but this base figure varies between age groups and ethnicities. 
Given knowledge of the prevalence of conditions, clinicians can preferentially consider 
candidate diagnoses for a set of symptoms by considering and eliminating diagnoses in 
order of their statistical likelihood. 
A second usage is as a pre-screening tool, selecting those patients at raised risk for a 
particular condition for screening (discuss screening only of benefit if there is a 
treatment for the condition that is commensurate with the condition’s risks, i.e. 
treatment for the common cold should be cheap and with few side effects; treatment for 
cancer can be expensive and have side effects, provided that these side effects are less 
harmful than the condition). 
Described here is a technique for estimating risks of defined conditions that is based on 
an individual's history of diagnoses of clinical events, combined with two major 
lifestyle factors, history of tobacco use and alcohol consumption, and age. Based on 
these data, individuals' records are matched against other records to discover those 
records which share a similar set of event codes, lifestyle factors and age. The set of 
similar records can then be examined to determine whether the prevalence of the 
condition of interest is raised when compared to the prevalence within the complete 
composite data set. 
 
7.1.2  Resources produced in previous chapters 
This work will utilise the resources described and validated in the previous chapters. 
These are: 
(i) A composite data set of records of clinical events derived from individuals, 
coded in a single coding system, Clinical Terms Version 3 (CTV3) and 
stored in a single file with each record comprising a list of clinical events, 
age and gender information; 
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(ii) A table of CTV3 event codes that contains, for each code, a ‘significance 
value’ that indicates whether an event code is an administration code, a 
symptom code or a diagnosis code, and a list of all parent codes up to the 
root node of the Clinical Terms Version 3 hierarchy; 
(iii) A set of codelists that list the CTV3 codes that indicate the presence of a 
particular condition or symptom; 
(iv) A list of the Top 10 most common conditions in the USA. 
 
7.2 Methods 
The risk of a particular individual developing a particular condition is affected by 
several factors: genetic predisposition and hereditary factors; environmental, dietary, 
employment and lifestyle choices; exposure to infectious diseases; chance. Some 
conditions are determined wholly by one of these factors (e.g. Methods for calculating 
an individual's risk of acquiring a particular condition can be calculated in a number of 
different ways: clinical markers from e.g. blood tests; genetic testing; environmental 
factors; lifestyle information. 
The composite data set was randomly split into two sets using the base R ‘sample’ 
funcion: a training set for derivation of factors and a test set to score the predictions 
made on the basis of these factors. The training set and the test set each comprised 50 % 
of the composite data set, giving 11566 records in the training set and 11567 in the test 
set. No matching of the two sets for tobacco or alcohol use history or for age was 
performed. 
A 50% training set/50 % test set split was used instead of the more common 90/10, 
80/20, or 75/25 splits for two reasons: with a larger training set the computer was 
running out of memory and with a smaller test set the numbers of patients with rare 
conditions in that test set was small and sometimes, for very low prevalence conditions, 
zero.  
Dobbin and Simon [262] in their analysis of optimal splits between training and test sets 
write that ‘the rule of thumb that assigns 2/3rds to the training set and1/3rdto the test set 
performs well’ but also note that ‘We discovered that the optimal proportion of cases 
for the training set tended to be in the range of 40% to 80% for the wide range of 
conditions studied.’ 
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Choice of methods: Explainability is challenging for neural network methods and 
although work is being done in producing explainable AI models, currently this 
explainability remains a challenge, particularly if it is established that clear 
explainability is required by the GDPR (see section 2.6.4). With the motivation of 
having an explainable, patient-centric approach to condition prediction, methods such as 
clustering or k nearest neighbours were clear choices. Additionally, Wu [200]notes that 
knn methods are ‘particularly well suited for multi-modal classes as well as applications 
in which an object can have many class labels’. Kim et al note that the k nearest 
neighbour method was “adaptive to relatively noisy training sets, simple to implement, 
and naturally handles multi-class  cases. [It] also has a history of high success rates in 
the medical field”  [143]. These methods have applicability to Case-Based Reasoning, 
in the retrieve part of the CBR process (see, for example,  Sae-Hyun Ji et al [263] for a 
discussion of the use of  nearest neighbour methods in Case-Based Reasoning. 
 
Two techniques for discovering similar patients were investigated: clustering of similar 
records into groups, and simple nearest neighbours by means of minimisation of a 
distance metric. These methods are briefly introduced in Sections 7.2.1 and 7.2.2. 
7.2.1 Clustering 
In this method, the distance of each record from the current record of interest is again 
calculated. This distance information is then used to form the set of records into 
subgroups. The prevalence of the condition of interest in the subgroup containing the 
record of interest is used to make a prediction on the presence or absence of the 
condition of interest in the record of interest. The optimum number of subgroups into 
which the records set is to be divided must be determined in advance. 
7.2.2 K nearest neighbours (KNN) 
In this method, the distance of each record from the current record of interest is 
calculated. Records are then ordered by their calculated distance from the record of 
interest. The ‘k’ closest records, where the optimum value for k is to be determined, are 
used to make a prediction on the presence or absence of the condition of interest in the 
record of interest. 
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KNN is a non-parametric algorithm and so makes no assumptions about the distribution 
of the data. This is valuable with the data used here. However, as a lazy learning 
algorithm, it may run slowly, particularly as the number of data points increases. In the 
case of the composite data set, the number of data points depends on both the number of 
records and the level of the CTV3 hierarchy used for the predictions.  
7.3 Choice of factors for record matching 
Apart from the choice of the number of clusters in the clustering method or the value of  
‘k’ in the nearest neighbours method, a number of other factors must be determined 
before predictions can be made using the record set. Indeed, these must be determined 
before the best values for the number of clusters or k can be determined. Factors to be 
determined in the technique described here are the level within the CTV3 hierarchy at 
which all event codes should be mapped; the minimum number of events that a record 
should have before it can be included in the analysis; the value of the number of clusters 
for the clustering method or the value of k (for the nearest neighbours method). 
7.3.1 Event code level 
Events are recorded in each record in the hierarchical clinical terminology Clinical 
Terms Version 3, as described in Chapter 4. Each CTV3 code, barring the root node, 
has a parent code and may have child codes. At the lowest level of the hierarchy, the 
granularity of the codes is finest and so can differentiate between records containing 
similar but not identical conditions. At higher levels of the hierarchy, information is less 
granular but related conditions are grouped together and so matching of records may be 
more successful. The total number of CTV3 codes reduces at higher levels of the 
hierarchy. 
Table 7.1 shows the number of unique CTV3 codes present at each level of the CTV3 
hierarchy, for both the complete CTV3 code set and the codes that are present in the 
composite data set. Figure 7.1 shows the cumulative count of unique codes present as 
the hierarchy is descended. Note that CTV3 codes that are introduced at higher levels of 
the hierarchy remain valid at lower levels of the hierarchy.  
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Depth 
level 
unique codes count 
(complete CTV3 code set) 
Unique codes count 
(composite data set only) 
1 1 1 
2 18 14 
3 450 139 
4 3532 702 
5 17000 2359 
6 66825 5804 
7 123613 9787 
8 169945 12708 
9 204285 14591 
10 226377 15492 
11 242009 16009 
12 251174 16195 
13 256860 16246 
14 258440 16252 
15 258785 16253 
16 258841 16253 
17 258848 16253 
18 258851 16253 
19 258853 16253 
20 258853 16253 
Table 7.1 Unique CTV3 codes present at each level of the CTV3 hierarchy 
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Figure 7.1 Unique CTV3 codes present in the complete CTV3 code set at each level 
of the CTV3 hierarchy 
 
Figure 7.2 Unique CTV3 codes present in the composite data set at each level of 
the CTV3 hierarchy 
 
Inspection of Figure 7.1 suggests that the rate of increase in the number of codes as the 
hierarchy is descended reduces at lower levels. Two methods for deriving the most 
useful level of the hierarchy to use (i.e. to which level of ancestor code to map CTV3 
codes from lower levels) were used: (i) determination of the point of inflection of the 
curve shown in Figure 7.2 and (ii) the level of the hierarchy at which there was no 
significant increase in the number of unique CTV3 codes as the hierarchy was 
descended.  
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To investigate whether the subset of codes in the composite data set was a consistent 
sample of the complete code set at each level of the CTV3 code hierarchy, the number 
of CTV3 codes in the composite data set was plotted against the total number of CTV3 
codes available, and a correlation coefficient calculated.  
The value calculated for the correlation coefficient R
2
 was 0.9877, suggesting a high 
degree of correlation. 
 
   
Figure 7.3 Comparison of number of codes in the composite data set vs number of 
codes in the complete CTV3 code set at each level 
7.3.1.1 Determination of point of inflection 
The point of inflection is the point on the curve at which a change in the direction of 
curvature occurs, in the case of Figure 7.1 from convex to concave. It is the point at 
which the rate of increase in the number of CTV3 codes starts to lessen as the hierarchy 
is descended. The point of inflection was calculated using the ‘bede’ function from the 
R package ‘inflection’ [264]. 
The point of inflection test was run on the complete set of CTV3 codes, returning a 
value of 7 for the level in the CTV3 hierarchy at which the point of inflection occurred. 
The test was repeated on only the CTV3 codes in the composite data set, again returning 
a value of 7. 
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7.3.1.2 By inspection 
It can be seen from Figure 7.1 that the increase in the number of CTV3 codes as the 
CTV3 hierarchy is descended reduces at the lowest level of the hierarchy. As well as 
being the point of inflection (section 7.3.1.1), it was also noted that level 7 was the level 
at which half the CTV3 codes had been absorbed into higher level codes. Level 11 was 
also chosen since below this point the increase in the number of codes was trivial and 
not expected to add any value to the analysis.  
With no further evidence to suggest which was the better level (7 or 11) for choosing 
the level of the CTV3 hierarchy at which to perform the nearest neighbour calculations, 
it was decided to use both values against the test set to see which performed better for 
each condition under consideration. 
 
 
 
7.3.2 Minimum number of clinical events 
The number of events recorded in the records varied from 1 to several hundred 
(minimum = 1; maximum = 332; mode = 7; standard deviation = 35.7). It was desired to 
include the maximum number of records in the analysis but also to ensure that there was 
sufficient information in each record for it to make a valid contribution to the analysis. 
No theoretical basis for determination of the minimum number of events per record was 
found and so the pragmatic decision was made to include 90 % of records, which 
excluded records comprising only three events or fewer. This decision was made on the 
basis that it would produce predictions for the majority of the records in the data set, 
excluding only those records with a small number of events. Increasing the minimum 
number of events to qualify for the analysis may increase the quality of the prediction 
but would reduce the number of records for which a prediction could be made. There 
was a need to balance being able to make a prediction for the highest number of 
individuals with the need for that prediction to have value. A high value for minimum 
events could have been chosen but this would restrict the individuals for whom 
predictions are being made and restrict the pool of their ‘nearest neighbours’ 
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Unique events in 
record 
Frequency Cumulative 
percentage 
1 979 4.2 % 
2 770 7.6 % 
3 954 11.7 % 
4 1171 16.7 % 
5 1205 22.0 % 
6 1211 27.2 % 
7 1290 32.8 % 
8 1177 37.9 % 
9 1086 42.5 % 
10 962 46.7 % 
11 845 50.4 % 
12 736 53.5 % 
13 677 56.5 % 
14 641 59.2 % 
15 590 61.8 % 
16 429 63.6 % 
17 467 65.7 % 
18 328 67.1 % 
19 304 68.4 % 
20 287 69.6 % 
Table 7.2 Frequency of number of event codes per record 
 
7.3.6 Choice of distance metric 
For both the clustering method and the k nearest neighbours method it is necessary to 
calculate the ‘distance’, ‘similarity’ or ‘dissimilarity’ between records. Note that 
‘distance’ will be used loosely, to refer to any method that calculates a value indicative 
of (dis)similarity or distance between records. 
There are many methods to calculate the distance between points in multidimensional 
space, as is the case with the records here which contain multiple events data, as well as 
age, gender, tobacco use and alcohol consumption data. A search of packages in the R 
programming language found 54 different methods implemented in functions available 
through various R packages. Table 7.3 lists the methods found and the R packages that 
implement them. The choice of methods investigated here was limited to those available 
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in at least one R package. For completeness, empirical tests of all distance measures 
available in R were performed. No account was made of the theoretical basis of each 
distance measure, although it is acknowledged that some of the metrics are not 
appropriate for use on the data set used here, for example the Bray-Curtis dissimilarity 
measure [265], intended to give an indication of the dissimilarity of ecological sites 
based on the counts of species present at the sites. 
 
7.3.6.1 Preliminary analysis of distance metrics. 
Each distance calculation method was run against a small sub-sample, comprising 1000 
event codes from 1000 records, randomly chosen from the complete data set. The same 
sub-sample was used for each method tested. Results were inspected for agreement and 
disagreement and validity for our particular data set. Note that some different methods 
give the same results when run against our binary data set. 
Having run each method from each package against our test data set, the subset of 
methods that give meaningful results was selected, with the package that ran the fastest 
for that test being chosen as the package to use for that test. 
Table 7.3 lists the distance calculation methods available in R, together with the 
libraries and functions that implement these methods, and the results from the first few 
cells of the distance matrix produced when run on the a sub-sample. Results were coded 
according to the results listed in Table 7.4. Note that some different methods give the 
same results when run against the binary sample data set.Although this does not imply 
that these methods were equivalent in their methods of calculation of distance metric, 
for the empirical, data-driven, purposes of the investigation in this section the ability of 
a method to differentiate between records was the important consideration. 
Each distance method was then run against a fuller sample of 5000 records from the 
training data set, including age, gender, alcohol and smoking codes as well as the event 
codes.  
In order to investigate the results returned by the different distance calculation methods, 
each method was run against a small test set and the results inspected. Some methods 
returned identical results, other methods returned results that were a simple multiple of 
other results, and yet other methods returned results that had no differentiation between 
different points in the sample. 
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R package: vegan amap wordspace fields stats parDist 
Distance method vegdist Dist dist.matrix rdist dist parDist 
euclidean A A A A A A 
maximum  B B  B B 
manhattan C C C  C C 
canberra B D C  D E 
binary  B   B B 
bray  B     B 
kulczynski  B      
jaccard  B      
gower  F      
altGower  B      
morisita  Z      
horn  B      
mountford  B     A 
raup   B      
binomial  G      
Chao B      
Cao       
mahalanobis H      
Pearson  B     
correlation  J     
spearman  K     
kendall  L     
minkowski   A  A A 
cosine   M    
simpson      Y 
simple      F 
russel      B 
phi      N 
ochiai      B 
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mozley      B 
stiles      Z 
tanimoto      P 
yule      X 
yule2      X 
bhjattacharyya      A 
chord      Q 
divergence      C 
dtw      R 
fjaccard      B 
geodesic      S 
hellinger      Q 
kullback      Z 
podani      T 
soergel      B 
wave      Z 
whittaker      B 
braun-blanquet      B 
dice      B 
fager      U 
hamman      V 
kulczynski1      B 
kulczynski2      B 
michael      W 
faith      Y 
Table 7.3 Distance calculation methods and their packages available in R 
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Result set Result set values 
A 
2, 3, 1.732051, 2.236068, 3.162278, 2.645751, 2.828427, 2, 3, 
3.605551, 2.236068, 2.645751, 2.236068, … 
B 1, 1, 1, 1, 1, 1, 1, … 
C [Results from set A, squared] 
D 
0.636537, 0.954805, 0.551257, 0.711670, 1.006454, 0.842059, 
0.900199, 0.636537, 0.954806, 1.147533, 0.711670, 0.842059, 
0.71167 … 
E [1 + results from set D] 
F 
0.03636364, 0.08181818, 0.02727273, 0.04545455, 0.09090909, 
0.06363636, 0.07272727, … 
G 
2.772589, 6.238325, 2.079442, 3.465736, 6.931472, 4.85203, 
5.545177, 2.772589, 6.238325, … 
H 
14.07125, 14.07125, 10.48701, 11.47232, 14.07125, 13.64563, 
14.07125, 13.1542, 14.07125, … 
J 
1.016038, 1.040219, 0, 1.022786, 1.043651, 1.032527, 1.036539, 
1.016038, 1.040219, 1.05295, … 
K 
27554, 52276, 14666, 23638, 48278, 51480, 53138, 26330, 42690, 
73138, 26416, 39894, 26048, … 
L 
0.07773144, 0.1411176, 0.04553795, 0.08056714, 0.1421184, 
0.1446205, 0.1497915, … 
M 
90, 90, NaN, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 90, 
90, … 
N 
0.9839618, 0.9597813, NaN, 0.9772138, 0.9563485, 0.9674729, 
0.9634608, 0.9839618, … 
P 
0.07017544, 0.1512605, 0.05309735, 0.08695652, 0.1666667, 
0.1196581, 0.1355932,  
Q 
1.414214 1.414214 NaN 1.414214 1.414214 1.414214 1.414214 
1.414214 1.414214 … 
R 2 5 3 1 6 3 4 2 5 8 1 3 1 3 2 2 3 3 1 7 
S 
1.570796 1.570796 NaN 1.570796 1.570796 1.570796 1.570796 
1.570796 1.570796 … 
T 
0.1434529 0.3152627 0.1080901 0.1784821 0.3486239 0.2475396 
0.281568 0.1434529 … 
U 
0.1339746 0.1339746 NaN 0.1339746 0.1339746 0.1339746 
0.1339746 0.1339746 … 
V 
0.07272727 0.1636364 0.05454545 0.09090909 0.1818182 
0.1272727 0.1454545 0.07272727 … 
W 
0.9989335 0.9929975 1 0.9978281 0.9916832 0.9954963 
0.9942682 0.9989335 0.9929975 … 
X [All 0] 
Y 
0.5181818, 0.5409091, 0.5136364, 0.5227273, 0.5454545, 
0.5318182, 0.5363636, 0.5181818, … 
Z [All NaN] 
Table 7.4 Indicative results from distance matrix calculations on small data 
sample. 
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The Yule distance metric did not produce meaningful results. This is assumed to be 
because it is intended for use on Boolean data; the inclusion of age in the data has 
caused the function available in the parDist package to fail, returning a value of 0 for 
all. The Kullback function similarly did not produced meaningful results. The kullback 
function compares probability distributions rather than Boolean or continuous data and 
so the data presented to this function is inappropriate – the function expects the sum of 
the value presented to be less than or equal to 1.  
Those results sets that did not produce results that would be useful in a distance matrix 
were excluded from consideration. Methods that produced the same result for the 
distance matrix as another method were also excluded from further analysis. This left a 
shorter list of methods for further investigation: Euclidean, Manhatten, Canberra (but 
not the version from the vegdist package), Gower, Morisita, binomial, Mahalanobis, 
correlation, Spearman, Kendall, Simpson. 
Note that although the absolute values returned by the various distance matrix methods 
may vary between methods, when individual records are ordered by these values, the 
ordering of the records may be the same. This reflects some loss of information in the 
change from cardinal to ordinal numbering. Section 7.2.1  investigates a clustering 
method to make predictions, in which the cardinal distance information is retained. 
For the k nearest neighbour method described in Section 7.2.2, a distance matrix 
method was sought that gave the most useful results on the set of records. For those 
methods that give similarly good results, the method that produces its results in the 
shortest time is preferred. 
Determination of best distance method 
(i) Brute force method 
Run every method against a sub-sample of 5000 records from the training set. 
Use the level, minimum events, and a set of values for k as factors. Age and 
gender were not included: the test was intended to investigate the solely the 
ability to find similarities based on event histories. The test was run on one 
condition: type 2 diabetes, since this has a high prevalence and is explicitly 
coded in event codes.  
Two CTV3 hierarchy levels were suggested, 7 and 11, and so both these will be 
used. Values for k were harder to establish a priori, and so a selection of 
arbitrary values was used: k = 100, k = square root of the number of valid 
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observations, k = half of the number of valid observations. Only one value for 
minimum events will be used, 4 (see section 7.3.2 for choice of minimum events 
value). This gives six permutations for testing the distance matrix methods. The 
results from each run will be ranked and a final ranking produced. 
For each run, each record will have a set of nearest neighbours. This set was 
tested for the prevalence of the condition under consideration, in this case type 2 
diabetes. Should the prevalence of the condition in the nearest neighbours set be 
higher than the prevalence in the whole records set (i.e. a prevalence in the 
nearest neighbours set significantly higher than the prevalence in the complete 
test set (p < 0.05)), the record was predicted to have the condition, otherwise it 
was predicted not to have the condition. The prediction was than compared to 
the actual state for the record, which was then scored as a true positive, true 
negative, false positive or false negative as appropriate. The complete set of 
prediction results is then aggregated and scored. The score used in this instance 
is the Matthews Correlation Coefficient (MCC), chosen due to it being a 
balanced measure of the quality of all predictions in a binary classification, and 
because it is insensitive to class size. 
Included in the table are the MCC scores resulting from a random allocation of 
positive and negative predictions to each record, allocations being made in 
proportion to the prevalence of the condition in the records sample. 
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Scoring method MCC 
random 0.102 
euclidean 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 27 72 
maximum 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 83 308 
manhattan 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 27 76 
canberra 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 254 1200 
binary 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 85 311 
bray  0.164 0.235 0.243 0.204 0.185 0.276 0.274 0.273 212 629 
kulczynski  0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 80 287 
jaccard  0.164 0.235 0.243 0.204 0.185 0.276 0.274 0.273 218 613 
gower  0.164 0.235 0.243 0.204 0.185 0.276 0.274 0.273 219 648 
altGower  0.164 0.235 0.243 0.204 0.185 0.276 0.274 0.273 221 643 
morisita  0.164 0.235 0.243 0.204 0.185 0.276 0.274 0.273 228 679 
horn  0.164 0.235 0.243 0.204 0.185 0.276 0.274 0.273 227 681 
mountford  0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 84 310 
raup   0.164 0.235 0.243 0.204 0.185 0.276 0.274 0.273 227 602 
binomial  0.164 0.235 0.243 0.204 0.185 0.276 0.274 0.273 247 663 
chao 0.164 0.235 0.243 0.204 0.185 0.276 0.274 0.273 214 686 
cao 0.164 0.235 0.243 0.204 0.185 0.276 0.274 0.273 214 634 
Mahalanobis 0.164 0.235 0.243 0.204 0.185 0.276 0.274 0.273 211 653 
Pearson 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 376 1152 
correlation 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 373 1278 
spearman 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 376 2434 
kendall 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 317 1281 
minkowski 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 445 1174 
cosine 0.164 0.235 0.243 0.204 0.185 0.276 0.274 0.273 1 2 
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simpson 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 90 314 
simple 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 84 291 
russel 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 82 292 
phi 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 81 294 
ochiai 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 84 300 
mozley 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 92 295 
stiles 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 84 289 
tanimoto 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 82 300 
yule 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 82 299 
yule2 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 87 294 
bhjattacharyya 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 85 288 
chord 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 80 301 
divergence 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 78 274 
dtw 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 79 314 
fjaccard 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 81 309 
geodesic 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 81 278 
hellinger 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 80 280 
kullback 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 78 297 
podani 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 78 285 
soergel 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 81 292 
wave 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 80 291 
whittaker 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 76 292 
braun-blanquet 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 81 282 
dice 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 81 280 
fager 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 80 277 
hamman 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 80 291 
kulczynski1 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 78 284 
kulczynski2 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 81 282 
michael 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 80 280 
faith 0.144 0.213 0.218 0.003 0.187 0.290 0.266 0.021 50 287 
Table 7.5 MCC scores and run times for various distance calculation methods 
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Run times (in seconds) are for running the distance matrix function only and do not 
include other sections of the program such as file reading and preparing the data for the 
distance function. All runs were on a Dell PC running 64-bit Windows 7 Enterprise, 
Intel Core i5-6500 4-core CPU running at 3.2 GHz, 8 GB RAM, with minimal other 
programs running. The ‘parDist’ function used all 4 cores in parallel to generate the 
distance matrix; other functions were single-core. 5000 records were read to test the 
different functions, and were prepared by removing administration codes and by 
removing records that had only administration codes or the target condition. 
With the exception of the cosine method, the results as ranked by F1-score fall into two 
distinct groups, with identical results within each group. All methods out-perform 
random prediction. The group with the better ranking F-scores contains the  bray, 
jaccard, gower, morisita, horn, raup, binomial, chao, cao and mahalanobis methods, 
each of which had similar run times. Without a priori knowledge of correlations within 
the data and with no other reason to select one method over another other, the binomial 
method was chosen to use in the later analysis. This method was developed to 
investigate the effect of habitat on fish populations [266] and works with binary and 
continuous data, and so has no theoretical barrier to use in this work. However, the 
cosine method performs substantially faster than any other method with only an 
apparently small reduction in effectiveness of prediction and so the cosine method was 
also be tested in the final analysis on the test data set, in order to compare its predictive 
performance against the binomial method.  
As described above, other factors that will be used are minimum number of events in a 
record to qualify for inclusion in the analysis, the level of the CTV3 hierarchy to which 
event codes should be relegated, and the size (or calculation method) of the nearest 
neighbours group on which to base prediction of presence or absence of a condition. A 
further consideration is the method by which the prevalence of the condition within a 
nearest neighbours group is deemed sufficiently high to warrant a positive prediction for 
the condition. 
Those factors (level, k, calculation method) for which no single value can be decided 
from first principles were be optimised on the training set and the resultant optimal set 
of factors used to evaluate the performance against the test set of records. 
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7.3.7 Prevalence significance calculation method: 
Once a set of nearest neighbours to a record has been produced, members of that nearest 
neighbours set are used to determine whether to predict the presence or otherwise of the 
condition of interest, i.e. condition positive or negative. There are several alternative 
methods suggested for determining whether the condition prediction should be 
‘positive’ or ‘negative’: 
(i) Simple majority vote: count the number of positive records in the nearest 
neighbours set and compare to the number of negative records. If there are 
more positive records, predict positive for the record of interest. Note that as 
the value of k increases (i.e. the size of the nearest neighbours set increases) 
the proportion of positive records in the nearest neighbours set will converge 
to the prevalence in the complete records set. For all conditions under 
consideration in this work, this prevalence is substantially less than 0.25 and 
so for large values of k (k > 50 % of the records set size), positive records 
cannot achieve a majority. 
(ii) High prevalence: if the prevalence of the condition in the nearest neighbours 
set is greater than a multiple (to be determined) of the prevalence calculated 
from  the complete records set, then predict positive for the record under 
consideration 
(iii) Prevalence in the nearest neighbours set significantly greater than prevalence in 
the non-nearest neighbours set: compare the proportion of the records in the 
nearest neighbours set that are positive for the condition of interest to the 
proportion of records in the remainder of the records set that are condition 
positive. If the proportion in the nearest neighbours set is positive then 
predict positive for the record of interest.  
 
Simple majority vote (i) was dismissed on the basis that the prevalence of any one 
condition would be very much less than 50 % and so it would be a challenge for any 
one group of records to have an intra-group prevalence high enough to trigger a positive 
vote. Conversely, simply setting the prevalence trigger level higher than an arbitrary 
threshold (ii) was dismissed because it takes no account of condition prevalence in the 
data set; the low (much less than 50%) prevelance of any one condition in the data set 
would make it difficult for any set to be scored as a ‘positive’. The method chosen was 
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(iii), comparing the prevalence within the group of interest against the prevalence in the 
rest of the record set, with a positive prediction for the condition made should the intra-
group prevalence be significantly higher than the population prevalence, by setting a p-
value threshold of 0.05. 
7.3.8 Scoring prediction success 
Once all records have had predictions made, the success of these predictions can be 
scored. Comparing the prediction for each record to the truth for each record has one of 
four possible outcomes: True Positive (i.e. the prediction was positive and the record 
actually contained the condition of interest); True Negative (i.e. the prediction was 
negative and the record did not contain the condition of interest); False Positive (i.e. the 
prediction for the record was positive but the record did not contain the condition); and 
False Negative (i.e. the prediction for the record was negative but the record did, in fact, 
contain the condition).  
Over the complete set of records, the number of True Positives, True Negatives, False 
Positive and False Negatives can be summed. Froom these total values a variety of 
statistical scores can be calculated: 
 Sensitivity, or Recall, or True Positive Rate: the proportion of records with the 
condition that were predicted to have the condition 
 Specificity, or True Negative Rate: the proportion of records without the 
condition that were not predicted to have the condition 
 Positive Predictive Value (PPV), or Precision: the proportion of those records 
predicted to be positive that actually were positive 
 Negative Predictive Value (NPV): the proportion of those records predicted to 
be negative that actually were negative 
 F-score: A measure of the accuracy of a test. It uses the Positive Predictive 
Value and the Sensitivity to calculate a score indicating the overall accuracy of a 
test. The F-score can be weighted to give more weight to PPV or to sensitivity 
according to the priorities for the test. The F1 score give equal weight to PPV 
and to sensitivity. 
 Matthews Correlation Coefficient: a statistic which endeavours to give a 
balanced single value for the quality of classifications, giving equal value to 
True Positives, True negatives, False positive and False Negatives in its 
calculation. 
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 Accuracy: the proportion of correct results (i.e. True Positive + True Negatives) 
to the total set size. 
 Likelihood Ratio: the ratio of the probability of the test result in diseased 
persons over the probability of the test result in non-diseased persons.  
 
This work endeavours to utilise the information in clinical records as a test that suggests 
which records indicates an increased likelihood of a condition and thus which patients 
may benefit from a more formal screening test. As a non-invasive test, at this stage, the 
test can give greater value to increased sensitivity rather than to increased specificity, 
i.e. the test should aim to include most patients who are likely to have the condition 
rather than exclude those patients who do not have the condition. To this end, the F2 
score was chosen as the primary statistic on which to optimise the input factors. 
7.4 Determination of best factors for clustering approach 
7.4.1 Method 
In this technique, a distance matrix giving the calculated distance between records is 
created, as it was for the nearest neighbours method. Note that for records that contain 
the condition of interest, events occurring later than that condition of interest are not 
included in the distance calculation since these events would not yet have occurred in a 
real world situation. An index date in the control patients was not imposed. See section 
6.8.1 for a discussion of the potential for bias here. Once the distance matrix has been 
formed, records are grouped together into groups or ‘clusters’, each cluster containing 
records that are more similar to each other than to those records placed in other clusters. 
Similarly to the nearest neighbours method, there are a number of input factors that can 
affect the output from the clustering algorithm: 
(i) the level of the CTV3 hierarchy at which event codes are to be aggregated; 
(ii) the minimum number of events per record to qualify for inclusion in the 
analysis; 
(iii) the method by which the distance matrix is calculated; 
(iv) the number of clusters into which the records are to be placed; 
(v) the clustering method; 
(vi) the method for calculating the predicted outcome for each record. 
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The choice of each of these factors can, in many cases, be informed by the preparation 
and analysis for the nearest neighbours method, and so the following factors are used: 
Minimum events per record: 4 events; 
Level of CTV3 hierarchy to which to group event codes: 7 or 11; 
Distance matrix formation method: binomial; 
The optimum number of clusters into which records are placed: to be determined; 
Clustering algorithm: to be determined from the set of clustering methods implemented 
in base R or in R library functions.  
Clustering method: agglomerative or divisive. 
Method for calculating the predicted outcome for each record: predict positive for a 
record if condition prevalence in the rest of the record’s cluster is significantly greater 
than population prevalence  
To determine the optimum number of clusters and the clustering method, each 
clustering algorithm-clustering method pair was used in turn and at both candidate 
levels of the CTV3 hierarchy on the training data set in order to generate the clustering 
hierarchy. This clustering hierarchy was then used to produce a set of clusterings, with 
the number of clusters ranging from 1 (i.e. all records placed in a single cluster) to the 
number of records clustered (i.e. all records placed singly in their own cluster). 
For each set of [CTV3 level – clustering algorithm – clustering method – number of 
clusters], the F2 score was calculated, using the same method as for the nearest 
neighbours technique. 
The best performing combination of factors was selected for use on the test set of 
records and the same set of results produced for each condition. 
In order to check that valid results were achieved, an exploratory analysis was 
performed using a selection of distance matrix method – clustering method pairs, on a 
subsample of the training set of records:  CTV3 hierarchy level=7, 3000 records, 500 
clusters, for a condition of type 2 diabetes. 
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ward.D 0.404 0.393 0.441 0.431 0.431 0.432 0.414 0.217 0.435 0.341 0.421 0.402 0.387 
ward.D2 0.414 0.394 0.412 0.424 0.434 0.430 0.405 0.228 0.433 0.348 0.440 0.406 0.399 
single 0.345 0.345 0.356 0.143 0.368 0.358 0.345 NA 0.358 0.371 0.378 0.345 0.357 
complete 0.367 0.367 0.410 0.423 0.414 0.423 0.367 0.210 0.418 0.443 0.430 0.373 0.394 
average 0.351 0.348 0.406 0.442 0.419 0.476 0.350 0.201 0.468 0.420 0.439 0.350 0.409 
mcquitty 0.362 0.371 0.469 0.435 0.442 0.452 0.369 0.122 0.463 0.393 0.413 0.379 0.404 
median 0.345 0.341 0.365 0.371 0.363 0.376 0.345 0.009 0.364 0.360 0.407 0.345 0.414 
centroid 0.345 0.347 0.357 0.363 0.380 0.371 0.345 0.037 0.368 0.368 0.430 0.345 0.429 
Table 7.6 F2 scores for distance method-clustering method combinations 
In summary, the following factors will be used in optimisation: 
Distance method: binomial, using the ‘vegdist’ function from the R ‘vegan’ library [267]. 
CTV3 hierarchy level: 7 or 11, results to determine which method to use 
Prevalence significance calculation method: to be determined 
K: to be determined 
 
7.5 Nearest neighbours method 
The clustering method has been described and investigated in 7.4 et seq. Some success for some 
investigated conditions was found, which are described in Chapter 8. A second method was also 
tested, the nearest neighbours method. This required determination of the best value for k, the 
number of neighbours to include in the nearest neighbours group. 
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7.5.1 Method for determination of best value for k 
7.5.1.1 Read in a random selection of 5000 records from the training set 
Exclude records with 3 or fewer clinical events (removes the data set size by about 10 %; further 
records filtering reduces the number of valid records by a further approximately 10 %). 
7.5.1.2 Remove the admin flags 
Retain the symptom and diagnosis flags. 
 
7.5.1.3 Inspect the list of events in each record for the presence of a code indicating the presence of 
the condition of interest.  
If there is a code or codes that indicates the presence of the condition of interest, remove those 
codes from the record and set a ‘has condition’ flag to be TRUE, otherwise retain all event codes 
and set the flag to be FALSE. 
7.5.1.4 For each of the CTV3 code levels previously determined (i.e. 7, 11): 
 Create the distance matrix using the distance method of choice (i.e. binomial) 
 For each record, order its neighbours according to distance from the record (from nearest 
neighbour to furthest neighbour) 
 For each record, cycle through the possible values of k for the k nearest neighbours, from 1 
to the size of the complete record set. At each value for k, calculate the prediction for the 
presence of the condition according to each of the methods discussed (absolute majority 
vote; prevalence greater than a range of factors; significantly larger prevalence in the nearest 
neighbour group). 
 
Results from these runs and calculations across k values and prediction calculation methods were 
evaluated in order to determine the best factors for each condition prediction. The F2 score was 
used to determine the best factors. 
 
Figure 7.4 shows the process used to predict presence or absence of a condition for records in the 
data set. 
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Figure 7.4 Process for predicting presence or absence of condition in the set of records  
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The steps within the program are described: 
 
[1] The program is started.   
 
[2] Initial set-up of program and CTV3 code information 
(i) Various flags and factors controlling the program flow are set: whether or not to use the age and 
gender information in each record; how many records to read and whether the records should be 
read at random from the data file or sequentially from the start of the file (for reproducibility during 
program testing), the value of beta in the calculation of the Fbeta score (a value for beta of 2 has 
been used consistently in this work). 
(ii) The R libraries required for particular functions in the program are loaded. 
(iii) A set of local functions are defined: 
 
a. calcOddsRatio(TN, FN, TP, FN, p) 
This function calculates the odds ratio. It takes as its input the values for true positives, true 
negatives, false positives and false negatives, and a p-value, and returns an odds ratio together with 
upper and lower confidence limits calculated using the p-value passed to the function. A default 
value of 0.05 (giving a confidence interval of 95 %) is used if no p-value is passed to the function. 
This function has been adapted from the work of Ronald Pearson [268].  
 
b. calcLikelihoodRatio(m, significance level) 
This function calculates the likelihood ratio. It takes as its input a 2x2 matrix of TP, FN, FP 
and TN values together with a significance level value. It returns a likelihood ratio together 
with upper and lower confidence limits calculated using the significance level passed to the 
function. This function has been adapted from the work of Tomas Karpati [269].  
 
c. createBitVectors() 
This function creates a binary vector indicating the presence or absence of particular event codes in 
each record. The vector is in the sequence of the set of event codes used as headings in the table of 
records read from the records file. 
 
d. getHigherCode() 
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This function takes as its inputs a CTV3 code and a value for a level in the CTV3 hierarchy. It 
returns the ancestor code for the input CTV3 code at the requested hierarchy level. 
 
e. includeFlagValue() 
This function returns the significance value (i.e. whether it is an administration code, a symptom 
code or a diagnosis code) of a code from the table of CTV3 codes hierarchy and significance values. 
It performs a simple lookup of the significance value using the input CTV3 code. 
 
f. TrueFalse() 
Checks whether an event code or set of events codes is in the codelist for the target condition. 
These functions are called as required in the program. 
(iv) The table of CTV3 codes, their ancestor codes in the CTV3 hierarchy, and each codes 
significance value is read into the program. 
 
[3] (i) The condition of interest is set for this run. The condition of interest must be a condition 
which has had a codelist of events previously created and stored. It is possible to select a set of 
conditions, each condition being tested sequentially. 
(ii) The level in the CTV3 event code hierarchy at which the analysis is to be performed is selected. 
The value of the level must be between 1 (the root node) and 19 (the deepest level of the hierarchy). 
It is possible to select a set of levels, each level being tested sequentially. 
(iii) The records set is read into the program. A number of options are available: 
(a) The file to be read: the full data set has been split into a training set and a test set 
(b) The number of records to be read from the file, or whether to read the complete file 
(c) If limiting the number of records to be read, whether these records should be selected 
randomly from the complete set of records in the file or sequentially from the start of the 
file. 
 
[4] The set of records read into the program is now prepared for analysis: 
(i) Records with fewer than the minimum required number of events are dropped. 
(ii) Records are examined for the presence of the condition of interest. Those with the condition (i.e. 
the record has one or more event codes in the codelist for the condition) are flagged as ‘positive’; 
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those without any event codes in the codelist are flagged as ‘negative’. Event codes that are in the 
codelist are dropped. 
(iii) Records that now only have event codes that are ‘administration’ codes (i.e. have a significance 
value of 0) are dropped from the analysis. 
(iv) Remaining records now have their event codes mapped to their ancestor codes at the chosen 
higher level of the CTV3 hierarchy. 
(v) A table of all remaining records is built containing their mapped CTV3 codes, age, smoking 
status and alcohol status. Each code has a column in the table; the presence of the code in any 
record is indicated by a value of 1 in that record’s row, otherwise a value of 0 is stored. 
(vi) If age is included as a dimension for input to the analysis, all age values are normalised, with 
the maximum value of 1 corresponding to the highest age value in the records set. If age is not to be 
included, all age values are set to 0. 
(vii) If gender is not to be included in the analysis, all values for gender are set to 0. 
(xiv) The prevalence of the condition of interest is calculated. This prevalence is used to randomly 
assign a prediction for presence of the condition to each record: the probability of a record being 
assigned a condition ‘positive’ value is equal to the condition prevalence in the record set. The 
random assignations are used to calculate F1, F2 and MCC scores as a baseline for comparison with 
the scores from the later analysis. 
 
[5] The distance matrix is built and ordered 
(i) A distance matrix (or, more precisely, a dissimilarity matrix) is calculated using the table of 
records and event codes from step 4(iv). The distance matrix calculation method is that suggested 
from step 6.2.1, the binomial method. This is implemented in the function ‘vegdist’ from the R 
package ‘vegan’ [267]. For a full discussion of the binomial method see [270].  
(ii) The distance matrix is ordered by reverse order of dissimilarity for each record, i.e. each record 
has a list of all records, reverse ordered by dissimilarity score. So the first record in each record’s 
list is the record itself, since it will be the least dissimilar record. 
 
[6] The prevalence of the condition in the least dissimilar neighbours is compared to the prevalence 
in the most dissimilar and appropriate predictions made 
(i) A value (or set of values, in the optimisation phase) for ‘k’ is chosen or calculated. k is, by 
convention, the variable used to the size of the nearest neighbour set.  
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(ii) For each record, the prevalence of the condition of interest in the k nearest neighbours set is 
calculated and compared to the prevalence in the remainder of the records set, using Pearson’s chi-
squared test for significance. A significance value of 0.05 has been used in this work. For those 
records where the nearest neighbours set has a significantly raised prevalence of the condition of 
interest, the record is predicted ‘positive’, otherwise the record is predicted ‘negative’. Predictions 
are recorded against each record. 
 
[7] Test the predictions against the actual presence of the condition 
(i) For each record, the prediction is compared to the actual presence of the condition. There are 
four possible results: a True Positive (TP), where both the prediction and the actual presence are 
positive; a False Positive (FP) where the prediction was positive but the actual presence was 
negative; a True Negative (TN), where both the prediction and actual presence were negative; and a 
False Negative (FN), where the prediction was negative but the original record did, in fact, contain 
an event code indicative of the condition.   
(ii) The sums of each of the numbers of TP, TN, FP and FN results are calculated. 
 
[8] A set of summary statistics is produced 
(i) From the TP, FP, TN and FN scores, a number of summary statistical scores are produced. These 
scores include sensitivity, specificity, positive predictive value (PPV), negative predictive value 
(NPV), F1, F2, MCC. In the optimisation phase, using the training set of records, the two candidate 
values for the CTV3 level and a range of values for k are used to calculate the predictions, with the 
combination of CTV3 level and k that produces the best F2 score being chosen as the combination 
to use in the testing phase. 
(ii) In the testing phase, using the testing set of records, additional statistical scores are generated:  
(a) The likelihood ratios, positive and negative (LR+ and LR-) 
(b) The odds ratio 
The likelihood ratios are used to illustrate the success, or otherwise, of this prediction method for 
each condition investigated. 
For each condition, a set of training runs was performed, drawing 5000 records at random from the 
training set of records. For each run, a range of values of k, from only 1 record in the nearest 
neighbour group to all records bar one in the nearest neighbours group. For each value of k in each 
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run the number of true positives, true negatives, false positives and false negatives was calculated 
and from these figures a value for F2 score at each value of k was calculated. The values for F2 
from all training runs were plotted against the values for k and a curve fitted to the data using a 
linear method implemented in the ‘lm’ function from the R ‘stats’ package. The maximum F2 value 
of this fitted curve was used to select the optimum value of k, i.e. the optimum size of the nearest 
neighbours group used to predict the state for each record. 
7.6 Training runs to determine best k 
Each condition is presented separately, since it was not known in advance whether any or all 
conditions could be grouped together for analysis. For each condition, a chart is shown of F2 score 
versus value of k for several runs. Each run has one calculation of the distance matrix and 
subsequent analysis of predictions based on a range of k values from one nearest neighbour to one 
less than the size of the valid records set. For each condition, test runs are repeated at the derived 
candidate values for best level of the CTV3 hierarchy, level 7 and level 11. 
Following a number of training runs, a curve is fitted to the data points using the linear method, for 
the level 7 set and the level 11 set. The maximum F2 value across the two curves is used to 
determine the optimum level and optimum value of k for each condition. 
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8 ESTIMATION OF CONDITION 
RISK: RESULTS 
8.1 Best factors for clustering method 
Results are presented for determination of the optimum level of the CTV3 hierarchy and the 
optimum number of clusters for the clustering method. The F2 score was used as the metric on 
which to optimise, which weights sensitivity greater than specificity. This was chosen in order to 
emphasise the benefit of this technique to select candidates for screening tests. By placing more 
weight on the calculated sensitivity than on the calculated specificity in choosing the optimum level 
of the CTV3 hierarchy and the optimum number of clusters, rather than giving them equal weight as 
would be the case for an F1 score, the method is intended to exclude fewer candidates for screening 
than would be the case than if the F1 score was used to determine the optimum factors.  
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8.1.1 Acute sinusitis 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for stress are shown in Figure 8.1 and Figure 8.2. 
 
Figure 8.1 F2 score versus number of clusters for acute sinusitis at CTV3 hierarchy level 7 
 
Figure 8.2 F2 score versus number of clusters for acute sinusitis at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.4587 with 2 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.4663 with 2 clusters. 
Selected factors were therefore CTV3 hierarchy level 11 with 2 clusters. 
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8.1.2 Allergic rhinitis 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for allergic rhinitis are shown Figure 8.3 and Figure 8.4. 
 
Figure 8.3 F2 score versus number of clusters for allergic rhinitis at CTV3 hierarchy level 11 
 
Figure 8.4 F2 score versus number of clusters for allergic rhinitis at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.5242 with 2 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.5289 with 3 clusters. 
Selected factors were therefore CTV3 hierarchy level 11 with 3 clusters. 
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8.1.3 Any cancer 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for any cancer are shown Figure 8.5 and Figure 8.6. 
 
Figure 8.5 F2 score versus number of clusters for any cancer at CTV3 hierarchy level 7 
 
Figure 8.6 F2 score versus number of clusters for any cancer at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.2393 with 130 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.1759 with 14 clusters. 
Selected factors were therefore CTV3 hierarchy level 7 with 130 clusters. 
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8.1.4 Asthma 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for asthma are shown in Figure 8.7 and Figure 8.8. 
 
Figure 8.7 F2 score versus number of clusters for thyrotoxicosis at CTV3 hierarchy level 7 
 
Figure 8.8 F2 score versus number of clusters for asthma at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.4023 with 2 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.3170 with 3 clusters. 
Selected factors were therefore CTV3 hierarchy level 7 with 2 clusters. 
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8.1.5 Autism spectrum disorder 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for autism are shown Figure 8.9 and Figure 8.10. 
 
Figure 8.9 F2 score versus number of clusters for autism at CTV3 hierarchy level 7 
 
Figure 8.10 F2 score versus number of clusters for autism at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0 with NA clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.0170 with 90 clusters. 
Selected factors were therefore CTV3 hierarchy level 11 with 90 clusters. 
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8.1.6 Breast cancer 
 Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for breast cancer are shown in Figure 8.11 and Figure 8.12. 
 
Figure 8.11 F2 score versus number of clusters for breast cancer at CTV3 hierarchy level 7 
 
Figure 8.12 F2 score versus number of clusters for breast cancer at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.1469 with 26 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.1619 with 920 clusters. 
Selected factors were therefore CTV3 hierarchy level 11 with 920 clusters. 
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8.1.7 Bronchitis 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for bronchitis are shown Figure 8.13 and Figure 8.14. 
 
Figure 8.13 F2 score versus number of clusters for bronchitis at CTV3 hierarchy level 7 
 
Figure 8.14 F2 score versus number of clusters for bronchitis at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.4807 with 2 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.4832 with 3 clusters. 
Selected factors were therefore CTV3 hierarchy level 11 with 3 clusters.  
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8.1.8 Colon cancer 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for colon cancer are shown in Figure 8.15 and Figure 8.16. 
 
Figure 8.15 F2 score versus number of clusters for colon cancer at CTV3 hierarchy level 7 
 
Figure 8.16 F2 score versus number of clusters for colon cancer at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.1077 with 1450 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.0972 with 380 clusters. 
Selected factors were therefore CTV3 hierarchy level 7 with 380 clusters. 
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8.1.9 Eczema 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for eczema are shown in Figure 8.17 and Figure 8.18. 
 
Figure 8.17 F2 score versus number of clusters for eczema at CTV3 hierarchy level 11 
 
Figure 8.18 F2 score versus number of clusters for eczema at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.3301 with 47 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.3255 with 70 clusters. 
Selected factors were therefore CTV3 hierarchy level 7 with 47 clusters. 
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8.1.10 Gastroparesis 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for gastroparesis are shown in Figure 8.19 and Figure 8.20. 
 
Figure 8.19 F2 score versus number of clusters for thyrotoxicosis at CTV3 hierarchy level 7 
 
Figure 8.20 F2 score versus number of clusters for gastroparesis at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.0704 with 13 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.1515 with 530 clusters. 
Selected factors were therefore CTV3 hierarchy level 11 with 530 clusters. 
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8.1.11 Gastro-oesophageal reflux disease 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for gastro-oesophageal reflux disease are shown in Figure 8.21 and Figure 8.22. 
 
Figure 8.21 F2 score versus number of clusters for gastro-intestinal reflux disease at CTV3 
hierarchy level 7 
 
Figure 8.22 F2 score versus number of clusters for gastro-intestinal reflux disease at CTV3 
hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.3742 with 2 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.3792 with 3 clusters. 
Selected factors were therefore CTV3 hierarchy level 11 with 3 clusters. 
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8.1.12 Gout 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for gout are shown in Figure 8.23 and Figure 8.24. 
 
Figure 8.23 F2 score versus number of clusters for thyrotoxicosis at CTV3 hierarchy level 7 
 
Figure 8.24 F2 score versus number of clusters for gout at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.1764 with 34 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.1864 with 37 clusters. 
Selected factors were therefore CTV3 hierarchy level 11 with 37 clusters. 
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8.1.13 Obesity 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for obesity are shown in Figure 8.25 and Figure 8.26. 
 
Figure 8.25 F2 score versus number of clusters for obesity at CTV3 hierarchy level 7 
 
Figure 8.26 F2 score versus number of clusters for obesity at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.4820 with 2 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.4903 with 3 clusters. 
Selected factors were therefore CTV3 hierarchy level 11 with 3 clusters. 
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8.1.14 Osteoarthritis 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for osteoarthritis are shown in Figure 8.27 and Figure 8.28. 
 
Figure 8.27 F2 score versus number of clusters for osteoarthritis at CTV3 hierarchy level 7 
 
Figure 8.28 F2 score versus number of clusters for osteoarthritis at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.3978 with 2 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.3958 with 2 clusters. 
Selected factors were therefore CTV3 hierarchy level 7 with 2 clusters. 
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8.1.15 Prader-Willi disease 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for Prader-Willi disease are shown in Figure 8.29 and Figure 8.30. 
 
Figure 8.29 F2 score versus number of clusters for Prader-Willi disease at CTV3 hierarchy 
level 7 
 
Figure 8.30 F2 score versus number of clusters for Prader-Willi disease at CTV3 hierarchy 
level 11 
At CTV3 hierarchy level 7, maximum F2 was 0 with NA clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0 with NA clusters. 
The low prevalence of Prader-Willi disease in the data set meant that it was not possible to deduce 
the optimum number of clusters. 
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8.1.16 Prostate cancer 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for prostate cancer are shown in Figure 8.31 and Figure 8.32. 
 
Figure 8.31 F2 score versus number of clusters for prostate cancer at CTV3 hierarchy level 11 
 
Figure 8.32 F2 score versus number of clusters for prostate cancer at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.1614 with 280 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.1278 with 514 clusters. 
Selected factors were therefore CTV3 hierarchy level 7 with 280 clusters. 
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8.1.17 Stress 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for stress are shown in Figure 8.33 and Figure 8.34. 
 
Figure 8.33 F2 score versus number of clusters for thyrotoxicosis at CTV3 hierarchy level 7 
 
Figure 8.34 F2 score versus number of clusters for stress at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.1971 with 150 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.1902 with 70 clusters. 
Selected factors were therefore CTV3 hierarchy level 7 with 150 clusters. 
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8.1.18 Thyrotoxicosis 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for thyrotoxicosis are shown in Figure 8.35 and Figure 8.36. 
 
Figure 8.35 F2 score versus number of clusters for thyrotoxicosis at CTV3 hierarchy level 7 
 
Figure 8.36 F2 score versus number of clusters for thyrotoxicosis at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.0599 with 660 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.0519 with 2 clusters. 
Selected factors were therefore CTV3 hierarchy level 7 with 660 clusters. 
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8.1.19 Type 2 diabetes 
Results of the analysis of F2 score versus the number of clusters at CTV3 hierarchy levels of 7 and 
11 for type 2 diabetes are shown in Figure 8.37 and Figure 8.38. 
 
Figure 8.37 F2 score versus number of clusters for type 2 diabetes at CTV3 hierarchy level 7 
 
Figure 8.38 F2 score versus number of clusters for type 2 diabetes at CTV3 hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.3642 with 2 clusters. 
At CTV3 hierarchy level 11, maximum F2 was 0.3730 with 3 clusters. 
Selected factors were therefore CTV3 hierarchy level 11 with 2 clusters. 
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8.1.20 Summary of training runs for best number of clusters 
The final set of best factors for each condition based on analysis of the training set has now been 
produced and is summarised in Table 6.25. Note that for two conditions, Prader-Willi Disease and 
autism (at level 7 only), the method failed to produce clusters. These conditions are the lowest 
prevalence conditions in the composite data set, and had no positive cases in the training set, thus 
the method was unable to determine the optimum number of clusters. 
 
Condition Best CTV3 
level 
Best no of 
clusters at 
CTV3 level 
F2 at best 
level and k 
Prevalence 
in training 
set 
Acute sinusitis 11 2 0.466 0.154 
Allergic rhinitis 11 3 0.529 0.198 
Any cancer 7 130 0.239 0.042 
Asthma 7 2 0.402 0.122 
Autism 11 90 0.017 0.001 
Breast cancer 11 920 0.162 0.011 
Bronchitis 7 3 0.483 0.159 
Colon cancer 7 359 0.108 0.005 
Eczema 7 104 0.330 0.054 
Gastroparesis 11 530 0..152 0.002 
Gout 11 37 0.186 0.024 
Obesity 11 3 0.490 0.160 
Osteoarthritis 7 2 0.398 0.117 
Prader-Willi - - - - 
Prostate cancer 7 280 0.161 0.111 
Reflux disease 11 3 0.379 0.109 
Stress 7 150 0.197 0.026 
Thyrotoxicosis 7 359 0.060 0.006 
Type 2 diabetes 11 3 0.373 0.102 
Table 8.1 Summary of results for optimum factors for the clustering method 
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8.2 Results from test runs for the clustering approach 
As discussed in 7.3.8, there are several useful indicators to show the success or otherwise of a test 
in predicting the presence or absence of a condition. A key indicator of the success of a screening 
test is the likelihood ratio (LR). The likelihood ratio is the ratio of the probability of the test result in 
diseased persons over the probability of the test result in a non-diseased person (see e.g. Shortliffe 
and Perreault [271] for a description of likelihood ratios and their calculation, and Jacobs et al [147] 
for an illustration of their use in practice). More specifically, the positive likelihood ratio (LR+) and 
the negative likelihood ratio (LR-) are defined as 
LR+ =  probability that the test is positive in diseased persons  
 probability that the test is positive in non-diseased persons 
 = TPR/FPR 
LR- =  probability that the test is negative in diseased persons 
 probability that the test is negative in non-diseased persons 
 =  FNR/TNR 
A test that discriminates well between those persons with a disease and those without the disease 
will have an LR+ much greater than one; likewise an effective test will have an LR- much less than 
one. A likelihood ratio (+ or -) of 1 indicates that the test has no value in discriminating between 
those with the disease and those without. 
Results are presented as positive and negative likelihood ratios, and as odds ratios. This is a 
standard way of presenting such results in the literature (see, for example, [147, 272, 273], with the 
likelihood ratios being calculated from the sensitivity and specificity values, and the odds ratio 
being calculated from the ratio of the positive and negative likelihood ratios (and so, by extension, 
also from the specificity and sensitivity). Clark [274] has a discussion of the calculation of 
likelihood ratios. 
For each condition, the likelihood ratios are calculated. The positive likelihood ratio is then used to 
calculate a post-test prevalence of the condition for those records predicted to be positive for the 
condition; the negative likelihood ratio is used to calculate a post-test prevalence of the condition 
for those records predicted to be negative for the condition. Results of these tests are presented as 
Fagan nomograms. Note that the 95 % confidence intervals for likelihood ratios are calculated; 
should the range of any of these confidence intervals include 1 (indicating that the test has no 
discriminatory value), it is concluded that the likelihood ratio is not significantly different from 1 
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and so the test cannot be said to have a significant discriminatory value. Results are for five runs per 
condition, each run drawing a random sample of 5000 records from the training set of records. 
Note that in the Fagan nomograms shown here, the positive likelihood is shown in red and the 
negative likelihood is shown in green, with no change to likelihood shown by a single black line.  
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8.2.1 Acute sinusitis 
 
Figure 8.39 Results for acute sinusitis using clustering 
True positives: 565; True negatives: 0; False positives: 3414; False negatives: 0 
Sensitivity: 1; Specificity: 0 
F1: 0.249; F2: 0.453; MCC: 0 
Positive predictive value: 0.142; Negative predictive value: - 
Positive likelihood ratio: 1 with 95 % CI: 1 to 1 
Negative likelihood ratio: - with 95 % CI: 0 to >100 
Odds ratio: - with 95 % CI: - to - 
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8.2.2 Allergic rhinitis 
 
Figure 8.40 Results for allergic rhinitis using clustering 
True positives: 667; True negatives: 278; False positives: 3018; False negatives: 41 
Sensitivity: 0.942; Specificity: 0.084 
F1: 0.304; F2: 0.5115; MCC: 0.037 
Positive predictive value: 0.181; Negative predictive value: 0.871 
Positive likelihood ratio: 1.03 with 95 % CI: 1.01 to 1.05 
Negative likelihood ratio: 0.69 with 95 % CI: 0.5 to 0.94 
Odds ratio: 1.5 with 95 % CI: 1.07 to 2.1 
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8.2.3 Any cancer 
 
Figure 8.41 Results for any cancer using clustering 
True positives: 46; True negatives: 3604; False positives: 232; False negatives: 130 
Sensitivity: 0.261; Specificity: 0.947 
F1: 0.216; F2: 0.241; MCC: 0.177 
Positive predictive value: 0.185; Negative predictive value: 0.965 
Positive likelihood ratio: 4.90 with 95 % CI: 3.70 to 6.50 
Negative likelihood ratio: 0.78 with 95 % CI: 0.71 to 0.85 
Odds ratio: 6.28 with 95 % CI: 4.36 to 9.05 
  
Chapter 8: Estimation of condition risk: Results 
275 
 
8.2.4 Asthma 
 
Figure 8.42 Results for asthma using clustering 
True positives: 475; True negatives: 0; False positives: 3522; False negatives: 0 
Sensitivity: 1; Specificity: 0 
F1: 0.212; F2: 0.403; MCC: - 
Positive predictive value: 0.119; Negative predictive value: - 
Positive likelihood ratio: 2.58 with 95 % CI: 1.97 to 3.36 
Negative likelihood ratio: 0.91 with 95 % CI: 0.88 to 0.95 
Odds ratio: 2.83 with 95 % CI: 2.09 to 3.82 
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8.2.5 Autism spectrum disorder 
 
Figure 8.43 Results for autism using clustering 
True positives: 3; True negatives: 3756; False positives: 237; False negatives: 5 
Sensitivity: 0.375; Specificity: 0.941 
F1: 0.024; F2: 0.05411; MCC: 0.059 
Positive predictive value: 0.013; Negative predictive value: 0.999 
Positive likelihood ratio: 6.32 with 95 % CI: 2.56 to 15.59 
Negative likelihood ratio: 0.66 with 95 % CI: 0.39 to 1.14 
Odds ratio: 9.51 with 95 % CI: 2.26 to 40.03 
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8.2.6 Breast cancer 
 
Figure 8.44 Results for breast cancer using clustering 
True positives: 14; True negatives: 3776; False positives: 152; False negatives: 36 
Sensitivity: 0.280; Specificity: 0.961 
F1: 0.130; F2: 0.174; MCC: 0.134 
Positive predictive value: 0.084; Negative predictive value: 0.991 
Positive likelihood ratio: 7.24 with 95 % CI: 4.52 to 11.59 
Negative likelihood ratio: 0.75 with 95 % CI: 0.63 to 0.89 
Odds ratio: 9.66 with 95 % CI: 5.10 to 18.29 
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8.2.7 Bronchitis 
 
Figure 8.45 Results for bronchitis using clustering 
True positives: 400; True negatives: 1082; False positives: 2311; False negatives: 219 
Sensitivity: 0.646; Specificity: 0.319 
F1: 0.240; F2: 0.386; MCC: -0.027 
Positive predictive value: 0.269; Negative predictive value: 0.988 
Positive likelihood ratio: 0.95 with 95 % CI: 0.89 to 1.01 
Negative likelihood ratio: 1.11 with 95 % CI: 0.71 to 1.02 
Odds ratio: 0.86 with 95 % CI: 0.71 to 1.02 
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8.2.8 Colon cancer  
 
Figure 8.46 Results for colon cancer using clustering 
True positives: 2; True negatives: 3843; False positives: 149; False negatives: 9 
Sensitivity: 0; Specificity: 0.967 
F1: 0; F2: 0; MCC: -0.010 
Positive predictive value: 0; Negative predictive value: 0.997 
Positive likelihood ratio: 4.87 with 95 % CI: 1.38 to 17.23 
Negative likelihood ratio: 0.85 with 95 % CI: 0.64 to 1.12 
Odds ratio: 5.73 with 95 % CI: 1.23 to 26.76 
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8.2.9 Eczema 
 
Figure 8.47 Results for eczema using clustering 
True positives: 83; True negatives: 3357; False positives: 445; False negatives: 124 
Sensitivity: 0.401; Specificity: 0.883 
F1: 0.226; F2: 0.306; MCC: 0.186 
Positive predictive value: 0.157; Negative predictive value: 0.964 
Positive likelihood ratio: 3.43 with 95 % CI: 2.84 to 4.13 
Negative likelihood ratio: 0.68 with 95 % CI: 0.61 to 0.76 
Odds ratio: 5.05 with 95 % CI: 3.76 to 6.78 
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8.2.10 Gastroparesis 
 
Figure 8.48 Results for gastroparesis using clustering 
True positives: 0; True negatives: 3935; False positives: 70; False negatives: 8 
Sensitivity: 0; Specificity: 0.983 
F1: 0; F2: 0; MCC: 0.006 
Positive predictive value: 0; Negative predictive value: 0.998 
Positive likelihood ratio: - with 95 % CI: 0 to 53.16 
Negative likelihood ratio: 1.02 with 95 % CI: 1.01 to 1.02 
Odds ratio: 0 with 95 % CI: 0 to >100 
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8.2.11 Gout 
 
Figure 8.49 Results for gout using clustering 
True positives: 27; True negatives: 3439; False positives: 445; False negatives: 59 
Sensitivity: 0.314; Specificity: 0.883 
F1: 0.095; F2: 0.164; MCC: 0.088 
Positive predictive value: 0.056; Negative predictive value: 0.983 
Positive likelihood ratio: 2.69 with 95 % CI: 1.94 to 3.72 
Negative likelihood ratio: 0.78 with 95 % CI: 0.67 to 0.9 
Odds ratio: 3.46 with 95 % CI: 2.17 to 5.51 
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8.2.12 Gastro-oesophageal reflux disease 
 
Figure 8.50 Results for gastro-intestinal reflux disease using clustering 
True positives: 402; True negatives: 0; False positives: 3559; False negatives: 0 
Sensitivity: 1; Specificity: 0 
F1: 0.184; F2: 0.361; MCC: 0.- 
Positive predictive value: 0.101; Negative predictive value: - 
Positive likelihood ratio: 1 with 95 % CI: 1 to 1 
Negative likelihood ratio: - with 95 % CI: 0 to >100 
Odds ratio: - with 95 % CI: - 
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8.2.13 Obesity 
 
Figure 8.51 Results for obesity using clustering 
True positives: 614; True negatives: 0; False positives: 3373; False negatives: 0 
Sensitivity: 1; Specificity: 0 
F1: 0.267; F2: 0.238; MCC: 0 
Positive predictive value: 0.154; Negative predictive value: - 
Positive likelihood ratio: 1 with 95 % CI: 1 to 1 
Negative likelihood ratio: - with 95 % CI: 0 to >100 
Odds ratio: - with 95 % CI: - 
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8.2.14 Osteoarthritis 
 
Figure 8.52 Results for osteoarthritis using clustering 
True positives: 477; True negatives: 0; False positives: 3534; False negatives: 0 
Sensitivity: 1; Specificity: 0 
F1: 0.213; F2: 0.202; MCC: 0 
Positive predictive value: 0.119; Negative predictive value: - 
Positive likelihood ratio: - with 95 % CI: - to - 
Negative likelihood ratio: - with 95 % CI: - to - 
Odds ratio: - with 95 % CI: - 
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8.2.15 Prostate cancer 
 
Figure 8.53 Results for prostate cancer using clustering 
True positives: 15; True negatives: 3735; False positives: 220; False negatives: 36 
Sensitivity: 0.294; Specificity: 0.944 
F1: 0.105; F2: 0.086; MCC: 0.114 
Positive predictive value: 0.064; Negative predictive value: 0.990 
Positive likelihood ratio: 5.29 with 95 % CI: 3.39 to 8.24 
Negative likelihood ratio: 0.75 with 95 % CI: 0.63 to 0.89 
Odds ratio: 7.07 with 95 % CI: 3.81 to 13.12 
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8.2.16 Stress 
 
Figure 8.54 Results for stress using clustering 
True positives: 27; True negatives: 3580; False positives: 296; False negatives: 92 
Sensitivity: 0.227; Specificity: 0.924 
F1: 0.122; F2: 0.169; MCC: 0.094 
Positive predictive value: 0.084; Negative predictive value: 0.975 
Positive likelihood ratio: 2.97 with 95 % CI: 2.1 to 4.21 
Negative likelihood ratio: 0.84 with 95 % CI: 0.76 to 0.92 
Odds ratio: 3.55 with 95 % CI: 2.27 to 5.54 
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8.2.17 Thyrotoxicosis 
 
Figure 8.55 Results for thyrotoxicosis using clustering 
True positives: 0; True negatives: 3833; False positives: 134; False negatives: 14 
Sensitivity: 0; Specificity: 0.966 
F1: 0; F2: 0; MCC: -0.011 
Positive predictive value: 0; Negative predictive value: 0.996 
Positive likelihood ratio: - with 95 % CI: - 
Negative likelihood ratio: 1.03 with 95 % CI: 1.03 to 1.04 
Odds ratio: 3.55 with 95 % CI: 2.27 to 5.54 
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8.2.18  Type 2 diabetes 
 
Figure 8.56  Results for type 2 diabetes using clustering  
True positives: 409; True negatives: 0; False positives: 3581; False negatives: 0 
Sensitivity: 1; Specificity: 0 
F1: 0.186; F2: 0.364; MCC: - 
Positive predictive value: 0.103; Negative predictive value: - 
Positive likelihood ratio: 1 with 95 % CI: 1 to 1 
Negative likelihood ratio: - with 95 % CI: - 
Odds ratio: - with 95 % CI: - 
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8.2.19 Summary of results from clustering 
A summary of the results from the test runs using the clustering method is shown in Table 8.2. 
Condition Positive 
Likelihood Ratio 
(95 % CI) 
Negative 
Likelihood 
Ratio (95 % CI) 
Condition 
Prevalence 
Clusters 
Acute sinusitis 1 (1 to 1) - 14.2 % 2 
Allergic rhinitis 1.03 (1.01 to 1.05) 0.69 (0.50 to 
0.94) 
17.7 % 3 
Any cancer 4.90 (3.70 to 6.50) 0.78 (0.71 to 
0.85) 
4.4 % 130 
Asthma 2.58 (1.97 to 3.36) 0.91 (0.88 to 
0.95) 
11.5 % 2 
Autism 6.32 (2.56 to 
15.59) 
0.66 (0.39 to 
1.14) 
0.2 % 90 
Breast cancer 7.24 (4.52 to 
11.59) 
0.75 (0.63 to 
0.89) 
1.3 % 920 
Bronchitis 0.95 (0.89 to 1.01) 1.11 (0.99 to 
1.25) 
15.4 % 3 
Colon cancer 4.87 (1.38 to 
17.23) 
0.85 (0.64 to 
1.12) 
0.3 % 359 
Eczema 3.43 (2.84 to 4.13) 0.68 (0.61 to 
0.76) 
5.2 % 104 
Gastro-intestinal 
reflux disease 
- - 10.15 % 3 
Gastroparesis - 1.02 (1.01 to 
1.02) 
0.2 % 530 
Gout 2.69 (1.94 to 3.72) 0.78 (0.67 to 0.9) 2.2 % 37 
Obesity - - 15.4 % 3 
Osteoarthritis - - 11.9 % 2 
Prostate cancer 5.29 (3.39 to 8.24) 0.75 (0.63 to 
0.89) 
1.3 % 280 
Stress 2.97 (2.10 to 4.21) 0.84 (0.76 to 
0.92) 
3.0 % 150 
Thyrotoxicosis - 1.03 (1.03 to 
1.04) 
0.4 % 359 
Type 2 diabetes 1 (1 to 1) - 10.3 % 3 
Table 8.2 Summary of results from test runs using clustering method 
It can be seen from the summary of the results that the clustering method for predicting presence or 
absence of a condition in the set of records generally discriminates well between positive and 
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negative-predicted groups when the optimum number of clusters derived from the training runs is 
high (> 3), even for conditions with low prevalence. For conditions with a low optimum number of 
clusters (2 or 3 clusters), the discrimination is generally poor. For these poor-discrimination 
conditions (acute sinusitis, asthma, gastro-intestinal reflux disease, obesity, osteoarthritis. Type 2 
diabetes) ,the method predicted all records to be positive for the condition of interest, appearing to 
have placed all records in one of the clusters which it then scored as a ‘positive’ cluster. Results are 
more fully discussed in Chapter 9. 
 
8.3 Best factors for nearest neighbours method 
After testing using the clustering method, and inspection of the results, a second method was 
implemented, in order to see if results could be improved. Results are presented for determination 
of the optimum level of the CTV3 hierarchy and the optimum value for k, the number of nearest 
neighbours, using a nearest neighbours method. Again, the F2 score was used as the metric on 
which to optimise, which weights sensitivity greater than specificity.  
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8.3.1 Acute sinusitis 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for acute sinusitis are shown in Figure 8.57 and Figure 8.58. 
 
Figure 8.57 F2 score versus size of nearest neighbours group for acute sinusitis at CTV3 
hierarchy level 7 
 
Figure 8.58 F2 score versus size of nearest neighbours group for acute sinusitis at CTV3 
hierarchy level 11 
At CTV3 hierarchy level 7, maximum F2 was 0.5143 at a value for k of 403. 
At CTV3 hierarchy level 11, maximum F2 was 0.5364 at a value for k of 399. 
Selected factors were therefore CTV3 hierarchy level 11 with a value of k of 399.  
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8.3.2 Allergic rhinitis 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for allergic rhinitis are shown in Figure 8.59 and Figure 8.60 . 
 
Figure 8.59 F2 score versus size of nearest neighbours group for allergic rhinitis at CTV3 
hierarchy level 7 
 
Figure 8.60 F2 score versus size of nearest neighbours group for allergic rhinitis at CTV3 
hierarchy level 7 
At CTV3 hierarchy level 7, maximum F2 was 0.5139 at a value of k of 2016. 
At CTV3 hierarchy level 11, maximum F2 was 0.5203 at a value of k of 2016. 
Selected factors were therefore CTV3 hierarchy level 11 with a value of k of 399.  
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8.3.3 Any cancer 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for any cancer are shown in Figure 8.61 and Figure 8.62. 
 
Figure 8.61 F2 score versus size of nearest neighbours group for any form of cancer 
 
Figure 8.62 F2 score versus size of nearest neighbours group for any form of cancer 
At CTV3 hierarchy level 7, maximum F2 was 0.3313 at a value for k of 286. 
At CTV3 hierarchy level 11, maximum F2 was 0.3821 at a value for k of 286. 
Selected factors were therefore CTV3 hierarchy level 11 with a value of k of 399. 
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8.3.4 Asthma 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for autism are shown in Figure 8.63 and Figure 8.64. 
 
Figure 8.63 F2 score versus size of nearest neighbours group for asthma 
 
Figure 8.64 F2 score versus size of nearest neighbours group for asthma 
At CTV3 hierarchy level 7, maximum F2 was 0.4806 at a value for k of 172. 
At CTV3 hierarchy level 11, maximum F2 was 0.4378 at a value for k of 2002. 
Selected factors were therefore CTV3 hierarchy level 7 with a value of k of 172. 
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8.3.5 Autism 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for autism are shown in Figure 8.65 and Figure 8.66. 
 
Figure 8.65 F2 score versus size of nearest neighbours group for autism 
 
Figure 8.66 F2 score versus size of nearest neighbours group for autism 
At CTV3 hierarchy level 7, maximum F2 was 0.2041 at a value for k of 240. 
At CTV3 hierarchy level 11, maximum F2 was 0.2632 at a value for k of 37. 
Selected factors were therefore CTV3 hierarchy level 7 with a value of k of 37. 
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8.3.6 Breast cancer 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for breast cancer are shown in Figure 8.67 and Figure 8.68. 
 
Figure 8.67 F2 score versus size of nearest neighbours group for breast cancer 
 
Figure 8.68 F2 score versus size of nearest neighbours group for breast cancer 
At CTV3 hierarchy level 7, maximum F2 was 0.2255 at a value for k of 525. 
At CTV3 hierarchy level 11, maximum F2 was 0.2030 at a value for k of 525. 
Selected factors were therefore CTV3 hierarchy level 7 with a value of k of 525. 
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8.3.7 Bronchitis 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for bronchitis are shown in Figure 8.69 and Figure 8.70. 
 
Figure 8.69 F2 score versus size of nearest neighbours group for bronchitis 
 
Figure 8.70 F2 score versus size of nearest neighbours group for bronchitis 
At CTV3 hierarchy level 7, maximum F2 was 0.4904 at a value for k of 3628. 
At CTV3 hierarchy level 11, maximum F2 was 0.4684 at a value for k of 2016. 
Selected factors were therefore CTV3 hierarchy level 7 with a value of k of 3628. 
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8.3.8 Colon cancer 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for colon cancer are shown in Figure 8.71 and Figure 8.72. 
 
Figure 8.71 F2 score versus size of nearest neighbours group for colon cancer 
 
Figure 8.72 F2 score versus size of nearest neighbours group for colon cancer 
At CTV3 hierarchy level 7, maximum F2 was 0.1198 at a value for k of 6. 
At CTV3 hierarchy level 11, maximum F2 was 0.1497 at a value for k of 1900. 
Selected factors were therefore CTV3 hierarchy level 11 with a value of k of 1900. 
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8.3.9 Eczema 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for eczema are shown in Figure 8.73 and Figure 8.74. 
 
Figure 8.73 F2 score versus size of nearest neighbours group for eczema 
 
Figure 8.74 F2 score versus size of nearest neighbours group for eczema 
At CTV3 hierarchy level 7, maximum F2 was 0.3736 at a value for k of 75. 
At CTV3 hierarchy level 11, maximum F2 was 0.3827 at a value for k of 273. 
Selected factors were therefore CTV3 hierarchy level 11 with a value of k of 273. 
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8.3.10 Gastro-oesophageal reflux disease 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for gastro-intestinal reflux disease are shown in Figure 8.75 and Figure 8.76. 
 
Figure 8.75 F2 score versus size of nearest neighbours group for gastro-intestinal reflux 
disease 
 
Figure 8.76 F2 score versus size of nearest neighbours group for gastro-intestinal reflux 
disease 
At CTV3 hierarchy level 7, maximum F2 was 0.4388 at a value for k of 403. 
At CTV3 hierarchy level 11, maximum F2 was 0.4485 at a value for k of 2016. 
Selected factors were therefore CTV3 hierarchy level 11 with a value of k of 2016. 
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8.3.11 Gastroparesis 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for gastroparesis are shown in Figure 8.77 and Figure 8.78. 
 
Figure 8.77 F2 score versus size of nearest neighbours group for gastroparesis 
 
Figure 8.78 F2 score versus size of nearest neighbours group for gastroparesis 
At CTV3 hierarchy level 7, maximum F2 was 0.1108 at a value for k of 2350. 
At CTV3 hierarchy level 11, maximum F2 was 0.0847 at a value for k of 30. 
Selected factors were therefore CTV3 hierarchy level 7 with a value of k of 2350. 
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8.3.12 Gout 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for gout are shown in Figure 8.79 and Figure 8.80. 
 
Figure 8.79 F2 score versus size of nearest neighbours group for gout 
 
Figure 8.80 F2 score versus size of nearest neighbours group for gout 
At CTV3 hierarchy level 7, maximum F2 was 0.2390 at a value for k of 406. 
At CTV3 hierarchy level 11, maximum F2 was 0.2348 at a value for k of 399. 
Selected factors were therefore CTV3 hierarchy level 7 with a value of k of 406. 
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8.3.13 Obesity 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for obesity are shown in Figure 8.81 and Figure 8.82. 
 
Figure 8.81 F2 score versus size of nearest neighbours group for obesity 
 
Figure 8.82 F2 score versus size of nearest neighbours group for obesity 
At CTV3 hierarchy level 7, maximum F2 was 0.4547 at a value for k of 2900. 
At CTV3 hierarchy level 11, maximum F2 was 0.4582 at a value for k of 2100. 
Selected factors were therefore CTV3 hierarchy level 11 with a value of k of 2100. 
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8.3.14 Osteoarthritis 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for osteoarthritis are shown in Figure 8.83 and Figure 8.84. 
 
Figure 8.83 F2 score versus size of nearest neighbours group for osteoarthritis 
 
Figure 8.84 F2 score versus size of nearest neighbours group for osteoarthritis 
At CTV3 hierarchy level 7, maximum F2 was 0.5058 at a value for k of 209. 
At CTV3 hierarchy level 11, maximum F2 was 0.5410 at a value for k of 209. 
Selected factors were therefore CTV3 hierarchy level 11 with a value of k of 209. 
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8.3.15 Prostate cancer 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for prostate cancer are shown in Figure 8.85 and Figure 8.86. 
 
Figure 8.85 F2 score versus size of nearest neighbours group for prostate cancer 
 
Figure 8.86 F2 score versus size of nearest neighbours group for prostate cancer 
At CTV3 hierarchy level 7, maximum F2 was 0.1771 at a value for k of 138. 
At CTV3 hierarchy level 11, maximum F2 was 0.2167 at a value for k of 138. 
Selected factors were therefore CTV3 hierarchy level 11 with a value of k of 138. 
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8.3.16 Stress 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for stress are shown in Figure 8.87 and Figure 8.88. 
 
Figure 8.87 F2 score versus size of nearest neighbours group for stress 
 
Figure 8.88 F2 score versus size of nearest neighbours group for stress 
At CTV3 hierarchy level 7, maximum F2 was 0.2446 at a value for k of 180. 
At CTV3 hierarchy level 11, maximum F2 was 0.2536 at a value for k of 180 
Selected factors were therefore CTV3 hierarchy level 11 with a value of k of 180. 
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8.3.17 Thyrotoxicosis 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for stress are shown in Figure 8.89 and Figure 8.90. 
 
Figure 8.89 F2 score versus size of nearest neighbours group for thyrotoxicosis 
 
Figure 8.90 F2 score versus size of nearest neighbours group for thyrotoxicosis 
At CTV3 hierarchy level 7, maximum F2 was 0.1263 at a value for k of 2350. 
At CTV3 hierarchy level 11, maximum F2 was 0.1695 at a value for k of 28. 
Selected factors were therefore CTV3 hierarchy level 11 with a value of k of 28. 
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8.3.18 Type 2 diabetes. 
Results of the analysis of F2 score versus size of the nearest neighbours group at CTV3 hierarchy 
levels of 7 and 11 for stress are shown in Figure 8.91 and Figure 8.92. 
 
Figure 8.91 F2 score versus size of nearest neighbours group for type 2 diabetes 
 
Figure 8.92 F2 score versus size of nearest neighbours group for thyrotoxicosis 
At CTV3 hierarchy level 7, maximum F2 was 0.5685 at a value for k of 300. 
At CTV3 hierarchy level 11, maximum F2 was 0.5473 at a value for k of 230. 
Selected factors were therefore CTV3 hierarchy level 7 with a value of k of 300. 
  
Chapter 8: Estimation of condition risk: Results 
310 
8.3.19 Summary of training runs for best k 
The final set of best factors for each condition based on analysis of the training set has now been 
produced and is summarised in Table 6.25. 
 
Condition Best CTV3 
level 
Best k at 
CTV3 level 
F2 at best 
level and k 
Prevalence 
in training 
set 
Acute sinusitis 11 399 0.536 0.154 
Allergic rhinitis 11 2016 0.530 0.198 
Any cancer 11 286 0.382 0.042 
Asthma 7 172 0.481 0.122 
Autism 11 37 0.263 0.001 
Breast cancer 7 525 0.226 0.011 
Bronchitis 7 3628 0.490 0.159 
Colon cancer 11 1900 0.150 0.005 
Eczema 11 273 0.383 0.054 
Gastroparesis 7 2350 0.111 0.002 
Gout 7 406 0.239 0.024 
Obesity 11 2100 0.458 0.160 
Osteoarthritis 11 209 0.541 0.117 
Prader-Willi     
Prostate cancer 11 138 0.217 0.111 
Reflux disease 11 2016 0.448 0.109 
Stress 11 180 0.254 0.026 
Thyrotoxicosis 11 28 0.169 0.006 
Type 2 diabetes 7 300 0.569 0.102 
Table 8.3 Summary of best factors for k nearest neighbours for optimum F2 score 
It should be noted that these factors have been determined on a subset of the data set. In particular 
the value of k for the number of nearest neighbours and for the number of clusters was not scaled up 
for use on the full data set. There are a number of ‘rules of thumb’ for choosing values for k, for 
example taking the square root of the number of samples, as suggested by Duda et al [275], 
however ultimately the optimum value for k is likely to be chosen empirically, as is the case with 
the work described here. Nevertheless, not scaling up the value of k for larger data sets is doubtless 
a limitation. 
These factors will be used as the input to the next stage of the process, seeing how well different 
techniques for predicting presence or absence of the condition from a set of near neighbours. 
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8.4 Results from test runs for nearest neighbours method 
As described in Section 8.2 for testing of the clustering method, the positive and negative likelihood 
ratios were calculated for test runs on each condition using the optimum factors derived in Section 
8.2 and shown in Table 8.4. Results of these tests are presented as Fagan nomograms. 
Five test runs were carried out, with each run drawing a random sample of 5000 records from the 
training set of records. The mean of the True Positive, True Negative, False Positive and False 
Negative counts from each run were used to calculate the scores given and to produce the 
nomograms.   
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8.4.1 Acute sinusitis 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.93. 
 
Figure 8.93 Results for acute sinusitis using nearest neighbours 
True Positives: 325; True Negatives: 2711; False Positives: 721; False Negatives: 244  
Sensitivity: 0.571; Specificity: 0.790 
F1: 0.402; F2: 0.489; MCC: 0.287  
Positive Predictive Value: 0.311; Negative Predictive Value: 0.917 
Positive Likelihood Ratio = 2.719 (2.469, 2.994) 
Negative Likelihood Ratio = 0.543 (0.493, 0.598) 
Odds ratio = 5.008; 95% CI = (4.161, 6.027)  
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8.4.2 Allergic rhinitis 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.94. 
 
Figure 8.94 Results for allergic rhinitis using nearest neighbours 
True Positives: 427; True Negatives: 2018; False Positives: 1270; False Negatives: 286 
Sensitivity: 0.599; Specificity: 0.614  
F1: 0.354; F2: 0.469; MCC: 0.165  
Positive Predictive Value: 0.252; Negative Predictive Value: 0.876 
Positive Likelihood Ratio = 1.55 (1.44, 1.669) 
Negative Likelihood Ratio = 0.654 (0.595, 0.718) 
Odds ratio = 2.372; 95% CI = (2.011, 2.799)  
 
Chapter 8: Estimation of condition risk: Results 
314 
8.4.3 Any cancer 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.95. 
 
Figure 8.95 Results for any cancer using nearest neighbours 
True Positives: 65; True Negatives: 3411; False Positives: 426; False Negatives: 114  
Sensitivity: 0.363; Specificity: 0.889  
F1: 0.194; F2: 0.269; MCC: 0.158  
Positive Predictive Value: 0.132; Negative Predictive Value: 0.968 
Positive Likelihood Ratio = 3.271 (2.641, 4.05) 
Negative Likelihood Ratio = 0.716 (0.641, 0.801) 
Odds ratio = 4.565; 95% CI = (3.312, 6.292) 
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8.4.4 Asthma 
Results of the test run showing the prior prevalence of asthma and the prevalences in the group 
predicted to have the condition and in the group predicted not to have the condition are shown in 
Figure 8.96. 
 
Figure 8.96 Results for asthma using nearest neighbours 
True Positives: 198; True Negatives: 2974; False Positives: 526; False Negatives: 290  
Sensitivity: 0.406; Specificity: 0.85  
F1: 0.327; F2: 0.37; MCC: 0.218  
Positive Predictive Value: 0.273; Negative Predictive Value: 0.911 
Positive Likelihood Ratio = 2.701 (2.364, 3.085) 
Negative Likelihood Ratio = 0.699 (0.649, 0.754) 
Odds ratio = 3.862; 95% CI = (3.152, 4.731) 
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8.4.5 Autism 
Results of the test run showing the prior prevalence of autism and the prevalences in the group 
predicted to have the condition and in the group predicted not to have the condition are shown in 
Figure 8.97. 
 
Figure 8.97 Results for autism using nearest neighbours 
True Positives: 1; True Negatives: 3867; False Positives: 121; False Negatives: 5 
Sensitivity: 0.167; Specificity: 0.970  
F1: 0.016; F2: 0.034; MCC: 0.018  
Positive Predictive Value: 0.008; Negative Predictive Value: 0.999 
Positive Likelihood Ratio = 5.493 (0.910, 33.158) 
Negative Likelihood Ratio = 0.854 (0.601, 1.229) 
Odds ratio = 6.392; 95% CI = (0.741, 70.848) 
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8.4.6 Breast cancer 
Results of the test run showing the prior prevalence of breast cancer and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.98. 
 
Figure 8.98 Results for breast cancer using nearest neighbours 
True Positives: 23; True Negatives: 3491; False Positives: 469; False Negatives: 22  
Sensitivity: 0.511; Specificity: 0.882  
F1: 0.086; F2: 0.171; MCC: 0.125  
Positive Predictive Value: 0.047; Negative Predictive Value: 0.994 
Positive Likelihood Ratio = 4.316 (3.203, 5.814) 
Negative Likelihood Ratio = 0.555 (0.411, 0.748) 
Odds ratio = 7.782; 95% CI = (4.303, 14.072)  
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8.4.7 Bronchitis 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.99. 
 
Figure 8.99 Results for bronchitis using nearest neighbours 
True Positives: 348; True Negatives: 2227; False Positives: 1144; False Negatives: 283  
Sensitivity: 0.552; Specificity: 0.661  
F1: 0.328; F2: 0.433; MCC: 0.16  
Positive Predictive Value: 0.233; Negative Predictive Value: 0.887 
Positive Likelihood Ratio = 1.625 (1.493, 1.769) 
Negative Likelihood Ratio = 0.679 (0.621, 0.743) 
Odds ratio = 2.394; 95% CI = (2.015, 2.844) 
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8.4.8 Colon Cancer 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.100. 
 
Figure 8.100 Results for colon cancer using nearest neighbours 
True Positives: 1; True Negatives: 3953; False Positives: 38; False Negatives: 15 
Sensitivity: 0.062; Specificity: 0.990  
F1: 0.036; F2: 0.049; MCC: 0.019  
Positive Predictive Value: 0.026; Negative Predictive Value: 0.996 
Positive Likelihood Ratio = 6.564 (0.959, 44.95) 
Negative Likelihood Ratio = 1.006 (0.834, 1.074) 
Odds ratio = 6.935; 95% CI = (0.893, 53.836) 
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8.4.9 Eczema 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.101. 
 
Figure 8.101 Results for eczema using nearest neighbours 
True Positives: 129; True Negatives: 3004; False Positives: 793; False Negatives: 78  
Sensitivity: 0.623; Specificity: 0.791  
F1: 0.229; F2: 0.369; MCC: 0.217  
Positive Predictive Value: 0.14; Negative Predictive Value: 0.975 
Positive Likelihood Ratio = 2.984 (2.639, 3.373) 
Negative Likelihood Ratio = 0.476 (0.399, 0.568) 
Odds ratio = 6.265; 95% CI = (4.679, 8.388)  
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8.4.10 Gastro-oesophageal reflux disease 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.102. 
 
Figure 8.102 Results for gastro-oesophageal reflux disease using nearest neighbours 
True Positives: 296; True Negatives: 1864; False Positives: 1718; False Negatives: 125  
Sensitivity: 0.703; Specificity: 0.52  
F1: 0.243 F2: 0.4; MCC: 0.137  
Positive Predictive Value: 0.147; Negative Predictive Value: 0.937 
Positive Likelihood Ratio = 1.466 (1.366, 1.574) 
Negative Likelihood Ratio = 0.571 (0.491, 0.663) 
Odds ratio = 2.569; 95% CI = (2.064, 3.199) 
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8.4.11 Gastroparesis 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.103. 
 
Figure 8.103 Results for gastroparesis using nearest neighbours 
True Positives: 2; True Negatives: 3760; False Positives: 225; False Negatives: 5  
Sensitivity: 0.286; Specificity: 0.944  
F1: 0.017; F2: 0.039; MCC: 0.031  
Positive Predictive Value: 0.009; Negative Predictive Value: 0.999 
Positive Likelihood Ratio = 5.06 (1.558, 16.438) 
Negative Likelihood Ratio = 0.757 (0.474, 1.21) 
Odds ratio = 6.684; 95% CI = (1.29, 34.644) 
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8.4.12 Gout 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.104. 
 
Figure 8.104 Results for gout using nearest neighbours 
True Positives: 47; True Negatives: 3158; False Positives: 750; False Negatives: 44 
Sensitivity: 0.516; Specificity: 0.808  
F1: 0.106; F2: 0.202; MCC: 0.12  
Positive Predictive Value: 0.059; Negative Predictive Value: 0.986 
Positive Likelihood Ratio = 2.691 (2.184, 3.317) 
Negative Likelihood Ratio = 0.598 (0.484, 0.74) 
Odds ratio = 4.498; 95% CI = (2.959, 6.837)   
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8.4.13 Obesity 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.105. 
 
Figure 8.105 Results for obesity using nearest neighbours 
True Positives: 348; True Negatives: 2267; False Positives: 1118; False Negatives: 267  
Sensitivity: 0.566; Specificity: 0.67  
F1: 0.334; F2: 0.443; MCC: 0.176  
Positive Predictive Value: 0.237; Negative Predictive Value: 0.895 
Positive Likelihood Ratio = 1.713 (1.575, 1.864) 
Negative Likelihood Ratio = 0.648 (0.591, 0.712) 
Odds ratio = 2.643; 95% CI = (2.219, 3.148) 
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8.4.14 Osteoarthritis 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.106. 
 
Figure 8.106 Results for osteoarthritis using nearest neighbours 
True Positives: 225; True Negatives: 3047; False Positives: 501; False Negatives: 229  
Sensitivity: 0.496; Specificity: 0.859  
F1: 0.381; F2: 0.443; MCC: 0.291  
Positive Predictive Value: 0.31; Negative Predictive Value: 0.93 
Positive Likelihood Ratio = 3.51 (3.103, 3.97) 
Negative Likelihood Ratio = 0.587 (0.536, 0.644) 
Odds ratio = 5.976; 95% CI = (4.859, 7.349) 
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8.4.15 Prostate cancer 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.107. 
 
Figure 8.107 Results for prostate cancer using nearest neighbours 
True Positives: 27; True Negatives: 3194; False Positives: 763; False Negatives: 14  
Sensitivity: 0.659; Specificity: 0.807 
F1: 0.065; F2: 0.142; MCC: 0.117 
Positive Predictive Value: 0.034; Negative Predictive Value: 0.996 
Positive Likelihood Ratio = 3.415 (2.715, 4.296) 
Negative Likelihood Ratio = 0.423 (0.276, 0.647) 
Odds ratio = 8.073; 95% CI = (4.213, 15.469) 
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8.4.16 Stress 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.108. 
 
Figure 8.108 Results for stress using nearest neighbours 
True Positives: 36; True Negatives: 3491; False Positives: 389; False Negatives: 73  
Sensitivity: 0.33; Specificity: 0.9  
F1: 0.135; F2: 0.209; MCC: 0.121  
Positive Predictive Value: 0.085; Negative Predictive Value: 0.98 
Positive Likelihood Ratio = 3.294 (2.481, 4.374) 
Negative Likelihood Ratio = 0.744 (0.652, 0.85) 
Odds ratio = 4.426; 95% CI = (2.929, 6.687) 
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8.4.17 Thyrotoxicosis 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.109. 
 
Figure 8.109 Results for thyrotoxicosis using nearest neighbours 
True Positives: 1; True Negatives: 3973; False Positives: 21; False Negatives: 16 
Sensitivity: 0; Specificity: 0.995  
F1: 0; F2: 0; MCC: 0.017  
Positive Predictive Value: 0; Negative Predictive Value: 0.996 
Positive Likelihood Ratio = 0 (0, 94.152) 
Negative Likelihood Ratio = 1.005 (1.003, 1.008) 
Odds ratio = 0; 95% CI = (0, -) 
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8.4.18 Type 2 diabetes 
Results of the test run showing the prior prevalence of acute sinusitis and the prevalences in the 
group predicted to have the condition and in the group predicted not to have the condition are 
shown in Figure 8.110. 
 
Figure 8.110 Results for type 2 diabetes using nearest neighbours 
True Positives: 324; True Negatives: 2320; False Positives: 1298; False Negatives: 64  
Sensitivity: 0.835; Specificity: 0.641  
F1: 0.322; F2: 0.51; MCC: 0.287  
Positive Predictive Value: 0.2; Negative Predictive Value: 0.973 
Positive Likelihood Ratio = 2.328 (2.188, 2.477) 
Negative Likelihood Ratio = 0.257 (0.205, 0.322) 
Odds ratio = 9.052; 95% CI = (6.865, 11.937)
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8.5 Summary of results for nearest neighbours and clustering 
methods. 
A summary of the results from both the nearest neighbours method and the clustering 
method for predicting the presence or absence of conditions in a record is shown in 
Table 8.4. 
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  Clustering Nearest neighbours 
Condition Prevalence Cluster
s 
Positive 
Likelihood 
Ratio (95 % CI) 
Negative 
Likelihood 
Ratio (95 % CI) 
K (level) Positive 
Likelihood Ratio 
(95 % CI) 
Negative 
Likelihood Ratio 
(95 % CI) 
Acute 
sinusitis 
14.2 % 2 1 (1 , 1) - 399 (11) 2.72 (2.479, 2.9 ) 0.54 (0.49, 0.60) 
Allergic 
rhinitis 
17.7 % 3 1.03 (1.01, 
1.05) 
0.69 (0.50, 
0.94) 
2016 (11) 1.55 (1.44, 1.67) 0.65 (0.60, 0.72) 
Any cancer 4.4 % 130 4.90 (3.70, 
6.50) 
0.78 (0.71, 
0.85) 
286 (11) 3.27 (2.641, 
4.05) 
0.72 (0.64, 0.80) 
Asthma 11.5 % 2 2.58 (1.97, 
3.36) 
0.91 (0.88, 
0.95) 
172 (7) 2.70 (2.364, 
3.09) 
0.70 (0.65, 0.75) 
Autism 0.2 % 90 6.32 (2.56, 
15.59) 
0.66 (0.39, 
1.14) 
37 (11) 5.49 (0.91, 
33.16) 
0.86 (0.60, 1.23) 
Breast cancer 1.3 % 920 7.24 (4.52, 
11.59) 
0.75 (0.63, 
0.89) 
525 (7) 4.32 (3.203, 
5.81) 
0.56 (0.41, 0.75) 
Bronchitis 15.4 % 3 0.95 (0.89, 
1.01) 
1.11 (0.99, 
1.25) 
3628 (7) 1.63 (1.493, 
1.77) 
0.68 (0.62, 0.74) 
Colon cancer 0.3 % 359 4.87 (1.38, 
17.23) 
0.85 (0.64, 
1.12) 
1900 (11) 6.56 (0.96, 
44.95) 
0.95 (0.83, 1.07) 
Eczema 5.2 % 104 3.43 (2.84, 0.68 (0.61, 273 (11) 2.98 (2.639, 0.48 (0.40, 0.57) 
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4.13) 0.76) 3.37) 
Gastro-
intestinal 
reflux disease 
10.15 % 3 - - 2016 (11) 1.47 (1.366, 
1.57) 
0.57 (0.49, 0.66) 
Gastroparesis 0.2 % 530 - 1.02 (1.01, 
1.02) 
2350 (7) 5.06 (1.558, 
16.44) 
0.76 (0.47, 1.21) 
Gout 2.2 % 37 2.69 (1.94, 
3.72) 
0.78 (0.67, 0.9) 406 (7) 2.69 (2.184, 
3.32) 
0.60 (0.48, 0.74) 
Obesity 15.4 % 3 - - 2100 (11) 1.713 (1.575, 
1.86) 
0.648 (0.59, 0.71) 
Osteoarthritis 11.9 % 2 - - 209 (11) 3.51 (3.10, 3.97) 0.59 (0.54, 0.64) 
Prostate 
cancer 
1.3 % 280 5.29 (3.39, 
8.24) 
0.75 (0.63, 
0.89) 
138 (11) 3.00 (2.24, 4.00) 0.58 (0.42, 0.79) 
Stress 3.0 % 150 2.97 (2.10, 
4.21) 
0.84 (0.76, 
0.92) 
180 (11) 3.29 (2.481, 
4.37) 
0.74 (0.65, 0.85) 
Thyrotoxicosi
s 
0.4 % 359 - 1.03 (1.03, 
1.04) 
28 (11) 0 (0, 94.15) 1.01 (1.00, 1.01) 
Type 2 
diabetes 
10.3 % 3 1 (1, 1) - 300 (7) 2.33 (2.188, 
2.48) 
0.26 (0.21, 0.32) 
Table 8.4 Summary of results from nearest neighbours method and clustering method
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8.6 Comparison to Logistic Regression 
Conditions selected for comparison were two high prevalence conditions (Allergic 
rhinitis, Bronchitis, obesity), two low prevelance conditions (Gastroparesis and autism – 
Prader-Willi Disease, the lowest-prevalence condition in the data set, was omitted due 
to its extreme low prevalence) and one mid-prevalence condition (eczema).  
Logistic regression performed using KNIME. The regression used stochastic average 
gradient solver since this was understood to work well with large tables and with tables 
where the number of columns is comparable to or greater than the number of rows[276], 
maximum epochs = 120, laplace priors (for high-dimensional data). Granularity levels 
of the CTV3 tree were chosen to be the same as previously established for the clustering 
and k nearest neighbours tests, i.e. level 7 and level 11. As for the clustering and k 
nearest neighbours tests, there was a 50% test / 50 % train split on the whole data set. 
Prior to performing the regression, input values were z-normalised.  
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Allergic 
Rhinitis 
KNN 11 0.354 0.469 0.599 0.614 1.55 0.654 2.372 
Allergic 
Rhinitis 
LR 7 0.076 0.052 0.042 0.983 2.443 0.975 2.508 
Allergic 
Rhinitis 
LR 11 0.113 0.080 0.067 0.974 2.518 0.959 2.626 
Bronchitis KNN 7 0.328 0.433 0.552 0.661 1.625 0.679 2.394 
Bronchitis LR 7 0.139 0.981 0.223 0.164 7.240 0.881 5.146 
Bronchitis LR 11 0.213 0.155 0.131 0.982 7.439 0.885 8.408 
Obesity KNN 11 0.334 0.443 0.566 0.67 1.713 0.648 2.643 
Obesity LR 7 0.34 0.269 0.233 0.984 14.823 0.779 19.030 
Obesity LR 11 0.409 0.326 0.287 0.979 13.422 0.729 18.420 
Chapter 8: Estimation of condition risk: Results 
 
 
334 
 
Gastroparesis KNN 7 0.017 0.039 0.286 0.944 5.06 0.757 6.684 
Gastroparesis LR 7 0 0 0 0.999 0 0 0 
Gastroparesis LR 11        
Autism KNN 11 0.016 0.034 0.167 0.970 5.493 0.854 6.392 
Autism LR 7 0 0 0 1 0 0 0 
Autism LR 11 0 0 0 1 0 0 0 
Eczema KNN 11 0.229 0.369 0.623 0.791 2.984 0.476 6.265 
Eczema LR 7 0.093 0.061 0.05 0.999 33.885 0.951 35.615 
Eczema LR 11 0.137 0.095 0.079 0.996 21.649 0.925 23.413 
 
 
 
KNN generally performed better than Logistic Regression when judged by F-scores 
(both F1 and F2), sensitivity and specificity, for all conditions (note that the low 
prevalence conditions – autism and gastroparesis – performed poorly with logistic 
regression, predicting no positive cases). However, for mid- and high-prevalence 
conditions, logistic regression produced a higher positive likelihood ratio than did KNN. 
KNN produced a lower negative likelihood ratio than did logistic regression in all cases 
(noting that logistic regression was unable to make predictions in the low prevalence 
condition cases). As a result of the logistic regression’s better performance in positive 
likelihood ratio, it also gave higher results for odds ratio than did KNN. This suggests 
that if the logistic regression predicts positive for a condition then there is greater 
confidence in the record containing that condition than if KNN predicts positive. 
However, if the logistic regression predicts negative for a record then there is less 
confidence that the record does truly not contain the condition than if the KNN 
predicted negative. 
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8.7 Conclusions 
For some conditions, the methods developed were able to predict the presence of a 
condition of interest, and both the nearest neighbours method and the clustering method 
were able to discriminate records likely to contain the condition against those unlikely 
to contain the condition. These conditions were: 
Acute sinusitis (knn method only), allergic rhinitis, any cancer, asthma, autism 
(clustering method only), breast cancer, bronchitis (knn method only), eczema, gastro-
intestinal reflux disease (knn method only), gout, obesity (knn method only), 
osteoarthritis (knn method only), prostate cancer, stress and type 2 diabetes (knn 
method only). 
For colon cancer, it was possible to identify a group of records with a raised likelihood 
of having the condition from the general records set, but not state that the remaining 
records had a lowered likelihood of containing the condition. 
For a few conditions it was not possible to identify groups with raised or lowered 
likelihoods of having particular conditions. These conditions were thyrotoxicosis and 
gastroparesis, both conditions with a low prevalence in the records set. Work using a 
larger record set may demonstrate the potential for applying these techniques to these 
conditions, since currently the absolute presence count of the lowest prevalence 
conditions is extremely small, and having a larger quantity of records with these low 
prevalence conditions may help in identifying clusters or establishing whether near 
neighbours for records with these conditions do or do not have a prevalence 
significantly higher (or lower) than the population prevalence. Currently the low 
numbers for these conditions mean that it is difficult to establish significance. 
The results show that for many conditions there may be value in utilising the event 
history contained in primary care records in order to select candidates for screening tests 
(e.g. diabetes) or for pre-emptive health advice (e.g. obesity or gout). 
One set of distance calculation methods was clearly better performing on this data set 
than other methods (the bray, jaccard, gower, morisita, horn, raup, binomial, chao, cao 
and mahalanobis methods, see section 7.3.6.1). It is not clear why these methods 
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performed best, although it can be noted that all these methods were developed for, or 
have been adopted for use for, ecological site similarity analysis and all are 
implemented in the ‘vegdist’ function in the R vegan package [267].  Other factors were 
less clear: for the majority of the conditions tests performance was better when event 
codes were aggregated at CTV3 hierarchy level 7, with others performing better at level 
11.There was no clear discriminator between these groups. The value of k for the k 
nearest neighbours was also a factor that was difficult to optimise perfectly, with the 
heuristic method used for the selection of k value for each condition not wholly 
satisfactory. 
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9 DISCUSSION 
9.1 Motivation and methods 
9.1.1 Primary motivations 
The general motivation for this work was to explore the secondary uses of medical 
records, looking at benefits for individuals, populations and for organisations. This was 
covered in the literature review of Chapter 2 and in the case studies of Chapter 4. A 
specific key motivation for this work was to investigate whether existing medical 
histories could be used to calculate revised likelihoods of individuals having particular 
conditions, and, if the likelihood was increased, to present that information at an 
individual level to clinicians, for example in a general practice surgery visit, or as a pre-
screening tool to select individuals calculated to be at increased risk of the condition and 
suggest them as candidates for screening. As an example of the benefit of discovering 
increased likelihood in some individuals, thyrotoxicosis was considered to be a 
condition which would benefit from early detection but whose discovery could be 
delayed due to the similarity of its symptoms with other more prevalent conditions. 
Conditions producing symptoms similar to those produced by early-stage thyrotoxicosis 
include depression, diabetes and viral infection.  
Rarely does a single factor guarantee that a disease will occur within an individual's 
lifetime - cigarette smoking, faulty genes, poor environment, workplace factors. But 
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each can modulate the risk of having a particular condition. Similarly, a history of other 
conditions does not guarantee the occurrence of another condition nor guarantee that it 
won't occur. 
9.1.2 Aggregation of data from disparate data sets 
Sets of records derived from disparate clinical data sets were combined into a single 
consolidated data set suitable for further analysis. Event codes within the composite 
data set were mapped to a common coding system of Clinical Terms Version 3. In 
creating the composite data set, the fields common to the data sets were identified and 
retained; fields present in only some of the source data sets were ignored. This was to 
ensure that the data set was as balanced as possible, with predictions not based on data 
fields that were available for only a subset of the data set. Event codes were mapped to a 
single coding system, Clinical Terms Version 3, chosen because of its simple 
hierarchical structure, the ready availability of a mapping table from Read Codes 
version 2 to CTV3, its alignment with, but relative simplicity when compared to, 
SNOMED CT, and its more modern categorisation of some term relationships. Mapping 
to this coding system was performed using an existing mapping table for events coded 
in Read v2 (Read v2 to CTV3, NHS TRUD) and via a semi-automatic indirect mapping 
technique for events coded in ICD-9-CM (ICD-9_CM to SNOMED CT via 
UMLS/Nadkarni; SNOMED CT to CTV3 via NHS TRUD). This was to ensure that all 
codes were in a common coding system that was relatively simple and understood. Of 
the 4342 unique ICD-9-CM codes in the US data set, 4328 (99.7 %) were mapped to 
CTV3 codes by a combination of automatic and manual techniques. Of those codes that 
were mapped, 96.0 % were mapped appropriately when judged by a domain expert. 
9.1.3 Generation of codelists 
Sets of event codes, or ‘codelists’, were generated, by primarily manual methods of 
searching the term descriptions for the complete CTV3 code set. As described in section 
5.4, successful searching relied on knowledge of differences between spellings and 
complete term names in US English versus British English. However it was not possible 
to be completely sure that all codes were included in the appropriate codelist: Some 
codes that were not included in the manual generation of codelists were discovered by 
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use of decision trees, also described in section 5.4, although this method of checking 
was only possible for codes that were in the composite data set. 
9.1.4 Development of techniques for record matching 
Individual records from the composite record set, each record containing a set of event 
codes, were then grouped according to similarities between the records. The grouping 
process used standard machine learning techniques of clustering and k nearest 
neighbours, but with significant data preparation. Target conditions were defined using 
the assembled codelists. For each method, optimum factors were derived, by initial 
analysis of the data set and by training runs, in order to simplify subsequent testing and 
to ensure that programs ran in a feasible time. The grouping process utilised the 
hierarchical structure of the CTV3 coding system to group similar codes. For any one 
chosen condition, the condition prevalence within the group of similar records was 
calculated and compared to the prevalence of the condition in the group of non-similar 
records. These prevalence calculations were used to determine the positive and negative 
likelihood ratios, showing whether prediction of presence of a condition in the records 
was significantly raised or lowered when compared to the prevalence in the complete 
records set. Results from the two approaches for the selection of conditions were 
generated and compared to see which conditions performed best and which method 
performed best. 
 
9.1.4.1 Clustering 
Clustering distributes the records in the data set into a set of groups according to each 
record’s similarity to other record assigned to the same group. The number of clusters 
must be pre-defined, as are a number of other important factors, including the measure 
by which similarity is measured and the technique used for creating the clusters. Once a 
record was placed into a cluster, a prediction was made regarding the presence or 
absence of a condition by calculating the prevalence of that condition in other records in 
the cluster and testing to see if that prevalence was significantly higher than the 
population or not. Factors used in Chapter 6 in the clustering method were to use the 
binomial method for calculating the similarity between records and the Ward.D2 
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method for forming clusters, each chosen following testing on a small sample of the 
complete data set. Other factors were selected separately for each condition following 
test runs on multiple samples from the test portion of the data set: these were the choice 
of level of the CTV3 hierarchy (choices were limited to level 7 or level 11 following 
analysis of the codes in the complete data set) and the optimum number of clusters. This 
analysis is shown in Chapter 6, section 6.2, with the results from that analysis shown in 
Table 9.1. 
Note that the prevalence of Prader-Willi disease is very small, meaning that there were 
insufficient number of records containing that condition for meaningful analysis. 
In the testing to determine the optimum number of clusters, a small number of clusters 
was suggested for some conditions, but a much larger number of clusters for other 
conditions. It appeared that conditions with a higher prevalence had a small number of 
clusters suggested (e.g. type 2 diabetes had 3 clusters suggested), whereas conditions 
with a low prevalence had a high number of clusters suggested (e.g. thyrotoxicosis had 
359 clusters suggested). It would seem that for low prevalence conditions, with few 
absolute numbers of cases in the data set, those cases are clustered with a small number 
of other records, whereas with high prevalence conditions, the cases are clustered with a 
high number of other records. Further investigation is required to determine what is 
causing this to happen, in particular whether the small number of cases in low 
prevalence conditions is insufficient to establish a strong pattern, or whether it is 
something intrinsic to the conditions that causes them to have a small or large number 
of clusters suggested. 
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Condition Best CTV3 
level 
Best no of 
clusters at 
CTV3 level 
F2 at best 
level and k 
Prevalence 
in training 
set 
Acute sinusitis 11 2 0.933 0.154 
Allergic rhinitis 11 3 1.058 0.198 
Any cancer 7 130 0.479 0.042 
Asthma 7 2 0.805 0.122 
Autism 11 90 0.034 0.001 
Breast cancer 11 920 0.324 0.011 
Bronchitis 7 3 0.966 0.159 
Colon cancer 7 359 0.215 0.005 
Eczema 7 104 0.660 0.054 
Gastroparesis 11 530 0.303 0.002 
Gout 11 37 0.373 0.024 
Obesity 11 3 0.981 0.160 
Osteoarthritis 7 2 0.796 0.117 
Prader-Willi - - - 0 
Prostate cancer 7 280 0.323 0.111 
Reflux disease 11 3 0.758 0.109 
Stress 7 150 0.394 0.026 
Thyrotoxicosis 7 359 0.120 0.006 
Type 2 diabetes 11 3 0.746 0.102 
Table 9.1 Summary of results for optimum factors for the clustering method 
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9.1.4.2 Nearest neighbours 
The nearest neighbours method starts with a record of interest and seeks to find the most 
similar, by some measure, records in the rest of the data set. The technique employed is 
described in Chapter 6. In summary, a distance matrix was formed for a sample from 
the training set, using the binomial method as previously established. This distance 
matrix contained a distance measure for every record in the training sample to every 
other record in the training sample. For each record, all other records were ordered by 
this distance. Those other records closest to the record of interest were classed as ‘near 
neighbours’ the prevalence of a condition in the set of nearest neighbours was then used 
to calculate a prediction for the record of interest. The optimum number (by convention, 
‘k’) of nearest neighbours, and the optimum level of the CTV3 hierarchy, was selected 
using multiple runs on the test set. 
This analysis is shown in Chapter 6, section 6.2, with the results from that analysis 
shown in Table 9.2. Again, the low prevalence of Prader-Willi disease means that there 
was an insufficient number of records containing that condition for meaningful analysis. 
In a similar manner to that for clustering (section 9.1.4.1), some conditions had a high 
value of k recommended, others had a low value of k recommended. There was a less 
consistent effect than for clustering, however, for example autism and gastroparesis, 
both low prevalence conditions in the data set, had values of k suggested of 37 and 2350 
respectively. It was noted, however, that for high prevalence conditions the plot of F2 
score against k in the testing phase produced relatively flat and smooth curves, with the 
value of F2 dropping only at high values for k, suggesting that cases in the neighbours 
were relatively evenly distributed closer to record of interest, but the density of the 
cases was falling at large distance from the record of interest. For low prevalence 
conditions this was not the case, with curves not being smooth, suggesting that for low 
prevalence conditions randomness has a large impact. This can be seen, for example, 
when comparing the curves of F2 score against k for colon cancer and for eczema, a 
typical low prevalence condition and a typical high prevalence condition. For colon 
cancer, the F2 vs k plot (Figures 8.71 and 8.72) has a noisy curve, and its corresponding 
nomogram (Figure 8.100) shows no significant Likelihood Ratio. However for eczema, 
the F2 vs K plots (Figures 8.73 and 8.74) are smooth and the corresponding nomogram 
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shows significantly raised positive likelihood ratio and significantly lowered negative 
likelihood ratio. Again, as for the cluster analysis, it cannot be stated absolutely whether 
this effect is due to the low or high prevalence of each condition, or something intrinsic 
to the condition - perhaps some conditions present a number of effects and related 
conditions, whereas other conditions exist in some isolation. Further work is needed to 
establish the reason for this behaviour. 
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Condition Best CTV3 
level 
Best k at 
CTV3 level 
F2 at best 
level and k 
Prevalence in 
training set 
Acute sinusitis 11 399 0.489 0.154 
Allergic rhinitis 11 2016 0.469 0.198 
Any cancer 11 286 0.269 0.042 
Asthma 7 172 0.370 0.122 
Autism 11 37 0.034 0.001 
Breast cancer 7 525 0.171 0.011 
Bronchitis 7 3628 0.433 0.159 
Colon cancer 11 1900 0.049 0.005 
Eczema 11 273 0.369 0.054 
Gastroparesis 7 2350 0.039 0.002 
Gout 7 406 0.202 0.024 
Obesity 11 2100 0.443 0.160 
Osteoarthritis 11 209 0.443 0.117 
Prader-Willi - - - - 
Prostate cancer 11 138 0.142 0.111 
Reflux disease 11 2016 0.400 0.109 
Stress 11 180 0.209 0.026 
Thyrotoxicosis 11 28 0 0.006 
Type 2 diabetes 7 300 0.510 0.102 
Table 9.2 Summary of best factors for k nearest neighbours for optimum F2 score 
 
9.1.5 What was found 
For each method, a group of records that were ‘similar’ to a record of interest were 
found. These similar records were then checked for presence or absence of the condition 
of interest (the condition of interest having been removed prior to grouping) and the 
prevalence of the condition of interest within the similar group was counted. Should this 
prevalence be significantly higher than the prevalence within the wider records set (i.e. 
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the ‘population’ prevalence), the record of interest was predicted to be positive for the 
condition of interest. This analysis was repeated for all records in the test set, enabling a 
total count of true positives, true negatives, false positives and false negatives to be 
calculated and so subsequently calculations of sensitivity, specificity, positive and 
negative likelihood ratios and odds ratio. Results are shown in Table 8.4. 
9.2 Results and implications for practice 
A number of conditions were tested, the list of conditions being drawn primarily from 
the Practice Fusion list of the most prevalent conditions in the USA, together with some 
lower prevalence conditions to test performance with less common conditions. 
It was found that for many conditions, both the clustering method and the nearest 
neighbours method could discriminate between records with a raised likelihood of 
containing the condition and those with a lesser likelihood of containing the condition. 
The nearest neighbours method was able to produce both significant positive likelihood 
ratios and significant negative likelihood ratios for more conditions. Both methods 
generally performed better with higher-prevalence conditions and less well with lower-
prevalence conditions. 
Table 9.3 (for clustering) and Table 9.4 (for nearest neighbours) show for which 
conditions the applied techniques were able to discriminate between raised and not 
raised/lowered likelihoods of the conditions. Those conditions in the lower right hand 
quadrant show a clear separation between raised and lowered likelihoods; those 
conditions in the upper left quadrant show no change in likelihoods after application of 
the grouping technique. It can be seen that the nearest neighbour technique produces 
more conditions (14 of  18) with both a significant positive likelihood ratio for those 
conditions predicted to be positive and a significant negative likelihood ratio for those 
conditions predicted to be negative than did the clustering method (7 of 18). 
Results for each condition, reasons for those results, and the implications for clinical 
practice are discussed in section 9.3. 
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 Positive Likelihood 
Ratio not significant 
Positive Likelihood 
Ratio significant 
Negative Likelihood 
Ratio not significant  
Acute sinusitis 
Bronchitis 
Gastroparesis 
Gastro-intestinal reflux 
disease 
Obesity 
Osteoarthritis 
Thyrotoxicosis 
Type 2 diabetes 
Allergic rhinitis 
Autism 
Colon cancer 
Negative Likelihood 
Ratio significant 
 Any cancer 
Asthma 
Breast cancer 
Eczema 
Gout 
Prostate cancer 
Stress 
 
Table 9.3 Successes and failures of the clustering method 
 Positive Likelihood 
Ratio not significant 
Positive Likelihood 
Ratio significant 
Negative Likelihood Ratio 
not significant  
Autism 
Colon cancer 
Thyrotoxicosis 
Gastroparesis 
Negative Likelihood Ratio 
significant  
 Acute sinusitis 
Allergic rhinitis 
Any cancer 
Asthma 
Breast cancer 
Bronchitis 
Eczema 
Gastro-intestinal reflux 
disease 
Gout 
Obesity 
Osteoarthritis 
Prostate cancer 
Type 2 diabetes 
Stress 
Table 9.4 Successes and failures of the nearest neighbours method 
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9.3 Implications for clinical practice 
Early discovery of a condition can often improve the chances of successful treatment or 
of mitigation of the effects of the condition and many conditions can be detected 
through screening tests on asymptomatic individuals. Disadvantages of screening tests 
include risks of harm to the individual if the screening test is an invasive test; 
inconvenience and/or stress to the individual; and financial cost to the individual and/or 
the health care system. It is therefore advantageous to perform screening tests on subsets 
of the population selected to be at great risk of the condition being screened for.  
Increased detection of conditions via screening can be beneficial, but of most use if 
effective treatment is available once a condition has been detected. Similarly, 
identifying population sub-groups as being at raised risk for a condition is beneficial 
only if treatments are available to address that raised risk. For example, many patients 
are known to have cardiovascular risk already but are not effectively treated [277].  
Results for likelihood ratios prediction, both positive (LR+) and negative (LR-) for each 
of the conditions investigated in this work are now presented, together with a brief 
discussion of the results and the implications for care. 
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9.3.1 Acute sinusitis 
Clustering method: LR+: 1 (1, 1); LR-: - 
Nearest neighbours method:  LR+: 2.72 (2.47, 2.99); LR-: 0.55 (0.4, 0.60) 
The test discriminates well between records that contain the condition and those that do 
not when using the nearest neighbours method: the positive likelihood ratio is 
significantly above 1, the negative likelihood ratio is significantly below 1. There is no 
discrimination between the groups when using the clustering method. 
Advantage of early detection: avoids possible further complications, particularly in 
immunocompromised patients, e.g. patients with diabetes, HIV or other conditions. 
Treatment available: Yes - generally nasal decongestants and/or antibiotics. 
. 
9.3.2 Allergic rhinitis 
Clustering method: LR+: 2.16 (1.92, 2.43); LR-: 0.69 (0.5, 0.94) 
Nearest neighbours method: LR+: 1.55 (1.44, 1.67); LR-: 0.65 (0.60, 0.72) 
The test discriminates well between records that contain the condition and those that do 
not. The positive likelihood ratio is significantly above 1, the negative likelihood ratio is 
significantly below 1, for both the clustering method and the KNN method. 
Advantage of early detection: There are advantages to early detection of allergic 
rhinitis, and allergic disease generally: “early diagnosis of allergic diseases makes 
specific immunotherapy more efficient. In this way, comorbidities can be avoided (e.g. 
bronchial asthma in patients with allergic rhinitis” [278]. 
Treatment available: Yes - antihistamines, decongestants, eye drops, nasal sprays, 
immunotherapy are all possible treatments for allergic rhinitis. 
 
9.3.3 Any cancer: 
Clustering: LR+: 4.90 (3.70, 6.50); LR-: 0.89 (0.71, 0.85) 
Nearest neighbours method: LR+ 3.27 (2.64, 4.05); LR-: 0.72 (0.64, 0.80) 
Advantage of early detection:  Treating cancers while they are still small and/or before 
they have spread can improve the chances of successful treatment. The WHO note that 
"Early diagnosis is particularly relevant for cancers of the breast, cervix, mouth, larynx, 
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colon and rectum, and skin" [279]. As well as a greater chance of successful treatment, 
early treatment is likely to require a lower level of treatment and so fewer side effects. 
Treatment available: Yes: radiotherapy, chemotherapy, surgery; 
 
 
9.3.4 Asthma:  
Clustering: LR+: 2.58 (1.97, 3.36); LR-: 0.91 (0.88, 0.95) 
Nearest neighbours method:  LR+: 2.70 (2.36, 3.09); LR-: 0.70 (0.65, 0.75) 
Both the clustering method and the nearest neighbours method discriminate well 
between records that contain the condition and those that do not. The positive likelihood 
ratio is significantly above 1, the negative likelihood ratio is significantly below 1. 
Advantage of early detection:  There are advantages of earlier positive diagnosis, 
particularly in the young: “The diagnosis of asthma is of severely delayed, a fact which 
influences the prognosis and efficacy of therapeutic interventions… inhaled steroids 
seem to have a disease-modifying effect if started early enough” [280] . “Early detection 
and counselling is expected to reduce the prevalence of asthma symptoms and improve 
health-related quality of life at age 6 years” [281]. 
Treatment available: There is, as yet, no cure for asthma, but treatment is available and 
beneficial in helping control the condition.  Treatments include use of inhalers or 
medication. 
 
9.3.5 Autism spectrum disorder:  
Clustering: LR+: 2.58 (6.32, 2.56, 15.59); LR-: 0.66 (0.39, 1.14) 
Nearest neighbours method: LR+: 5.49 (0.91, 33.16); LR-: 0.86 (0.60, 1.23) 
The clustering method was able to identify well a group of records with a higher 
likelihood of containing the condition autism spectrum disorder, although the group 
with reduced likelihood was not significantly lower in likelihood. The nearest 
neighbours method was not able to discriminate between the two groups. 
Advantage of early detection: There are some advantages to early detection of autism 
spectrum disorder: “intervention for childhood autism based on applied behavior 
Chapter 9: Discussion 
 
 
350 
 
analysis and delivered intensively … during the preschool period can bring about 
significant changes in children’s functioning” [282]. 
Treatment available: Although there is no ‘cure’ for autism spectrum disorder, specialist 
interventions can improve communication, educational and social development in those 
with the condition. Some conditions associated with autism spectrum disorder, such as 
epilepsy, ADHD, can be treated with appropriate medication. 
9.3.6 Breast cancer:  
Clustering: LR+: 7.24 (4.52, 11.59); LR-: 0.75 (0.63, 0.89) 
Nearest neighbours method: LR+: 4.31 (3.20, 5.81); LR-: 0.56 (0.41, 0.75) 
Both the clustering method and the nearest neighbours method discriminate well 
between records that contain the condition and those that do not. The positive likelihood 
ratio is significantly above 1, the negative likelihood ratio is significantly below 1. 
Advantage of early detection: “tumour stage at diagnosis of breast cancer … greatly 
affects overall survival” [283]  
Treatment available: Radiotherapy, chemotherapy, surgery, hormone therapy 
 
9.3.7 Bronchitis:  
Clustering: LR+: 0.95 (0.89, 1.01); LR-: 1.11 (0.71, 1.02) 
Nearest neighbours method:  LR+: 1.63 (1.49, 1.77); LR-: 0.68 (0.62, 0.74) 
The test discriminates between records that contain the condition and those that do not 
when using the nearest neighbours method but is less successful when using the 
clustering method, where a group with significant positive likelihood ratio for the 
condition was identified, but a group with significant lowered likelihood ratio. 
Advantage of early detection: There is little advantage to early treatment prior to 
condition becoming symptomatic, although there is a possible delay in condition onset 
or reduction in condition severity if early lifestyle changes are made – cigarette smoking 
is the most common cause of chronic bronchitis. 
Treatment available: There is no direct treatment available for the cure of bronchitis, 
however a healthy diet, exercise and not smoking can all help to alleviate symptoms. 
Some medications are available to alleviate symptoms. 
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9.3.8 Colon cancer:  
Clustering: LR+: 4.87 (1.38, 17.23); LR-: 0.85 (0.64, 1.12) 
Nearest neighbours method:  LR+: 6.56 (0.96, 44.95); LR-: 0.95 (0.83, 1.07) 
The clustering method was able to identify groups with a raised likelihood of colon 
cancer, but not groups with a lowered likelihood. The nearest neighbours method was 
unable to identify groups with significantly raised or lowered likelihood ratio. 
Advantage of early detection: 5-year survival if detected at Stage I is over 90 %; 5-year 
survival if not treated until Stage IV is only 11 % (National Cancer Institute’s SEER 
database, quoted at https://www.cancer.org/cancer/colon-rectal-cancer/detection-
diagnosis-staging/survival-rates.html) 
Treatment available: Early stage colon cancer may be treatable by surgery alone. Later 
stage colon cancer may require chemotherapy and/or radiotherapy in addition to 
surgery. 
 
9.3.9 Eczema:  
Clustering: LR+: 3.43 (2.84, 4.13); LR-: 0.68 (0.61, 0.76) 
Nearest neighbours method: LR+: 2.98 (2.64, 3.37); LR-: 0.48 (0.40, 0.57) 
Both the clustering method and the nearest neighbours method discriminate well 
between records that contain the condition and those that do not. The positive likelihood 
ratio is significantly above 1, the negative likelihood ratio is significantly below 1 for 
both methods. 
Advantage of early detection: Early intervention in young people may help not only to 
alleviate the symptoms of eczema but also to prevent other allergic diseases such as 
asthma or allergic rhinitis [284]. 
Treatment available: “Atopic dermatitis is not curable… the treatment of atopic 
dermatitis aims to minimise the number of exacerbations of the disease, so-called flares 
[and] reduce the duration and degree of the flare” [285]. 
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9.3.10 Gastro-oesophageal reflux disease:  
Clustering: LR+: 1 (1, 1); LR-: - 
Nearest neighbours method:  LR+: 1.47 (1.37, 1.57); LR-: 0.57 (0.49, 0.67) 
The clustering method could not discriminate between groups with raised likelihood and 
lowered likelihood of the condition. The nearest neighbours method did discriminate 
well between the two groups, with the positive likelihood ratio being significantly above 
1 and the negative likelihood ratio significantly below 1. 
Advantage of early detection: “Early detection and treatment of GERD in children may 
prevent, attenuate, or heal complications such as failure to thrive or feeding refusal as 
well as pulmonary, ear-nose-and-throat disorders, erosive esophagitis, and peptic 
stricture” [286]. “Early detection can help prevent minor heartburn from becoming a 
major health issue” [287]. 
 Treatment available: Several treatment options are available, including medication, or 
surgery. Lifestyle changes may help to alleviate the condition, with weight loss, eating 
smaller but more frequent meals, decreasing stress and avoiding alcohol being 
beneficial.  
 
9.3.11 Gastroparesis:  
Clustering: LR+: 1 (0, 53.16); LR-: 1.02 (1.01, 1.02) 
Nearest neighbours method: LR+: 5.06 (1.56, 16.44); LR-: 0.76 (0.47, 1.21) 
Identification of groups with significant positive likelihood ratios or significant negative 
likelihood ratios was not demonstrated by the clustering method by was so with the 
nearest neighbours method.  
Advantage of early detection: Gastroparesis can reduce the ability to control blood sugar 
in individuals with diabetes and so early identification of the presence of gastroparesis 
can help with blood sugar management. 
Treatment available: Gastroparesis cannot usually be cured but some actions can help 
control the condition: eating smaller, more frequent meals, softer or liquid foods; 
chewing foods; drinking non-fizzy drinks with meals. Some medications may help 
alleviate the symptoms. Surgery may also be required in more serious cases. 
Chapter 9: Discussion 
 
 
353 
 
 
9.3.12 Gout:  
Clustering: LR+: 2.69 (1.94, 3.72); LR-: 0.78 (0.67, 0.90) 
Nearest neighbours method: LR+: 2.69 (2.18, 3.32); LR-: 0.60 (0.48, 0.74) 
Both the clustering method and the nearest neighbours method discriminate well 
between records that contain the condition and those that do not. The positive likelihood 
ratio is significantly above 1, the negative likelihood ratio is significantly below 1. 
Advantage of early detection: reducing the level of uric acid prevents the formation of 
crystals in joints and tissues which trigger attacks of gout. Other benefits of reducing 
levels of uric acid include reducing the risk of liver disease. 
Treatment available: anti-inflammatory drugs to alleviate the symptoms, with steroids 
for more severe cases. Keeping an affected joint cool can help reduce the symptoms. To 
prevent recurrence, medications are available. Lifestyle changes can help reduce the risk 
of recurrence. 
 
9.3.13 Obesity:  
Clustering: LR+: 1 (1, 1); LR-: - 
Nearest neighbours method:  LR+: 1.71 (1.58, 1.86); LR-: 0.65 (0.59, 0.71) 
The clustering method could not discriminate between groups with raised likelihood and 
lowered likelihood of the condition. The nearest neighbours method did discriminate 
well between the two groups, with the positive likelihood ratio being significantly above 
1 and the negative likelihood ratio significantly below 1. 
Advantage of early detection: Can help to ensure that diet and exercise is sufficient for 
treatment, ensuring that more major treatment is not required and that risks of 
conditions associated with obesity are not raised. 
Treatment available: diet and exercise. Medication is also available. In severe cases 
surgery may be appropriate. 
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9.3.14 Osteoarthritis 
Clustering: LR+: - ; LR-: - 
Nearest neighbours method: LR+: 3.51 (3.10, 3.97); LR-: 0.59 (0.54, 0.64) 
The nearest neighbours method discriminates well between records that contain the 
condition and those that do not. The positive likelihood ratio is significantly above 1, 
the negative likelihood ratio is significantly below 1. The clustering method is 
ineffective here. 
Advantage of early detection: There is an advantage to positive prediction: 
“osteoarthritis typically develop over a long period of time, offering a long window of 
time to potentially alter its course… it’s etiology is multifactorial… with highly 
modifiable risk factors of mechanical overload, obesity and joint injury” and 
“Osteoarthritis  ... currently lacks disease-modifying treatments” [288]  So early 
detection of pre-osteoarthritis may lead to treatments and lifestyle changes that could 
delay or prevent full osteoarthritis developing. 
Treatment available: There is, as yet, no cure for osteoarthritis. However, treatment 
once presence of condition is detected is available, including the use of medication to 
reduce pain and lifestyle changes such as weight loss and exercise. For more severe 
cases, surgery may be required. 
. 
 
9.3.15 Prostate cancer: 
Clustering: LR+:  5.29 (3.39, 8.25); LR-:  0.75 (0.63, 0.89) 
Nearest neighbours method: LR-: 3.42 (2.72, 4.30); LR-: 0.42 (0.28, 0.65) 
Both the clustering method and the nearest neighbours method discriminate well 
between records that contain the condition and those that do not. The positive likelihood 
ratio is significantly above 1, the negative likelihood ratio is significantly below 1. 
Advantage of early detection: it is unclear if the benefits of early detection outweigh the 
risks of detection and treatment 
Chapter 9: Discussion 
 
 
355 
 
Treatment available: treatment depends on the stage of the cancer. Radiotherapy and/or 
chemotherapy treatments are available but slow-growing prostate cancers may simply 
be left under observation. 
 
9.3.16 Stress: 
 
Clustering: LR+:  2.97 (2.1, 4.21); LR-: 0.84 (0.76, 0.92) 
Nearest neighbours method:  LR+: 3.29 (2.48, 4.37); LR-: 0.74 (0.65, 0.85) 
Both the clustering method and the nearest neighbours method discriminate well 
between records that contain the condition and those that do not. The positive likelihood 
ratio is significantly above 1, the negative likelihood ratio is significantly below 1. 
Advantage of early detection: A number of conditions are related to stress, including 
cardiovascular disease, asthma and Alzheimer’s disease. Early intervention to reduce 
stress may reduce the risk of other conditions. 
Treatment available: Treatments available for stress include medication, cognitive 
behaviour therapy and other talking therapies, alternative therapies 
9.3.17 Thyrotoxicosis: 
 
Clustering: LR+:  - ; LR-: 1.03 (1.03, 1.04) 
Nearest neighbours method: 1 (0, 94.15); LR-: 1.01 (1.00, 1.01) 
Neither the clustering method nor the nearest neighbours method were able to identify 
groups with a significant positive likelihood for thyrotoxicosis or a significant negative 
likelihood. This is likely due to the low prevalence of the condition (0.6 % in the 
composite data set) but may be due to factors intrinsic to the condition. 
Advantage of early detection: There are advantages to early diagnosis of thyrotoxicosis: 
“treatment of subclinical hyperthyroidism may decrease the risk of atrial fibrillation and 
may decrease the risk of low bone density in menopausal women” [289]. 
Treatment once presence of condition is detected: available. Medication can suppress 
thyroid function to normal levels. Radioiodine treatment can destroy some of the 
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thyroid function. Surgery can remove some or all of the thyroid. Any shortfall in 
function following over-treatment can be compensated by medication. 
 
9.3.18 Type 2 diabetes: 
Clustering: LR+:  1 (1, 1); LR-:  - 
Nearest neighbours method: LR+: 2.33 (2.19, 2.48); LR-: 0.26 (0.21, 0.32) 
The test discriminates well between records that contain the condition and those that do 
not. The positive likelihood ratio is significantly above 1, the negative likelihood ratio is 
significantly below 1.  
Advantage of early detection: “the burden of the disease could be further reduced with 
early intervention to address prediabetes, as mounting evidence suggests that this 
approach could prevent, or at least delay, progression to overt diabetes. However, most 
people do not benefit from this, as prediabetes is largely underdiagnosed” [290].  
Treatment available: Medication and dietary & exercise changes can control type 2 
diabetes. Pre-diabetes can be control by lifestyle changes including diet, exercise and 
smoking cessation 
 
9.4 Comparison to existing work 
 The produced composite data set had condition prevalences similar to those 
reported in the literature for the developed world and had age and gender demographics 
in accordance to those figures published by the UK and USA governments. The age and 
gender demographics in the composite data set were also no different to those in the 
source data sets. The objective for producing a composite data set and the intention for 
its use reflected the ambitions suggested by Celi et al [197] for the analysis of data sets 
from multiple sources. Other techniques for predicting likelihoods of future conditions 
are described in the literature, e.g. [56] for prediction of diabetes risk or [291] for 
prediction of cardiovascular disease risk, but in each case the risk calculation is based 
on prior knowledge of risk factors, whereas the techniques described here do not rely on 
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any prior knowledge (save the code grouping by common ancestors in the CTV3 
hierarchy) and have the potential to suggest further risk factors. 
The code mappings generated for ICD-9-CM to CTV3 produced a success rate similar 
to that reported by Nadkarni and Darer [189] for their manual (though software-
assisted) mapping of ICD-9-CM to SNOMED CT.  
 
 
9.5 Implications for research 
9.5.1 Research privacy 
If it can be demonstrated that there is an optimum  level or levels of the CTV3 hierarchy 
to perform work such as that described here, it can be hypothesised that useful data for 
research can be released with coding at a less granular level than in the originally 
recorded data but can still produce useful research, audit or predictive results. 
Decreasing granularity can be  a way of increasing privacy –  it may increase privacy by 
increasing the k-number in k-anonymity (see [292] for a discussion of k-anonymity) - 
but by decreasing the granularity it may decrease the research potential of the data 
should fine detail be required.  
9.5.2 Computer processing requirements 
Use of CTV3 codes at a higher level of the hierarchy may reduce RAM requirements 
for processing and reduce processing time, in essence by dimensionality reduction. The 
number of unique event codes on which the algorithms are run is reduced by 
aggregating similar events (as determined by common ancestors in the CTV3 hierarchy) 
into single parent codes. 
9.5.3 Discovery of risk factors 
Although the methods described cannot deduce the aetiology of medical conditions it 
can provide pointers towards risk factors by investigation of the most common event 
codes within clusters or near neighbour groups with raised condition prevalence. 
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9.6 Study limitations and future work 
9.6.1 Small data set size 
One limitation of the work was the relatively small data set size, requiring development 
of techniques to compensate for this. The primary technique employed was to work 
with less granular levels of the CTV3 hierarchy, trading a decrease in granularity for an 
increase in nearest neighbour matching.. Conditions with low prevalence had, of course, 
very few occurrences in the data set and so did not perform as well as conditions with 
greater prevalence. Although it was assumed that this was due to low prevalence, it is 
possible that the performance was due to the nature of the condition. Analysis using a 
large quantity of data, or data that is skewed to contain a quantity of the rarer conditions 
higher than their general prevalence would usually give, would allow for this to be 
investigated further. 
9.6.2 Codelists not verified 
Codelists may not be complete: any codes that should be in the list but aren’t may 
increase the likelihood ratios. This was mitigated by CART analysis which suggested 
codes that divided the data set into those records that were more likely to have the 
condition and those that were less likely, however this method was not foolproof and 
could only suggest codes that were in the composite data set and not in the complete 
CTV3 code set. Codelists have not been clinically validated for accuracy. 
9.6.3 Time period of adjusted likelihoods 
Records were predicted to have an increased or not increased likelihood of particular 
conditions, but there was no time period set on this prediction. So rather than predicting 
an increased likelihood within 1 year, 5 years or 10 years, a lifetime increased 
likelihood was presented. This may not be useful for some conditions.  
9.6.4 Weighting of events 
There was no weighting of event codes to allow for severity - a condition or symptom 
was either present or absent. Equally, no allowance was made for the age of an event, 
i.e. whether it was a recent event or occurred further into the past. However, without a 
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priori knowledge of which events take have effects which increase with time and which 
events have effects which lessen with time it is difficult to decide how to allow for this. 
9.6.5 Coding system used 
The choice of coding system on which to converge was Clinical Terms Version 3. 
During the course of this work, this coding system was deprecated by the UK 
Department of Health, with the NHS mandated to use SNOMED CT in its place, the 
conversion to take place by April 2010. SNOMED CT is a more complex system and it 
is not clear how well the techniques applied here would work under SNOMED CT. 
9.6.6 Coincidence of predictors and conditions 
The technique has been tested by removing conditions of interest from records and 
making predictions based on the remaining events in the record. However it is not clear 
whether individuals who have yet to be diagnosed with a condition of interest will have 
yet had the events  that are predictive of those conditions, i.e. the symptoms or diseases 
which match them with records that contain the condition of interest.  
 
9.6.7 Future work 
There are a number of areas for further research, many of which seek to address the 
study limitations. The analysis can be repeated using the existing methods but 
translating event codes to SNOMED CT and comparing results to those described here. 
The slow run time of the methods empoyed was disappointing and limited development 
of the techniques. This would have implications for use in clinical practice: currently the 
system takes around 30 minutes to run on a sample of 5,000 records. This is likely to be 
too long for opportunistic likelihood predictions for an individual arriving in a clinic, 
although acceptable for use in identification of individuals appropriate for screening or 
invitation to consultation. 
Other machine learning techniques can be applied to the data set, with comparison of 
the results and the running times to the analysis performed here. These other techniques 
include neural networks, decision trees, correspondence analysis and others. 
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There may be potential for combining the results from the work described here with 
results from genomic analysis, combining nature with nurture: a person’s genes can 
predict the risks of various conditions, but for some conditions these risks can be 
modified by events that occur later in life. For example, an individual may genomically 
have a raised risk of diabetes, but their lifestyle can also have an effect on this risk. 
Other factors can be brought in to the analysis: geographic factors such as index of 
deprivation, occupation history and ethnicity. Allowance must also be made for 
accidents and random factors. 
 
9.7 Contributions to knowledge 
9.7.1 Code mapping 
A system was developed to generate code mappings between two coding systems, 
indirectly via a third coding system. This addressed a gap in the available code 
mappings, a mapping from ICD-9-CM to CTV3. Although developed to aid in the 
generation of that specific code mapping, the system is generalizable.  
9.7.2 Codelists 
Codelists are sets of codes from clinical coding systems that indicate the presence of 
particular conditions. Very few existing codelists were found and so a set of codelists 
defining each condition evaluated in this work was assembled. These codelists were of 
CTV3 codes and were intended to include the entire CTV3 code set, without restriction 
to the CTV3 codes in the data used using data volunteered by in this work. The codelists 
produced for this work are shown in the Appendix 2. 
9.7.3 Analysis techniques 
Using existing machine learning methods a number of techniques were developed in 
order to optimise the effectiveness of these methods. These included, in particular, 
analysing and utilising the hierarchical structure of the CTV3 coding system, and 
assignation of significance codes to each CTV3 event code. Analysis of the coding 
system hierarchy, and subsequent testing, derived an effective level of the CTV3 
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hierarchy at which to operate with the methods and data employed in this work, 
allowing for aggregation of similar codes to increase the chances of finding matching 
records but retaining sufficient granularity to distinguish between dissimilar records. It 
is believed that the values selected for the candidate optimum levels of the CTV3 
hierarchy (i.e. levels 7 and 11) will remain generally true, since they are the result of 
inspection and analysis of the CTV3 hierarchy (see section 7.3.1); however the final 
choice of level must be determined by performing test runs on the condition being 
investigated – note that there are many more conditions than the relatively small number 
analysed in this work. Values for the optimum number of near neighbours or for the 
optimum number of clusters were produced independently for each condition. 
9.7.4 Other contributions 
 
 Peer reviewer for: Leo Anthony Celi, Andrew J Zimolzak, David J Stone. 
Dynamic Clinical Data Mining: Search Engine-Based Decision Support. JMIR 
Med Inform 2014;2(1):e13) doi:10.2196/medinform.3110 [197] 
 Presentation: Jonathan Turner, Peter Weller. "Modulation of Medical Condition 
Likelihood by Patient History Similarity." Medicine 2.0'14 Europe (Malaga, 
Spain, 10th October 2014) (& also chair of this session) 
 Presentation: Turner J, Istad TS, Olerud HM, Flatabø S, Liland A, Ali W, 
Kjærheim K. "EPI-CT: International Epidemiological Paediatric CT Study. Data 
extraction and patient privacy protection: The approach in Norway." At IPEM 
Data: storage, management, generation and legislation, London, 16th April 2013 
 
9.8 Summary 
Examples from the literature have been given, showing a number of trends. Successful 
use of clinical records data for other purposes use well-coded data or utilise natural 
language processing of free text fields; it is a challenge to use coded data from a typical 
electronic medical record system and a greater challenge to combine data from several 
systems. 
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Data from electronic medical records systems has been utilised both in near-real-time 
(e.g. for detection of disease outbreaks) and retrospectively (e.g. for selection of patients 
suitable for clinical trials).  
Some work by others has been done on general predictions of future health events based 
on lifetime clinical histories, using a variety of techniques, and development in this 
areas has continued in recent years (see section 2.7 for a review of some of the 
particular methods and areas where this work has been done). However, the work 
presented here is suggested as a useful starting point for a relatively explainable and 
understandable system of prediction of raised likelihood of conditions, which has 
performed well when benchmarked against a well–established method, logistic 
regression. 
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APPENDIX 2: CODELISTS 
 
Codelists were used in validation of the composite data set in chapter 5 and in 
determination of the presence of a condition in a record for risk prediction in chapter 6, 
since most conditions had many codes that indicated their presence, with different codes 
indicating a variation of the condition. Some rarer conditions had a codelist containing 
only one code. 
The codes listed here are Read Codes Clinical Terms Version 3. 
 
Codelist for acute sinusitis 
Short name: acuteSinusitis 
Number of codes: 18 
CHILD CTERM 
H01yz Other acute sinusitis NOS 
XaNkV Acute rhinosinusitis 
XE0Xm Acute sinusitis 
H135. Recurrent sinusitis 
XM1QH Sinusitis 
H01.. Sinusitis (& acute) 
XE0Yp (Ac sinusitis: [NOS][ethmoidl][sphenoidl]) or 
([pansinusit]) 
H010. Acute maxillary sinusitis 
H012. Acute ethmoidal sinusitis 
H011. Acute frontal sinusitis 
H013. Acute sphenoidal sinusitis 
X00m3 Suppurative sinusitis with complications 
X00m4 Recurrent acute sinusitis 
X00m5 Barotraumatic sinusitis 
H01y0 Acute pansinusitis 
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H01y. Other acute sinusitis 
H01z. Acute sinusitis NOS 
Hyu00 [X]Other acute sinusitis 
 
Codelist for allergic rhinitis 
Short name: allergicRhinitis 
Number of codes: 18 
XE0Z5 (Allerg rhinitis: [NOS][perenn][season]) or 
(vasomotor rhin) 
X00kx Acute irritant rhinitis 
X00lB Perennial allergic rhinitis with seasonal 
variation 
XE0Y5 Allergic rhinitis 
Xa0lX Seasonal allergic rhinitis 
X00lA Perennial allergic rhinitis 
H17z. Allergic rhinitis NOS 
Hyu21 [X]Other allergic rhinitis 
XE0Y6 Allergic rhinitis due to other allergens 
XE0Y7 Allergic rhinitis due to unspecified allergen 
H17.. Rhinitis: [perennial] or [allergic] 
H172. (Hay fever) or (allergic rhinitis) due to 
unspecif allergen 
XE2QI Allergic rhinitis due to pollens 
Hyu20 [X]Other seasonal allergic rhinitis 
X00l8 Hay fever - other allergen 
X00l9 Hay fever - unspecified allergen 
X1020 Hay fever with asthma 
H170. Pollinosis (& allergic rhinitis due to pollens) 
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Codelist for anxiety 
Short name: anxiety 
Number of codes: 38 
CHILD CTERM 
1466 H/O: anxiety state 
XaECG Anxiety counselling 
XE1aW (Anxiety state (& [states][panic attack])) or 
(pseudocyesis) 
E200. Anxiety disorder 
E2002 Generalised anxiety disorder 
X00Sb Mixed anxiety and depressive disorder 
XE1YA Phobic anxiety disorder 
E2920 Separation anxiety disorder 
X00RP Organic anxiety disorder 
E2000 Anxiety state unspecified 
E2004 Chronic anxiety 
E2005 Recurrent anxiety 
E200z Anxiety state NOS 
X00Sc Anxiety hysteria 
Eu41y [X] Anxiety disord: [other specified] or [anxiety 
hysteria] 
E2924 Adjustment reaction with anxious mood 
Eu930 [X]Separation anxiety disorder of childhood 
E2D0z Disturbance anxiety and fearfulness 
childhood/adolescent NOS 
Eu40. [X]Phobic anxiety disorders 
Eu40y [X]Other phobic anxiety disorders 
Eu40z [X]Phobic anxiety disorder, unspecified 
Eu41. [X]Other anxiety disorders 
Eu46. [X]Other neurotic disorders 
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Eu413 [X]Other mixed anxiety disorders 
Eu41z [X]Anxiety disorder, unspecified 
XE1Zj [X]Other specified anxiety disorders 
Eu46z [X]Neurotic disorder, unspecified 
Ua2Dl Alleviating anxiety 
Eu412 [X]Mixed anxiety and depress disord (& mild anxiet 
depressn) 
Eu410 [X]Panic disorder [episodic paroxysmal anxiety] 
E202. Phobic disorders (& [social] or [phobic anxiety]) 
Xa0XX Anxiety about fainting 
Xa0XY Anxiety about having a heart attack 
13WB. Maternal: [concern] or [anxiety] 
Ua1Fp Acknowledging anxiety 
XaABU Castration anxiety complex 
Ub0qs Anxiety management training 
XaL0q Referral for guided self-help for anxiety 
 
 
Codelist for any form of cancer 
Short name: anyCancer 
Number of codes: 200 
 
CHILD CTERM 
XaPyg Seen in fast track suspected cancer clinic 
X78PC Extrahepatic bile duct carcinoma 
B162. Malignant tumour of ampulla of Vater 
X78Pf Malignant tumour of endocrine pancreas 
B340. Malignant neoplasm of nipple and areola of female 
breast 
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B34y. Malignant neoplasm of other site of female breast 
B350. Malignant neoplasm of nipple and areola of male 
breast 
B35z. Malignant neoplasm of other site of male breast 
B430. Malignant neoplasm of corpus uteri, excluding 
isthmus 
B431. Malignant neoplasm of isthmus of uterine body 
X78Pn Benign tumour of spleen 
XE1w7 Benign tumour of breast 
XE1wL Neoplasm of uncertain behaviour of urinary organs 
OS/NOS 
B932. Neoplasm of uncertain behaviour of skin 
Xa98f Adnexal and skin appendage tumour 
Xa98i Cystic, mucinous and serous tumour 
Xa98t Ductal, lobular and medullary tumour 
XM1FK Paraganglioma and glomus tumour 
XM1FS Giant cell tumour 
X77nC Benign basal cell tumour 
X77nA Malignant basal cell tumour 
XM1FG Carcinoid tumour - argentaffin 
X77oj Malignant stromal tumour 
Xa0Sr Lymphoreticular tumour 
Xa0KB Tumour of external ear 
Xa0KF Tumour of lung 
XaIpL Cancer diagnosis discussed 
Xa0os Tumour of eyelid 
X78Pz Tumour of trachea 
X78Q6 Tumour of bronchus 
Xa0H4 Tumour of pericardium 
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Xa0De Carcinoid tumour of intestine 
X78PA Tumour of extrahepatic bile duct 
X78PF Tumour of ampulla of Vater 
X78PO Tumour of body of pancreas 
X78PR Tumour of tail of pancreas 
X78Pp Tumour of peritoneum 
B49.. Malignant tumour of urinary bladder 
B46.. Malignant tumour of prostate 
Xa1Ib Tumour of testis 
Xa1Id Tumour of tunica vaginalis 
B441. Malignant tumour of fallopian tube 
B43.. Malignant tumour of body of uterus 
XE1wH Carcinoma in situ of cervix 
X77nX Somatostatinoma 
Xa98R Tumour of adrenal cortex 
Xa0ED Tumour of adrenal medulla 
Xa0GU Odontogenic tumour of jaw 
XaIlg Procedure started 
X77n8 Benign squamous cell tumour 
X77n1 Squamous carcinoma in situ 
X77mz Malignant squamous tumour 
Xa98A Papillary carcinoma 
Xa98B Verrucous carcinoma 
Xa98E Squamous cell carcinoma 
Xa98D Squamous cell carcinoma in situ 
X77n9 Papilloma 
Xa98G Basal cell carcinoma 
Xa98L Metastatic adenocarcinoma 
X77nK Adenocarcinoma in adenomatous polyp 
Xa98Y Solid carcinoma 
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Xa98e Clear cell adenocarcinoma 
Xa98P Follicular adenocarcinoma 
X77na Chromophobe tumour 
X77ng Malignant endometrioid tumour 
X77oM In situ melanocytic morphology 
X77oI Malignant melanocytic lesion 
X77pm Nerve sheath tumour 
Xa0a9 Neuroepithelial tumour morphology of uncertain 
origin 
Xa0aA Choroid plexus-derived tumours 
Xa0aF Embryonal neuroepithelial tumour 
Xa0aI Pineal tumour morphology 
Xa0aL Olfactory neuroepithelial-derived tumours 
Xa0aQ Meningeal-derived tumours 
XaImo Lymphoma staging system 
XaIma Gleason grading of prostate cancer 
Xa0DI Tumour of gastrointestinal tract 
X78PD Carcinoma in situ of extrahepatic bile duct 
X78PZ Neoplastic cyst of exocrine pancreas 
X78Pq Malignant tumour of peritoneum 
Xa0WG Primary malignant tumour of peritoneum 
Xa0Bp Melanocytic tumour of skin 
Xa0D7 Malignant tumour of fibrous tissue 
Xa0Pj Tumour of soft tissue 
B34.. Malignant neoplasm of female breast 
B35.. Malignant neoplasm of male breast 
B440. Malignant tumour of ovary 
XE1w9 Benign tumour of ovary 
XE2vS Malignant brain tumour 
X77nb Prolactinoma 
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X78id Malignant tumour of male genital organ 
X78iC Malignant tumour of female genital organ 
XE2vO Malig neop of bone, connective tissue, skin and 
breast 
XE2vP Malignant neoplasm of genitourinary organ 
XE2vR Malignant neoplasm of other and unspecified sites 
Xa0KC Malignant tumour of external ear 
X78gN Malignant tumour of large intestine 
B337. Malignant neoplasm of skin of lower limb and hip 
B33z. Malignant neoplasm of skin NOS 
Xa0CD Malignant tumour of skin with pilar differentiation 
Xa97s Malignant tumour of soft tissue 
B44.. Malignant neoplasm of ovary and other uterine 
adnexa 
B45.. Malig neop of other and unspecified female genital 
organs 
B47.. Malignant tumour of testis 
XE2vQ Malig neop of kidney and other unspecified urinary 
organs 
BB... Tumour morphology 
X7A8T Anatomical site notations for tumour staging 
X7A6B Generic tumour staging descriptors 
X7A8A Generic anatomical site tumour invasion status 
X7A78 Specific tumour staging descriptors 
Xa0LF Tumour stages 
Xa0LI Metastasis stages 
X7A6M Tumour histopathological grade status values 
X7A6W Venous tumour invasion status values 
X7A6b Scleral tumour invasion status 
X7A6l Additional tumour staging descriptors 
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X7A6w Tumour volume 
X7A74 Generic tumour risk status stages 
X7A6C TNM tumour staging classifications 
X7A6S Lymphatic tumour invasion status stages 
X7A6g Residual tumour status stages 
X7A70 Generic tumour extent 
X7A79 Liver tumour staging descriptors 
X7A7G Lymphoma staging descriptors 
X7A7q Langerhans cell histiocytosis stages 
X7A7S Stannards retinoblastoma stages 
X7A7A Liver tumour size index 
X7A7D Timing of liver tumour staging 
X7A7H Lymphoma staging symptom status values 
X7A7K Lymphomatous extranodal involvement status 
values 
X7A7T Optic nerve tumour invasion status in 
retinoblastoma staging 
X7A7Y Choroidal tumour invasion status in retinoblastoma 
staging 
X7A7e Lymph nodal tumour invasion status in 
retinoblastoma staging 
X7A7h Brain tumour invasion status in retinoblastoma 
staging 
X7A7r Num of org systems involved Langerhans cell 
histiocytosis 
X7A7u Organ failure due to Langerhans cell histiocytosis 
X7A80 Axillary lymph node level 
X7A84 Abdominal lymph node tumour invasion status 
X7A8B Lung involvement stages 
X7A8F H+ 
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X7A8G Liver sectors 
X7A8L Markers for liver tumour staging 
X90Tt Tumour stage T1a 
X90Tw Tumour stage T1b 
X90U2 Tumour stage T3b 
Xa0IM Tumour status 
XM1FR Blood vessel tumour 
X78ef Malignant tumour 
Xa0KG Malignant tumour of lung 
B410. Malignant neoplasm of endocervix 
B411. Malignant neoplasm of exocervix 
B41y. Malignant neoplasm of other site of cervix 
B41z. Malignant neoplasm of cervix uteri NOS 
X77nE Adenocarcinoma 
X77nO Endocrine tumour morphology 
X77nf Endometrioid tumour 
XE1wF Carcinoma in situ of digestive organ 
Xa0IC Size of occurrence 
X7A6A Cancer staging 
Xa98g Sweat gland tumour 
Xa0Dg Carcinoid tumour of large intestine 
X90CP Tumour stage T1 
X90CX Tumour stage T2 
X90CZ Tumour stage T3 
Xa0ID Tumour stage T4 
X7A7V Node stage N1 
X7A7W Node stage N2 
X7A7X Node stage N3 
X7A7m Metastasis stage M1 
Xa0aS Meningeal sarcoma 
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Xa7OT Excision of basal cell carcinoma 
Xa7Oh Excision of skin carcinoma 
Xa97r Intrahepatic bile duct carcinoma 
B1503 Hepatocellular carcinoma 
XE2vT Secondary malignant neoplasm of other specified 
sites 
Xa988 Large cell carcinoma 
Xa989 Small cell carcinoma 
X70Ld Intraepidermal squamous cell carcinoma - Bowen's 
type 
X77n0 Metastatic squamous cell carcinoma 
Xa98H Basal cell carcinoma - sclerosing type 
Xa98Q Papillary carcinoma - follicular variant 
Xa98k Cystadenocarcinoma 
Xa98m Serous cystadenocarcinoma 
Xa98o Papillary cystadenocarcinoma 
Xa98r Mucinous cystadenocarcinoma 
Xa98s Papillary mucinous cystadenoma 
X77nz Non-infiltrating intraductal carcinoma 
X77o6 Thecoma 
X77oe Malignant myomatous tumour 
XM1FP Brenner tumour 
X77oz Malignant haemangioma 
XaIlC Cancer dataset administrative items 
XM1FQ Plasma cell tumour 
XaIls Cancer treatment related morbidity 
XaIlp Reason for change in radiotherapy course 
XaIlf Reason for change in planned chemotherapy 
treatment 
XaIlc Presence of primary site synchronous tumours 
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XaIlD Basis of cancer diagnosis 
XaIlO Reason for no specific anti-cancer treatment 
XaL1F Fast track cancer referral 
 
 
 
 
 
Codelist for asthma 
Short name: asthma 
Number of codes: 131 
CHILD CTERM 
14B4. H/O: asthma 
XaIer Asthma follow-up 
XaIfK Asthma medication review 
H33.. Asthma 
X1024 Aspirin-sensitive asthma with nasal polyps 
XaLPE Nocturnal asthma 
X101x Allergic asthma 
XE0YT Non-allergic asthma 
X1023 Drug-induced asthma 
173A. Exercise-induced asthma 
X1025 Occupational asthma 
XaKdk Work aggravated asthma 
H440. Byssinosis 
H441. Cannabinosis 
Xa0lZ Asthmatic bronchitis 
Xa9zf Acute asthma 
XE0YW Asthma attack 
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Xa1hD Exacerbation of asthma 
Ua1AX Brittle asthma 
X101u Late onset asthma 
H332. Mixed asthma 
H33z. Asthma unspecified 
H44.. Pneumopathy due to inhalation of other dust 
X101t Childhood asthma 
H330. Asthma: [extrins - atop][allerg][pollen][childh][+ hay 
fev] 
H3300 (Hay fever + asthma) or (extr asthma without status 
asthmat) 
H331. (Intrinsic asthma) or (late onset asthma) 
H33z0 (Severe asthma attack) or (status asthmaticus NOS) 
H33zz (Asthma:[exerc ind][allerg NEC][NOS]) or (allerg 
bronch NEC) 
XE0ZR Asthma: [intrinsic] or [late onset] 
XE0ZT Asthma: [NOS] or [attack] 
XE0YX Asthma NOS 
XaYZh Number days absent from school due to asthma in 
past 6 month 
X102C Factitious asthma 
XE0YQ Allergic atopic asthma 
X1021 Allergic non-atopic asthma 
H330z Extrinsic asthma NOS 
X101y Extrinsic asthma with asthma attack 
X101z Allergic asthma NEC 
XE0YR Extrinsic asthma without status asthmaticus 
XE0YS Extrinsic asthma with status asthmaticus 
XaJFG Aspirin-induced asthma 
H47y0 Detergent asthma 
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X1026 Baker's asthma 
X1027 Colophony asthma 
X1028 Grain worker's asthma 
X1029 Sulphite-induced asthma 
XE0YV Status asthmaticus NOS 
XaBU3 Asthma monitoring status 
663N. Asthma disturbing sleep 
663O. Asthma not disturbing sleep 
663P. Asthma limiting activities 
663Q. Asthma not limiting activities 
XaDvK Asthma - currently active 
XE0ZP Extrinsic asthma - atopy (& pollen) 
H3310 Intrinsic asthma without status asthmaticus 
H331z Intrinsic asthma NOS 
X1022 Intrinsic asthma with asthma attack 
XE0YU Intrinsic asthma with status asthmaticus 
H3311 Intrins asthma with: [asthma attack] or [status 
asthmaticus] 
XM0s2 Asthma attack NOS 
H3301 Extrins asthma with: [asthma attack] or [status 
asthmaticus] 
H33z1 Asthma attack (& NOS) 
663U. Asthma management plan given 
663V. Asthma severity 
663W. Asthma prophylactic medication used 
8791 Further asthma - drug prevention 
XM1Xb Asthma monitoring 
XM1Xg Chronic respiratory disease monitoring 
XaBAQ Recent asthma management 
XaIQ4 Change in asthma management plan 
Chapter 11: Appendices 
 
 
436 
 
XaIeq Asthma annual review 
XaIu6 Asthma monitoring by doctor 
X1020 Hay fever with asthma 
XaJ2A Did not attend asthma clinic 
8793 Asthma control step 0 
8794 Asthma control step 1 
8795 Asthma control step 2 
8796 Asthma control step 3 
8797 Asthma control step 4 
8798 Asthma control step 5 
X102D Status asthmaticus 
XaQij Under care of asthma specialist nurse 
663F. Oral steroids started 
663G. Oral steroids stopped 
663Y. Steroid dose inhaled daily 
663a. Oral steroids used since last appointment 
663c. Nebulisation since last appointment 
663d. Emergency asthma admission since last appointment 
XaDZF Antiasthmatic agent 
XaINb Asthma causes daytime symptoms 1 to 2 times per 
month 
XaINc Asthma causes daytime symptoms 1 to 2 times per 
week 
XaINd Asthma causes daytime symptoms most days 
XaIIW Asthma accident and emergency attendance since last 
visit 
XaIIX Asthma treatment compliance satisfactory 
XaIIY Asthma treatment compliance unsatisfactory 
XaIIZ Asthma daytime symptoms 
XaINa Asthma never causes daytime symptoms 
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XaINf Asthma limits walking up hills or stairs 
XaINg Asthma limits walking on the flat 
XaINh Number of asthma exacerbations in past year 
XaINi Number of times bronchodilator used in one week 
XaINj Number of times bronchodilator used in 24 hours 
XaIoE Asthma night-time symptoms 
XaIww Asthma trigger 
XaY2V Asthma never causes night symptoms 
Xaa7Q No asthma trigger identified by subject 
XaIQD Step up change in asthma management plan 
XaIQE Step down change in asthma management plan 
XaINZ Asthma causes night symptoms 1 to 2 times per 
month 
XaXZm Asthma causes night time symptoms 1 to 2 times per 
week 
XaXZp Asthma causes symptoms most nights 
XaIuG Asthma confirmed 
XaLIm Asthma trigger - respiratory infection 
XaLIn Asthma trigger - seasonal 
XaLIr Asthma trigger - animals 
XaLJS Asthma trigger - cold air 
XaLJT Asthma trigger - damp 
XaLJU Asthma trigger - emotion 
XaObi Asthma trigger - airborne dust 
XaObj Asthma trigger - exercise 
XaObk Asthma trigger - pollen 
XaObl Asthma trigger - tobacco smoke 
XaObm Asthma trigger - warm air 
XaYja Asthma trigger - wind 
XaYpF Asthma trigger - perfume 
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8H2P. Emergency admission, asthma 
XaYb8 Asthma self-management plan agreed 
XaYZB Asthma self-management plan review 
21262 Asthma resolved 
x02IG Corticosteroids used in the treatment of asthma 
 
 
Codelist for autism 
Short name: autism 
Number of codes: 5 
CHILD CTERM 
X00TM Autistic spectrum disorder 
E14.. 
Psychoses with origin in 
childhood 
XE2v2 Childhood autism 
E1400 Active infantile autism 
E1401 Residual infantile autism 
 
 
Codelist for back pain 
Short name: backPain 
Number of codes: 41 
CHILD CTERM 
8HTH. Referral to back pain clinic 
Xa7mE Psychogenic back pain 
E2780 Psychogenic pain unspecified 
E2782 Psychogenic backache 
XE1bM Psychalgia: [tension backache] or [other] 
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XaZdZ Low back pain clinical pathway 
16C5. C/O - low back pain 
16C7. C/O - upper back ache 
Xa0ws Thoracic back pain 
Xa0wt Low back pain 
X75s1 Sacral back pain 
XaIIv Chronic back pain 
16C.. Backache symptom 
16C2. Backache 
16C3. Backache with radiation 
16C4. Back pain worse on sneezing 
16C6. Back pain without radiation NOS 
16CZ. Backache symptom NOS 
X75rz Acute back pain with sciatica 
XE1FE Backache, unspecified 
XaINe Exacerbation of backache 
N145. 
(Backache unspecified) or (back pain unspecified 
& [acute]) 
XE1He (Backache NOS) or (back pain [& low]) 
Xa0wp Acute thoracic back pain 
Xa0wq Thoracic trigger point syndrome 
Xa0wr Thoracic segmental dysfunction 
Xa0sM Acute low back pain 
Xa0sK Chronic low back pain 
Xa0wu Mechanical low back pain 
X75s3 Posterior compartment low back pain 
Xa0wv Lumbar trigger point syndrome 
Xa0ww Lumbar segmental dysfunction 
N1420 Lumbago with sciatica 
Xa7mB Postural low back pain 
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XE0rW Lumbar ache - renal 
XE1FB Pain in lumbar spine 
N142. 
(Back pain:[lumb sp][low][ac lum]) or (lumbalg) 
or (lumbago) 
Xa0xt Post-surgery back pain 
XM1GI Back pain 
N12.. 
(Intervert disc: [disord][displ][slip]) or (acute back 
pain) 
N143. Acute back pain &/or sciatica 
 
 
 
Codelist for bronchiectasis 
Short name: bronchiectasis 
Number of codes: 15 
CHILD CTERM 
A115. Tuberculous bronchiectasis 
H34.. Bronchiectasis 
P861. Congenital bronchiectasis 
X100m Acquired bronchiectasis 
H340. Recurrent bronchiectasis 
H34z. Bronchiectasis NOS 
XE1NO 
(Congenital resp anomalies NOS) or 
(bronchiectasis - congen) 
X100l Congenital cystic bronchiectasis 
H341. Post-infective bronchiectasis 
X100n Idiopathic bronchiectasis 
X100o Obstructive bronchiectasis 
X100p Toxin-induced bronchiectasis 
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X100t Post-lung transplantation bronchiectasis 
X100q Bronchiectasis due to toxic aspiration 
X100r Bronchiectasis due to toxic inhalation 
 
 
 
Codelist for bronchitis 
Short name: bronchitis 
Number of codes: 90 
CHILD CTERM 
XM1R4 H/O: bronchitis 
14B3. H/O: [COAD] or [bronchitis] 
XE0tj 
H/O: [obstructive airway disease(& chronic)] or 
[bronchitis] 
H0608 Acute haemophilus influenzae bronchitis 
H060B Acute coxsackievirus bronchitis 
X100A Acute chlamydial bronchitis 
XaREU Aspergillus bronchitis 
H301. Laryngotracheobronchitis 
H30.. 
Bronchitis: [unspecif (& chest infectn)] or [recurr 
wheezy] 
XE0ZL 
(Simple chron bronchitis)/(smok cough)/(sen 
tracheobronchit) 
H06z. Acute bronchitis or bronchiolitis NOS 
XaDth Acute infective tracheobronchitis 
Xa0lW Acute laryngotracheobronchitis 
H300. Tracheobronchitis NOS 
H3122 
Acute exacerbation of chronic obstructive airways 
disease 
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H312z Obstructive chronic bronchitis NOS 
H310. Simple chronic bronchitis 
XE0YM Purulent chronic bronchitis 
X101j Occupational chronic bronchitis 
H31y1 Chronic tracheobronchitis 
H3121 Emphysematous bronchitis 
H31y. Other chronic bronchitis 
H31z. Chronic bronchitis NOS 
XE0YL Bronchitis unspecified 
XE0ZN Chronic: [bronchitis NOS] or [tracheobronchitis] 
H310z Simple chronic bronchitis NOS 
Xa0lZ Asthmatic bronchitis 
H460. Bronchitis and pneumonitis due to chemical fumes 
H460z 
Bronchitis and pneumonitis due to chemical fumes 
NOS 
Xaa7C Eosinophilic bronchitis 
XE0Qw Whooping cough 
H0606 Acute pneumococcal bronchitis 
H0609 Acute Neisseria catarrhalis bronchitis 
H0607 Acute streptococcal bronchitis 
H060x Acute bacterial bronchitis unspecified 
H060C Acute parainfluenza virus bronchitis 
H060D Acute respiratory syncytial virus bronchitis 
H060F Acute echovirus bronchitis 
H060E Acute bronchitis due to rhinovirus 
H060w Acute viral bronchitis unspecified 
XaYYt Acute bronchiolitis due to human metapneumovirus 
H0615 
Acute bronchiolitis due to respiratory syncytial 
virus 
X100D Acute bronchiolitis due to adenovirus 
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XaDtg Tracheobronchitis 
XaDtP Bronchitis 
H4600 Acute bronchitis due to chemical fumes 
XE0Zd Acute chemical bronchitis 
XaDtB Acute infective bronchitis 
H0600 Acute fibrinous bronchitis 
H0601 Acute membranous bronchitis 
H0602 Acute pseudomembranous bronchitis 
H0604 Acute croupous bronchitis 
H060v Subacute bronchitis unspecified 
H060z Acute bronchitis NOS 
XM1QX Acute wheezy bronchitis 
H060. Acute bronchitis (& wheezy) 
H06.. Acute bronchitis and bronchiolitis 
XE0Yt 
Acute: [bronchitis]/[chest 
infections]/[tracheobronchitis] 
H30z. Bronchitis NOS 
H311. Mucopurulent chronic bronchitis 
H311z Mucopurulent chronic bronchitis NOS 
H313. Mixed simple and mucopurulent chronic bronchitis 
XM1QT Acute fibrinous laryngotracheobronchitis 
H3120 Chronic asthmatic bronchitis 
X1007 Acute bacterial bronchitis 
X1009 Acute mycoplasmal bronchitis 
H0603 Acute purulent bronchitis 
X100B Acute viral bronchitis 
Hyu10 
[X]Acute bronchitis due to other specified 
organisms 
X1006 Chest infection - unspecified bronchitis 
XE0Xr Acute bronchitis 
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H31.. Chronic bronchitis 
H0605 Acute tracheobronchitis 
X104u Acute toxic tracheobronchitis 
 
 
Codelist for bronchus cancer 
Short name: bronchusCancer 
Number of codes: 17 
CHILD CTERM 
X78Q7 Malignant tumour of bronchus 
X78QB Benign tumour of bronchus 
X78Q8 Squamous cell carcinoma of bronchus 
X77nT Carcinoid bronchial adenoma 
X78kV Metastasis to bronchus 
B221. Malignant neoplasm of main bronchus 
B2210 Malignant neoplasm of carina of bronchus 
B2220 Malignant neoplasm of upper lobe bronchus 
B2230 Malignant neoplasm of middle lobe bronchus 
B2240 Malignant neoplasm of lower lobe bronchus 
XaEJe 
Squamous cell carcinoma of bronchus in left 
lower lobe 
XaEJf 
Squamous cell carcinoma of bronchus in left 
upper lobe 
XaEJg 
Squamous cell carcinoma of bronchus in right 
lower lobe 
XaEJh 
Squamous cell carcinoma of bronchus in right 
middle lobe 
XaEJi 
Squamous cell carcinoma of bronchus in right 
upper lobe 
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Xa98a Bronchial adenoma 
X78QD Papilloma of bronchus 
 
 
Codelist for chronic pulmonary obstructive disease 
Short name: COPD 
Number of codes: 24 
CHILD CTERM 
XaZd1 Acute non-infective exacerbation of COPD 
Xa35l 
Acute infective exacerbation chronic obstruct 
airway disease 
H3y0. 
Chronic obstruct pulmonary dis with acute lower 
resp infectn 
X101i 
Chron obstruct pulmonary dis wth acute 
exacerbation, unspec 
XaX3c Discussion about COPD exacerbation plan 
XaPZH 
COPD patient unsuitable for pulmonary 
rehabilitation 
XaIUt COPD self-management plan given 
XaIet 
Chronic obstructive pulmonary disease annual 
review 
XaIu7 
Chronic obstructive pulmonary disease monitoring 
by nurse 
XaIu8 
Chronic obstructive pulmonary disease monitoring 
by doctor 
XaRCG Step down change in COPD management plan 
XaRCH Step up change in COPD management plan 
XaXCa 
Chronic obstructive pulmonary disease 3 monthly 
review 
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XaXCb 
Chronic obstructive pulmonary disease 6 monthly 
review 
XaXnt GP OOH service notified of COPD care plan 
XaJFu Admit COPD emergency 
XaYbA COPD self-management plan agreed 
XaYZO COPD self-management plan review 
XaK8R 
COPD accident and emergency attendance since last 
visit 
XaK8S Emergency COPD admission since last appointment 
XaKzy Multiple COPD emergency hospital admissions 
XaXzy 
Preferred place of care for next exacerbation of 
COPD 
XaY0w Referral to COPD community nursing team 
 
Codelist for cystic fibrosis 
Short name: cysticFibrosis 
Number of codes: 14 
CHILD CTERM 
XaZr7 Exacerbation of cystic fibrosis 
XaREZ 
Cystic fibrosis with distal intestinal obstruction 
syndrome 
C3700 Cystic fibrosis with no meconium ileus 
C3702 Cystic fibrosis with pulmonary manifestations 
C3703 Cystic fibrosis with intestinal manifestations 
C370z Cystic fibrosis NOS 
XaBDb Cystic fibrosis with other manifestations 
XaREa Liver disease due to cystic fibrosis 
XaXi9 Cystic fibrosis related cirrhosis 
XaMzI Cystic fibrosis related diabetes mellitus 
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XaQvc Cystic fibrosis monitoring 
XaVvv Seen in cystic fibrosis clinic 
XaQvd Cystic fibrosis annual review 
 
 
 
Codelist for eczema 
Short name: eczema 
Number of codes: 27 
CHILD CTERM 
14F1. H/O: eczema 
XaQfn Referral to eczema clinic 
G831. Varicose veins of the leg with eczema 
G832. Varicose veins of the leg with ulcer and eczema 
XaEJY 
Varicose veins of leg in long saph vein distribn 
with eczema 
XaEJZ 
Varicose veins of leg in short saph vein distrib 
with eczema 
X505K Eczema 
XaY4o Infected eczema 
X505N Atopic dermatitis of hands 
M113. Flexural atopic dermatitis 
X505O Inverse pattern atopic dermatitis 
X505P Discoid atopic dermatitis 
X505Q Erythrodermic atopic dermatitis 
X505R Follicular atopic dermatitis 
X505S Pruriginous atopic dermatitis 
XaBsL Chronic lichenified atopic dermatitis 
X505T Photosensitive atopic dermatitis 
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X505U Photoaggravated atopic dermatitis 
M112. Infantile eczema 
M115. Besnier's prurigo 
M117. Atopic neurodermatitis 
M11z. Atopic dermatitis NOS 
XE1C6 Atopic eczema/dermatitis NOS 
M11.. Atopic dermatitis and related conditions 
M111. Atopic dermatitis 
 
Codelist for emphysema 
Short name: emphysema 
Number of codes: 35 
CHILD CTERM 
H32.. Emphysema 
H3203 (Bullous emphysema with collapse) or (tension 
pneumatocoele) 
H32y1 Emphysema: [acute interstitial] or [atrophic - senile] 
X101n Pulmonary emphysema 
H32y2 MacLeods syndrome 
H321. Panlobular emphysema 
H322. Centrilobular emphysema 
H32y. Other emphysema 
H32z. Emphysema NOS 
H3202 Giant bullous emphysema 
H3200 Segmental bullous emphysema 
H3201 Zonal bullous emphysema 
H320z Chronic bullous emphysema NOS 
XE0YN Bullous emphysema with collapse 
H32y0 Acute vesicular emphysema 
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Hyu30 [X]Other emphysema 
XE0YO Atrophic (senile) emphysema 
XE0YP Other emphysema NOS 
H32yz (Sawyer-Jones syndrome) or (other emphysema NOS) 
Q312y Perinatal interstitial emphysema or related condition 
OS 
Q312z Perinatal interstitial emphysema or related condition 
NOS 
Qyu34 [X]Oth conds relat/interstial emphysema orig 
perinatl period 
X101o Pulmonary emphysema in alpha-1 PI deficiency 
X101p Toxic emphysema 
H320. Chronic bullous emphysema 
H582. Compensatory emphysema 
X101q Congenital lobar emphysema 
X101r Scar emphysema 
XaIQg Interstitial pulmonary emphysema 
H4640 Chronic emphysema due to chemical fumes 
XaIQh Mediastinal emphysema 
H581. (Emphysema 
[interstitial]/[mediastinal])/(pneumomediastinum) 
XE1oC Subcutaneous emphysema 
Q3123 Perinatal pulmonary interstitial emphysema 
Q312. Perinatal interstitial emphysema and related 
conditions 
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Codelist for gastro-intestinal reflux disease or reflux esophagitis 
Short name: refluxDisease 
Number of codes: 14 
CHILD CTERM 
X3003 Gastro-oesophageal reflux disease 
XE0bv Oesophagitis (& [reflux]) or oesophageal reflux 
XE0aL Gastro-oesophageal reflux disease with 
oesophagitis 
XE0aO Gastro-oesophageal reflux disease without 
oesophagitis 
X3005 Peptic stricture of oesophagus 
J1020 Gastro-oesophageal reflux disease with 
ulceration 
Xa9Bz Barrett's oesophagus 
J1011 Acid reflux &/or oesophagitis 
J1016 (Ulcerative oesophagitis) or (Barrett's 
oesophagus) 
J10y4 Oesophageal reflux (& [without mention of 
oesophagitis]) 
X70jT Radionuclide gastro-oesophageal reflux study 
X70fi Gastro-oesophageal reflux X-ray study 
 
 
Codelist for gastroparesis 
Short name: gastroparesis 
Number of codes: 1 
CHILD CTERM 
X301s Gastroparesis 
 
Chapter 11: Appendices 
 
 
451 
 
Codelist for hiatus hernia 
Short name: hiatusHernia 
Number of codes: 16 
CHILD CTERM 
X30BB Sliding hiatus hernia 
X30BC Rolling hiatus hernia 
X30BE Mixed hiatus hernia 
PA6.. Congenital hiatus hernia 
XaC18 Hiatus hernia - irreducible 
XaC19 Hiatus hernia with gangrene 
XaC1A Hiatus hernia with obstruction 
XaC1B Simple hiatus hernia 
XaC2M Hiatus hernia NOS 
X30BD Rolling hiatus hernia with gastric volvulus 
Xa9Ze Hiatus hernia repair 
760K4 Boerema repair of hiatus hernia 
760K0 Transthoracic hiatus hernia repair (& [Allison] 
or [Mason]) 
X30BA Hiatus hernia 
XaJlJ Laparoscopic repair of hiatus hernia 
 
Codelist for hyperlipidaemia 
Short name: hyperlipidaemia 
Number of codes: 13 
CHILD CTERM 
Cyu8D [X]Other hyperlipidaemia 
U60C6 [X]Antihyperlipidaem/antiarterioscl drg caus adv 
ef ther use 
XE13A Disord lipid metab (& [Fredrick types] or 
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[hyperlipidaemia]) 
X40Wy Hyperlipidaemia 
X40Vm Familial combined hyperlipidaemia 
XE11U Mixed hyperlipidaemia 
C324. Hyperlipidaemia NOS 
X40XI Primary combined hyperlipidaemia 
X40XO Secondary combined hyperlipidaemia 
Xa2hC Dietary advice for hyperlipidaemia 
C3202 Hyperlipidaemia, group A 
C322. (Mix hyperlipid) or (Fredr lip: [IIb][III]) or 
(xanthom tub) 
XaJYh Hyperlipidaemia clinical management plan 
 
 
Codelist for hypertension 
Short name: hypertension 
Number of codes: 134 
CHILD CTERM 
X30BB Sliding hiatus hernia 
X30BC Rolling hiatus hernia 
X30BE Mixed hiatus hernia 
PA6.. Congenital hiatus hernia 
XaC18 Hiatus hernia - irreducible 
XaC19 Hiatus hernia with gangrene 
XaC1A Hiatus hernia with obstruction 
XaC1B Simple hiatus hernia 
XaC2M Hiatus hernia NOS 
X30BD Rolling hiatus hernia with gastric volvulus 
Xa9Ze Hiatus hernia repair 
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760K4 Boerema repair of hiatus hernia 
760K0 Transthoracic hiatus hernia repair (& [Allison] 
or [Mason]) 
X30BA Hiatus hernia 
XaJlJ Laparoscopic repair of hiatus hernia 
 
Codelist for hypothyroidism 
Short name: hypothyroidism 
Number of codes: 55 
CHILD CTERM 
XaLUg Hypothyroidism review 
Xa0l7 Congenital hypothyroidism with diffuse goitre 
X40H8 Congenital hypothyroidism without goitre 
C03y. Other specified congenital hypothyroidism 
XE107 Congenital hypothyroidism NOS 
C03z. Congenital hypothyroidism: [cretinism] or [NOS] 
X40HN Radioactive iodine-induced hypothyroidism 
X40Hx Hypothyroidism due to coupling defect 
X40Hy Hypothyroidism due to deiodase defect 
F3814 Myasthenic syndrome due to hypothyroidism 
X40HF Hypothyroidism due to Hashimoto's thyroiditis 
X40HG Hypothyroidism due to TSH receptor blocking 
antibody 
X40HM Postablative hypothyroidism 
C043. Other iatrogenic hypothyroidism 
C043z Iatrogenic hypothyroidism NOS 
C040. Hypothyroidism: [postsurgical] or [post ablative] 
XE109 Post-surgical hypothyroidism 
C0410 Irradiation hypothyroidism 
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C041. Other postablative hypothyroidism 
C041z Postablative hypothyroidism NOS 
C0430 Hypothyroidism resulting from para-aminosalicylic 
acid 
C0431 Hypothyroidism resulting from phenylbutazone 
C0432 Hypothyroidism resulting from resorcinol 
X40Hq Euthyroid hypothyroxinaemia 
X40IB Subclinical iodine deficiency hypothyroidism 
C042. Iodine hypothyroidism 
X40I7 Congenital iodine deficiency hypothyroidism 
XaJ9F Subclinical hypothyroidism 
C03.. Congenital hypothyroidism 
XE108 Acquired hypothyroidism 
Cyu11 [X]Other specified hypothyroidism 
Xa3ec Hypothyroidism - congenital and acquired 
C04.. Hypothyroidism: &/or (acquired) 
C04z. Hypothyroid (& [pretib myxoed][acq goitr][NOS][thyr 
insuf]) 
XE124 Hypothyroidism - congen and acquir (& 
[cretinism][myxoedem]) 
X40HE Autoimmune hypothyroidism 
Q4337 Neonatal jaundice with congenital hypothyroidism 
X769C Hypothyroid facies 
X40IQ Hypothyroidism 
X40HH Borderline hypothyroidism 
X40HI Compensated hypothyroidism 
X40HL Iatrogenic hypothyroidism 
X40HO Drug-induced hypothyroidism 
X40HP Post-infectious hypothyroidism 
C04y. Other acquired hypothyroidism 
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X40HD Hypothyroid goitre, acquired 
XE10A Hypothyroidism NOS 
Xa3ed Acquired hypothyroidism NOS 
C04z0 Premature puberty due to hypothyroidism 
1432 H/O: hypothyroidism 
Xa08g Transient neonatal hypothyroidism 
XaJYj Hypothyroidism clinical management plan 
XaOjl Hypothyroidism annual review 
 
Codelist for lung cancer 
Short name: lungCancer 
Number of codes: 68 
CHILD CTERM 
XE1yR Ca trachea/bronchus/lung NOS 
B2231 Malignant neoplasm of middle lobe of lung 
B223z Malignant neoplasm of middle lobe, bronchus or lung 
NOS 
XE1yN Ca middle lobe bronchus/lung 
B2241 Malignant neoplasm of lower lobe of lung 
B224z Malignant neoplasm of lower lobe, bronchus or lung 
NOS 
XE1yP Ca lower lobe bronchus/lung 
Xa3A5 Metastasis to lung of unknown primary 
X2032 Pulmonary tumour embolism 
X78kX Secondary lymphangitic carcinoma 
X78QU Carcinoma in situ of lung parenchyma 
B812. Carcinoma in situ of bronchus and lung 
B81z. Carcinoma in situ of respiratory organ NOS 
B8122 Carcinoma in situ of upper lobe bronchus and lung 
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B8123 Carcinoma in situ of middle lobe bronchus and lung 
B8124 Carcinoma in situ of lower lobe bronchus and lung 
B812z Carcinoma in situ of bronchus or lung NOS 
B907. Neoplasm of uncertain behaviour trachea, bronchus 
and lung 
B90z. Neoplasm of uncertain behaviour of respiratory 
organs OS/NOS 
B9072 Neoplasm of uncertain behaviour of lung 
B907z Neop of uncertain behaviour of trachea, bronchus or 
lung NOS 
X78QS Non-small cell lung cancer 
X78QF Malignant tumour of lung parenchyma 
X78QV Benign tumour of lung parenchyma 
X78QG Adenocarcinoma of lung 
X78QI Carcinoid tumour of lung 
X78QJ Carcinoma of lung parenchyma 
X78QQ Epithelioid haemangioendothelioma of lung 
X78QR Lymphomatoid granulomatosis of lung 
XaBAp Bronchioloalveolar adenocarcinoma of lung 
X78QK Large cell carcinoma of lung 
X78QN Small cell carcinoma of lung 
X78QP Squamous cell carcinoma of lung 
X78QL Clear cell carcinoma of lung 
X78QM Giant cell carcinoma of lung 
X78QO Oat cell carcinoma of lung 
X78QW Histiocytoma of lung 
X78QX Adenoma of lung 
Byu50 (Mesothelioma of lung) or ([X]mesothelioma of other 
sites) 
B570. Metastasis to lung 
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Xa3A4 Metastasis to bronchus of unknown primary 
Xa0KG Malignant tumour of lung 
B22.. Malignant neoplasm of trachea, bronchus and lung 
B225. Malignant neoplasm of overlapping lesion of 
bronchus & lung 
XE1yF (Bronchus carc) or (lung carc) or (Ca 
trachea/bronchus/lung) 
B222z Malignant neoplasm of upper lobe, bronchus or lung 
NOS 
XE1yL Ca upper lobe bronchus/lung 
B7230 Benign neoplasm of carina of bronchus 
B7231 Benign neoplasm of main bronchus 
B7232 Benign neoplasm of upper lobe bronchus and lung 
B7233 Benign neoplasm of middle lobe bronchus and lung 
B7234 Benign neoplasm of lower lobe bronchus and lung 
B723z Benign neoplasm of bronchus or lung NOS 
B723. Benign neoplasm of lung (& [bronchus]) 
X78QE Tumour of lung parenchyma 
XaFr7 Local recurrence of malignant tumour of lung 
X78QT Pancoast tumour 
B2211 Malignant neoplasm of hilus of lung 
B2221 Malignant neoplasm of upper lobe of lung 
B223. Malignant neoplasm of middle lobe, bronchus or lung 
B224. Malignant neoplasm of lower lobe, bronchus or lung 
B22y. Malignant neoplasm of other sites of bronchus or 
lung 
Byu20 [X]Malignant neoplasm of bronchus or lung, 
unspecified 
XE1vb Malignant neoplasm of upper lobe, bronchus or lung 
XE1vc Malignant neoplasm of bronchus or lung NOS 
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B222. Malig neopl of upper lobe/bronchus/lung: (& 
[Pancoast synd]) 
B22z. Malig neopl lung: [of bronchus or lung NOS] or [lung 
cancer] 
 
Codelist for obesity 
Short name: obesity 
Number of codes: 77 
CHILD CTERM 
222A. O/E - obese 
XE1h3 O/E - weight 10-20% over ideal 
XE1h4 O/E - weight greater than 20% over ideal 
XM1YD O/E - overweight 
22A4. O/E - overweight (& [weight 10-20% over ideal]) 
22A5. O/E weight: [>20% over ideal] or [obese] 
XaZ0S Anti-obesity drug therapy 
Xaa0k Childhood obesity 
X40YM Android obesity 
X40YN Gynaecoid obesity 
X40YO Generalised obesity 
XE2Q3 Localised obesity 
X40YQ Morbid obesity 
X76BU Central obesity 
X40YT Simple obesity 
X76BV Peripheral obesity 
XSCIZ Adult-onset obesity 
XSCIX Lifelong obesity 
C3800 Obesity due to excess calories 
C3801 Drug-induced obesity 
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Cyu70 [X]Other obesity 
Xa0Cx Pulmonary hypertension with extreme obesity 
L161. (Gest oedem/nonhypertens excess wt gain) or (mat 
obesit syn) 
X40Lm Hypothalamic obesity 
X40YR Pickwickian syndrome 
C3802 Extreme obesity with alveolar hypoventilation 
XaBM0 Simple obesity NOS 
66C4. Has seen dietitian - obesity 
66C8. Attends slimming clinic 
66CC. Wants to lose weight 
66CD. Difficulty maintaining weight loss 
66CE. Reason for obesity therapy - occupational 
9OK1. Attends obesity monitoring 
9OK2. Refuses obesity monitoring 
9OK3. Obesity monitoring default 
9OK9. Obesity monitoring deleted 
9OKA. Obesity monitoring check done 
XaKiY Weight management programme offered 
XaKiZ Weight management plan started 
XaKia Weight management plan completed 
1444 H/O: obesity 
C38z. Obesity and other hyperalimentation NOS 
66C5. Treatment of obesity changed 
66C6. Treatment of obesity started 
66C7. Treatment of obesity stopped 
66CA. Ideal weight discussed 
66CZ. Obesity monitoring NOS 
XE1T7 Target weight discussed 
XaX5k Inter risk health ass overwt ob gen adv hlthy wgt 
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lifestyle 
XaX5l Int risk health ass overwt ob advice about diet 
physical act 
XaX5m Inter risk hlth overwght obesity adv diet phys act 
cons drug 
XaX5n Inter risk hlth owt ob adv diet phy ac cons dgs cons 
surgery 
9OKZ. Obesity monitoring admin.NOS 
XM1U4 Obesity clinic administration 
XaX5e Risk health associa overweight obesity, at no 
increased risk 
XaX5f Risk health associ overweight and obesity, at 
increased risk 
XaX5g Risk health associated overweight and obesity, at 
high risk 
XaX5h Risk health associ overweight and obesity, at very 
high risk 
22K2. Body mass index high K/M2 
22K4. Body mass index index 25-29 - overweight 
22K5. Body mass index 30+ - obesity 
XaJJH Body mass index 40+ - severely obese 
C380. Obesity 
C38.. Obesity and other hyperalimentation 
Cyu7. [X]Obesity and other hyperalimentation 
Xa2hD Dietary advice for obesity 
XE1T6 Obesity monitoring 
66C.. Weight monitoring (& obesity) 
66C9. Weight: [target discussed] or [loss advised] 
XE13Y (Hyperalimentation including obesity) or (adiposity) 
XE2Nc Obesity monitoring admin. 
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9OK4. Obesity monitoring first letter 
9OK5. Obesity monitoring second letter 
9OK6. Obesity monitoring third letter 
9OK7. Obesity monitoring verbal invite 
9OK8. Obesity monitoring telephone invite 
XaKko Obesity resolved 
 
 
Codelist for osteoarthritis 
Short name: osteoarthritis 
Number of codes: 151 
CHILD CTERM 
N0507 Heberden's nodes with arthropathy 
N0503 Bouchard's nodes with arthropathy 
N0500 Generalised osteoarthritis of unspecified site 
N0502 Generalised osteoarthritis of multiple sites 
N050z Generalised osteoarthritis NOS 
XE1DW Generalised osteoarthritis of the hand 
N0501 (Heberden nodes) or (Bouchard nodes) or (gen 
osteoarth hand) 
N0510 Localised, primary osteoarthritis of unspecified site 
N0511 Localised, primary osteoarthritis of the shoulder 
region 
N0512 Localised, primary osteoarthritis of the upper arm 
N0513 Localised, primary osteoarthritis of the forearm 
N0514 Localised, primary osteoarthritis of the hand 
N0515 Localised, primary osteoarthritis of the pelvic 
region/thigh 
N0516 Localised, primary osteoarthritis of the lower leg 
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N0517 Localised, primary osteoarthritis of the ankle and 
foot 
N0518 Localised, primary osteoarthritis of other specified 
site 
N051z Localised, primary osteoarthritis NOS 
N051A Coxarthrosis resulting from dysplasia, bilateral 
N0529 Post-traumatic coxarthrosis, bilateral 
N0520 Localised, secondary osteoarthritis of unspecified 
site 
N0521 Localised, secondary osteoarthritis of the shoulder 
region 
N0522 Localised, secondary osteoarthritis of the upper arm 
N0523 Localised, secondary osteoarthritis of the forearm 
N0524 Localised, secondary osteoarthritis of the hand 
N0526 Localised, secondary osteoarthritis of the lower leg 
N0527 Localised, secondary osteoarthritis of the ankle and 
foot 
N0528 Localised, secondary osteoarthritis of other specified 
site 
N052z Localised, secondary osteoarthritis NOS 
XE1DX Localised, secondary osteoarthritis of pelvic 
region/thigh 
N0525 (Loc 2ndry osteoarth pelv regn/thigh) or (coxae 
malum senil) 
N0530 Localised osteoarthritis, unspecified, of unspecified 
site 
N0531 Localised osteoarthritis, unspecified, of shoulder 
region 
N0532 Localised osteoarthritis, unspecified, of the upper 
arm 
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N0533 Localised osteoarthritis, unspecified, of the forearm 
N0534 Localised osteoarthritis, unspecified, of the hand 
N0537 Localised osteoarthritis, unspecified, of the ankle and 
foot 
N0538 Localised osteoarthritis, unspecified, of other spec 
site 
N0539 Arthrosis of first carpometacarpal joint, unspecified 
N053z Localised osteoarthritis, unspecified, NOS 
XE1DY Localised osteoarthritis, unspecified, pelvic 
region/thigh 
XE1DZ Localised osteoarthritis, unspecified, of the lower leg 
N0540 Oligoarticular osteoarthritis, unspec, of unspecified 
sites 
N0541 Oligoarticular osteoarthritis, unspecified, of shoulder 
N0542 Oligoarticular osteoarthritis, unspecified, of upper 
arm 
N0543 Oligoarticular osteoarthritis, unspecified, of forearm 
N0544 Oligoarticular osteoarthritis, unspecified, of hand 
N0545 Oligoarticular osteoarthritis, unspecified, of 
pelvis/thigh 
N0546 Oligoarticular osteoarthritis, unspecified, of lower leg 
N0547 Oligoarticular osteoarthritis, unspecified, of 
ankle/foot 
N0548 Oligoarticular osteoarthritis, unspecified, other spec 
sites 
N0549 Oligoarticular osteoarthritis, unspecified, multiple 
sites 
N054z Osteoarthritis of more than one site, unspecified, NOS 
NyuC7 [X]Other hypertrophic osteoarthropathy 
X702z Toe osteoarthritis NOS 
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N051. Localised, primary osteoarthritis 
N05z9 Osteoarthritis NOS, of shoulder 
N05zB Osteoarthritis NOS, of acromioclavicular joint 
N05zC Osteoarthritis NOS, of elbow 
XaEGf Localised, primary osteoarthritis of elbow 
N05zE Osteoarthritis NOS, of wrist 
XaEGd Localised, primary osteoarthritis of the wrist 
X703H Osteoarthritis of distal interphalangeal joint 
X703I Osteoarthritis of proximal interphalangeal joint 
X703J Osteoarthritis of metacarpophalangeal joint of finger 
X7035 Finger osteoarthritis NOS 
N05zH Osteoarthritis NOS, of DIP joint of finger 
N05zG Osteoarthritis NOS, of PIP joint of finger 
N05zJ Osteoarthritis NOS, of hip 
XaYQD Patellofemoral osteoarthritis 
N05zL Osteoarthritis NOS, of knee 
N05zN Osteoarthritis NOS, of ankle 
N05zP Osteoarthritis NOS, of subtalar joint 
N352. Hallux rigidus - acquired 
N05zS Osteoarthritis NOS, of 1st metatarsophalangeal joint 
N05zU Osteoarthritis NOS, of interphalangeal joint of toe 
XaEGe Localised, primary osteoarthritis of toe 
N061. Arthritis secondary to trauma 
Xa1jD Arthritis due to bleeding disorder 
XE2sp Neuropathic arthropathy 
N0505 Secondary multiple arthrosis 
N052. Localised, secondary osteoarthritis 
X7039 Spondylosis 
X703A Osteoarthritis of spinal facet joint 
X703B Osteoarthritis of shoulder joint 
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X703C Osteoarthritis of acromioclavicular joint 
X703D Osteoarthritis of elbow 
X703E Osteoarthritis of wrist 
X703F Osteoarthritis of first carpometacarpal joint 
X703G Osteoarthritis of finger joint 
X703K Osteoarthritis of hip 
X703L Osteoarthritis of knee 
X703M Osteoarthritis of ankle 
X703N Osteoarthritis of subtalar joint 
X703O Osteoarthritis of first metatarsalphalangeal joint 
X703P Osteoarthritis of toe joint 
XaBmY Osteoarthritis of foot joint 
N053. Localised osteoarthritis, unspecified 
XM1NQ Osteoarthritis of metacarpophalangeal joint 
Xa3gQ Osteoarthritis - hand joint 
Xa3gR Osteoarthritis - ankle/foot 
Xa3gS Osteoarthritis - other joint 
N0535 (Otto pel)(hip osteoart NOS)(loc osteoart uns pel 
reg/thigh) 
N0536 Osteoarthritis: [localised low leg unsp] or 
[patellofemoral] 
XE2Qb Kaschin-Beck disease 
X704S Malemud disease 
N060. (Kaschin-Beck disease) or (endemic polyarthritis) 
N312. Hypertrophic osteoarthropathy 
14G2. H/O: osteoarthritis 
XaIna Exacerbation of osteoarthritis 
X7041 Localised osteoarthritis 
N050. Generalised osteoarthritis 
X703Q Secondary osteoarthritis 
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X704R Endemic osteoarthritis 
X7038 Idiopathic osteoarthritis 
N0506 Erosive osteoarthrosis 
N054. Oligoarticular osteoarthritis, unspecified 
XE1Da Osteoarthritis NOS 
XE1Gm Osteoarthritis -multiple joint 
N05.. Osteoarthritis (& [allied disorders]) 
N05z. [Joint degeneration] or [osteoarthritis NOS] 
X7043 Coxae malum senilis 
X7042 Otto's pelvis 
N05z0 Osteoarthritis NOS, of unspecified site 
N05z1 Osteoarthritis NOS, of shoulder region 
N05z8 Osteoarthritis NOS, other specified site 
N05zA Osteoarthritis NOS, of sternoclavicular joint 
N05zD Osteoarthritis NOS, of distal radioulnar joint 
N05zF Osteoarthritis NOS, of metacarpophalangeal joint 
N05zK Osteoarthritis NOS, of sacroiliac joint 
N05zM Osteoarthritis NOS, of tibiofibular joint 
N05zQ Osteoarthritis NOS, of talonavicular joint 
N05zR Osteoarthritis NOS, of other tarsal joint 
N05zT Osteoarthritis NOS, of lesser metatarsophalangeal 
joint 
X7030 Foot osteoarthritis NOS 
X7031 Ankle osteoarthritis NOS 
XE1Db Osteoarthritis NOS, of the upper arm 
XE1Dc Osteoarthritis NOS, of the forearm 
XE1Dd Osteoarthritis NOS, of the hand 
XE1De Osteoarthritis NOS, pelvic region/thigh 
XE1Df Osteoarthritis NOS, of the lower leg 
XE1Dg Osteoarthritis NOS, of ankle and foot 
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N05z2 Osteoarthritis NOS: [of the upper arm] or [elbow] 
N05z3 Osteoarthritis NOS: [of the forearm] or [wrist] 
N05z4 Osteoarthritis NOS: [hand] or [finger] or [thumb] 
N05z5 Osteoarthritis NOS: [pelvic region and/or thigh] or 
[hip] 
N05z6 Osteoarthritis NOS: [lower leg] or [knee] 
N05z7 Osteoarthritis NOS: [ankle &/or foot] or [toe] 
X7034 Thumb osteoarthritis NOS 
XaLsk Delivery of rehabilitation for osteoarthritis 
XE1DV Osteoarthritis 
N11.. (Spondyl & allied dis) or (arthr spine) or (osteoarth 
spine) 
 
Codelist for pleural effusion 
Short name: pleuralEffusion 
Number of codes: 12 
CHILD CTERM 
H51y0 Encysted pleurisy 
H51yz Other pleural effusion 
Xa0lb Pleural effusion 
XE0Zl (Pleural effusion NOS) or (haemothorax) or 
(hydrothorax) 
XE2wM Pleural empyema 
Xa0IL Malignant pleural effusion 
X1012 Benign asbestos pleural effusion 
X1013 Drug-induced pleural effusion 
XaB1L Haemorrhagic pleural effusion 
H51y. Other pleural effusion excluding mention of 
tuberculosis 
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H51z. Pleural effusion NOS 
Hyu70 [X]Pleural effusion in conditions classified 
elsewhere 
 
Codelist for pneumonia 
Short name: pneumonia 
Number of codes: 143 
CHILD CTERM 
14B2. H/O: pneumonia 
H24y6 Typhoid pneumonia 
A116. Tuberculous pneumonia 
X100L Meningococcal pneumonia 
XE0YH Pneumococcal lobar pneumonia 
AyuK3 [X]Streptococ pneumon/cause/disease classified/oth 
chapters 
A3By4 Mycoplasmal pneumonia 
X100G Atypical pneumonia 
AyuK9 [X]Mycoplasma pneumoniae [PPLO]cause/dis 
classifd/oth chaptr 
H242. Ornithosis with pneumonia 
H2470 Candidal pneumonia 
H2471 Pneumonia with coccidioidomycosis 
H2472 Pneumonia with histoplasmosis 
AB4z5 Histoplasmosis with pneumonia 
H24y5 Toxoplasma pneumonia 
X100E Pneumonia 
H2701 Influenza with pneumonia, influenza virus identified 
H2y.. Other specified pneumonia or influenza 
H2z.. Pneumonia or influenza NOS 
Chapter 11: Appendices 
 
 
469 
 
H22y. Pneumonia due to other specified bacteria 
H22z. Bacterial pneumonia NOS 
H2230 Group B streptococcal pneumonia 
H22yz Pneumonia due to bacteria NOS 
XaDtl Legionnaire's disease 
H23z. Pneumonia due to specified organism NOS 
X100h Giant cell pneumonia 
H247z Pneumonia with systemic mycosis NOS 
H24yz Pneumonia with other infectious diseases EC NOS 
H260. Lobar pneumonia due to unspecified organism 
XE0YJ Bronchopneumonia due to unspecified organism 
XaBE9 Basal pneumonia due to unspecified organism 
H270. Influenzal pneumonia 
H2700 Influenza with bronchopneumonia 
H270z Influenza with pneumonia NOS 
SP131 Other aspiration pneumonia as a complication of care 
H56y0 Endogenous lipoid pneumonia 
H5303 Abscess of lung with pneumonia 
H5830 Acute eosinophilic pneumonia 
X100P Fetal pneumonia 
X100a Neonatal pneumonia 
Xa0B7 Congenital viral pneumonia 
Xa0B8 Congenital bacterial pneumonia 
Q310y Other specified congenital pneumonia 
Q310z Congenital pneumonia NOS 
Qyu32 [X]Congenital pneumonia due to other organisms 
H2... Pneumonia and influenza 
H24.. (Pneumonia) or (chest infection) with infectious 
diseases EC 
XaZ1l Hospital acquired pneumonia 
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XaZ1k Community acquired pneumonia 
XaDsa Infective pneumonia 
X100M Bronchopneumonia 
X100X Haemorrhagic pneumonia 
H5400 Hypostatic pneumonia 
Xa0lY Lobar pneumonia 
H56y1 Interstitial pneumonia 
XaFrU Postoperative pneumonia 
H5302 Gangrenous pneumonia 
Hyu0G [X]Pneumonia in other diseases classified elsewhere 
XM0rv Pneumonia NOS 
XaJEl Bilateral pneumonia 
XE0ZF Pneumonia and influenza &/or pneumonia 
XE0ZH Pneumonia: [lobar] or [pneumococcal] 
H24y0 Actinomycotic pneumonia 
H222. Haemophilus influenzae pneumonia 
H22y2 Legionella pneumonia 
X100J Pneumococcal pneumonia 
A0222 Salmonella pneumonia 
H224. Staphylococcal pneumonia 
H220. Pneumonia due to Klebsiella pneumoniae 
H221. Pseudomonal pneumonia 
H22y0 Escherichia coli pneumonia 
H22y1 Proteus pneumonia 
H244. Tularaemia pneumonia 
H243. Pertussis pneumonia 
H245. Anthrax pneumonia 
H24y1 Nocardial pneumonia 
H223. Streptococcal pneumonia 
X100Y Mycobacterial pneumonia 
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H22.. Other bacterial pneumonia 
H232. Pneumonia due to pleuropneumonia-like organism 
Hyu09 [X]Pneumonia due to other aerobic gram-negative 
bacteria 
Hyu0A [X]Other bacterial pneumonia 
Hyu0C [X]Pneumonia in bacterial diseases classified 
elsewhere 
XaBfJ Secondary bacterial pneumonia 
H21.. Pneumococcal pneumonia (& lobar) 
H25.. Bronchopneumonia: [unspec organism] or [chest 
infect - unsp] 
X100O Neonatal chlamydial pneumonia 
X100S Pulmonary mucormycosis 
H24y2 Pneumocystis carinii pneumonia 
H246. Pneumonia with aspergillosis 
AB405 Histoplasma capsulatum with pneumonia 
Hyu0E [X]Pneumonia in mycoses classified elsewhere 
Xa0Y7 Non-tuberculous mycobacterial pneumonia 
Q310. Congenital pneumonia 
Xa0B9 Acquired neonatal pneumonia 
X70Ua Capillaria aerophila chest infection 
Hyu0F [X]Pneumonia in parasitic diseases classified 
elsewhere 
X100f Mononuclear interstitial pneumonia 
X102k Seasonal crypt organising pneumonia, biochemical 
cholestasis 
X1035 Cholesterol pneumonia 
X1038 Lupus pneumonia 
H571. Rheumatic pneumonia 
X1039 Traumatic pneumonia 
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A7893 HIV disease resulting in Pneumocystis carinii 
pneumonia 
X100d Rickettsial pneumonia 
XaYYu Pneumonia due to human metapneumovirus 
X100e Glandular fever pneumonia 
H200. Adenoviral pneumonia 
H202. Parainfluenzal pneumonia 
H201. Pneumonia due to respiratory syncytial virus 
H20y. Viral pneumonia NEC 
H20z. Viral pneumonia NOS 
Hyu08 [X]Other viral pneumonia 
Hyu0D [X]Pneumonia in viral diseases classified elsewhere 
H20.. Viral pneumonia (& chest infection) 
H247. Pneumonia with other systemic mycoses 
H24y. Pneumonia with other infectious diseases EC 
H24z. Pneumonia with infectious diseases EC NOS 
Q3100 Congenital staphylococcal pneumonia 
Q3101 Congenital group A haemolytic streptococcal 
pneumonia 
Q3102 Congenital group B haemolytic streptococcal 
pneumonia 
Q3103 Congenital Escherichia coli pneumonia 
Q3104 Congenital pseudomonal pneumonia 
Qyu31 [X]Congenital pneumonia due to other bacterial 
agents 
Xa0BA Meconium pneumonitis 
Xa0BB Neonatal aspiration pneumonia 
X70Eg Pneumonitis due to fetal aspiration 
Xa7nL Basal pneumonia 
Xa7nU Right upper zone pneumonia 
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Xa7nT Right middle zone pneumonia 
Xa7nP Left upper zone pneumonia 
Xa7nN Right lower zone pneumonia 
Xa7nM Left lower zone pneumonia 
X100H Bacterial pneumonia 
XE0YG Viral pneumonia 
X100R Fungal pneumonia 
X100b Pneumonia due to parasitic infestation 
XaDsb Congenital infective pneumonia 
H23.. Pneumonia due to other specified organisms 
H26.. Pneumonia due to unspecified organism 
Hyu0B [X]Pneumonia due to other specified infectious 
organisms 
Hyu0H [X]Other pneumonia, organism unspecified 
XE0YI Pneumonia with infectious diseases EC 
 
 
Codelist for Prader-Willi syndrome or Cushing’s disease 
Short name: praderWillli 
Number of codes: 14 
CHILD CTERM 
C150. Cushing's syndrome 
X40MD Adrenal Cushing's syndrome 
X40MB ACTH-dependent Cushing's syndrome 
C1500 Idiopathic Cushing's syndrome 
C1501 Iatrogenic Cushing's syndrome 
X40ME Cyclical Cushing's syndrome 
C150z Cushing's syndrome NOS 
Cyu45 [X]Other Cushing's syndrome 
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PKy0. (Multi syst cong anom NEC) or (Prader-Willi) or 
(Noonan syn) 
PKy93 Prader-Willi syndrome 
C1502 Pituitary-dependent Cushing's disease 
C1503 Ectopic ACTH secretion causing Cushing's 
syndrome 
F3951 Myopathy in Cushing's disease 
 
Codelist for stress 
Short name: stress 
Number of codes: 45 
CHILD CTERM 
XM0As Stress and adjustment reaction 
Eu4.. [X]Neurotic, stress-related and somatoform 
disorders 
Ryu58 [X]State of emotional shock and stress, unspecified 
X761N Anxiety and fear 
XM012 Mental distress 
1B1J. Emotional: [problem] or [upset] 
XaX58 Delayed post-traumatic stress disorder follow 
military comb 
XaX56 Chronic post-traumatic stress disorder follow 
military comb 
XaX55 Acute post-traumatic stress disorder follow military 
combat 
E2831 Acute post-trauma stress state 
E29y1 Other post-traumatic stress disorder 
XaEFB Chronic post-traumatic stress disorder 
XaI8j Stress counselling 
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13H4. Marital problems (& [stress]) 
XE0pM Stress at home 
X76AY Work stress 
XM1aI Stress at work 
XM1aJ Work worries 
Xa18j Combat fatigue 
Xa18v Shell shock 
E2830 Acute situational disturbance 
E280. Acute panic state due to acute stress reaction 
E281. Acute fugue state due to acute stress reaction 
E282. Acute stupor state due to acute stress reaction 
E283. Other acute stress reactions 
E283z Other acute stress reaction NOS 
E284. Stress reaction causing mixed disturbance of 
emotion/conduct 
XE1Yn Acute stress reaction NOS 
E28.. Acute reaction to stress (& [combat fatigue]) 
Eu430 [X]Ac stress react (& [crisis][psych shock][combat 
fatigue]) 
Xa19c Normal grief reaction 
Ua18k Abnormal grief reaction 
E2900 Grief reaction ( & [bereavement reaction]) 
XE1Ym Acute stress reaction 
X00Sf Post-traumatic stress disorder 
Xa7mz Carer stress syndrome 
E29.. Adjustment disorder 
1B1L. Stress-related problem 
Eu43y [X]Other reactions to severe stress 
Eu43z [X]Reaction to severe stress, unspecified 
XE1bo Acute reaction to stress (& [post-traum] or [shell-
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shock]) 
XM1Am Undue concern and preoccupation with stressful 
events 
Ua165 Feeling stressed 
9ON1. Attends stress monitoring 
9ON2. Refuses stress monitoring 
 
Codelist for thyrotoxicosis 
Short name: thyrotoxicosis 
Number of codes: 49 
CHILD CTERM 
C0240 Thyrotoxicosis from ectopic thyroid nodule with 
no crisis 
C0241 Thyrotoxicosis from ectopic thyroid nodule with 
crisis 
C024z Thyrotoxicosis from ectopic thyroid nodule NOS 
C02z0 Thyrotoxicosis without mention of goitre or cause 
no crisis 
C02z1 Thyrotoxicosis without mention of goitre, cause 
with crisis 
C02zz Thyrotoxicosis NOS 
F3816 Myasthenic syndrome due to thyrotoxicosis 
XE1g7 (Perinatal endocr/metab NOS) or (thyrotoxicosis - 
perinatal) 
X40Gx HCG-induced thyrotoxicosis 
X40H0 Thyrotoxicosis on thyroxine therapy 
X40H1 Iodine-induced thyrotoxicosis 
X40H2 Amiodarone-induced thyrotoxicosis 
X40I4 Pituitary thyroid hormone resistance 
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X40H5 Thyrotoxicosis due to TSHoma 
X40Hd Chronic thyroiditis with transient thyrotoxicosis 
X40Gk Thyrotoxicosis due to Graves' disease 
XE104 Thyrotoxicosis 
C02.. ([Thyrotoxicosis] or [hyperthyroidism]) or (toxic 
goitre) 
C020. Toxic diffuse goitre (& [Basedow disease] or 
[Graves dis]) 
X40Gl Thyrotoxicosis due to Hashimoto's thyroiditis 
X40Gn Thyrotoxicosis due to acute thyroiditis 
X40Go Toxic nodular goitre 
C024. Thyrotoxicosis from ectopic thyroid nodule 
X40Gs T3 toxicosis 
X40Gt Borderline thyrotoxicosis 
X40Gu Autonomous thyroid function 
X40Gv Apathetic thyrotoxicosis 
X40Gw Thyrotoxicosis in pregnancy 
Q443. Neonatal thyrotoxicosis 
X40Gy Factitia thyrotoxicosis 
X40Gz Iatrogenic thyrotoxicosis 
X40H4 Thyrotoxicosis due to inappropriate TSH 
secretion 
X40H7 Thyrotoxicosis due to struma ovarii 
C02z. Thyrotoxicosis without mention of goitre or other 
cause 
Cyu13 [X]Other thyrotoxicosis 
XE106 Thyrotoxicosis of other specified origin 
Xa3eb Thyrotoxicosis with or without goitre 
C02y. Thyrotoxicosis: [other specified origin] or 
[factitia] 
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XE122 Thyrotoxicosis: [+/- goitr][tox goitr][Graves 
dis][thyr nod] 
C02y0 Thyrotoxicosis of other specified origin with no 
crisis 
C02y1 Thyrotoxicosis of other specified origin with crisis 
C02yz Thyrotoxicosis of other specified origin NOS 
 
Codelist for type 2 diabetes 
Short name: T2Diabetes 
Number of codes: 32 
CHILD CTERM 
66A.. Diabetic monitoring 
XaX3o Diabetic dietary review 
XaOPu Latent autoimmune diabetes mellitus in adult 
XaOPt Maternally inherited diabetes mellitus 
X40J5 Type II diabetes mellitus 
X40J6 Insulin treated Type 2 diabetes mellitus 
C1011 Type 2 diabetes mellitus with ketoacidosis 
C1031 Type II diabetes mellitus with ketoacidotic coma 
XaF05 Type II diabetes mellitus with nephropathy 
XaIzQ Type II diabetes mellitus with persistent 
proteinuria 
XaIzR Type II diabetes mellitus with persistent 
microalbuminuria 
C1096 Type II diabetes mellitus with retinopathy 
XaFmA Type II diabetes mellitus with diabetic cataract 
XaJQp Type II diabetes mellitus with exudative 
maculopathy 
XaEnp Type II diabetes mellitus with mononeuropathy 
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XaEnq Type II diabetes mellitus with polyneuropathy 
XaKyX Type II diabetes mellitus with gastroparesis 
XM19j [EDTA] Diabetes Type II associated with renal 
failure 
C1090 Type II diabetes mellitus with renal 
complications 
C1091 Type II diabetes mellitus with ophthalmic 
complications 
C1092 Type II diabetes mellitus with neurological 
complications 
C1094 Type II diabetes mellitus with ulcer 
C1095 Type II diabetes mellitus with gangrene 
C1097 Type II diabetes mellitus - poor control 
L1806 Pre-existing diabetes mellitus, non-insulin-
dependent 
XaELQ Type II diabetes mellitus without complication 
XaFWI Type II diabetes mellitus with hypoglycaemic 
coma 
XaFn7 Type II diabetes mellitus with peripheral 
angiopathy 
XaFn8 Type II diabetes mellitus with arthropathy 
Xa2hA Dietary advice for type II diabetes 
X405J Postmortem caesarean section 
XaFn9 Type II diabetes mellitus with neuropathic 
arthropathy 
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APPENDIX 3: LOCAL R FUNCTIONS 
A several R functions were written or adapted to use across all programs used in this 
work. They are shown here. 
 
######################################################## 
# local functions  
######################################################## 
 
calcOddsRatio <- function(n00, n01, n10, n11, alpha = 0.05){ 
  #from https://www.r-bloggers.com/computing-odds-ratios-in-r/ 
  #  Compute the odds ratio between two binary variables, x and y, 
  # as defined by the four numbers nij: 
  #    n00 = number of cases where x = 0 and y = 0 
  #    n01 = number of cases where x = 0 and y = 1 
  #    n10 = number of cases where x = 1 and y = 0 
  #    n11 = number of cases where x = 1 and y = 1 
  # 
  OR <- (n00 * n11)/(n01 * n10) 
  # 
  #  Compute the Wald confidence intervals: 
  # 
  siglog <- sqrt((1/n00) + (1/n01) + (1/n10) + (1/n11)) 
  zalph <- qnorm(1 - alpha/2) 
  logOR <- log(OR) 
  loglo <- logOR - zalph * siglog 
  loghi <- logOR + zalph * siglog 
  ORlo <- exp(loglo) 
  ORhi <- exp(loghi) 
  oframe <- data.frame(LowerCI = ORlo, OR = OR, UpperCI = ORhi, alpha = alpha) 
  oframe 
} 
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calcLikelihoodRatio <- function(m, sig.level=0.95) { 
  # from Tomas Karpati, https://rdrr.io/github/karpatit/mechkar/src/R/mechkar.R 
   
  alpha <- 1 - sig.level 
  a <- m[1, 1] 
  b <- m[1, 2] 
  c <- m[2, 1] 
  d <- m[2, 2] 
  spec <- d/(b+d) 
  sens <- a/(a+c) 
  lr.pos <- sens/(1 - spec)   
   
  if (a != 0 & b != 0 ) { 
    sigma2 <- (1/a) - (1/(a+c)) + (1/b) - (1/(b+d)) 
    lower.pos <- lr.pos * exp(-qnorm(1-(alpha/2))*sqrt(sigma2)) 
    upper.pos <- lr.pos * exp(qnorm(1-(alpha/2))*sqrt(sigma2))  
  } else if ( a == 0 & b == 0 ) { 
    lower.pos <- 0 
    upper.pos <- Inf 
  } else if ( a == 0 & b != 0 ) { 
    a.temp <- (1/2) 
    spec.temp <- d/(b+d) 
    sens.temp <- a.temp/(a+c) 
    lr.pos.temp <- sens.temp/(1 - spec.temp)   
    lower.pos <- 0 
    sigma2 <- (1/a.temp) - (1/(a.temp+c)) + (1/b) - (1/(b+d)) 
    upper.pos <- lr.pos.temp * exp(qnorm(1-(alpha/2))*sqrt(sigma2)) 
  } else if (a != 0 & b == 0) { 
    b.temp <- (1/2) 
    spec.temp <- d/(b.temp+d) 
    sens.temp <- a/(a+c) 
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    lr.pos.temp <- sens.temp/(1 - spec.temp)  
    sigma2 <- (1/a) - (1/(a+c)) + (1/b.temp) - (1/(b.temp+d)) 
    lower.pos <- lr.pos.temp * exp(-qnorm(1-(alpha/2))*sqrt(sigma2)) 
    upper.pos <- Inf   
  } else if ( (a == (a+c)) & (b == (b+d)) ) { 
    a.temp <- a - (1/2) 
    b.temp <- b - (1/2) 
    spec.temp <- d/(b.temp+d) 
    sens.temp <- a.temp/(a+c) 
    lr.pos.temp <- sens.temp/(1 - spec.temp)  
    sigma2 <- (1/a.temp) - (1/(a.temp+c)) + (1/b.temp) - (1/(b.temp+d)) 
    lower.pos <- lr.pos.temp * exp(-qnorm(1-(alpha/2))*sqrt(sigma2)) 
    upper.pos <- lr.pos.temp * exp(qnorm(1-(alpha/2))*sqrt(sigma2))  
  } 
   
  lr.neg <- (1 - sens)/spec 
  if (c != 0 & d != 0) { 
    sigma2 <- (1/c) - (1/(a+c)) + (1/d) - (1/(b+d)) 
    lower.neg <- lr.neg * exp(-qnorm(1-(alpha/2))*sqrt(sigma2)) 
    upper.neg <- lr.neg * exp(qnorm(1-(alpha/2))*sqrt(sigma2))  
  } else if (c == 0 & d == 0) { 
    lower.neg<- 0 
    upper.neg <- Inf 
  } else if (c == 0 & d != 0) { 
    c.temp <- (1/2) 
    spec.temp <- d/(b+d) 
    sens.temp <- a/(a+c.temp) 
    lr.neg.temp <- (1 - sens.temp)/spec.temp     
    lower.neg <- 0 
    sigma2 <- (1/c.temp) - (1/(a+c)) + (1/d) - (1/(b+d)) 
    upper.neg <- lr.neg.temp * exp(qnorm(1-(alpha/2))*sqrt(sigma2)) 
  } else if ( c != 0 & d == 0 ) { 
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    d.temp <- (1/2) 
    spec.temp <- d.temp/(b+d) 
    sens.temp <- a/(a+c) 
    lr.neg.temp <- (1 - sens.temp)/spec.temp   
    sigma2 <- (1/c) - (1/(a+c)) + (1/d.temp) - (1/(b+d)) 
    lower.neg <- lr.neg.temp * exp(-qnorm(1-(alpha/2))*sqrt(sigma2)) 
    upper.neg <- Inf   
  } else if ( (c == (a+c)) & (d == (b+d)) ) { 
    c.temp <- c - (1/2) 
    d.temp <- d - (1/2) 
    spec.temp <- d.temp/(b+d) 
    sens.temp <- a/(a+c.temp) 
    lr.neg.temp <- (1 - sens.temp)/spec.temp    
    sigma2 <- (1/c.temp) - (1/(a+c)) + (1/d.temp) - (1/(b+d)) 
    lower.neg <- lr.neg.temp * exp(-qnorm(1-(alpha/2))*sqrt(sigma2)) 
    upper.neg <- lr.neg.temp * exp(qnorm(1-(alpha/2))*sqrt(sigma2))  
  } 
  list( 
    lr.pos=lr.pos, lower.pos=lower.pos, upper.pos=upper.pos, 
    lr.neg=lr.neg, lower.neg=lower.neg, upper.neg=upper.neg 
  ) 
} 
 
#function to create a binary vector showing whether or not event codes are present for a 
patient 
createBitVectors <- function(x){ # x is concatDF[row,], y is eventCodesGroup 
  bitvector <- eventCodesGroup %in% x; 
  return(bitvector) 
} 
 
#function to look up "include" flag for an event code 
#getFlag <- function(x) { 
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#  event_flag <- include_flags[(match(x, include_flags$CHILD)),]$auto_flag; 
#  return(event_flag) 
#} 
 
#function to look up ancestor code for an event code 
getHigherCode <- function(x,y) { 
  column_name <- paste("PARENT.",y,sep=""); 
  new_code <- include_flags[(match(x, include_flags$CHILD)),column_name]; 
  return(new_code) 
} 
 
#function to find position of most recent diagnosis code ('diagnosis' code as per flag 
table) 
most_recent_diagnosis_position <- function(x) { 
  mrdp <- min(which(include_flags[match(x, include_flags$CHILD),]$auto_flag == 2)); 
#most recent diagnostic position 
  if (mrdp == Inf) mrdp <- NA; 
  return(mrdp); 
} 
 
#function to find the code of the most recent diagnosis code ('diagnosis' code as per flag 
table) 
mostRecentDiagnosisCode <- function(x) { # x is concatDF row, y is name of position 
variable 
  mrdc <- x[as.integer(tail(x,n=1))] 
} 
 
#function to look up the 'include flag' value for a code as stored in the flag table 
includeFlagValue <- function(x) { 
  flag_value <- include_flags[match(x, include_flags$CHILD),]$auto_flag 
  return(as.integer(flag_value)); 
} 
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#function to generate true-false vector of any event in condition set occurring 
TrueFalse <- function(x) { 
  TFvalue <- x %in% targetCode; 
  return(TFvalue); 
} 
 
#function to get predicted TRUE/FALSE value for presence of a condition for a patient 
in a cluster 
get_prediction <- function(x) { 
  prediction <- as.logical(cc[match(x, cc$cluster),]$TrueFalsePred) 
  return(prediction) 
} 
 
get_predictedRisk <- function(x) { 
  predictedRisk <- as.numeric(cc[match(x, cc$cluster),]$prevalence) 
  return(predictedRisk); 
} 
 
######################################################## 
# end of local functions  
######################################################## 
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APPENDIX 4: R CODE TO AUTOMATICALLY ASSIGN 
SIGNIFICANCE LEVELS TO CTV3 CODES 
This program reads in CTV3 codes from the CTV3 table, assigns the code the 
significance of its parent code, and then corrects significance assignments as necessary. 
Corrections have only been made down to level 4 of the CTV3 hierarchy, beyond which 
level it was more practical to descend the CTV3 hierarchy, assign each code the 
significance of its parent, and once all codes had received a significance value, 
manually inspect the codes and their significances and correct as necessary. Note that 
the significances must be assigned and corrected in sequence of descending level in the 
CTV3 hierarchy since, initially, each code assumes the significance of its parent code. 
 
cat("\nReading the full CTV3 codes flags and tree table and codes present in our data 
set...\n"); 
#read in original CTV3 tree: 
CTV3_flags <- read.csv("tree_rev_with_root_node.csv", header=TRUE, 
stringsAsFactors=FALSE); # for ALL codes in TRUD CTV3 table 
#read in revised CTV3 tree with corrected local codes: 
CTV3_flags_local <- read.csv("finalIncludeFlagStatusForCTV3.csv", header = TRUE, 
stringsAsFactors = FALSE); # list of all CTV3 codes with manually-assigned/corrected 
flags for CTV3 codes in our data set 
#CTV3_flags$flag <- CTV3_flags$INCLUDE 
#colnames(CTV3_flags)[colnames(CTV3_flags) == "INCLUDE"] <- "flags"  # rename 
the 'INCLUDE' flag column to 'flags' for consistency with code below 
 
#read in the list of unique codes in our data set 
unique_codes_list <- read.csv("unique_codes_in_merged_data_set.csv", header=TRUE, 
stringsAsFactors=FALSE); 
 
CTV3_flags$flag <- NA; # add column for semi-automatically generated flags 
CTV3_flags$flag_auto <- NA; # add column for automatically generated flags 
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###################################    Level 1   
################################### 
 
#set "level 1" codes flag to 0 as our seed 
CTV3_flags[(CTV3_flags$CHILD == "....."),]$flag <- 0 
 
#work on level 1 codes - in fact only one code -  
LEVEL.1.CODES <- unique(CTV3_flags$PARENT.1); # list of unique "level 1" codes 
(these should all be ".....) 
cat("\n", length(LEVEL.1.CODES), "Level 1 codes: ", LEVEL.1.CODES, "\n") 
# set the level 1 codes to 0 (this should just be one CHILD code) 
#CTV3_flags[(CTV3_flags$CHILD %in% LEVEL.1.CODES),]$flag <- 0; # set the 
level 1 codes to 0 (this should just be one CHILD code) 
#CTV3_flags[(CTV3_flags$PARENT == "....."),]$flag <- 
CTV3_flags[(CTV3_flags$CHILD %in% LEVEL.1.CODES),]$flag 
###################################    Level 2   
################################### 
 
#work on level 2 codes 
LEVEL.2.CODES <- unique(CTV3_flags$PARENT.2); # list of unique "level 2" codes 
(not many of these) 
LEVEL.2.CODES <- LEVEL.2.CODES[!(LEVEL.2.CODES %in% 
LEVEL.1.CODES)] 
LEVEL.2.CODES <- LEVEL.2.CODES[(LEVEL.2.CODES %in% 
unique_codes_list$CTV3)] 
#LEVEL.2.CODES <- CTV3_flags[(CTV3_flags$CHILD %in% 
LEVEL.2.CODES),]$CHILD # list of all codes at this levle 
#codes <- CTV3_flags[(CTV3_flags$PARENT %in% LEVEL.1.CODES),]$flag; 
cat("\n", length(LEVEL.2.CODES), "Level 2 codes: ", LEVEL.2.CODES, "\n") 
for (j in LEVEL.2.CODES) { # go through the list of unique codes that are present at 
this level 
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  parent <- CTV3_flags[(CTV3_flags$CHILD == j),]$PARENT # get the parent code 
for the current code 
  parent_flag <- CTV3_flags[(CTV3_flags$CHILD == parent),]$flag # get the flag 
value for the parent code 
  CTV3_flags[(CTV3_flags$CHILD == j),]$flag <- parent_flag  # assign the parent flag 
value to the child code 
  CTV3_flags[(CTV3_flags$CHILD == j),]$flag_auto <- parent_flag 
  manualCode <- CTV3_flags_local[(CTV3_flags_local$CTV3 == j),]$flag 
  cat("\n",CTV3_flags[(CTV3_flags$CHILD == j),]$CHILD, 
CTV3_flags[(CTV3_flags$CHILD == j),]$CTERM, 
CTV3_flags[(CTV3_flags$CHILD == j),]$flag_auto, 
CTV3_flags[(CTV3_flags$CHILD == j),]$flag, manualCode); 
} 
 
codeAll <- CTV3_flags[!is.na(CTV3_flags$flag),]; 
codeAll2 <- codeAll[codeAll$CHILD %in% LEVEL.2.CODES,] 
code0 <- codeAll2[(codeAll2$flag == 0),]; 
code1 <- codeAll2[(codeAll2$flag == 1),]; 
code2 <- codeAll2[(codeAll2$flag == 2),]; 
 
cat("\nCodes present at level2:", length(codeAll$CHILD), "; New codes introduced at 
level2:", length(codeAll2$CHILD),"; flag0:", length(code0$CHILD),"; 
flag1:",length(code1$CHILD), "; flag2:",length(code2$CHILD), "sum: ", 
(length(code0$CHILD)+length(code1$CHILD)+length(code2$CHILD))); 
 
###################################    Level 3   
################################### 
 
#work on level 3 codes 
LEVEL.3.CODES <- unique(CTV3_flags$PARENT.3); # list of unique "level 3" codes 
(not many of these) 
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LEVEL.3.CODES <- LEVEL.3.CODES[!(LEVEL.3.CODES %in% 
c(LEVEL.1.CODES, LEVEL.2.CODES))] 
LEVEL.3.CODES <- LEVEL.3.CODES[(LEVEL.3.CODES %in% 
unique_codes_list$CTV3)] 
LEVEL.3.CODES <- sort(LEVEL.3.CODES); 
 
#cat("\n", length(LEVEL.3.CODES), "Level 3 codes: ", LEVEL.3.CODES, "\n") 
for (j in LEVEL.3.CODES) { # go through the list of unique codes that are present at 
this level 
  parent <- CTV3_flags[(CTV3_flags$CHILD == j),]$PARENT # get the parent code 
for the current code 
  parent_flag <- CTV3_flags[(CTV3_flags$CHILD == parent),]$flag # get the flag 
value for the parent code 
  CTV3_flags[(CTV3_flags$CHILD == j),]$flag <- parent_flag  # assign the parent flag 
value to the child code 
  CTV3_flags[(CTV3_flags$CHILD == j),]$flag_auto <- parent_flag 
  manualCode <- CTV3_flags_local[(CTV3_flags_local$CTV3 == j),]$flag 
 
  if (length(manualCode) > 0) { 
    CTV3_flags[(CTV3_flags$CHILD == j),]$flag <- manualCode; 
  } 
  cat("\n",CTV3_flags[(CTV3_flags$CHILD == j),]$CHILD, 
CTV3_flags[(CTV3_flags$CHILD == j),]$CTERM, 
CTV3_flags[(CTV3_flags$CHILD == j),]$flag_auto, 
CTV3_flags[(CTV3_flags$CHILD == j),]$flag, manualCode); 
   
    #if (parent_flag != 0) { 
  #  cat("\n",CTV3_flags[(CTV3_flags$CHILD == j),]$CHILD, 
CTV3_flags[(CTV3_flags$CHILD == j),]$CTERM, 
CTV3_flags[(CTV3_flags$CHILD == j),]$flag_auto, 
CTV3_flags[(CTV3_flags$CHILD == j),]$flag); 
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  #cat("\n",CTV3_flags[(CTV3_flags$CHILD == j),]$CHILD, 
CTV3_flags[(CTV3_flags$CHILD == j),]$CTERM, 
CTV3_flags[(CTV3_flags$CHILD == j),]$PARENT, 
CTV3_flags[(CTV3_flags$CHILD == j),]$PTERM, CTV3_flags[(CTV3_flags$CHILD 
== j),]$flag_auto, CTV3_flags[(CTV3_flags$CHILD == j),]$flag); 
  #} 
} 
 
codeAll <- CTV3_flags[!is.na(CTV3_flags$flag),]; 
codeAll3 <- codeAll[codeAll$CHILD %in% LEVEL.3.CODES,] 
code0 <- codeAll3[(codeAll3$flag == 0),]; 
code1 <- codeAll3[(codeAll3$flag == 1),]; 
code2 <- codeAll3[(codeAll3$flag == 2),]; 
 
cat("\nAll codes present at level3:", length(codeAll$CHILD), "; New codes introduced 
at level3:",length(codeAll3$CHILD),": flag0:", length(code0$CHILD),"; 
flag1:",length(code1$CHILD), "; flag2:",length(code2$CHILD), "sum: ", 
(length(code0$CHILD)+length(code1$CHILD)+length(code2$CHILD))); 
 
write.csv(code0, "level3code0.csv");write.csv(code1, 
"level3code1.csv");write.csv(code2, "level3code2.csv"); 
 
###################################    Level 4   
################################### 
 
#work on level 4 codes 
 
LEVEL.4.CODES <- unique(CTV3_flags$PARENT.4); # list of unique "level 4" codes 
LEVEL.4.CODES <- LEVEL.4.CODES[!((LEVEL.4.CODES %in% 
c(LEVEL.1.CODES, LEVEL.2.CODES, LEVEL.3.CODES)))]; 
LEVEL.4.CODES <- LEVEL.4.CODES[(LEVEL.4.CODES %in% 
unique_codes_list$CTV3)] 
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LEVEL.4.CODES <- sort(LEVEL.4.CODES); 
 
for (j in LEVEL.4.CODES) { # go through the list of unique codes that are present at 
this level 
  parent <- CTV3_flags[(CTV3_flags$CHILD == j),]$PARENT # get the parent code 
for the current code 
  parent_flag <- CTV3_flags[(CTV3_flags$CHILD == parent),]$flag # get the flag 
value for the parent code 
  CTV3_flags[(CTV3_flags$CHILD == j),]$flag <- parent_flag  # assign the parent flag 
value to the child code 
  CTV3_flags[(CTV3_flags$CHILD == j),]$flag_auto <- parent_flag 
  manualCode <- CTV3_flags_local[(CTV3_flags_local$CTV3 == j),]$flag 
  if (length(manualCode) > 0) { 
    CTV3_flags[(CTV3_flags$CHILD == j),]$flag <- manualCode; 
  } 
  cat("\n",CTV3_flags[(CTV3_flags$CHILD == j),]$CHILD, 
CTV3_flags[(CTV3_flags$CHILD == j),]$CTERM, 
CTV3_flags[(CTV3_flags$CHILD == j),]$flag_auto, 
CTV3_flags[(CTV3_flags$CHILD == j),]$flag, manualCode); 
} 
 
 
codeAll <- CTV3_flags[!is.na(CTV3_flags$flag),]; 
codeAll4 <- codeAll[codeAll$CHILD %in% LEVEL.4.CODES,] 
code0 <- codeAll4[(codeAll4$flag == 0),]; 
code1 <- codeAll4[(codeAll4$flag == 1),]; 
code2 <- codeAll4[(codeAll4$flag == 2),]; 
 
cat("\nAll codes present at level4:", length(codeAll$CHILD), "; New codes introduced 
at level4:",length(codeAll4$CHILD),": flag0:", length(code0$CHILD),"; 
flag1:",length(code1$CHILD), "; flag2:",length(code2$CHILD), "sum: ", 
(length(code0$CHILD)+length(code1$CHILD)+length(code2$CHILD))); 
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write.csv(code0, "level4code0.csv");write.csv(code1, 
"level4code1.csv");write.csv(code2, "level4code2.csv"); 
 
###################################    Level 5   
################################### 
 
#work on level 5 codes 
LEVEL.5.CODES <- unique(CTV3_flags$PARENT.5); # list of unique "level 4" codes 
LEVEL.5.CODES <- LEVEL.5.CODES[!((LEVEL.5.CODES %in% 
c(LEVEL.1.CODES, LEVEL.2.CODES, LEVEL.3.CODES, LEVEL.4.CODES)))]; 
LEVEL.5.CODES <- LEVEL.5.CODES[(LEVEL.5.CODES %in% 
unique_codes_list$CTV3)] 
 
for (j in LEVEL.5.CODES) { # go through the list of unique codes that are present at 
this level 
  parent <- CTV3_flags[(CTV3_flags$CHILD == j),]$PARENT # get the parent code 
for the current code 
  parent_flag <- CTV3_flags[(CTV3_flags$CHILD == parent),]$flag # get the flag 
value for the parent code 
  CTV3_flags[(CTV3_flags$CHILD == j),]$flag <- parent_flag  # assign the parent flag 
value to the child code 
  CTV3_flags[(CTV3_flags$CHILD == j),]$flag_auto <- parent_flag 
  manualCode <- CTV3_flags_local[(CTV3_flags_local$CTV3 == j),]$flag 
  if (length(manualCode) > 0) { 
    CTV3_flags[(CTV3_flags$CHILD == j),]$flag <- manualCode; 
  } 
  #cat("\n",CTV3_flags[(CTV3_flags$CHILD == j),]$CHILD, 
CTV3_flags[(CTV3_flags$CHILD == j),]$CTERM, 
CTV3_flags[(CTV3_flags$CHILD == j),]$flag_auto, 
CTV3_flags[(CTV3_flags$CHILD == j),]$flag, manualCode); 
} 
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codeAll <- CTV3_flags[!is.na(CTV3_flags$flag),]; 
codeAll5 <- codeAll[codeAll$CHILD %in% LEVEL.5.CODES,] 
code0 <- codeAll5[(codeAll5$flag == 0),]; 
code1 <- codeAll5[(codeAll5$flag == 1),]; 
code2 <- codeAll5[(codeAll5$flag == 2),]; 
 
cat("\nAll codes present at level5:", length(codeAll$CHILD), "; New codes introduced 
at level5:",length(codeAll5$CHILD),": flag0:", length(code0$CHILD),"; 
flag1:",length(code1$CHILD), "; flag2:",length(code2$CHILD), "sum: ", 
(length(code0$CHILD)+length(code1$CHILD)+length(code2$CHILD))); 
 
write.csv(code0, "level5code0.csv"); 
write.csv(code1, "level5code1.csv"); 
write.csv(code2, "level5code2.csv"); 
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APPENDIX 5: CTV3 CODES AND SIGNIFICANCE FLAGS 
A sample table of CTV3 codes together with their assigned significance flags is shown 
here. Code 0 implies an administration-type code that has little or no clinical 
significance and is not used for analysis. Code 1 implies a symptom-type code; code 2 
implies a diagnosis of a condition. Both are used in the analysis. 
 
CTV3 
CODE 
PARENT 
CODE 
Significance 
flag 
CTV3 CODE 
DESCRIPTION 
PARENT CODE 
DESCRIPTION 
XaBVJ ..... 0 Clinical findings Read thesaurus 
9.... ..... 0 Administration Read thesaurus 
Xa22Y ..... 0 Operations, 
procedures and 
interventions 
Read thesaurus 
X78FG ..... 0 Staging and scales Read thesaurus 
0.... ..... 0 Occupations Read thesaurus 
XE1Tr 22... 0 Adult health 
examination 
General examination 
of patient 
XM1Xs 22... 0 Screening - health 
check 
General examination 
of patient 
XE0qh 167.. 1 Pale - symptom Colour symptom 
16AZ. 16A.. 1 Stiff neck symptom 
NOS 
Stiff neck symptom 
16A.. 16A2. 1 Stiff neck symptom Stiff neck 
17Z1. 17... 1 No respiratory 
symptoms 
Respiratory 
symptoms 
17ZZ. 17... 1 Respiratory 
symptom NOS 
Respiratory 
symptoms 
XE0qq 1738 2 Dyspnoea Difficulty breathing 
17Z.. 17ZZ. 1 Respiratory Respiratory 
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symptoms NOS symptom NOS 
1822 182.. 1 Central chest pain Chest pain 
X70Gv A.... 2 Bacterial disease Infective disorder 
X70Iu A.... 2 Viral disease Infective disorder 
X70OW A.... 2 Protozoal disease Infective disorder 
AB... A.... 2 Mycoses Infective disorder 
1829 182.. 1 Retrosternal pain Chest pain 
1823 182.. 1 Precordial pain Chest pain 
1828 182.. 1 Atypical chest pain Chest pain 
PG52. X78BM 2 Osteopetrosis Dysplasia with 
increased bone 
density 
Xa99T X78Dz 2 Neurofibromatosis Phakomatoses 
PK5.. X78Dz 2 Tuberous sclerosis Phakomatoses 
X78EV X78ES 2 Congenital 
malformation of 
thyroid gland 
Congenital 
malformation of the 
endocrine glands 
PJ63. X78Ex 2 Turner's syndrome Sex chromosome 
abnormality - female 
phenotype 
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APPENDIX 6: R CODE FOR CLUSTERING 
Shown here is the body of the program used to determine the optium factors for 
clustering. The same basic code is used for the training and testing phases. In the 
training phase, the program loops over all options for the number of clusters and the 
options for CTV3 hierarchy level. In the testing phase, these values are fixed. Not 
shown are the header section of the program, which sets the working directory, reads in 
the local R functions, opens the required R libraries and reads in the conditions 
codelists. 
 
 
for (condition in c("acuteSinusitis", "allergicRhinitis", "asthma", "anyCancer", 
"prostateCancer", "stress", "T2Diabetes", "thyrotoxicosis","autism", "obesity", 
"osteoarthritis", "praderWilli", "breastCancer", 
"bronchitis","colonCancer","eczema","refluxDisease", "gastroparesis", "gout" )) {  
   
  targetCode <- eval(parse(text = condition)); 
   
  for (minEventsCount in c(4)) {      
    for (granularity_group in c(granularity_group_set)) { 
       
      runNo <- runNo + 1; 
       
      ######################################################## 
      # read in data files 
      ######################################################## 
       
      cat("\n\nRun", runNo, "at", format(Sys.time(), date.format), "Condition:", condition, 
"Maximum",nrows,"records; minimum events per record =", minEventsCount, "; 
granularity level =", granularity_group, "\nreading data files ..."); 
      #read in the patient event histories. First build the file name to read. Use nrows to 
limit the number of lines read 
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      dataFileName <- "train50.csv"; 
       
      #then read the first nrows rows from the record data file, or a random selection of 
nrows from the full records data file: 
      #concatDF <- read.csv(dataFileName, nrows=nrows, header=TRUE, fill=TRUE, 
stringsAsFactors = FALSE);      
      concatDF <- read.csv(dataFileName, header=TRUE, fill=TRUE, stringsAsFactors = 
FALSE); 
      concatDF <- concatDF[sample(nrow(concatDF), nrows), ]; 
      concatDF[concatDF[,] == ""] <- NA; # convert empty string values (i.e. "no event") 
to NA 
       
      #drop columns that are all NA 
      #first get maximum number of codes at this level of granularity 
      max_events_count <- max(concatDF$unique.events.count); 
      #then drop the surplus columns and a couple of empty columns for safety: 
      concatDF <- concatDF[,-c((7+max_events_count):length(concatDF[1,]))]; 
      concatDF[,(length(concatDF)+1):(length(concatDF)+2)] <- NA 
       
      #read in "include" flag look-up table 
      include_flags <- read.csv("include_flags_AHD.csv", 
header=TRUE,fill=TRUE,stringsAsFactors = FALSE); 
       
      ######################################################## 
      # end of read in data files 
      ######################################################## 
       
      ######################################################## 
      # do preparatory work on read data files 
      ######################################################## 
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      cat(" preparing data files ..."); 
       
      #get list of Read Codes present AT THIS LEVEL 
      eventCodesIn <- unique(unlist(concatDF[,-c(1:6)])) # drop the first 6 columns of 
demographic information and leave only the event codes 
      eventCodesIn <- eventCodesIn[!is.na(eventCodesIn)] #get final list of all event 
codes 
 
      concatDF$mostRecentDiagnosisCode <- 
apply(concatDF,1,mostRecentDiagnosisCode) #find position in concatDF of most 
recent diagnosis code 
       
      #drop the patients who have no diagnostic event - i.e. where the 
mostRecentDiagnosisCode is NA - since they are of no use to us 
      concatDF <- subset(concatDF, !is.na(concatDF$mostRecentDiagnosisCode)) 
      #drop the patients who have a target diagnostic event but no other events - they are 
also of no use to us 
      concatDF <- subset(concatDF, (concatDF$unique.events.count > minEventsCount)) 
       
      #get counts of number of event codes, number of patients, highest number of events 
for a patient 
      number_of_eventCodesIn <- length(eventCodesIn) # how many event codes there in 
the data set at this level for this (sub)set of patients 
      number_of_patientsIn <- length(concatDF$patid) # how many patients left after 
removing those with no events of interest 
      number_of_patient_eventsIn <- max(concatDF$unique.events.count) #maximum 
number of events for a patient 
       
      ######################################################## 
      # end of preparatory work on read data files 
      ######################################################## 
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      ######################################################## 
      # set up data frame ready for input into clustering  
      ######################################################## 
       
      cat(" preparing data at higher Read Code level ..."); 
       
      #need to flag up that the patient has the condition and remove the codes that mean 
they have the condition 
      #for each patient in concatDF, replace each event code with 1 (if in the condition 
list) or 0 (if not in the condition list) 
      concatDFisCondition <- 
apply(concatDF[,7:(7+number_of_patient_eventsIn)],2,TrueFalse) 
      #for each patient, get the total number of events that are in the condition list 
      concatDF$has.condition <- apply(concatDFisCondition,1,sum) >= 1; 
      #concatDF$has.condition <- concatDF$has.condition >= 1 
      #now remove the events that are in the condition list by replacing them with NA 
      # duplicate the event data frame and then replace event Codes with their ancestor 
codes 
      #concatDF_higher <- concatDF[,7:(length(concatDF[1,])-3)]; #probably don't need 
this now that the succeeding lines shuffle up the NA values... 
       
      for (i in 1:number_of_patientsIn) { 
        concatDF[i,(which(concatDFisCondition[i,] == TRUE)+6)] <- NA 
      } 
       
      concatDF_higher <- concatDF[,7:(length(concatDF[1,])-3)]; #probably don't need 
this now that the succeeding lines shuffle up the NA values... 
      #concatDF_higher_old <- concatDF[,7:(length(concatDF[1,])-3)]; #probably don't 
need this now that the succeeding lines shuffle up the NA values... 
       
      concatDF_higher <- mapply(getHigherCode, concatDF[,7:(length(concatDF[1,])-
3)],granularity_group); 
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      for (i in 1:length(concatDF_higher[,1])) { 
        concatDF_higher[i,duplicated(concatDF_higher[i,])] <- NA 
      } 
       
      #some of the codes in the event sequence are NA - remove these, shuffle up the 
existing event codes and fill with NA at the end of the event sequence 
      lentemp2 <- length(concatDF_higher[1,]); 
      for(i in 1:length(concatDF_higher[,1])) { 
        temp1 <- concatDF_higher[i,]; 
        temp1 <- temp1[!is.na(temp1)] # try replacing these two lines with temp1 <- 
concatDF[!is.na(concatDF[i,7:(concatDF[i,]$unique.events.count+6)])] 
        lentemp1 <- length(temp1);  
        #concatDF_higher[i,] <- temp1; 
        if (lentemp1 > 0) { 
          concatDF_higher[i,1:lentemp1] <- temp1; 
          concatDF_higher[i,(lentemp1+1):lentemp2] <- NA; 
        } 
      } 
       
      #now put these higher level read codes back in to concatDF, replacing the lower 
level codes 
      concatDF[,7:(length(concatDF[1,])-3)] <- concatDF_higher 
       
 
      ######################################################## 
      # do work on higher level data files 
      ######################################################## 
       
      #get list of codes present AT THIS LEVEL 
      eventCodesGroup <- unique(unlist(concatDF[,7:(length(concatDF[1,])-3)])) # drop 
the first 6 columns of demographic information and leave only the event codes 
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      eventCodesGroup <- eventCodesGroup[!is.na(eventCodesGroup)] #get final list of 
all event codes 
       
      #drop the patients who have no diagnostic event - i.e. where the 
mostRecentDiagnosisCode is NA 
      ###### do we need to do this? we're no longer trying to predict events other than the 
condition of interest     
      concatDF <- subset(concatDF, !is.na(concatDF$mostRecentDiagnosisCode)) 
      #drop the patients who have a target diagnostic event but no other events 
      concatDF <- subset(concatDF, (concatDF$unique.events.count > 1))  #### use this 
to control minimum number of events for a patient 
       
      #get counts of number of event codes, number of patients, highest number of events 
for a patient 
      number_of_eventCodesGroup <- length(eventCodesGroup) # how many event 
codes there in the data set at this level for this (sub)set of patients 
      number_of_patientsGroup <- length(concatDF$patid) # how many patients left after 
removing those with no events of interest 
      number_of_patient_eventsGroup <- max(concatDF$unique.events.count) 
#maximum number of events for a patient 
       
      if (nrow(concatDF) > nrows) { 
        concatDF <- concatDF[sample(nrow(concatDF), nrows), ]; 
      } 
      number_of_patientsGroup <- nrow(concatDF); 
       
      ######################################################## 
      # end of work on higher level data files 
      ######################################################## 
       
      #set up an empty data frame of patients(rows) by events (columns) 
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      eventTable <- setNames(data.frame(matrix(ncol = 
(number_of_eventCodesGroup+4), nrow = number_of_patientsGroup)), 
c("patid","gender","marital","age", eventCodesGroup)) 
       
      #populate the data frame 
      eventTable[,1:4] <- concatDF[,1:4]; # assign patient IDs, gender, marital status, age, 
       
      #now use the createBitVectors function to assign "present" or "absent" for each code 
against each patient 
      eventTable[,5:(number_of_eventCodesGroup+4)] <- 
t(as.matrix(apply(concatDF[,7:(number_of_patient_eventsGroup+6)],1,createBitVector
s))) 
       
      #drop the event codes which are only admin codes (i.e. the 'include flag' value is 0 
for that event code) 
      eventCodes_flags <- data.frame(includeFlagValue(eventCodesGroup), 
stringsAsFactors = FALSE); #look up the 'include flag' value for each code 
      eventCodes_and_flags <- cbind.data.frame(eventCodesGroup,eventCodes_flags, 
stringsAsFactors = FALSE); # create local look-up table of event codes and their look-
up flags 
      colnames(eventCodes_and_flags)[2] <- "flag"; 
      eventCodes_to_drop <- eventCodes_and_flags[eventCodes_and_flags[,2] == 0,1]; 
      eventTable <- eventTable[,!(names(eventTable) %in% eventCodes_to_drop)] # 
remove the columns from the eventTable where column names (i.e. event codes) are in 
'eventCodes_to_drop' 
      number_of_eventCodesGroup <- number_of_eventCodesGroup-
length(eventCodes_to_drop) # need to adjust the number of event codes to show the 
surviving codes 
       
      eventTable$targetTrueFalse <- as.logical(concatDF$has.condition) # so we know 
which patients have had the condition of interest and which haven't 
      eventTable$marital <- NULL; # drop marital status 
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      if (useAge == TRUE) { 
        ageMax <- max(eventTable$age); # set max age for age scaling 
        eventTable$age <- eventTable$age/ageMax; # scale ages of patients 0 to 1 
      } else eventTable$age <- 0; #  
      eventTable[eventTable == TRUE] <- 1 #change value of 'TRUE' to '1' 
      eventTable[eventTable == FALSE] <- 0 #change value of 'FALSE' to '0' 
       
      if (useGender == TRUE) { 
        eventTable[eventTable$gender == "F","gender"] <- 0; # set 0 for female 
        eventTable[eventTable$gender == "M","gender"] <- 1; # set 1 for male 
        eventTable$gender <- as.numeric(eventTable$gender); 
      } else { 
        eventTable$gender <- 0; 
      } 
       
      number_of_eventCodes <- length(eventTable[1,])-4 
            
      ######################################################## 
      # end of set up data frame ready for input into clustering  
      ######################################################## 
       
      ######################################################## 
      # get prevalence of condition 
      ######################################################## 
       
      group_prevalence <- 
sum(eventTable$targetTrueFalse)/length(eventTable$targetTrueFalse); 
       
      cat("\nCondition:", condition,"; prevalence:", group_prevalence,"; number of 
records with condition:",sum(eventTable$targetTrueFalse),"; total valid 
records:",length(eventTable$targetTrueFalse)); 
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      ######################################################## 
      # form distance matrix 
      ######################################################## 
       
        
      n <- dim(eventTable[,(2:(number_of_eventCodesGroup+3))])[1]; # n is the number 
of rows in the event table 
      nn_dup = matrix(0,n,n); 
      nnTF_dup <- matrix(FALSE, n, n); 
       
      cat("\n\nForming distance matrix using", dist.method) 
       
      if (dist.method %in% c("euclidean", "manhattan", "cosine")) { 
        cat(" from dist.matrix .... \nStart time:",format(Sys.time(), date.format)); 
        dist.mat <- 
dist.matrix(as.matrix(eventTable[,(2:(number_of_eventCodesGroup+3))]), 
method=dist.method, as.dist=TRUE); #get distance matrix 
        #dist.mat <- dist.mat[2:(length(dist.mat)-1)]; # drop the "nearest" neighbour - it is 
our record of interest 
        R_function <- "dist.matrix"; 
        cat("; End time: ",format(Sys.time(), date.format)); 
      } else if (dist.method %in% c("tanimoto", "dtw", "podani", "hamman", "michael", 
"faith", "mountford", "simpson", "fjaccard")) { 
        cat(" from parDist .... \nStart time:",format(Sys.time(), date.format)); 
        dist.mat <- 
parDist(as.matrix(eventTable[,(2:(number_of_eventCodesGroup+3))],method=dist.met
hod, threads=(no_cores))); 
        R_function <- "parDist" 
        cat("; End time: ",format(Sys.time(), date.format)); 
      } else if (dist.method %in% c("canberra")) { 
        cat(" from dist .... \nStart time:",format(Sys.time(), date.format)); 
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        dist.mat <- 
dist(as.matrix(eventTable[,(2:(number_of_eventCodesGroup+3))],method=dist.method)
); 
        R_function <- "parDist"; 
        cat("; End time: ",format(Sys.time(), date.format)); 
      } else if (dist.method %in% c("gower", "binomial", "mahalanobis", "cao", "chao")) 
{ 
        cat(" from vegdist .... \nStart time:",format(Sys.time(), date.format)); 
        dist.mat <- 
vegdist(as.matrix(eventTable[,(2:(number_of_eventCodesGroup+3))],method=dist.meth
od, binary=dist.binary, upper=FALSE)); 
        R_function <- "parDist" 
        #cat("; End time: ",format(Sys.time(), date.format)); 
      } else if (dist.method %in% c("correlation", "spearman", "kendall")) { 
        cat(" from Dist .... \nStart time:",format(Sys.time(), date.format)); 
        dist.mat <- 
Dist(as.matrix(eventTable[,(2:(number_of_eventCodesGroup+3))],method=dist.method, 
nbproc=no_cores, upper=FALSE)); 
        R_function <- "parDist" 
        cat("; End time: ",format(Sys.time(), date.format)); 
      } else { 
        cat("\nDistance method",dist.method,"not found: skipping") 
      } 
       
      dist.matrix <- as.matrix(dist.mat, nrow=n); # convert the distance matrix to a 
standard matrix with n rows 
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      ######################################################## 
      # do clustering 
      ######################################################## 
       
      for (hclust_method in cluster_method) { 
         
        cat("\nCondition = ", condition, "; distance method = ", dist.method, "; Clustering 
using", hclust_method,"..."); 
         
        clust.res <- hclust(dist.mat,method=hclust_method) 
        plot(clust.res); 
         
        if (length(eventTable$patid) < clustersMax) clustersMax <- 
length(eventTable$patid) 
         
        line <- data.frame(clusterNo=numeric(), level=numeric(), condition=character(), 
no_of_patients=numeric(), sensitivity=numeric(), specificity=numeric(), 
youden=numeric(), F1=numeric(), PPV=numeric(), FPV=numeric(), correct=numeric(), 
incorrect=numeric(), not_scored <- numeric(), stringsAsFactors=FALSE); 
        count <- 0; 
        cluster_set <- c(2:50, seq(60, (clustersMax-51), 10), (clustersMax-
50):clustersMax); 
        for (i in clusterNumbers) { 
        for (i in clusters_set) { 
          count <- count+1; 
          temp_frame <- data.frame(temp=numeric()); 
          line <- data.frame(line, temp_frame); 
          colnames(line)[(count+12)] <- paste("cluster",i,sep=""); 
        } 
        temp_frame <- data.frame(total=numeric(),stringsAsFactors = FALSE); 
        line <- data.frame(line, temp_frame); 
        trackingTable <- eventTable[,c("patid", "targetTrueFalse")] 
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        trackingTableRisk <- eventTable[,c("patid", "targetTrueFalse")] 
         
        ccF1 <- data.frame(computer_name=character(), date=character(), runNo = 
integer(), dist_method=character(), dist.binary=logical(), hclust_method=character(), 
condition=character(), nrows=integer(), validPatients=integer(), 
minEVentsCount=integer(), level=integer(), clusters = integer(), prior=numeric(), 
TP=integer(), TN=integer(), FP=integer(), FN=integer(), sensitivity=numeric(), 
specificity=numeric(), F1=numeric(), adj_F1=numeric(), F2=numeric(), 
adj_F2=numeric(), PPV=numeric(), NPV=numeric(), MCC=numeric(), 
R_function=character(), stringsAsFactors=FALSE); 
 
        cat("\nCycling through cluster numbers"); 
      
        for (clusterNo in clusters_set) { 
          cat("\n\nStart cluster", clusterNo,"...") 
          cluster.cut <- cutree(clust.res, k = clusterNo);   # k - an integer scalar or vector 
with the desired number of groups;   
          results <- data.frame(patid=eventTable$patid, 
true.outcome=eventTable$targetTrueFalse, predicted.cluster=cluster.cut, 
stringsAsFactors=FALSE); 
          eventT <- table(results[,3], as.logical(results[,2])) 
           
          #set up a data frame of patients(rows) by events (columns) 
          cc <- data.frame(cluster = numeric(), ConditionNeg = numeric(), conditionPos = 
numeric(), NoPatients = numeric(), prevalence = numeric()) 
           
          for (i in 1:clusterNo) { 
            cc[i,1] <- rownames(eventT)[i]; 
            cc[i,2] <- eventT[i,1]; 
            cc[i,3] <- eventT[i,2]; 
            cc[i,4] <- sum(eventT[i,1:2]); 
            cc[i,5] <- cc[i,3]/cc[i,4]; # this includes our patient of interest - shouldn't  
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          } 
           
          cc$TrueFalsePred <- NA; 
           
          j <- i+1; 
          cc[j,1] <- "All"; 
          cc[j,2] <- length(results[,2])-sum(results[,2]); 
          cc[j,3] <- sum(results[,2]); 
          cc[j,4] <- length(results[,2]); 
          cc[j,5] <- sum(results[,2])/length(results[,2]); 
           
          TP <- 0; TN <- 0; FP <- 0; FN <- 0; NPT <- 0; NPF <- 0; 
           
          for (patient in results[,1]) { 
          trueOutcome <- as.numeric(results[results$patid == patient,]$true.outcome); 
 # did our patient have the condition? 
          predictedCluster <- results[results$patid == patient,]$predicted.cluster; # what 
cluster is our patient in? 
          rawPositive <- cc[predictedCluster,]$conditionPos;  # number of positive patients 
in the cluster - INCLUDING our patient of interest 
          rawNegative <- cc[predictedCluster,]$ConditionNeg;  # number of negative 
patients in the cluster - INCLUDING our patient of interest 
          rawNoPatients <- cc[predictedCluster,]$NoPatients;  # total number of patients in 
the cluster - INCLUDING our patient of interest 
          adjustedNoPatients <- rawNoPatients - 1; # number of patients in the cluster after 
removing our patient of interest 
          adjustedPositive <- rawPositive - trueOutcome; # number of positive patients in 
the cluster after removing our patient of interest 
          adjustedNegative <- rawNegative - (1 - trueOutcome); # number of negative 
patients in the cluster after removing our patient of interest 
           
           
Chapter 11: Appendices 
 
 
510 
 
            if (adjustedNoPatients > 0) { # if we have enough "other" patients in the cluster 
to calculate an in-cluster prevalence 
              Ao <- adjustedPositive; Bo <- (sum(results[,2]) - rawPositive); Co <- 
adjustedNegative; Do <- length(results[,2]) - rawNoPatients - Bo; 
              Ae <- (Ao+Bo)*(Ao+Co)/(Ao+Bo+Co+Do) 
              Be <- (Ao+Bo)*(Bo+Do)/(Ao+Bo+Co+Do) 
              Ce <- (Co+Do)*(Ao+Co)/(Ao+Bo+Co+Do) 
              De <- (Co+Do)*(Bo+Do)/(Ao+Bo+Co+Do) 
              CsqCalc <- (Ao-Ae)*(Ao-Ae)/Ae + (Bo-Be)*(Bo-Be)/Be + (Co-Ce)*(Co-
Ce)/Ce + (Do-De)*(Do-De)/De; 
              p <- 1; 
              if (is.nan(CsqCalc)) { 
                CsqCalc <- 0; 
              } 
              if (CsqCalc > 3.84) p <- 0.05; 
              if (CsqCalc > 6.64) p <- 0.01; 
              if (p < 0.05) { 
                adjustedClusterPrediction <- 1; 
              } else { 
                adjustedClusterPrediction <- 0; 
              } 
            } 
           
            cc[predictedCluster,]$TrueFalsePred <- adjustedClusterPrediction; # classifies a 
cluster's prediction as 'TRUE' if prevalence significantly > pop'n prevalence 
             
            if (trueOutcome == 1) { # if our patient of interest really did have the condition 
              if (adjustedClusterPrediction == 1) { # and we predicted this 
                TP <- TP + 1; 
              } else if (adjustedClusterPrediction == 0) { # and we didn't predict it 
                FN <- FN + 1; 
              } else if (adjustedClusterPrediction == -1) { 
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                NPT <- NPT + 1; # no prediction made since our patient in a singleton cluster 
              } else cat("adjustedClusterPredictionT = ", adjustedClusterPrediction); 
            } else if (trueOutcome == 0) { # if our patient of interest didn't have the 
condition 
              if (adjustedClusterPrediction == 1) { # but we predicted that they did 
                FP <- FP + 1; 
              } else if (adjustedClusterPrediction == 0) { # or we correctly predicted that 
they didn't 
                TN <- TN + 1; 
              } else if (adjustedClusterPrediction == -1) { 
                NPF <- NPF + 1; # no prediction made since our patient in a singleton cluster 
              } else cat("adjustedClusterPredictionF = ", adjustedClusterPrediction); 
              #} # else cat("clusterPrediction = ", adjustedClusterPrediction); # safety check 
            } # else cat("trueOutcome = ", trueOutcome); # safety check 
          } 
          results <- data.frame(results, 
predicted.TrueFalse=get_prediction(results$predicted.cluster), 
predicted.Risk=get_predictedRisk(results$predicted.cluster), 
PosPatients=cc[results$predicted.cluster,]$conditionPos, 
totalPatients=cc[results$predicted.cluster,]$NoPatients); 
         
          cat("\nCondition:", condition, "; clustering method: ", hclust_method, "; 
Clusters:", clusterNo, ";", nrows, "recs; level:", granularity_group); 
          cat("\nTP:",TP, "; FP:", FP, "; TN: ", TN, "; FN:", FN,"; NP: ", (NPF+NPT),";"); 
          cat(dist.method,";",hclust_method); 
          sensitivity <- TP / (TP + FN); # aka recall 
          specificity <- TN / (TN + FP); 
          cat("; sens:", format(round(sensitivity,3),nsmall=3), "; spec: ", 
format(round(specificity,3),nsmall=3)); 
           
          PPV <- TP / (TP+ FP); # aka precision 
          NPV <- TN / (TN + FN); 
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          F1 <- 2 * (PPV * sensitivity) / (PPV + sensitivity) 
          cat("; F1 = ", F1); 
           
          #now add in the singleton clusters to the calculation 
          adj_TN <- TN + NPF; 
          adj_FN <- FN + NPT; 
          adj_PPV <- TP / (TP+ FP); # aka precision 
          adj_NPV <- adj_TN / (adj_TN + adj_FN); 
          adj_sensitivity <- TP / (TP + adj_FN); # aka recall 
          adj_specificity <- adj_TN / (adj_TN + FP); 
          # cat("; PPV = ", PPV, "; NPV = ", NPV); 
          adj_F1 <- 2 * (adj_PPV * adj_sensitivity) / (adj_PPV + adj_sensitivity) 
          if (is.nan(adj_F1)) adj_F1 <- 0; 
          cat("; adj_F = ", adj_F1); 
           
          ccF1[clusterNo,]$clusters <- clusterNo; 
          ccF1[clusterNo,]$TP <- TP; 
          ccF1[clusterNo,]$FP <- FP; 
          ccF1[clusterNo,]$TN <- TN; 
          ccF1[clusterNo,]$FN <- FN; 
          ccF1[clusterNo,]$sensitivity <- sensitivity; 
          ccF1[clusterNo,]$specificity <- specificity; 
          ccF1[clusterNo,]$F1 <- F1; 
          ccF1[clusterNo,]$computer_name <- computer_name; 
          ccF1[clusterNo,]$date <- date_today; 
          ccF1[clusterNo,]$nrows <- nrows; 
          ccF1[clusterNo,]$condition <- condition; 
          ccF1[clusterNo,]$dist.method <- dist.method; 
          ccF1[clusterNo,]$dist.binary <- dist.binary; 
          ccF1[clusterNo,]$hclust_method <- hclust_method; 
          ccF1[clusterNo,]$level <- granularity_group; 
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          beta <- 2; 
           
          F2 <- 2 * ((1 + 
beta*beta)*((ccF1[clusterNo,]$TP/(ccF1[clusterNo,]$TP+ccF1[clusterNo,]$FP)) * 
ccF1[clusterNo,]$sensitivity)) / 
(beta*beta*(ccF1[clusterNo,]$TP/(ccF1[clusterNo,]$TP+ccF1[clusterNo,]$FP)) + 
ccF1[clusterNo,]$sensitivity); 
          if (is.nan(F2)) F2 <- 0 
          cat("; F2:",F2); 
          adj_F2 <- 2 * ((1 + beta*beta)*((TP/(TP+FP)) * adj_sensitivity)) / 
(beta*beta*(TP/(TP+FP)) + adj_sensitivity); 
          cat("; adj_F2:",adj_F2); 
           
          ccF1[clusterNo,]$adj_F1 <- adj_F1; 
          ccF1[clusterNo,]$F2 <- F2; 
          ccF1[clusterNo,]$adj_F2 <- adj_F2; 
          ccF1[clusterNo,]$R_function <- "dist"; 
           
          MCC <- ((TP*TN)-(FP*FN)) / sqrt((TP+FP)*(TP+FN)*(TN+FP)*(TN+FN)); 
          write.table(t(c(computer_name, date_today, runNo, dist.method, dist.binary, 
hclust_method, condition, nrows,length(eventTable$targetTrueFalse), minEventsCount, 
granularity_group, clusterNo, group_prevalence, TP, TN, FP, FN, sensitivity, 
specificity, F1, adj_F1, F2, adj_F2, MCC, PPV, NPV, MCC)), file=outputFileName, 
append=TRUE,col.names=FALSE, row.names=FALSE, sep=",");           
           
        } 
         
        beta <- 2; 
        ccF1$Fbeta <- 2 * ((1 + beta*beta)*((ccF1$TP/(ccF1$TP+ccF1$FP)) * 
ccF1$sensitivity)) / (beta*beta*(ccF1$TP/(ccF1$TP+ccF1$FP)) + ccF1$sensitivity) 
         
        ccF1$runNo <- runNo; 
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        ccF1 <- ccF1[complete.cases(ccF1$computer_name),]; 
         
        ####################################################### 
        # end of do clustering 
        ######################################################## 
         
        sensitivity <- TP/(TP + FN); # aka recall 
        specificity <- TN/ (TN + FP); 
        PPV <- TP / (TP + FP); # aka precision 
        NPV <- TN / (TN + FN); 
        #TP[,j] <- TP; FP[,j] <- FP; TN[,j] <- TN; FN[,j] <- FN; 
        #prevPPV[,j] <- prevTPlocal / (prevTPlocal + prevFPlocal); 
        F1 <- 2 * (PPV * sensitivity) / (PPV + sensitivity); 
        #prevF2[,j] <- 2 * ((1 + beta*beta)*((TP/(TP+FP)) * TP / (TP + FN))) / 
(beta*beta*(TP/(TP+FP)) + TP / (TP + FN)); 
        F2 <- ((1 + (beta*beta))*PPV * sensitivity) / ((beta*beta*PPV) + sensitivity); 
        MCC <- ((TP*TN)-(FP*FN)) / sqrt((TP+FP)*(TP+FN)*(TN+FP)*(TN+FN)) 
         
        LRpos <- sensitivity/(1- specificity); 
        LRneg <- (1 - sensitivity)/specificity; 
        m <- matrix(c(TP, FN, FP, TN),2); 
        m_lr.ci <- calcLikelihoodRatio(m); 
        m_odds_ratio <- calcOddsRatio(TP, FP, FN, TN); 
         
        cat("\n", condition, ";", dist.method, "; level = ", granularity_group); 
        cat("; clusters:", clusters_set, "; TP:", TP, "; TN:", TN, "; FP:", FP, "; FN:", FN, "; 
total:", TP+FP+TN+FN); 
        cat("\nSensitivity:", sensitivity, "Specificity:", specificity, "F1:", F1, ": F2:", F2, "; 
MCC:", MCC, "; PPV:", PPV, "; NPV:", NPV); 
        cat("\nPos Likelihood Ratio =", m_lr.ci$lr.pos, "(",m_lr.ci$lower.pos, ",", 
m_lr.ci$upper.pos,")"); 
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        cat("; Neg Likelihood Ratio =", m_lr.ci$lr.neg, "(",m_lr.ci$lower.neg, ",", 
m_lr.ci$upper.neg,")") 
         
        cat("\nOdds ratio = ", m_odds_ratio$OR, "; 95% CI = (", m_odds_ratio$LowerCI, 
",", m_odds_ratio$UpperCI, ")"); 
         
        test.result <- "+"; 
        probs.pre.test <- group_prevalence; 
        LR_pos <- round(m_lr.ci$lr.pos,2); 
        if (is.nan(LR_pos)) LR_pos<-1; 
        LR_neg <- round(m_lr.ci$lr.neg,2); 
        if (is.nan(LR_neg)) LR_pos<-1; 
        LR_pos_lower <- round(m_lr.ci$lower.pos,2); 
        LR_pos_upper <- round(m_lr.ci$upper.pos,2); 
        LR_neg_lower <- round(m_lr.ci$lower.neg,2); 
        LR_neg_upper <- round(m_lr.ci$upper.neg,2); 
        OR <- round(m_odds_ratio$OR,2); 
        OR_lower <- round(m_odds_ratio$LowerCI,2); 
        OR_upper <- round(m_odds_ratio$UpperCI,2); 
         
      plotname <- paste("Fagan_test_clustering_test_random_", condition, "_", 
clusters_set,"_",computer_name, ".jpg", sep="") 
      jpeg(plotname, width = 6, height = 5, units = 'in', res = 300) 
         
        opar <- par(no.readonly = T) 
        on.exit(par(opar)) 
        par(mar = c(1.5, 6, 2, 6)) 
        stato <- ifelse(test.result == "+", "disease", "no disease") 
        if (probs.pre.test > 1 | probs.pre.test < 0 | LR_pos < 0 | is.infinite(LR_pos) | 
is.nan(LR_pos) | test.result %in% c("+", "-") == F) { 
          cat("wrong values !!") 
        } else { 
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          logits <- function(p) log(p/(1 - p)) 
        } 
        logits.pre <- logits(probs.pre.test) 
        logits.pos.post <- log(LR_pos) + logits.pre 
        probs.pos.post.test <- exp(logits.pos.post)/(1 + exp(logits.pos.post)) 
        logits.pos.post_lower <- log(LR_pos_lower) + logits.pre 
        probs.pos.post.test_lower <- exp(logits.pos.post_lower)/(1 + 
exp(logits.pos.post_lower)) 
        logits.pos.post_upper <- log(LR_pos_upper) + logits.pre 
        probs.pos.post.test_upper <- exp(logits.pos.post_upper)/(1 + 
exp(logits.pos.post_upper)) 
         
        logits.neg.post <- log(LR_neg) + logits.pre 
        probs.neg.post.test <- exp(logits.neg.post)/(1 + exp(logits.neg.post)) 
        logits.neg.post_lower <- log(LR_neg_lower) + logits.pre 
        probs.neg.post.test_lower <- exp(logits.neg.post_lower)/(1 + 
exp(logits.neg.post_lower)) 
        logits.neg.post_upper <- log(LR_neg_upper) + logits.pre 
        probs.neg.post.test_upper <- exp(logits.neg.post_upper)/(1 + 
exp(logits.neg.post_upper)) 
         
        compl.logit.pre <- logits(1 - probs.pre.test) 
        compl.logit.post <- logits(1 - probs.pre.test) 
         
        LR.vec <- c(0.001, 0.002, 0.005, 0.01, 0.02, 0.05, 0.1, 0.2, 
                    0.5, 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000) 
        prob.vec <- c(0.001, 0.002, 0.003, 0.005, 0.007, 0.01, 0.02, 
                      0.03, 0.05, 0.07, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 
                      0.8, 0.9, 0.93, 0.95, 0.97, 0.98, 0.99, 0.993, 0.995, 
                      0.997, 0.998, 0.999) 
        plot(0, 0, type = "n", ylim = range(logits(prob.vec)), axes = F, 
             xlab = "", ylab = "") 
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        axis(2, rev(logits(prob.vec)), 100 * prob.vec, pos = -1, 
             las = 1, cex.axis = 0.7) 
        axis(2, rev(logits(prob.vec)), 100 * prob.vec, pos = -1, 
             tck = 0.03, labels = F) 
        axis(4, logits(prob.vec), 100 * prob.vec, pos = 1, las = 1, 
             cex.axis = 0.7) 
        axis(4, logits(prob.vec), 100 * prob.vec, pos = 1, tck = 0.03, 
             labels = F) 
        axis(2, log(LR.vec[1:10])/2, LR.vec[1:10], pos = 0, las = 1, 
             cex.axis = 0.7) 
        axis(2, log(LR.vec[1:10])/2, LR.vec[1:10], pos = 0, tck = 0.03, 
             labels = F) 
        axis(4, log(LR.vec[10:19])/2, LR.vec[10:19], pos = 0, las = 1, 
             cex.axis = 0.7) 
        axis(4, log(LR.vec[10:19])/2, LR.vec[10:19], pos = 0, tck = 0.03, 
             labels = F) 
        text(0, 4.5, "Likelihood ratio", cex = 1.2) 
        segments(-1, compl.logit.pre, 1, logits.pos.post, lwd = 1.5, 
                 col = 2) 
        segments(-1, compl.logit.pre, 1, logits.pos.post_lower, lwd = 1.5, 
                 col = 2) 
        segments(-1, compl.logit.pre, 1, logits.pos.post_upper, lwd = 1.5, 
                 col = 2) 
         
         
        segments(-1, compl.logit.pre, 1, logits.neg.post, lwd = 1.5, 
                 col = 3) 
        segments(-1, compl.logit.pre, 1, logits.neg.post_lower, lwd = 1.5, 
                 col = 3) 
        segments(-1, compl.logit.pre, 1, logits.neg.post_upper, lwd = 1.5, 
                 col = 3) 
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        x_neg <- c(-1, -1, 1, 1); 
        y_neg <- c(compl.logit.pre, compl.logit.pre, logits.neg.post_lower, 
logits.neg.post_upper); 
        polygon(x_neg,y_neg, col="green"); 
         
        x_pos <- c(-1, -1, 1, 1); 
        y_pos <- c(compl.logit.pre, compl.logit.pre, logits.pos.post_lower, 
logits.pos.post_upper); 
        polygon(x_pos,y_pos, col="red"); 
       
        segments(-1, compl.logit.pre, 1, logits(probs.pre.test), lwd = 1.5, col = 1) 
    
        mtext(side = 2, text = "Prior probability(%)", line = 2,cex = 1.2) 
        mtext(side = 4, text = "Posterior probability(%)", line = 2, cex = 1.2, las = 3) 
         
        title(main=condition); 
        text(0, -6.3, paste("Prior prob. of disease =", round(100 * probs.pre.test, 2), "% \n", 
                      "Post test prob. of disease+ =", ifelse(test.result == "+", round(100 * 
probs.pos.post.test,2), round(100 * (1 - probs.pos.post.test), 2)), "%", "\n", 
                      "Likelihood ratio+ ", "=", round(LR_pos, 
2),"(",LR_pos_lower,",",LR_pos_upper,")", "\n",  
                      "Likelihood ratio- ", "=", round(LR_neg, 2),"(", LR_neg_lower,",", 
LR_neg_upper,")", "\n", 
                     "Odds ratio = ", OR, "(", OR_lower, ",", OR_upper, ")","\n"), cex = 0.7) 
        dev.off() 
        if (writeColNames == TRUE) { 
          write.table(t(c("condition","dist_method", 
"sampleSize","validPatients","minEventsCount", "granularityLevel","k", "Prior", 
"Posterior_pos", "Post_pos_lower", "Post_pos_upper",  "Posterior_neg", 
"Post_neg_lower", "Post_neg_upper", "TP", "TN", "FP", "FN", "Sensitivity", 
"Specificity", "F1","F2", "MCC", "PPV", "NPV", "LR_pos", "LR_pos_lower", 
"LR_pos_upper", "LR_neg", "LR_neg_lower", "LR_neg_upper","OR", "OR_lower", 
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"OR_upper")),file=outputFileName,append=TRUE,col.names=FALSE, 
row.names=FALSE, sep=","); 
          writeColNames <- FALSE; 
        } 
      } 
      } 
    } 
  } 
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APPENDIX 7: R CODE FOR NEAREST NEIGHBOURS 
Using the nearest neighbours method used the same basic R code as for the clustering 
method, replacing the clustering section of the clustering program shown in Appendix5 
with distance matrix and nearest neighbours code. Those sections only are shown here. 
 
The same basic code is used for the training and testing phases. In the training phase, 
the program loops over all options for the value of k and the options for CTV3 
hierarchy level. In the testing phase, these values are fixed. 
    ######################################################## 
      # nearest neighbours 
      ######################################################## 
       
        cat("\nCalculating nearest neighbours...");  
        # for each record, order its nearest neighbours best on the distance matrix.        for 
(i in 1:n) { 
          nn_dup[i,] <- order(dist.matrix[i,]); 
        } 
        eventTable$generatedID <- 1:n; 
        outcomes <- eventTable$targetTrueFalse; 
        names(outcomes) <- eventTable$generatedID; 
        # for each record, generate a table of "has condition" or "does not have the 
condition" for each of a record's neighbours 
        for (j in 1:n) { 
          nnTF_dup[,j] <- outcomes[nn_dup[,j]]; 
        } 
         
        ######################################################## 
        # end do nearest neighbours 
        ######################################################## 
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APPENDIX 8: APPROVALS 
 
 
Senate Research Ethics Committee 
Application for Approval of Research Involving Human Participants 
 
Please tick the box for which Committee you are submitting your application to 
 Senate Research Ethics Committee  
 Cass Business School 
 School of Arts & School of Social Sciences Research Ethics Committee 
 School of Health Sciences Research Ethics Committee 
 School of Informatics 
 Learning Development Centre 
 
For Senate applications: return one original and eight additional hardcopies of the 
completed form and any accompanying documents to Anna Ramberg, Secretary to 
Senate Research Ethics Committee, University Research Office, Northampton Square, 
London, EC1V 0HB. Please also email an electronic copy to 
 (indicating the names of those signing the hard copy). 
 
For School of Arts & School of Social Sciences Research Ethics Committee submit a 
single copy of the application form and all supporting documentation to your 
Department’s Research and Ethics Committee by email.  
 
For School of Health Sciences applications: submit all forms (including the Research 
Registration form) electronically (in Word format in a single document) to 
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For School of Informatics applications: a single copy of the application form and all 
supporting documents should be emailed to Stephanie Wilson  
 
For Learning Development Centre a single copy of the application form and all the 
supporting documentations should be emailed to Pam Parker   
 
Refer to the separate guidelines while completing this form. 
 
PLEASE NOTE 
 Please determine whether an application is required by going through the 
checklist before filling out this form. 
 Ethical approval MUST be obtained before any research involving human 
participants is undertaken. Failure to do so may result in disciplinary procedures 
being instigated, and you will not be covered by the University’s indemnity if 
you do not have approval in place. 
 You should have completed every section of the form 
 The Signature Sections must be completed by the Principal Investigator (the 
supervisor and the student if it is a student project) 
 
Project Title: 
Self-reported health histories via anonymous web survey 
 
 
Short Project Title (no more than 80 characters):  
Self-reported health histories via anonymous web survey 
 
 
Name of Principal Investigator(s) (all students are require to apply jointly with their 
supervisor and all correspondence will be with the supervisor): 
Jonathan Turner 
Dr Peter Weller 
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Post Held (including staff/student number): 
Jonathan Turner:  
Dr Peter Weller 
 
Department(s)/School(s) involved at City University London: 
Centre for Health Informatics 
 
 
If this is part of a degree please specify type of degree and year 
PhD Health Informatics year 3 
 
Date of Submission of Application: 
2/5/2014 
 
 
 
1. Information for Non-Experts  
 
Lay Title (no more than 80 characters) 
Self-reported health histories via anonymous web survey 
 
Lay Summary / Plain Language Statement (no more than 400 words) 
This research project is intended to collect anonymous information on individuals' 
recollections of their health events throughout their life, for the purpose of (i) 
comparing individuals’ aggregated recollections of events to those stored in average 
health records and (ii) to see whether such individual-recalled event data can be used 
to modulate predictions of future health events. 
 
Survey respondents will be invited to list, to the best of their recollection and without 
historical time limit, personal health events and ongoing conditions including, but not 
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limited to, those events that were reported to or required the intervention of a general 
practitioner or other healthcare professional.  
 
Respondents will also be invited to note their age group, weekly exercise habits, 
smoking status and alcohol consumption, and country of birth. In order to preserve 
anonymity, respondents will not be asked for their name, exact age or current country 
of residence.  
 
Respondents who know the principal investigator will be discouraged from returning 
their information (they will be warned that by doing so they may inadvertently reveal 
medical conditions that they would prefer not to) but, given the anonymous nature of 
the process, cannot be prevented from participating. However, the investigators 
undertake not to attempt to re-identify any individuals from their submitted data. 
 
Once data have been collected, they will be used: 
 
i) To see how individuals’ recollections of medical conditions compare, on 
average, to the quantity and detail of events typically stored in general 
practice records; 
ii) As input to a health event prediction algorithm, in order to see whether 
patient-recalled data is of adequate quality to have practical use in such an 
algorithm. 
 
 
 
 
2. Applicant Details 
 
This project involves:  
(tick as many as apply) 
 Staff Research   Doctoral Student  
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 Undergraduate   M-level Project 
 Externally funded  External 
investigators 
 Collaboration  Other  
Provide details of 
collaboration and/or 
other 
      
     
Address for correspondence (including email address and telephone number) 
(Principal Investigator) 
Jonathan Turner, Centre for Health Informatics, City University London, Northampton 
Square, London EC1V 0HB 
 
(No City University telephone number) 
 
 
 
Other staff members involved  
Title, Name 
& Staff 
Number 
Post Dept & 
School 
Phone Email 
Dr Peter 
Weller 
Senior 
Lecturer 
Computer 
Science / 
MCSE 
  
                              
                              
                              
 
All students involved in carrying out the investigation  
Name & Student 
Number 
Course / Year Dept & School Email 
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Jonathan Turner 
 
PhD Health 
Informatics year 
3 
Centre for 
Health 
Informatics, 
School of 
Informatics 
                        
                        
                        
 
External co-investigators 
Title & Name Post Institution Phone Email 
-                         
                              
                              
                              
 
Please describe the role(s) of all the investigators including all student(s)/external co-
investigator(s) in the project, especially with regards to interaction with study 
participants. 
Jonathan Turner has designed the study, will place the questionnaire form on the web 
and will be responsible for the promotion of the study, data collection and analysis 
and participant anonymity. 
 
 
 
If external investigators are involved, please provide details of their indemnity cover. 
No external investigators are involved 
 
 
 
Application Details 
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2.1 Is this application being submitted to another ethics committee, or has it been 
previously submitted to an ethics committee? This includes an NHS local Research 
Ethics Committee or a City University London School Research Ethics Committee or 
any other institutional committee or collaborating partners or research site. (See the 
guidelines for more information on research involving NHS staff/patients/ premises.) 
        YES  NO  
 
If yes, please provide details for the Secretary for the relevant authority/committee, as 
well as copies of any correspondence setting out conditions of approval. 
- 
 
 
2.2 If any part of the investigation will be carried out under the auspices of an outside 
organisation, e.g. a teaching hospital, please give details and address of organisation. 
N/A 
 
 
 
 
2.3 Other approvals required – has permission to conduct research in, at or through 
another institution or organisation been obtained?      YES  NO  
 
If yes, please provide details and include correspondence 
      
 
 
2.4 Is any part of this research project being considered by another research ethics 
committee?        YES  NO  
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If yes, please give details and justification for going to separate committees, and attach 
correspondence and outcome 
      
 
 
2.5 Duration of Project    
Start date:  1/6/2014  Estimated end date:1/10/2015 
 
 
Funding Details 
 
2.6 Please provide details of the source of financial support (if any) for the proposed 
investigation. 
No expenses are expected to be incurred by this project 
 
 
2.6a Total amount of funding being sought:   
 
2.6b Has funding been approved?     YES  NO  
 
If no, please provide details of when the outcome can be expected 
      
 
2.6c Does the funding body have any requirements regarding retention, access and 
storage of the data?       YES  NO  
 
If yes, please provide details 
      
 
 
 
0 
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International Research 
 
2.7 Is any part of the research taking place outside of England/Wales? (if not go to 
section 3)         YES  NO 
 
 
If yes, please provide details of where 
Respondents completing the web form could be outside England/Wales – there are no 
geographic restrictions. Data will be collected, stored and processed in England. 
 
2.7a Have you identified and complied with all local requirements concerning ethical 
approval & research governance*?     YES  NO  
 
 
2.7b Please provide details of the local requirements, including contact information. 
      
 
 
2.7c Please give contact details of a local person identified to field initial complaints 
local so the participants can complain without having to write to or telephone the UK   
All contact with participants will be via a web page which will contain information on 
how to contact the project team -likely to be the email address for Jonathan Turner at 
City University London  
 
 
*Please note many countries require local ethical approval or registration of research 
projects, further some require specific research visas. If you do not abide by the local 
rules of the host country you will invalidate your ethical approval from City University 
London, and may run the risk of legal action within the host country.   
 
3. Project Details 
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3.1 Provide the background, aim and explanation for the proposed research.  
This research project is intended to collect anonymous information on individuals' 
recollections of their health events throughout their life. Data collected will be used 
 
i) To see how individuals’ recollections of medical conditions compare, on 
average, to the quantity and detail of events typically stored in general 
practice records; 
ii) As input to a health event prediction algorithm, in order to see whether 
patient-recalled data is of adequate quality to have practical use in such an 
algorithm. 
 
Survey respondents will be invited to list, to the best of their recollection and without 
historical time limit, personal health events and ongoing conditions including, but not 
limited to, those events that were reported to or required the intervention of a general 
practitioner or other healthcare professional.  
 
Respondents will also be invited to note their age group, weekly exercise habits, 
smoking status and alcohol consumption, and country of birth. In order to preserve 
anonymity, respondents will not be asked for their name, exact age or current country 
of residence.  
 
 
 
 
 
3.2 Provide a summary and brief explanation of the design, methodology and plan for 
analysis that you propose to use. 
Individuals will be asked to provide a few items of personal information - age group, 
smoking status, alcohol consumption, weekly exercise - and a list of health events that 
they can recall suffering from, together with the age at which they suffered these 
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events. 
 
Data will be collected anonymously by convenience sampling via a short web 
questionnaire. 
 
Once data have been collected they will be analysed 
i) by indication of smoking status, alcohol consumption, exercise quantity against 
conditions recorded by participants and known to be linked to these factors. This is to 
help understand how the sample compares to the general population. 
ii) against those recorded in formal general practice records, to see how well the 
individuals' recollection of their health conditions compares with the formal records, 
for average number of conditions recorded per individual and distribution of recorded 
conditions (e.g. are more serious conditions more likely to be recalled?).  
iii) as input to a health event predictor algorithm, to see how well predictions based on 
patient-supplied data perform compared to predictions based on formal medical 
records. 
 
Comparisons will be at an aggregated level, i.e. , i.e. we will be looking to see how 
condition prevalences indicated by the survey responses compare to those indicated 
by published data, e.g. from the Quality and Outcomes Framework, Practice Fusion 
Insight or other published work (e.g. Blak et al, Generalisability of The Health 
Improvement Network (THIN) database, Informatics in Primary Care 2011). 
Individuals providing information to the survey will not be identified in the study and 
it will not be possible to link them to particular GP records.  
 
 
 
3.3 Please explain your plans for dissemination, including whether participants will be 
provided with any information on the findings or outcomes of the project. 
This project forms part of Jonathan Turner's PhD work and results will be included 
there. Results will also be made available on the website used for data collection and a 
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paper will be submitted to an appropriate journal or conference. It will not be possible 
to send results directly to participants due to the anonymous nature of data collection. 
 
 
 
 
 
3.4 What do you consider are the ethical issues associated with conducting this research 
and how do you propose to address them? 
Ethical issues are primarily around collection of personal, individual data. For this 
project, survey respondents are asked not to identify themselves; potential 
respondents are asked not to participate if they feel that they know the investigators in 
order to avoid the possibility of the investigators having the potential to identify 
participants by some unique combination of information supplied. 
 
 
 
 
 
3.5 How is the research intended to benefit the participants, third parties and/or local 
community? 
The research will not directly benefit the participants but may provide benefits to 
future patients, to the wider community and a general contribution to knowledge. 
 
 
 
 
3.6a Will invasive procedures (for example medical or surgical) be used? 
         YES  NO  
 
3.6b If yes, what precautions will you take to minimise any potential harm? 
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3.7a Will intrusive procedures (for example psychological or social) be used? 
         YES  NO  
 
3.7b If yes, what precautions will you take to minimise any potential harm? 
      
 
 
3.8a In the course of the investigation might pain, discomfort (including psychological 
discomfort), inconvenience or danger be caused?    YES  NO  
 
 
3.8b If yes, what precautions will you take to minimise any potential harm? 
      
 
 
3.9 Please describe the nature, duration and frequency of the procedures? 
      
 
 
 
4. Information on participants 
 
4.1a How many participants will be involved?  
The number of participants will be limited by time, dissemination speed of the survey 
invitation and response rate, but there is no absolute limit at which recruitment will 
halt. It is expected that meaningful results will be obtained once 50 responses are 
received.  
This has been calculated by use of the the sample size calculator at 
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http://www.raosoft.com/samplesize.html, using 10% margin of error, 95% 
confidence, 20,000 population size and 10% response distribution (very roughly the 
proportion of diabetes or hypertension in the general Western population), which gave 
a sample size of 35, which I rounded up to 50 to allow for invalid or incomplete 
questionnaires). 
 
4.1b What is the age group and gender of the participants? 
Participants are asked if they are 18 years old or older and excluded if they are 
younger than this. Not limited by gender. 
 
4.1c Explain how you will determine your sample size and the selection criteria you will 
be using. Specify inclusion and exclusion criteria. If exclusion of participants is made 
on the basis of age, gender, ethnicity, race, disability, sexuality, religion or any other 
factor, please explain and justify why. 
Inclusion criteria: all adults who have access to the world wide web. 
Exclusion criteria: There are no exclusion criteria. Participants are not asked for their 
ethnicity, race, sexuality, religion or whether they have any disabilities. 
 
 
 
4.2 How are the participants to be identified, approached and recruited, and by whom? 
Participants are self-selecting, approached via general postings on Facebook, Twitter, 
LinkedIn and emails to general or professional discussion groups (specifically 
excluding those used by individuals to discuss medical conditions or care). Directly 
targeted invitations to named individuals will not be used. 
 
 
4.3 Describe the procedure that will be used when seeking and obtaining consent, 
including when consent will obtained. Include details of who will obtain the consent, 
how are you intending to arrange for a copy of the signed consent form for the 
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participants, when will they receive it and how long the participants have between 
receiving information about the study and giving consent. 
Consent will be asked for at the time of participation in the survey. Due to the 
anonymous nature of the survey, participants will not be asked for a signature, merely 
to tick a box saying that they give their consent for their anonymous response to be 
used. 
 
 
 
4.4 How will the participant’s physical and mental suitability for participation be 
assessed? Are there any issues related to the ability of participants to give informed 
consent themselves or are you relying on gatekeepers on their behalf?  
Due to the anonymous nature of the survey, it is not possible to assess participants’ 
suitability for participation.  
 
 
 
4.5 Are there any special pressures that might make it difficult to refuse to take part in 
the study? Are any of the potential participants in a dependent relationship with any of 
the investigators (for instance student, colleague or employee) particularly those 
involved in recruiting for or conducting the project? 
Responses to the survey are anonymous and it will not be possible to ascertain 
whether any individual has or has not participated. There are no pressures on 
individuals to participate. Individuals known to the principal investigator are 
encouraged not to participate for the reasons outlined in 3.4 
 
 
 
4.6 Will the participant’s doctor be notified?    YES  NO  
(If so, provide a sample letter to the subject’s GP.) 
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4.7 What procedures are in place for the appropriate referral of a study participant who 
discloses an emotional, psychological, health, education or other issue during the course 
of the research or is identified by the researcher to have such a need? 
It will not be possible to identify any study participants who have need of referral due 
to the anonymous nature of the survey and so such procedures are not possible. 
 
 
4.8 What steps will be taken to safeguard the participants from over-research? (I.e. to 
ensure that the participants are not being used in multiple research project.) 
Participants are self-selecting from the general population and so it is assumed that 
they are comfortable with their participation. 
 
 
 
4.9 Where will the research take place?  
Data will be collected and analysed at City University London but participants will 
complete the survey over the world wide web from any location that is convenient for 
them. 
 
 
4.10 What health and safety issues, if any, are there to consider?  
There are no health and safety issues for participants or investigators beyond their 
usual use of networked computers within the City University London working space. 
 
 
4.11 How have you addressed the health and safety concerns of the participants, 
researchers and any other people impacted by this study? (This includes research 
involving going into participants’ homes.) 
There are no health and safety issues for participants or investigators beyond their 
usual use of networked computers. 
 
Chapter 11: Appendices 
 
 
537 
 
 
4.12 It is a University requirement that an at least an initial assessment of risk is 
undertaken for all research and if necessary a more detailed risk assessment be carried 
out. Has a risk assessment been undertaken?*  YES  NO  
 
 
4.13 Are you offering any incentives or rewards for participating?  YES  NO  
If yes please give details 
      
 
 
*Note that it is the Committee’s prerogative to ask to view risk assessments.  
 
5. Vulnerable groups 
 
5.1 Will persons from any of the following groups be participating in the study? (if not 
go to section 6) 
Adults without capacity to consent   
Children under the age of 18  
Those with learning disabilities   
Prisoners   
Vulnerable adults  
Young offenders (16-21 years)  
Those who would be considered to have a particular dependent 
relationship with the investigator (e.g. those in care homes, 
students, employees, colleagues) 
 
 
 
5.2 Will you be recruiting or have direct contact with any children under the age of 18?  
         YES  NO  
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5.2a If yes, please give details of the child protection procedures you propose to adopt 
should there be any evidence of or suspicion of harm (physical, emotional or sexual) to 
a young person. Include a referral protocol identifying what to do and who should be 
contacted. 
      
 
 
 
5.2b Please give details of how you propose to ensure the well-being of the young 
person, particularly with respect to ensuring that they do not feel pressured to take part 
in the research and that they are free to withdraw from the study without any prejudice 
to themselves at anytime. 
      
 
 
 
 
5.3 Will you be recruiting or have direct contact with vulnerable adults? YES  NO 
 
 
5.3a If yes, please give details of the protection procedures you propose to adopt should 
there be any evidence of or suspicion of harm (physical, emotional or sexual) to a 
vulnerable adult. Include a referral protocol identifying what to do and who should be 
contacted. 
      
 
 
 
 
5.3b Please give details of how you propose to ensure the well-being of the vulnerable 
adult, particularly with respect to ensuring that they do not feel pressured to take part in 
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the research and that they are free to withdraw from the study without any prejudice to 
themselves at anytime. You should indicate how you intend to ascertain that person’s 
views and wishes. 
Although vulnerable adults are not being targeted in this survey, a proportion of the 
general population being targeted may be classed as vulnerable. Information provided 
with the survey will make it clear that (a) the survey is anonymous, (b) that it does not 
form part of their medical care, (c) if they have concerns about their health they 
should consult their general practitioner or equivalent and (d) they can abandon 
participation in the survey at any time without and ill-effect on themselves. Any 
individual’s survey results will only be made available to the researchers once the 
individual has completed the study by clicking the ‘complete and send’ button on 
their web browser; at this point it will be assumed that they are comfortable with 
sending the data they have entered. 
 
 
 
5.3c Please give details of any City staff or students who will have contact with 
vulnerable adults and/or will have contact with young people (under the age of 18) and 
details of current (within the last 3 years) City University London Disclosure and 
Barring check.  
Name Dept & School Student/Staff 
Number 
Date of DBS  Type of 
disclosure  
                              
                              
                              
                              
 
5.3d Please give details of any non-City staff or students who will have contact with 
vulnerable adults and/or will have contact with young people (under the age of 18) and 
details of current (within the last 3 years) Disclosure and Barring check. 
Name Institution Address of Date of DBS  Type of 
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organisation 
that requested 
the disclosure 
disclosure 
                              
                              
                              
                              
 
5.4 Will you be recruiting any participants who fall under the Mental Capacity Act 
2005?          YES  NO  
 
If so you MUST get approval from an NHS NRES approved committee (see separate 
guidelines for more information). 
 
 
6. Data Collection 
 
6.1a Please indicate which of the following you will be using to collect your data  
Please tick all that apply 
Questionnaire   
Interviews   
Participant observation   
Focus groups   
Audio/digital-recording interviewees or events   
Video recording   
Physiological measurements   
Quantitative research (please provide details)  
Other  
Please give details 
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6.1b What steps, if any, will be taken to safeguard the confidentiality of the participants 
(including companies)?  
Individuals will participate in the research by completing an on-line questionnaire. 
They are not asked for their name or location and are asked for their age group, not 
precise age. IP numbers are neither captured nor stored.  
 
 
6.1c If you are using interviews or focus groups, please provide a topic guide 
      
 
 
 
7. Confidentiality and Data Handling 
 
7.1a Will the research involve: 
 
 complete anonymity of participants (i.e. researchers will not 
meet, or know the identity of participants, as participants, as 
participants are a part of a random sample and are required to 
return responses with no form of personal identification)? 
 
 anonymised sample or data (i.e. an irreversible process 
whereby identifiers are removed from data and replaced by a 
code, with no record retained of how the code relates to the 
identifiers. It is then impossible to identify the individual to 
whom the sample of information relates)? 
 
 de-identified samples or data (i.e. a reversible process 
whereby identifiers are replaced by a code, to which the 
researcher retains the key, in a secure location)? 
 
 subjects being referred to by pseudonym in any publication 
arising from the research? 
 
 any other method of protecting the privacy of  
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participants? (e.g. use of direct quotes with specific 
permission only; use of real name with specific, written 
permission only) 
Please give details of ‘any other method of protecting the privacy of participants’ is 
used 
      
 
 
7.1b Which of the following methods of assuring confidentiality of data will be 
implemented? 
Please tick all that apply 
 data to be kept in a locked filing cabinet  
 data and identifiers to be kept in separate, locked filing 
cabinets 
 
 access to computer files to be available by password only  
 storage at City University London  
 stored at other site  
If stored at another site, please 
give details 
 
      
 
 
7.1c Who will have access to the data? 
Access by named researcher(s) only     YES  NO  
Access by people other than named researcher(s)   YES  NO  
 
If people other than the named researcher(s), please explain by whom and for what 
purpose 
In addition to the named researchers, data will be available on request to the 2
nd
 
supervisor and to PhD examiners.      
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7.2a Is the data intended for reuse or to be shared as part of longitudinal research?  
         YES  NO  
 
7.2b Is the data intended for reuse or to be shared as part of a different/wider research 
project now, or in the future?      YES  NO  
 
7.2c Does the funding body (e.g. ESRC) require that the data be stored and made 
available for reuse/sharing?      YES  NO  
 
7.2d If you have responded yes to any of the questions above, explain how you are 
intending to obtain explicit consent for the reuse and/or sharing of the data. 
 
 
 
 
 
7.3 Retention and Destruction of Data 
 
7.3a Does the funding body or your professional organisation/affiliation place 
obligations or recommendations on the retention and destruction of research data? 
        YES  NO  
 
If yes, what are your affiliations/funding and what are the requirements? (If no, please 
refer to University guidelines on retention.) 
      
 
 
 
7.3bHow long are you intending to keep the data? 
Twelve months beyond the end date of the PhD research (as noted in section 2.5) 
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7.3c How are you intending to destroy the data after this period?  
Deletion of data files 
 
 
 
 
8. Curriculum Vitae 
 
CV OF APPLICANTS (Please duplicate this page for each applicant, including external 
persons and students involved.)  
 
NAME: Jonathan Turner 
CURRENT POST (from) October 2011 
Title of Post: Research Student 
Department:  Centre for Health Informatics 
Is your post funded for the duration of this 
proposal? 
N/A 
Funding source (if not City University London) Self 
Please give a summary of your training/experience that is relevant to this research 
project 
I am a current PhD research student in the Centre for Health Informatics at City 
University London. I have previously obtained a MSc in Health Informatics from City 
University London. 
 
I have worked for both PACSnet and ImPACT, medical device evaluation units based 
at St George's Hospital London who provided reports on medical devices for NICE 
and the MHRA. This work included working on clinial information systems 
containing real patient information. I have also worked as manager of PACS and RIS 
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systems in hospitals, again working with real patient data. These posts have ensured 
an appreciation of the need and requirements for data confidentiality.  
I am registered with the Health Professions Council and am a full member of both the 
Institute of Physics and Engineering in Medicine and the Institute of Physics, these 
memberships carrying with them an obligation of professional behaviour. 
 
 
 
 
 
 
 
 
 
NAME: Dr Peter Weller 
CURRENT POST (from) 2003 
Title of Post: Senior Lecturer 
Department:  Computer Science 
Is your post funded for the duration of this 
proposal? 
Yes 
Funding source (if not City University London) n/a 
Please give a summary of your training/experience that is relevant to this research 
project 
 
I have 16 years experience in the Health Informatics arena and in that time have 
carried out a large number of projects involving health data collection, including data 
from operating theatres and A&E departments. Recently I was awarded an NHS 
Innovation challenge award for the analysis of a web based questionnaire on Carpal 
tunnel syndrome. 
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8.1 Supervisor’s statement on the student’s skills and ability to carry out the proposed 
research, as well as the merits of the research topic (up to 500 words) 
I fully support this application. Jonathan has strong experience in analysing patient 
records both from his MSc project work and practical experience in the NHS. The 
project is timely and has a great potential to provide clinicians (mainly GPs) with a 
novel tool for predicting possible illness for individual patients. The use of patient 
data is essential for this work so it is requested that this application be approved. 
 
 
 
 
 
 
 
 
 
 
Supervisor’s Signature 
Print Name 
 
 
9. Participant Information Sheet and 10. Consent Form  
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Please use the templates provided below for the Participant Information Sheet and 
Consent Form. They should be used for all research projects and by both staff and 
students. Note that there are occasions when you will need to include additional 
information, or make slight changes to the standard text – more information can be 
found under the application guidelines.  
 
 
11. Additional Information  
      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
12. Declarations by Investigator(s) 
 
 I certify that to the best of my knowledge the information given above, together with 
any accompanying information, is complete and correct. 
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 I have read the University’s guidelines on human research ethics, and accept the 
responsibility for the conduct of the procedures set out in the attached application. 
 I have attempted to identify all risks related to the research that may arise in 
conducting the project. 
 I understand that no research work involving human participants or data can 
commence until full ethical approval has been given 
 
 
 
Print Name Signature 
 
Principal Investigator(s) 
(student and supervisor if 
student project) 
Jonathan Turner 
 
 
 
 
Dr Peter Weller 
 
Associate Dean for 
Research (or equivalent) 
or authorised signatory  
 
       
 
Date 
      
 
 
 
 
9. Template for Participant Information Sheet  
 
This page will be adapted for presentation on the world wide web.  
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Branded web page – clear identification of the University as the responsible institution  
 
Title of study Self-reported health histories via anonymous web survey 
 
Standard text:  
We would like to invite you to take part in a research study. Before you decide whether 
you would like to take part it is important that you understand why the research is being 
done and what it would involve for you. Please take time to read the following 
information carefully and discuss it with others if you wish. Ask us if there is anything 
that is not clear or if you would like more information. 
 
What is the purpose of the study?  
 
This research project is intended to collect anonymous information on individuals' 
memories of their health events that have occurred in their life to date. 
 
You will be invited to list, to the best of your recollection, personal health events and 
ongoing conditions including, but not limited to, those events that you reported to, or 
required the intervention of, a general practitioner or other healthcare professional.  
 
You will also be invited to note your age group, weekly exercise habits, smoking status 
and alcohol consumption, and country of birth. In order to preserve your anonymity, 
you will not be asked for your name, exact age or current country of residence. The IP 
number of the computer you are using will not be collected. 
 
If you know the principal investigators of this study you are discouraged from 
participating in the study, in case you inadvertently reveal information that you would 
prefer not to. However, in any case, the investigators undertake not to attempt to 
reidentify any individuals from their submitted data. 
 
Once data have been collected, they will be used: 
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i) To see how individuals’ recollections of medical conditions compare, on 
average, to the quantity and detail of events typically stored in general 
practice records; 
ii) As input to a health event prediction algorithm, in order to see whether patient-
recalled data is of adequate quality to have practical use in such an 
algorithm. 
 
 
Why have I been invited? 
Any adult with access to the world wide web is able to participate in this study. 
 
Do I have to take part?  
Participation in this project is entirely voluntary. You do not have to take part and can 
stop completing the short survey at any point without penalty. All responses are 
anonymous and we will not know who has or who has not participated in the study. 
 
 
What will happen if I take part?  
If you decide to take part, you will be asked to complete a short survey on this website. 
We expect that you will take less than 10 minutes to complete the survey and you 
should complete the survey only once. 
 
 
 
What are the possible disadvantages and risks of taking part?  
There are no disadvantages or risks involved in taking part in this study. 
 
What are the possible benefits of taking part? 
There are no direct benefits to you in participating in this study. Indirect benefits 
include benefits to future patients, to the wider community and a contribution to 
knowledge. 
 
Chapter 11: Appendices 
 
 
551 
 
 
Will my taking part in the study be kept confidential?  
All data will be collected anonymously. At no point will we know the identity of any of 
the participants. In addition to the data anonymity, the data will be kept secure and 
accessed only by the research team. 
 
What will happen to results of the research study? 
The results of this project will be written up as part of a PhD thesis and may also be 
published in an appropriate journal or presented at a conference. No individual will be 
identifiable as part of this process.  
 
Should you wish to be sent a copy of any report or publication that results from this 
study, please contact  to request a copy. You do not have to 
have participated in the study to request a copy of the report. 
 
What will happen if I don’t want to carry on with the study?  
You will be asked only to complete a short questionnaire as part of this study and will 
be asked to do this only once. However, even if you agree to complete the 
questionnaire, you are free to stop at any point before you complete it. 
 
What if there is a problem? 
 
If you have any problems, concerns or questions about this study, you should ask to 
speak to a member of the research team. If you remain unhappy and wish to complain 
formally, you can do this through the University complaints procedure. To complain 
about the study, you need to phone . You can then ask to speak to the 
Secretary to Senate Research Ethics Committee and inform them that the name of the 
project is: 'Self-reported health histories via anonymous web survey' 
 
You could also write to the Secretary at:  
Anna Ramberg 
Secretary to Senate Research Ethics Committee  
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Research Office, E214 
City University London 
Northampton Square 
London 
EC1V 0HB                                      
 
 
City University London holds insurance policies which apply to this study. If you feel 
you have been harmed or injured by taking part in this study you may be eligible to 
claim compensation. This does not affect your legal rights to seek compensation. If you 
are harmed due to someone’s negligence, then you may have grounds for legal action.  
 
Who has reviewed the study? 
This study has been approved by City University London [insert which committee here] 
Research Ethics Committee 
 
Further information and contact details 
For further information on this project, or to request a copy of reports and publications 
arising from it, please contact: 
Jonathan Turner 
Research student,  
Centre for Health Informatics, City University London 
 
 
or his supervisor: 
Dr Peter Weller 
Head of Centre 
Centre for Health Informatics, City University London 
 
 
Thank you for taking the time to read this information sheet.  
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 Researcher’s checklist for compliance with the Data Protection Act, 1998 
 
This checklist is for use alongside the Guidance notes on Research and the Data 
Protection Act 1998.  Please refer to the notes for a full explanation of the requirements. 
 
You may choose to keep this form with your research project documentation so that you 
can prove that you have taken into account the requirements of the Data Protection Act. 
 
 
  REQUIREMENT 
 
 
 
 
 A Meeting the conditions for the research exemptions: 
 
    
1 The information is being used exclusively for research purposes. 
 
   Mandatory 
2 You are not using the information to support measures or 
decisions relating to any identifiable living individual. 
 
   Mandatory 
3 You are not using the data in a way that will cause, or is likely to 
cause, substantial damage or substantial distress to any data 
subject. 
 
   Mandatory 
4 You will not make the result of your research, or any resulting 
statistics, available in a form that identifies the data subject. 
 
   Mandatory 
 B Meeting the conditions of the First Data Protection Principle: 
 
  
1 You have fulfilled one of the conditions for using personal data, 
e.g. you have obtained consent from the data subject.  Indicate 
which condition you have fulfilled here:  
 
Participants are asked to give consent before supplying any 
personal information. All data collected is collected 
anonymously. 
   Mandatory 
2 If you will be using sensitive personal data you have fulfilled one 
of the conditions for using sensitive personal data, e.g. you have 
obtained explicit consent from the data subject.  Indicate which 
   Mandatory if 
using sensitive 
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condition you have fulfilled here:  
Participants are asked to give consent before supplying any 
personal information. All data collected is collected 
anonymously. 
 
data 
3 You have informed data subjects of: 
i. What you are doing with the data; 
ii. Who will hold the data, usually City University London; 
iii. Who will have access to or receive copies of the data. 
 
   Mandatory 
unless B4 
applies 
4 You are excused from fulfilling B3 only if all of the following 
conditions apply: 
i. The data has been obtained from a third party; 
ii. Provision of the information would involve 
disproportionate effort; 
iii. You record the reasons for believing that disproportionate 
effort applies, please also give brief details here: 
____________________________________________________
____________________________________________________
____________________________________________________
____________________________________________________ 
N.B.  Please see the guidelines above when assessing 
disproportionate effort. 
 
 Required only 
when claiming 
disproportionate 
effort 
 C Meeting the conditions of the Third Data Protection Principle: 
 
  
1 You have designed the project to collect as much information as 
you need for your research but not more information than you 
need. 
 
   Mandatory 
 D Meeting the conditions of the Fourth Data Protection Principle: 
 
  
1 You will take reasonable measures to ensure that the information 
you collect is accurate. 
 
   Mandatory 
2 Where necessary you have put processes in place to keep the 
information up to date. 
 
 Mandatory 
 E Meeting the conditions of the Sixth Data Protection Principle: 
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 1  You have made arrangements to comply with the rights of 
the data subject.  In particular you have made 
arrangements to: 
i. Inform the data subject that you are going to use their 
personal data. 
ii. Stop using an individual’s data if it is likely to cause 
unwarranted substantial damage or substantial distress to 
the data subject or another. 
iii. Ensure that no decision, which significantly affects a data 
subject, is based solely on the automatic processing of 
their data. 
iv. Stop, rectify, erase or destroy the personal data of an 
individual, if necessary. 
Please give brief details of the measures you intend to take here: 
____________________________________________________
____________________________________________________
____________________________________________________
____________________________________________________
____________________________________________________ 
 
   Mandatory 
 
 
